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   I 
Summary 
 
Tolerance against self is a necessary feature of the immune system to prevent 
autoimmunity. Hence during B cell development, a number of central and peripheral 
developmental checkpoints ensure the deletion of self-reactive B cells and selection of 
tolerant B cells. For example, antigen-driven ligation of the B cell receptor (BCR) on 
immature  B  cells  results,  by  default,  in  receptor  editing,  anergy  and/or  apoptosis, 
whereas it provides survival, proliferative and effector differentiation signals to mature 
B cells. Moreover, various factors can influence the functional outcome downstream of 
BCR ligation. Thus, T helper cell-derived signals, such as those following ligation of the 
CD40 receptor, can rescue pathogen-specific immature B cells from growth arrest and 
apoptosis, thereby providing a mechanism in which cells programmed to die because 
of their immature status can survive after receiving appropriate T cell help. On the other 
hand, mitogenic BCR-mediated signalling of mature B cells can be suppressed by co-
ligation  of  the  inhibitory  receptor  FcγRIIb.  This  allows  the  maintenance  of  B  cell 
homeostasis  in  the  periphery,  as  cross-linking of  the  BCR  and  FcγRIIb  by  immune 
complexes  enables  the  system  to  terminate  ongoing  immune  responses  following 
clearance of pathogens. The precise signalling mechanisms involved in dictating these 
differential functional outcomes remain to be elucidated but it is becoming increasingly 
clear that the developmental stage as well as the integration of various extracellular 
signals  decide  the  cell’s  fate.  The  core  aim  of  this  study  has  therefore  been  to 
characterise the signalling pathways coupling BCR ligation to survival, proliferation and 
apoptosis during development. In particular, it was planned to focus on the differential 
signalling  mechanisms  involved  in  the  negative  selection  of  immature  B  cells  and 
FcγRIIb-mediated homeostatic regulation of mature B cells. 
Negative  selection  of  self-reactive  immature  B  cells  constitutes  a  major 
mechanism of sustaining central tolerance. The WEHI-231 cell line provides a well-
established  model  system  for  dissecting  the  signalling  mechanism  underlying  such 
clonal  deletion  of  immature  B  cells  as  these  cells,  which  have  the  phenotype  of 
immature B cells, undergo growth arrest and apoptosis following stimulation of their 
BCR. Previously, this laboratory has identified ERK signalling as a key regulator of 
immature  B  cell  fate.  Thus,  spontaneously  proliferating WEHI-231  B  cells  exhibit  a 
sustained yet cyclic pattern of ERK activation that is necessary for their survival and 
proliferation.  By  contrast,  BCR-ligation  induces  a  strong transient  activation  of  ERK 
followed  by  sustained  downregulation  of  the  cyclic  activation  pattern  observed  in 
spontaneously  proliferating  cells.  However,  the  pathways  linking  BCR  ligation  with 
suppression of ERK signalling and consequent growth arrest have not been delineated 
in full. For example, in B cells, the Ras/Raf-1/MEK cascade is considered to be a major   II 
pathway  regulating  ERK  activation  and  consistent  with  this,  this  laboratory  has 
previously shown that overexpression of Ras can rescue WEHI-231 B cells from BCR-
mediated  growth  arrest.  However,  although  MEK  activation  was  found  to  be 
compromised under conditions of BCR-driven growth arrest, such BCR-signalling did 
not suppress Ras activation indicating that other pathways normally contributed to the 
MEK-dependent activation of ERK in spontaneously proliferating WEHI-231 cells.  
The data presented in this thesis now provide evidence for the existence of a 
second pathway controlling ERK activation in immature B cells, the Rap/B-Raf/MEK 
cascade, which has now been implicated in the maintenance of cycling ERK activation 
observed in spontaneously proliferating WEHI-231 B cells. BCR signalling was found to 
reduce the levels of active Rap, hence providing a mechanism for the BCR-mediated 
uncoupling of the Ras-independent, MEK-dependent ERK activation contributing to the 
cycling  ERK  signalling  responsible  for  survival  and  proliferation  of  WEHI-231  cells. 
Consistent with the role of Rap in promoting such ERK signalling, additionally, it has 
now been demonstrated that levels of SPA-1, a negative regulator of Rap, increase 
upon BCR-stimulation indicating that this may be the mechanism by which the BCR 
signals to uncouple the Rap/B-Raf/MEK pathway.  
Although  ERK  had  previously  been  identified  as  the  major  regulatory element 
governing survival and proliferation of immature B cells, the pathways linking ERK to 
the regulation of survival/apoptosis and cell cycle progression have been only poorly 
characterised. This study has now highlighted the connection between sustained ERK 
signalling and the stabilisation of c-Myc protein levels. For example, abrogation of ERK 
activity  by  BCR-ligation,  or  pharmacological  inhibition,  reduced  c-Myc  levels  in  a 
transcription-independent fashion  indicating  regulation  at  the  post-translational  level. 
This proposal was corroborated by analysis of the phosphorylation status of c-Myc that 
indicated that ERK signalling promoted the expression of stabilised forms (S62) of c-
Myc  and  reduced  the  expression  of  those  (T58)  targeting  c-Myc  for  proteosomal 
degradation.  The  importance  of  such  c-Myc  stabilisation  was  illustrated  by  Laser 
Scanning  Cytometric  analysis  that  revealed  that  the  increasing  levels  of  c-Myc 
expressed by individual WEHI-231 B cells correlated with their cell cycle progression, 
presumably  reflecting  widely  established  findings  that  c-Myc  promotes  cell  cycle 
progression by increasing the expression and activation of cyclin/Cdk complexes and 
reducing  the  levels  of  Cdk  inhibitors  such  as  p27.  Consistent  with  this,  negative 
signalling via the BCR, or suppression of ERK activation by pharmacological inhibition, 
also increased p27 levels and resulted in the reduction of the hyperphosphorylation of 
retinoblastoma  (Rb)  proteins  required  for  transition  through  the  G1-S-phase 
checkpoint. As Rb is a target of cyclin/Cdks, collectively these data further confirm the   III 
links not only between BCR-signalling and c-Myc stability but also the differential cell 
fate decisions of apoptosis, survival and/or cell cycle progression.  
By  contrast,  in  mature  B  cells,  BCR-signalling  is  linked  to  survival  and 
proliferation.  However,  to  prevent  autoimmunity  resulting from  an  expanded  pool  of 
potentially weakly autoreactive B cells, such survival and proliferation of mature B cells 
needs  to  be  homeostatically  regulated.  Hence,  the  immune  system  has  evolved 
inhibitory signalling cascades such as that triggered by cognate immune-complexes co-
ligating  the  BCR  and  FcγRIIb  to  terminate  ongoing  antigen-driven  responses.  This 
study has emphasised the crucial role of caspase 8 in the apoptosis of mature B cells 
resulting from such co-ligation of the BCR and FcγRIIb and has indicated that such 
caspase 8 activation is likely to be downstream of Fas signalling. Consistent with this, 
blocking  the  Fas/FasL  death  receptor  cascade  was  found  to  reduce  the  levels  of 
apoptosis  detected  and  B  cells  from  MRL/MpJ-Fas
lpr  mice,  a  strain  harbouring  a 
mutation  causing  the  abrogation  of  Fas  expression,  exhibited  defective  apototic 
responses  upon  such  BCR/FcγRIIb  co-ligation.  Thus,  Fas/FasL  death  receptor 
signalling might be a major mechanism underpinning the FcγRIIb-mediated apoptosis 
pathway. 
Finally,  to  determine  whether  dysfunctional  regulation  of  FcγRIIb-mediated 
signalling  plays  a  role  in  human  autoimmune  conditions,  B  cells  from  patients  with 
Rheumatoid arthritis and Systemic lupus erythematosus were examined. Overall, the 
homeostatic regulatory responses between B cells from healthy controls and RA and 
SLE patients were not found to be significantly different. However, the B cells derived 
from  a  small  proportion  of  RA  and  SLE  patients  were  found  to  exhibit  defective 
FcγRIIb-mediated inhibitory responses. Moreover, significant differences were found in 
the ratio of FcγRIIb1/FcγRIIb2 expression between the cohorts of healthy controls and 
RA and SLE patients. The RA and SLE patients expressed relatively higher levels of 
the FcγRIIb2 isoform which promotes antigen-processing suggesting that these B cells 
may play some role in priming autoreactive responses in such individuals. Thus, as 
these  inflammatory  disorders  constitute  spectrum  diseases,  such  defects  in  the 
regulation  of  B  cell  responses  could  be  one  of  the  contributing  factors  aggravating 
autoimmune disease development in some subgroups of patients. 
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1  Introduction 
   
1.1  The immune system 
 
The immune system is the body’s defence against infections caused by pathogens 
like bacteria, viruses and parasites. It consists of cells and molecules that ensure that the 
pathogen  is  removed  from  the  body  before  it  can  cause  too  much  damage.  The  first 
barriers a pathogen has to overcome to enter the host are of a physical nature. Thus, the 
skin and the mucosal surfaces can prevent the entry of the majority of pathogens and 
inactivate others by the production of antimicrobial substances. If a microbe passes these 
first barriers, then innate immunity provided by cells such as phagocytes (macrophages 
and granulocytes) and natural killer (NK) cells provides the first line of defense. The major 
mechanism for recognition of foreign antigens by these cells are PRRs (pattern recognition 
receptors)  which  bind  PAMPs  (pathogen  associated  molecular  patterns)  leading  to  the 
initiation of an innate immune response. The specificities of these innate immune system 
receptors are germ-line encoded meaning that their repertoire for pathogen recognition is 
limited and predetermined. PAMPs are structures shared by many classes of pathogens 
ensuring that the innate immune response recognises and combats a broad spectrum of 
pathogens in the first few days of infection whilst the adaptive immune system becomes 
activated.  Moreover,  innate  cells,  via  their  role  in  antigen  presentation  are  crucial  for 
priming of the specific adaptive response. 
The  adaptive  immune  response  is  highly  specific  and  extremely  diverse  and 
comprises two branches: humoral (B cells) and cellular (T cells) immunity. T cells are not 
able to recognise protein antigen in its native form. Their antigen recognition receptor, the 
TCR (T cell receptor) binds to peptides derived from antigen in the context of MHC (major 
histocompatibility complex) molecules expressed at the surface of cells. Depending on the 
class of MHC (I or II) the T cell is able to interact with, one can differentiate between 
cytotoxic T cells (CTLs) which recognise peptide presented in combination with MHC class 
I (present on all nucleated cells) and T helper cells (TH cells) which recognise peptide 
bound to MHC II (mainly expressed on antigen presenting cells; APCs). The major function 
of CTLs is the killing of infected or tumour cells whereas TH cells provide help to other cell 
classes in the form of either cytokines or engagement of surface costimulatory molecules. 
There is a third class of T cells, the so called T regulatory cells which play a homeostatic  
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role in keeping an ongoing immune response in check after the removal of the pathogen 
and by this way preventing a harmful overreaction of the immune system.  
The  other  arm  of  the  adaptive  immune  response  is  humoral  immunity  which  is 
dependent on B cells, the producers of antibodies. The Immunoglobulin (Ig) molecule is 
made up of four chains, two identical heavy (55-70kD) and light chains (~24kD) linked by 
disulphide bonds. Both heavy and light chains consist of Ig domains – two in each light 
chain and varying numbers, depending on the antibody subclass, on the heavy chain. The 
heavy and light chains both feature an amino terminal V (variable) region and a constant 
(C) region at the carboxy terminus of the protein. The amino acid sequence of the variable 
regions  varies  between  molecules  from  different  B  cell  clones  thereby  creating  the 
specificity of antibodies as the opposing V regions of the heavy and light chains comprise 
the antigen binding site (Fig.1.1). The high number of antibodies with different V regions 
and hence different binding specificities is achieved by random genetic recombination of 
the genes encoding the variable regions of the heavy and light chain. Thus, the variable 
region  of  the  heavy  chain  is  generated  by  the  recombination  of  DH  segments  to  JH 
segments followed by the joining of the VH region to the pre-assembled DHJH segment 
(Fig.1.2). The mammalian genome encodes about 300 variable (VH) genes, 30 diversity 
(DH)  genes  and  6 joining  (JH)  genes  allowing  the  potential  creation of  50,000 different 
heavy chains via somatic recombination. To further increase diversity the enzyme TdT 
(terminal  deoxynucleotide  transferase)  randomly  adds nucleotides  into  the  heavy chain 
genes without following a template. Similarly to the heavy chain, the light chain protein is 
also  generated  by  somatic  recombination  but  it  is  encoded  by  two  genes,  kappa  and 
lambda, which further doubles the number of potential light chains, as both genes encode 
multiple V and J segments. In contrary to the heavy chain gene, the gene encoding the 
light chain lacks a D segment and is therefore created via a single recombination event. 
The V region furthermore contains three so called CDRs (complementarity-determining 
region). These regions are areas of high variability where most mutations occur during 
somatic hypermutation. They are located in the part of the V region which takes part in the 
antibody-antigen  interaction  and  thus  influences  the  binding  capacity  of  the  antibody 
(Fig.1.3).  
The  B  cell  receptor  (BCR)  consists  of  an  antigen-binding  component  –  the 
membrane bound Ig molecule – and the signal-transducing units Igα and Igβ (CD79a and 
b, reviewed in [1]). In the majority of cases, binding of antigen to the BCR on a naïve 
mature B cell will lead to its activation when T cell help is provided. Ultimately the B cell 
will develop into an antibody-secreting cell producing large amounts of antibody specific 
for the antigen which activated the B cell in the first place. Every B cell clone produces an  
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antibody with a unique specificity that can carry out various functions depending on their 
isotype. There are five different antibody isotypes: IgA, IgD, IgE, IgG and IgM (Fig.1.1). 
Before their activation naïve mature B cells express IgM and IgD on their surface and upon 
activation some clones can secrete IgM. The IgD isotype has so far not been found in a 
secreted form and its major function therefore seems to be signal transduction. Secreted 
IgM can form a pentamer thereby increasing antigen binding-avidity and a major function 
of soluble IgM is the activation of the classical pathway of complement. The complement 
system comprises a family of proteins which can bind to antibody-coated pathogens, or 
directly to pathogens and initiate a cascade which ultimately leads to the creation of a 
pore-forming complex and hence the destruction of the pathogen. 
Upon receiving T cell help in the form of cytokines and CD40-ligation, B cells can 
undergo isotype-switching. This process leads to the expression of heavy chains other 
than the   chain (IgM). The precise inflammatory environment and the specific types of 
cytokines  generated  dictate  the  isotype  that  the  B  cell  produces  subsequently.  The 
infection with, for example, large parasites such as helminths, induces an inflammatory 
environment favourable to the production of IgE antibodies which then coat the parasite 
and  drive  the  activation  of  granulocytes,  a  cell  class  which  can  release  their  cytotoxic 
granular  contents,  helping  to  combat  pathogens  that  are  too  big  to  be  engulfed  by 
phagocytes. On the other hand, a bacterial or viral infection induces cytokines that drive B 
cells to switch to the expression of IgG isotypes. These antibodies can coat pathogens by 
binding to their specific antigen expressed on the microbe’s surface and thus carry out 
various  functions  such  as  the  opsonisation  of  pathogens,  thereby  targeting  them  for 
enhanced recognition by phagocytes. Moreover, binding of IgG can cause neutralisation 
which inactivates the pathogen or its toxins and prevents their entry into host cells. Finally, 
IgA antibodies comprise a very specialised isoytpe. IgA dimers or trimers, joined via the so 
called  J  chain  (joining  chain)  can  be  transported  across  the  epithelial  barrier  into  the 
mucosal surfaces of the gastro-intestinal and respiratory tract creating an additional barrier 
to pathogens entering through these surfaces. Through the production of different isotypes 
B  cells  can  therefore  adjust  to  various  pathogens  creating  a  specific  inflammatory 
environment ensuring the production of antibody isotypes best suited to protect against the 
different types of pathogens. 
 
1.2  B cell development  
 
There are three major subsets of B cells – B-2 follicular B cells, marginal zone (MZ) 
B cells and B-1 B cells. The follicular B cell subset is the major B cell class involved in the  
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adaptive humoral immune response, whilst B-1 B cells and marginal zone B cells appear 
to function as more innate-like subsets of B cells. For example, B-1 B cells are the major 
producers of “natural antibodies”, a class of IgM antibodies which are polyreactive and 
function to provide a first line of defense against microbial infection [2]. These antibodies 
are  able  to  bind  to  multiple  different  self  and  foreign  antigens  although  usually  with 
relatively low affinity. Natural antibodies are present in healthy individuals in the absence 
of  antigenic  stimulation  and  as  they  recognise  conserved  pathogen  antigens  such  as 
phosphorylcholine or lipopolysaccharide (LPS), can hence contribute to the initial innate 
immune  response  [2].  Furthermore,  B-1  B  cells  express  a  reduced  number  of  BCR 
specificities,  compared to  B-2  follicular  B  cells  [2]  again  consistent  with  their status  of 
innate-like immune cells, similar to γδ T cells. B-1 B cells are mainly found in the peritoneal 
and pleural cavities but also in the spleen and the intestine and they make up about 5% of 
the general B cell population (reviewed in [3]). 
B-1 B cells are therefore a first line of defence which leads to the rapid production of 
antibodies especially against T-independent antigens like phosphorylcholine or LPS [2]. 
There are two subtypes of B-1 cells, B-1a and B-1b. Both cell types express low levels of 
CD11b, but only B-1a cells express CD5, a marker which was originally used to distinguish 
B-1 from B-2 B cells [2]. It has recently been shown that B-1a and B-1b B cells have 
distinct  functions.  Thus,  B-1a  B  cells  were  found  to  provide  protection  from  acute 
Streptococcus pneumoniae infection through the production of natural antibodies whereas 
B-1b cells contributed to the adaptive antibody response to this infection [4]. Moreover, B-
1b but not B-1a B cells were found to be crucial for the induction of long-lasting T-cell 
independent immunity to Borrelia hermsii due to the production of pathogen-specific IgM 
[5].  MZ  B  cells,  similarly  to  B-1  B  cells,  are  important  in  the  rapid  response  against 
pathogens, particularly blood-borne bacteria. MZ B cells reside in the marginal zone of the 
spleen, locating them at the blood-lymphoid interface between white and red pulp. The 
blood  circulating  through  the  spleen  slows  down  in  this  area  allowing  the  efficient 
encounter of MZ B cells with their antigens. Similarly to B-1 B cells, MZ B cells rapidly 
develop  into  antibody-producing  cells  thereby  providing  protection  from  blood-borne 
pathogens  during  the  time  it  takes  for  the  adaptive  immune  response  to  become 
established [6]. The B cell subclass crucial for the humoral adaptive immune response are 
conventional, follicular B-2 B cells. Unlike B-1 and MZ B cells these cells undergo somatic 
hypermutation and isotype switching and therefore contribute to the production of high 
affinity antibodies.  
In mice, follicular B cells start their development in the bone marrow but also in the 
foetal liver before birth. Their progenitors are haematopoietic stem cells (HSC) which are  
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pluripotent and potentially able to develop into other immune cell lineages, like T cells, or 
myeloid lineage cells. The first step in their developmental process is the commitment of 
HSC to the lymphoid lineage as indicated by their expression of c-kit and the Interleukin-7 
(IL-7)  receptor  α-chain  (CD127)  [7].  At  this  stage,  called  common  lymphoid  progenitor 
(CLP), the progeny can give rise to B, T and NK cells. The major transcription factors 
determining  whether  pluripotent  cells  commit  to  the  B  cell  lineage  are  the  paired  box 
transcription  factors  PAX-5/BSAP,  E2A  and  EBF1  (reviewed  in  [8]).  The  first  stage  at 
which cells are recognised as committed B cells is called the pre-pro-B cell stage and this 
can be distinguished by the expression of the B220 isoform of CD45, the lack of CD19, low 
levels  of  CD24  and  little  or  no  immunoglobulin  (Ig)  rearrangement  [9]  (Fig.1.4).  The 
regulation  of  this  step  of  lineage  commitment  depends  on  expression  of  different 
transcription  factors.  For  example,  the  lack  of  E2A  [10]  was  shown  to  impair  the 
development of B cells at the pro-B cell stage whilst EBF-deficient cells do not progress to 
the pre-B cell stage [11].  
Pro-B cells are the next stage in the development at which the cells upregulate CD19 
and  express  CD10  but  not  surface  immunoglobulin.  These  cells  also  upregulate 
recombination-activating  gene-1  (RAG-1)  and  RAG-2,  enzymes  that  are  necessary  to 
generate double stranded DNA breaks during the heavy and light chain rearrangement 
process. If those molecules are missing no µ heavy chain can be produced and the cells 
do not undergo any further development [12]. The DNA-PK repair complex has also been 
shown  to  be  needed  for  successful  rearrangement  as  B  cells  from  Scid/Scid  (severe 
combined immunodeficiency) mice display a developmental block at the pro-B cell stage 
[13]. This is because the scid mutation affects the activity of the DNA-PK repair complex 
which  is  involved  in  the  joining  of  the  segments  during  V(D)J  recombination  [14]. 
Consistent with upregulation of RAG-1 and RAG-2, the early pro-B cell stage is identified 
by the initiation of heavy chain rearrangement starting with the joining of one DH and one 
JH  gene.  The  transition  to  the  late  pro-B  cell  stage  is  marked  by  the  joining  of  a  VH 
segment  to  the  pre-arranged  DHJH  complex  (Fig.1.2).  Pro-B  cells  are  also  the  first 
developmental  stage  expressing  Igα  and  Igβ  (CD79a  and  CD79b).  These  signalling 
molecules are expressed in a complex with the chaperone molecule calnexin and were 
found to be crucial for further developmental progress, as mice lacking Igα and/or Igβ are 
arrested at the pro-B cell stage [15]. Presumably, Igα/Igβ are needed for the transduction 
of  signals  permitting  the  survival  and  development  of  pro-B  cells  into  pre-B  cells. 
Consistent with this, cross-linking of CD79b was shown to induce the phosphorylation of 
various signalling transducers such as Syk, Btk and Vav leading to the activation of ERK 
(extracellular signal-regulated kinase) [15,16]. Moreover, such CD79b-mediated signalling  
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allowed arrested pro-B cells to mature into pre-B cells further confirming the importance of 
Igβ [16]. Interestingly, heavy chain rearrangement did not depend on this Igα/Igβ-mediated 
signalling  indicating  that  different  pathways  regulate  V(D)J  recombination  and 
developmental progress [17]. The succesful expression and signalling of Igα/Igβ initiates 
the maturation to pre-B cell. At this stage the B cell expresses the rearranged µ heavy 
chain in combination with λ5 and VpreB (SLC, surrogate light chain) to yield the pre-BCR 
which associates with Igα and Igβ on the surface of the cell [18] (Fig.1.5). A functional pre-
BCR is necessary to permit the B cell to reach the next developmental stage. For example, 
it has been postulated that the association of the rearranged heavy chain with the invariant 
SLC  allows  signalling  that  ensures  that  only  B  cells  expressing  correctly  folded  heavy 
chains can develop further [19]. It is not clear what exact role the pre-BCR plays in the 
downregulation  of  RAG  and  TdT  enzymes  and  progression  to  the  next  developmental 
stage,  as  pre-B  cells  from  mice  unable  to  express  SLC  were  still  capable  of 
downregulating RAG and TdT [20]. Recently, it has been shown that the pre-BCR might 
also provide one of the earliest checkpoints in negative selection of autoreactive B cell 
clones. For example, autoreactive B cells from mice lacking expression of SLC were found 
to be able to escape negative selection leading to higher production of anti-nuclear DNA 
antibodies in these mice [21]. Thus, in the presence of SLC, pre-B cells expressing heavy 
chains  likely  to  produce  DNA-reactive  antibodies  undergo  negative  selection  [21].  This 
process seems to be antigen-independent as pro-B cells expressing these specific heavy 
chains intracellularly were also depleted from the repertoire [21]. Besides taking part in 
positive and negative selection of pre-B cells, the successful expression of a functional 
heavy chain also leads to the block of rearrangement on the other heavy chain allele, a 
process called allelic exclusion [22,23]. If the rearrangement of both heavy chain alleles 
fails the cell undergoes programmed cell death by apoptosis. 
Following allelic exclusion, the expression of the functional pre-BCR also initiates 
light chain rearrangement. Thus, V to J recombination leads to the expression of functional 
κ  or  λ  light  chain  which  then  associates  with  the  µ  heavy  chain  (Fig.1.4).  Surface 
expression of functional µ heavy and light chain complexes (IgM) is a characteristic feature 
of immature B cells. From the immature B cell stage onwards, the clonal selection process 
is  Ag-dependent.  Thus,  immature  B  cells  binding  with  high  affinity  to  self-antigen  are 
subjected to a process called negative selection which leads to either receptor editing or 
apoptosis [24] depending on the localisation of the cells. Thus, autoreactive immature B 
cells  in  the  bone  marrow  default  to  receptor  editing  whereas  apoptosis  and  therefore 
deletion seems to be the default response for immature B cells in the periphery [25]. Upon 
binding to self-antigen, induction of receptor editing allows immature B cells to express the  
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RAG genes again and undergo further light chain recombination in this way producing a 
new light chain molecule which might change the specificity of the BCR, therefore allowing 
the cell to escape deletion or anergy [26]. The response of immature B cells  with low 
affinity for self-antigens is less well characterised. For example, it has been shown that 
membrane-bound low-affinity auto-antigens are as effective at inducing negative selection 
as  high-affinity  antigens  [27].  Soluble  low-affinity  self-antigens  on  the  other  hand  were 
found to preferentially induce positive selection of B cells into the B-2 B cell pool [28]. 
Thus, depending on the nature and affinity/avidity of the self-antigen, B cells will undergo 
either positive or negative selection. 
Immature B cells that survive negative selection are released from the bone marrow 
into the circulation to migrate to the secondary lymphoid organs such as the spleen. These 
transitional-immature (T1) B cells are sensitive to BCR-induced apoptosis for a few days 
following  their  emigration  from  the  bone  marrow  [29],  a  feature  that  ensures  that  self-
reactive B cells that do not encounter their specific antigen in the bone marrow are deleted 
in the periphery. The initiation of IgD expression on T1 B cells indicates their development 
into (T2) transitional B cells. Recently, the existence of another transitional B cell subset 
(T3)  has  been  proposed.  These  cells  can  be  identified  as  B220
+AA4.1
+CD23
+sIgM
low 
thereby only differing from T2 cells in their lower expression of IgM [30]. It has therefore 
been hypothesised that these cells simply represent T2 cells on the brink of developing 
into mature B cells or alternatively, B cells targeted for deletion or anergy. In support of the 
latter,  Merrell  et  al  defined  this  T3  population  as  an  antigen-induced  unresponsive 
population  in  a  transgenic  BCR  model  and  consistent  with  this,  also  found  a  high 
percentage of self-reactive cells to be present in the T3 population of non-transgenic mice 
[31]. 
The survival of T2 cells and mature B cells depends on multiple factors, the major 
being BCR and B cell activating factor (BAFF) signalling. Many molecules involved in BCR 
signalling, such as Syk, BLNK (B cell linker protein, also known as SLP-65), Btk and NF-
κB (Nuclear factor- κB) signalling have been found to be necessary for the survival of T2 
and mature peripheral B cells indicating that BCR signalling initiates signals needed for the 
developmental progression or survival of these cells [32]. In recent years, the importance 
of BAFF in the survival and development of B cells has become clear as loss of BAFF 
signalling was shown to lead to loss of mature and T2 B cells [33]. There appears to be 
crosstalk between BCR AND BAFF receptor signalling as BCR signalling was shown to 
upregulate BAFF receptor expression [34] and BCR and BAFF receptor signalling appears 
to be integrated at the level of NF-κB regulation. For example, BCR signalling provides 
optimal levels of p100 NF-κB which are then processed downstream of BAFF receptor  
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signalling stimulating survival [35]. Thus, transitional B cells which are not or only weakly 
self-reactive and able to induce BCR and BAFF receptor signalling progress to the next 
developmental stage, mature naïve B cells [36].  
Antigen ligation of the BCR on mature B cells leads to activation, proliferation and 
differentiation  rather  than  cell  cycle  arrest  or  apoptosis  as  seen  with  immature  cells. 
Nevertheless,  antigen  has  to  be  recognised  in  the  right  environment  as  the  full 
development into an activated effector B cell generally depends on the presence of TH 
cells, their cytokines or other activation signals like TLR (Toll-like receptor) ligands [37]. 
Indeed,  a  mature  B  cell  has  three  main  developmental  possibilities  after  activation  – 
becoming  an  antibody  secreting  plasma  cell,  a  memory  B  cell  or  participating  in  the 
germinal  centre  (GC)  reaction.  In  a  T  cell-dependent  response,  the  initial  antibody 
production is due to the rapid extrafollicular proliferative focus response [38]. The first step 
in this response is the acquisition of antigen by B cells in the blood or in lymph nodes while 
they are re-circulating [39]. B cells encountering antigen in the blood will migrate to the T 
cell zone of the spleen [39] where antigen-stimulated B cells will interact with primed T 
cells  resulting  in  entry  into  the  cell  cycle  as  well  as  commitment  to  the  plasma  cell 
programme  induced  by  the  upregulation  of  B  lymphocyte  induced  maturation  protein-1 
(Blimp-1; reviewed in [40]). Moreover, such antigen-activated B cells form extrafollicular 
foci where they can further differentiate into, often short-lived, plasma cells and secret 
antibodies.  Notably,  during  this  type  of  response,  B  cells  do  not  undergo  somatic 
hypermutation [41]. 
Alternatively, B cells that do not develop into such plasma cells can enter primary 
follicles where they initiate the GC reaction and undergo somatic hypermutation with the 
help of follicular TH and dendritic cells [42]. The major objective of somatic hypermutation 
is the selection of B cells with higher affinity for their antigen. Why some B cells enter the 
plasma cell development pathway directly rather than take part in the GC reaction remains 
to be elucidated. However, a recent publication by Paus and colleagues [43] indicates that 
the affinity of the B cell determines whether it takes part in the GC reaction or not. For 
example, by testing various antigen concentrations and densities in a transgenic mouse 
model they found that high affinity clones are preferentially recruited into the extrafollicular 
reaction whilst intermediate and low affinity B cells are more likely to enter the GC reaction 
where  they  have  the  chance  to  increase  their  binding  affinity,  and  hence,  positive 
selection. 
The GC reaction starts around day 4-5 after antigen encounter: activated B cells first 
migrate  into  the  dark  zone  of  the  germinal  centre  where  they  keep  proliferating,  lose 
surface  Ig  expression  and  start  somatic  hypermutation  (centroblasts)  (Fig.1.6).  After  
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having mutated their Ig CDRs, the cells stop dividing (centrocytes) and express their new 
receptor. The migration between light and dark zone is regulated by a chemokine gradient 
and differential expression of chemokine receptors on centroblasts and centrocytes. For 
example, centroblasts express CXCR4 and follow the CXCL12 gradient towards the light 
zone,  whereas  centrocytes  express  CXCR5 which  makes  them responsive  to  CXCL13 
expressed in the dark zone thereby allowing shuttling of cells between the dark and light 
zone [44]. Only centrocytes with high affinity receptors are selected and allowed to survive. 
The major criteria influencing the decision between survival and death of B cells in the 
germinal centre include the affinity of the mutated BCR as well as costimulatory signals 
received. Thus, expression of CD40 has been shown to be crucial during GC reactions, as 
lack of this molecule or its ligand abrogates GC formation [45]. CD40 ligand (CD154) is 
expressed not only on activated T cells taking part in the GC reaction, but also by B cells 
themselves [46] with interaction of CD40 and its ligand resulting in survival and cell cycle 
progression of GC B cells [47]. As GC B cells are by default prone to apoptosis due to a 
changed balance of anti- and pro-apoptotic Bcl-2-family members and other regulators of 
apoptosis such as Fas and p53 [48,49], the lack of positive signals such as CD40 ligation 
will otherwise lead to cell death. Changes in transcription factor expression are also very 
important  for  determining  B  cell  selection  and  plasma  cell  development.  Indeed,  Bcl-6 
expression has been found to be essential for the formation of germinal centres and GC B 
cells [50] due to its’ repression of Blimp-1, the major regulator of plasma cell induction. 
Cells positively selected during the GC reaction then either develop into plasma cells or 
memory cells. The mechanisms underlying the decision between these two options have 
not been fully elucidated yet, but there is evidence that expression of a high affinity BCR 
skews towards selection into the plasma cell pool [51], whereas memory B cell selection 
might be a more random process as indicated by the constant recruitment of B cells into 
the memory B cell pool during the GC reaction [52]. 
Development  of  plasma  cells  is  highly  regulated,  especially  at  the  transcriptional 
level. In order for B cells to develop into plasma cells, Pax5 needs to be downregulated 
[53]  and  Blimp-1  expression  induced  [54]  leading  to  cell  cycle  arrest  due  to  c-Myc 
downregulation [55] and induction of the immunoglobulin secretory programme [56]. Blimp-
1 itself can be upregulated by multiple signals including cytokines, such as IL-21 [57], and 
TLR ligation and more effectively if these signals are combined with BCR ligation [58]. 
Moreover, cells that have been selected into the plasma cell pool are then allowed to leave 
the GC reaction by way of Blimp-1 induced downregulation of CXCR5 expression [56] and 
upregulation of CXCR4 and CXCR3 resulting in the migration of these cells to the bone 
marrow  or  sites  of  inflammation  [59].  Plasma  cells  migrating  to  the  bone  marrow  can  
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become part of the long-lived (> 1 year) plasma cell compartment creating a source of 
long-lasting  antibody  production  [60].  By  contrast, the  other fate  of  post-GC  cells  is  to 
become  memory  cells  which  are  important  for  the  secondary  response  to  repeated 
encounter with the same pathogen. These cells express high affinity antigen receptors and 
can  rapidly  develop  into  plasma  cells  ensuring  a  fast  response  if  the  same  pathogen 
infects the organism again [61].  
Besides follicular B cells, B-1 cells and MZ B cells can also develop into antibody 
producing  plasma  cells  upon  antigen-stimulation,  usually  providing  a  quicker  response 
than follicular B cells due to the lack of time-consuming selection and mutation processes 
seen in GC reactions [40]. The exact mechanisms leading to development of marginal 
zone and B-1 B cells are not fully elucidated yet, but there has recently been a plethora of 
studies using multiple systems to further dissect these developmental pathways. A major 
contribution to the field has come from Montecino-Rodriguez and co-workers who showed 
the existence of a B-1 B cell specific progenitor which can be found in foetal and adult 
bone marrow [62] (Fig.1.7). These cells are lineage (lin)-negative (negative for markers 
expressed on macrophages, granulocytes, natural killer cells and T cells, as well as IgM
+ B 
cells) and further defined by the expression of CD19, AA4.1 and the lack or low levels of 
CD45R.  Reconstitution experiments  showed  that  they  preferentially  develop into  B-1  B 
cells. This strengthens the hypothesis of two different lineages developing seperately into 
B-1 and B-2 B cells, a theory that has its origin in studies showing that foetal-derived 
progenitors preferably reconstitute the B-1 B cell compartment whereas adult bone marrow 
progenitors are more efficient at reconstitution of the B-2 B cell pool [63,64] which could be 
explained by the higher percentage of CD19
+CD45R
-/low B-1 B cell progenitors in the foetal 
compartment. Further confirmation of the above-mentioned studies has come from Tung et 
al [65] using CD138 and MHC II as additional markers to distinguish between the different 
developmental progenitors. Thus, according to their classification CD138
−, CD138
int, and 
CD138
hi, respectively, CD138 provided a further marker to differentiate the progenitors for 
B-1a, B-1b, and B-2 cells. By contrast, follicular and MZ B cells are thought to derive from 
the same bone marrow derived precursor [66], diverging into two different populations after 
the  T2  stage  of  development,  thus  splenocytes  defined  by  B220
+AA4.1
lowCD21/35
high 
CD23
+ expression are thought to be MZ B cell precursors [67].  
An alternative hypothesis which was favoured before distinct B-1 B cell progenitors 
had been discovered, proposed one common progenitor for both B-1 and B-2 B cells and 
explained the development of separate lineages by differences in antigen-dependent BCR-
signalling. Thus, after encountering certain B-1 B cell-specific antigens, B-2 B cells were 
found to develop a B-1 B cell phenotype [68]. Due to the discovery of specific progenitors,  
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this hypothesis has now been questioned but the general idea that varying strength of 
BCR-antigen interaction influences the development of different B cell subsets still holds 
true suggesting that despite the existence of distinct lineage progenitors, there may be 
plasticity  in  development.  For  example,  it  has  been  shown  that  development  of  B-2 
follicular B cells, MZ or B-1 B cells can depend on the BCR-antigen binding specificity and 
affinity [69]. Thus, in general, in the preferred model, weak BCR-antigen interactions are 
thought to lead to MZ B cell development whereas intermediate and strong interactions 
would  lead  to  follicular  and  B-1  B  cell  development,  respectively  (reviewed  in  [70]). 
Besides BCR-antigen affinity, BCR specificity seems to be important in the B cell selection 
process as shown by preferential selection of weakly autoreactive specificities into the B-1 
and MZ B cell pool [70]. 
 
1.3  B cell tolerance 
 
The  development  and  maturation  of  lymphocytes  is  tightly  regulated  to  ensure 
tolerance against self with B and T cells having to pass through a process called negative 
selection during their early development. In the case of B cells this happens in the bone 
marrow  at  the  immature  B  cell  stage  as  a  high  percentage,  up  to  75%  [71],  of  early 
immature B cells express BCRs that are polyreactive or self-reactive  with high affinity. 
Immature B cells and newly emigrated transitional B cells (see also section 1.2) therefore 
need to react to antigenic stimulation in a different way from mature B cells. Thus cross-
linking of the BCR on immature, but not mature, B cells leads to induction of either anergy 
or apoptosis. Anergy is a state of unresponsiveness in which B cells receiving constant 
signalling through the BCR lose the ability to be activated by antigenic stimulation. Some 
of the features defining anergic B cells include a reduced lifespan and an impaired ability 
to interact with T cells [72]. Anergy therefore silences potentially harmful autoreactive B 
cells preventing their activation. 
However, some self-reactive cells manage to evade negative selection in the bone 
marrow (central tolerance) which has made it necessary for the immune system to evolve 
further checkpoints in the periphery to deal with lower affinity autoreactive B cells (Fig.1.8). 
The mechanisms of peripheral tolerance include induction of anergy [72], downregulation 
of  B  cell  responses  by  inhibitory  receptors  such  as  FcγRIIb  [73]  and  exclusion  of 
autoreactive clones from GC reactions [74]. Moreover, the dependence of the majority of B 
cells  on  a  second  (T  cell-dependent)  signal  to  get  activated  upon  antigen  encounter 
ensures that autoreactive B cells generally do not get activated in the periphery. Thus, if a  
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naïve  mature  B  cell  binds  its  antigen  without  further  cognate  T  cell  help  (CD40 
engagement or cytokine help) it will be rendered unresponsive or undergo apoptosis. 
In  people  with  autoimmune  disease  one  or  more  of  the  tolerance  checkpoints 
mentioned above may be disturbed. For example, it has been shown that exclusion of 
autoreactive clones from the GC reaction is faulty in Systemic lupus erythematosus (SLE) 
patients [75]. Furthermore, analysis of the self- and poly-reactive antibody repertoire in 
SLE  and  Rheumatoid  arthritis  (RA)  patients  indicated  the  disturbance  of  various 
checkpoints in peripheral B cell development, allowing a higher percentage of self-reactive 
clones to escape from selection compared to healthy controls [76]. The implications of 
defects in B cell selection in autoimmune disease will be further discussed in Chapter 4. 
 
1.4  Effector functions of B cells 
 
Recently,  evidence  has  accumulated  that  B  cells  do  not  only  act  as  antibody-
secreting cells. For example, they are effective secondary antigen presenting cells (APC) 
[77] due to their efficient antigen uptake following BCR internalisation. In addition, they can 
also act as effector B cells producing cytokines or indeed, as regulatory cells dampening 
ongoing immune responses. B effector cells were originally thought only to originate from 
follicular  B  cells  rather  than  B-1  or  MZ  B  cells  [78]  as  the  first  reports  indicating  the 
importance of B cell-produced cytokines came from studies showing that development of 
follicles depends on lymphotoxin-α produced by B cells [79]. Similar to TH cells, effector B 
cells can be divided into two subsets, Be-1 and Be-2 B cells: thus, Be-1 cells are induced 
by TH1 cells resulting in IL-12 and IFNγ production by those B cells [80] whereas Be-2 B 
cells develop in a TH2 specific milieu further inducing IL-13 and IL-4 production [80,81]. 
Cytokines produced by these activated Be-1 and Be-2 cells can then in turn influence the 
immune response by further skewing TH cell differentiation towards expansion of TH1 or 
TH2 cells.  
The third functional subset of B effector cells are regulatory B cells (reviewed in [82]). 
Thus, B cells have been shown to be able to regulate auto-inflammatory diseases such as 
inflammatory  bowel  disease,  EAE  (Experimental  autoimmune  encephalomyelitis),  and 
disease models of SLE and RA [82,83]. The regulatory function of these cells in the above-
mentioned studies appears to be IL-10 dependent, but further studies have shown that 
TFGβ-producing  B  cells  might  be  able  to  carry  out  regulatory  functions  as  well  [84]. 
Regulatory  B  cells  cannot  be  detected  in  normal  healthy  individuals  as  they  are  only 
induced upon inflammation and need an inflammatory environment for their development 
[82]. In addition to IL-10 production, such regulatory B cells might have other properties  
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such as the ability to downregulate ongoing T cell responses or recruit T regulatory cells 
via their Ag-presenting capacity. Moreover, antibodies produced by such B cells might help 
clear apoptotic bodies containing potentially dangerous auto-antigens or regulate dendritic 
cells through engagement of various Fc receptors such as the inhibitory receptor FcγRIIb 
[85]. The origin of regulatory B cells is still controversial as all three B cell subsets are 
capable of producing IL-10, with B-1 and MZ B cells being the major producers of this 
cytokine. This led to the hypothesis that most regulatory B cells originate from B-1 or MZ B 
cells  and  transfer  studies  have  confirmed  the  existence  of  regulatory  B  cells  in  these 
subsets  [86,87].  Furthermore,  multiple  studies  have  recently  defined  B  regulatory  cells 
which share features with MZ or MZ-precursor cells [86]. Nevertheless, there is evidence 
that B regulatory cells might also originate from B-2 follicular B cells, as indicated by their 
production of IgG and IgA by these cells rather than the B-1/MZ B cell-associated IgM [82].  
 
1.5  B cell signalling 
 
The Ig component of the BCR is not able to signal per se but rather signals through 
its’  accessory transducing  molecules,  Igα  and Igβ. These  proteins  both  contain  ITAMs 
(immunoreceptor tyrosine-based activation motif) which confer their signalling ability [88]. 
ITAMs comprise an 15-20 amino acid long motif that is defined by two YxxL sequences 
flanking  seven  to  twelve  variable  residues  (YxxLx(7-12)YxxL).  Upon  receptor  stimulation, 
members  of  the  Src-family  of  non-receptor  PTKs  (protein  tyrosine  kinases)  become 
activated enabling them to phosphorylate the tyrosines in the ITAMs [89]. Thus, PTKs like 
Lyn  are  normally  associated  with  the  BCR  in  an  inactive  form  and  unfold  upon  BCR 
stimulation to adopt their active conformation. Once activated they phosphorylate the ITAM 
[90] which enables it to bind SH2 (Src homology 2) domain-containing proteins like Lyn 
itself, Syk, Btk, PLCγ (Phospholipase Cγ), BLNK, Grb2 and Vav all of which play important 
roles in various downstream signalling cascades. Moreover, the number of docking sites 
for SH2 containing transducers is further increased by phosphorylation of adaptor proteins 
like BLNK by Syk.  
B  cells  can  react  in  various  ways  to  BCR  ligation  including  proliferation,  growth 
arrest, apoptosis and differentiation depending on their maturation status, costimulatory or 
regulatory signals, signal strength and duration. It is therefore no surprise that the signal 
cascades activated by BCR ligation are complex involving crosstalk between pathways 
and  differential  recruitment  of  component  isoforms.  Nevertheless,  the  three  major 
pathways  associated  with  BCR  signalling  in  mature  B  cells  are  the  PI3  kinase  
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(phosphoinositide-3-kinase), PLCγ and MAP (mitogen-activated protein) kinase pathways 
[91] (Fig.1.9). 
 
1.5.1  PI3 kinase pathway 
PI3 kinases catalyse the phosphorylation of the inositol lipids like PI, PI-(4)-P and PI-
(4,5)-P2  to  produce  PI-(3)-P,  PI-(3,4)-P2  and  PI-(3,4,5)-P3  (PIP3),  respectively  [92], 
molecules which are normally present in the cell at very low levels and are able to recruit 
SH2 and PH (pleckstrin homology) domain-containing proteins to the membrane where 
they  can  be  activated. PLCγ,  Btk,  Vav,  PDK1/2 (3′-phosphoinositide-dependent  protein 
kinase) and Akt are a few such signalling proteins that can bind to PI-(3,4)-P2 and PI-
(3,4,5)-P3  via  their  SH2  or  PH  domains  [93-96].  PI3  kinases  can  be  divided  into  four 
subclasses: IA, IB, II and III [97]. Of those four, only class IA and IB enzymes were found 
to  be  able  to  produce  PI-(3,4,5)-P3.  Class  IA  PI3  kinases  are  made  up  of  a  catalytic 
(p110α, p110β or p110δ) and a regulatory subunit (p85α, p55α, p50α, p85β, p55γ) and the 
various  isoforms  of  the  regulatory  and  catalytic  subunits  can  bind  to  each  other 
interchangeably  creating  multiple  different  combinations.  The  binding  to  tyrosine-
phosphorylated motifs on receptors such as the BCR is mediated by two SH2 domains 
located in the regulatory subunit [98]. Some of the isoforms of the regulatory subunits 
contain  further  domains  such  as  SH3  and  breakpoint  cluster  region  homology  (BH) 
domains, the latter of which is responsible for the interaction of PI3 kinase with members 
of the Rac and Cdc42 subfamilies [97]. The second class of PI3 kinases able to produce 
PI-(3,4,5)-P3, IB,  so far  only  consists  of  one  family  member  PI3  Kγ,  composed  of  the 
catalytic p110γ and the regulatory p101 subunits. PI3 Kγ appears to be mainly activated 
downstream of G-protein coupled receptors (GPRC) such as chemokine receptors [97]. 
Expression of the p110γ and p110δ subunits is mainly restricted to lymphocytes whereas 
the other class I subunits are ubiquitously expressed. The function of class II and III PI3 
kinases is not as well studied as the class I molecules, but it has been shown that they are 
involved in vesicular trafficking [97]. PI3 kinase inhibitors wortmannin and LY294004 have 
been  useful tools  in  defining  the  role  of  PI3 kinase  in  specific  cellular  processes  [97], 
however, these inhibitors are not isoform-specific and therefore other tools, such as using 
gene targeting in mice, have had to be used to dissect the importance of specific PI3 
kinase isoforms.  
For example, with respect to the regulatory subunits, deletion of p85β indicated a 
negative  regulatory  role  for  this  isoform  in  T  cell  expansion,  as  p85β
-/-  cells  showed 
increased levels of proliferation and were less susceptible to cell death due to CD3 and IL-
2 stimulation [99]. Furthermore, p85β appears to be involved in CD28 signalling in T cells  
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as shown by reduced c-Cbl and Cbl-b downregulation and defective T cell differentiation 
and induction of secondary immune responses in p85β-deficient mice [100]. By contrast, in 
insulin signalling depletion of p85α was found to increase PI3 kinase dependent responses 
[97].  Moreover,  p85α  was found  to  be  involved  in  regulating  separation  of  the  cytosol 
during  fibroblast  cytokinesis  by  way  of  influencing  Cdc42  and  septin-2  activation  and 
localisation,  respectively  [101].  Interestingly,  this  latter  function  of  p85α  seems  to  be 
independent of PI3 kinase activity further increasing the complexity of PI3 kinase signalling 
by showing that regulatory subunits can influence signalling in the absence of dimerisation 
with  a  catalytic  subunit  [101].  The  above  mentioned  studies  have  to  be  interpreted 
carefully  though,  as  the  effects  of  p85  deletion  are  complicated  by  the  role  the  p85 
subunits appear to play in the stabilisation of the p110 catalytic subunits [97]. 
Similarly, there are many studies analysing the effect of genetic deletion or mutation 
of the catalytic subunits. Thus, by introducing an inactivating mutation, the p110δ isoform 
has been shown to be involved in many different cellular processes. For example, p110δ 
was shown to be needed for TH1 and TH2 cell cytokine secretion [102], differentiation of 
TH1 and TH2 cells in vitro as well as clonal expansion and differentiation of T cells in vivo 
[103]. Furthermore, CD4
+CD25
+Foxp3
+ Treg activity was found to be reduced due to lack 
of p110δ [104]. Another catalytic subunit, p110γ, also seems to play an important role in 
the regulation of T cell responses but in this case, p110γ-deficient CD4 and CD8 T cells 
displayed  reduced  ability  to  migrate  to  sites  of  inflammation  in  the  periphery  in  vivo 
[105,106].  Moreover,  during T  cell  development,  deficiency  of  p110γ  leads  to  a partial 
defect in pre-TCR-dependent differentiation inducing a change in the CD4/CD8 T cell ratio 
[107]. T cells are not the only subset of immune cells in which PI3 kinase signalling plays 
an important role. For example, the third catalytic subunit, p110β, seems to play a role in 
macrophage  signalling.  Indeed,  deletion  of  p110β  in  RAW  264.7  cells  increased  LPS-
stimulated inducible nitric oxide (NO) synthase as well as IL-12 expression indicating its 
negative regulatory role in TLR-induced activation of these processes [108]. In addition, it 
was  shown  to  be  required  for  Fcγ  receptor-mediated  phagocytosis  by  primary 
macrophages [109]. Further studies in macrophages showed that p110β, contrary to what 
was  thought  to  that  point,  can  be  coupled  to  GPCR  (stromal  cell-derived  factor, 
sphingosine-1-phosphate and lysophosphatidic acid ligand/receptor interactions) as well 
as tyrosine kinase signalling. Hence, p110β might allow GPCR-linked PI3 kinase signalling 
in cell populations with little or no p110γ expression, the subunit normally activated by 
GPCR signalling [110]. 
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1.5.1.1  PI3 kinases & B cell responses 
A number of studies dissecting the role of specific subunits of the PI3 kinase family 
have  underscored  the  importance  of  this  signalling  cascade  in  B  cell  responses.  To 
analyse the effects of the lack of all three p85α isoforms (p85α, p55α and p50α) triple-
knockout mice deficient for all three isoforms of p85α were created. However, due to the 
premature death of these animals, chimeric RAG-2-deficient mice had to be created to 
study  the  full  impact  of  deletion  of  all  these  regulatory  subunits.  The  lack  of  all  three 
p85α isoforms led to a reduction in peripheral mature B cells and serum antibody levels. 
Furthermore,  the  surviving  B  cells  showed  reduced  responsiveness  to  BCR  or  CD40 
stimulation as well as modulated survival responses upon IL-4 treatment [111]. Similarly, 
mice deficient for p85α, but still expressing the short p85α isoforms p55α and p50α, were 
found to suffer from a severe reduction of transitional and mature follicular, MZ as well as 
CD5
+ peritoneal B cells indicating that p85α is involved in the differentiation of all these 
subsets. Indeed, in p85α-deficient mice, B cell development was found to be arrested at 
the pro-B cell stage. Moreover, the proliferative and T-independent antibody production 
responses  of  the  residual  B  cells  were  inhibited  [112]  suggesting  that  lack  of  p85α 
expression can not be compensated for by its shorter isoforms p55α and p50α.  
Consistent with these findings, the catalytic p110δ subunit seems to be especially 
important  in  B  cell  biology  as  p110δ-deficient  animals  were  also  found  to  display  a 
reduction of follicular B cell numbers, due to a block in pro-B cell differentiation, as well as 
a lack of B-1 B cells. As with the regulatory mutants, the remainder of peripheral B cells in 
these p110δ deficient mice are characterised by reduced BCR-mediated Ca
2+ signalling 
and proliferative capacity and in vivo the germinal centre reaction and responses to both 
T-dependent  and  T-independent  antigens  are  severely  compromised  [113].  Moreover, 
expression of a dominant negative catalytically inactive form of p110δ leads to impaired B 
and T cell responses due to reduced antigen receptor signalling [114]. It was proposed 
that besides the primary effects of lack of p110δ on T cell signalling, such T cell responses 
might be downregulated due to a defect of B cell-mediated antigen presentation. Indeed, 
although B cells expressing the inactive form of p110δ were as effective at BCR-mediated 
antigen uptake as the wild-type (WT) cells, the mutant cells did show a marked defect in 
their ability to stimulate T cells. Thus, p110δ B cells presented lower levels of antigenic 
peptide-MHCII complexes on their surface leading to impaired F-actin polarisation at the T 
cell-interaction site and thereby hampering the effective interaction of B and T cells [115]. 
Further studies also showed that lack of p110δ diminishes chemotactic responses of B 
cells, particularly those to CXCL13, thereby reducing the migration to Peyer’s patches and 
splenic white pulp cords [116]. Altered migration of B cells could therefore also influence  
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immune responses by inhibiting correct homing of cells to inflammatory sites or sites of B 
and T cell interaction important for initiation of an effective response. 
 
1.5.1.2  PI3 kinases & B cell signalling 
BCR  ligation  rapidly  triggers  PI3  kinase  activation  [97].  Multiple  studies  have 
indicated that Syk is important in such BCR-mediated activation of PI3 kinase in that this 
tyrosine kinase phosphorylates CD19 and the adaptor protein B-cell PI3 kinase adaptor 
(BCAP) on tyrosine in the right context for PI3 kinase binding [98]. In addition, another 
Syk-dependent mechanism of PI3 kinase activation involves the phosphorylation of Cbl 
and  the  downstream  recruitment  and  activation  of  PI3  kinase  due  to  a  Cbl-induced 
conformational change of the p85 subunit [117]. However, PI3 kinases IA and IB can also 
be activated by Ras, potentially via allosteric modulation or reorientation of the PI3 kinase 
[118]  and  another  Syk-independent  mechanism  for  the  activation  of  PI3  kinase  might 
involve  Vav3-dependent  activation  of  Rac1  which  in  turn  increases  the  activity  of  PI3 
kinase [119].  
One  of the  major  downstream  effectors  of PI3 kinase signalling  in  B  cells  is  Btk 
which  can  be  recruited  to  the  plasma  membrane  via  its’  PH  domain  by  PI-(3,4,5)-P3 
produced by PI3 kinase (Fig.1.9). Activation of Btk is achieved by autophosphorylation of 
two regulatory tyrosines as well as phosphorylation by Lyn [120,121] and this is dependent 
on p110δ activity as p110δ-deficient B cells display reduced phosphorylation of Btk [122]. 
Recruitment of Btk is important for the induction of the PLCγ2 signalling pathway which in 
turn leads to production of Inositol-(1,4,5)-triphosphate (IP3) and diacylglycerol (DAG) and 
consequent  Ca
2+  and  protein  kinase  C  (PKC)  signalling.  PI-(3,4,5)-P3  produced  by  PI3 
kinase plays additional roles in the activation of PLCγ2 by mediating its translocation to the 
membrane and thereby into close proximity to Btk, as well as ehancing PLCγ2 activity in 
an  SH2  domain-dependent  fashion  [123,124].  Consistent  with  these  findings,  p110δ-
deficient B cells displayed impaired IP3 production, emphasising the importance of PI3 
kinase in maximal PLCγ2 activation [122]. 
The other major downstream outcome of PI3 kinase signalling in B cells is activation 
of PKB (protein kinase B)/Akt which predominantly acts to promote cell survival. The initial 
step in this cascade is the recruitment of PDK1 to the membrane via its PH domain [95]. 
The exact mechanism for activation of PDK1 is not known, but autophosphorylation is the 
most likely event. PDK1 is needed for the phosphorylation of PKB/Akt on threonine 308 
[125]. However, phosphorylation at this single residue is not sufficient for full activation as 
further phosphorylation on serine 473 was shown to be crucial for optimal PKB/Akt activity. 
The enzyme carrying out this modification has not been identified yet, but there are some  
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candidates such as mTOR (mammalian target of rapamycin), ILK (integrin-linked kinase) 
or even PKB/Akt itself by autophosphorylation [126].  
Although fully activated PKB/Akt transduces several cellular responses, the major 
functional outcome is enhancement of survival. For example, PKB/Akt inhibits activation of 
the executioner apoptotic protease caspase 9 and regulates forkhead-related transcription 
factors  [127]. These  transcription factors  are  involved  in  the  regulation  of many  genes 
associated with cell survival such that by regulating forkhead-related transcription factors, 
PKB/Akt is therefore able to suppress expression of Bim and Puma, two pro-apoptotic 
BH3-only proteins [126]. Moreover, PKB/Akt can phosphorylate the pro-apoptotic Bad at 
serine 136 initiating Bad’s association with 14-3-3 proteins and thereby its’ sequestration 
from  the  mitochondria  and  inactivation.  Another  pro-apoptotic  Bcl-2-family  member 
regulated by PKB/Akt is Bax which gets phosphorylated at an inhibitory site by PKB/Akt 
[128].  PKB/Akt  does  not  only  inhibit  pro-apoptotic  mechanisms  as  it  also  upregulates 
pathways  inducing  expression  of  survival  factors  such  as  the  NF-κB  pathway.  For 
example,  PKB/Akt  activates  IKKα,  one  of  the  kinases  that  phosphorylate  IκB  thereby 
leading to the targeting of IκB for degradation [129] and releasing the suppression of NF-
κB which in turn is then able to upregulate the expression of Bcl-xL, a pro-survival member 
of the Bcl-2-family. Moreover, recruitment of PKCζ to the plasma membrane via its PH 
domain is potentially another mechanism linking PI3 kinase, via creation of PH domain 
docking sites, to B cell survival via activation of NF-κB. Once recruited to the membrane 
PKCζ gets activated by Ras [130] allowing it to phosphorylate NF-κB thereby enhancing its 
transcriptional activity [131]. 
 
1.5.2  PLCγ pathway 
PLCγ is recruited to the BCR by phosphorylated BLNK bringing it into close proximity 
with  Btk  and  Syk  leading  to  its  phosphorylation  and  activation  and  subsequent 
downstream  signalling  [132].  Translocation  of  PLCγ  to  the  plasma  membrane  is  also 
required to bring it into close proximity to its substrate PI-(4,5)-P2 which it converts to the 
important second messengers diacylglycerol (DAG) and Inositol-(1,4,5)-triphosphate (IP3). 
IP3 binds to IP3-receptors on the endoplasmic reticulum leading to release of intracellular 
calcium followed by entry of extracellular calcium [132] thereby activating calcium sensitive 
molecules such as calcineurin, protein kinase C isoforms (the conventional isoforms α, β, 
γ) as well as JNK (c-Jun NH2-terminal kinase) [133]. IP3 binding to its receptors on the 
endoplasmic reticulum can further affect the localisation of molecules like Bcl-2 [134] and 
the activation of enzymes like PLA2 [135], calpain [136] and protein kinase II. Likewise,  
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DAG is needed for the activation of all phorbol ester-sensitive isoforms of PKCs (α, β, γ, δ, 
ε, η, θ) [137] (Fig.1.9).  
Thus,  the  family  of  PKC  enzymes  represent  the  major  downstream  effectors 
activated  by  PLCγ  signalling.  PKCs  have  been  shown  to  play  diverse  roles  in  B  cells 
ranging  from  the  induction  of  proliferation  to  initiation  of  apoptosis,  depending  on  the 
specific isoform and the developmental stage of the B cell involved. As indicated above, 
PKCs are dividided into three subtypes – the classical PKCs (α, β1, β2, γ), the novel PKCs 
(δ, ε, η, θ) and the atypical PKCs (ξ, λ, τ). The classical PKCs depend on Ca
2+ as well as 
DAG for their activation whereas novel PKCs are regulated by DAG and the atypical PKCs 
need neither Ca
2+ nor DAG for their activation [137]. B cells express many of these PKC 
isoforms (α, β, δ, ε, η, ξ, λ) and all of these have been shown to be recruited and activated 
downstream of BCR-ligation [138]. Due to the availability of isoform-specific PKC-deficient 
animals the importance of the different isoforms has been addressed, but PKCβ and PKCδ 
are the best-studied PKC isoforms in B cells. Thus, analysis of PKCβ knock-out animals 
indicated that this isoform is important in B cell responses as such mice displayed reduced 
numbers of B cells in the periphery, a complete lack of B-1 B cells and reduced antibody 
responses [139]. The defect in PKCβ knock-out B cells has been identified as an inability 
to activate NF-κB signalling downstream of the BCR, consistent with findings that NF-κB is 
a crucial transcription factor involved in the activation of genes involved in survival and 
activation of B cells by e.g. increasing the expression of anti-apoptotic molecules like Bcl-
xL and Bcl-2 [131,140]. The reduction of NF-κB activation in PKCβ-deficient B cells is due 
to the requirement of PKCβ for the efficient recruitment of IKK to the plasma membrane. 
As  mentioned  before,  IKKβ  activation  is  needed  for  the  phosphorylation-mediated 
degradation of IκB and consequential release of NF-κB. The exact mechanism of how 
PKCβ-mediated localisation of IKKβ to the plasma membrane initiates its phophorylation is 
not known yet, but recent findings have implicated BCL10, MALT1 and Carma1 in the 
connection of PKC and NF-κB signalling, making them interesting candidates [138]. Unlike 
PKCβ,  the  novel  PKC  isoform  PKCδ  does  not  appear  to  transduce  activatory  signals 
downstream of the BCR, but rather, it appears to be an important mediator of negative 
regulation of B cells, as indicated by hyper B cell expansion and progressive development 
of an autoimmune phenotype in PKCδ deficient mice [141]. This autoimmune phenotype 
seems to be caused by a severe impairment of peripheral tolerance in these mice [141]. 
Although,  the  functional  effectors  of  PKCδ  in  B  cell  signalling  responsible  for  this 
phenotype  have  not  yet  been  elucidated,  modulation  of  NF-κB  does  not  appear  to  be 
involved.  By  contrast,  it  has  been  proposed  that  negative  regulation  of  IL-6  by  PKCδ-
mediated mechanisms may be responsible for this phenotype [138] as IL-6 is an important  
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B cell differentiation factor supporting the germinal center reaction and development of 
isotype-switched B cell clones [142]. Changes of IL-6 expression due to lack of inhibition 
by PKCδ could therefore induce de-regulated B cell differentiation and expansion. 
 
1.5.3  The MAP kinase (MAPK) pathway  
MAP kinase (mitogen activated protein kinase) is the generic term for a family of 
serine-threonine protein kinases which can be subdivided into three distinct groups. The 
ErkMAP  kinases  (extracellular  signal-regulated  kinase),  the  c-Jun  N-terminal  kinases 
(JNK) and  the  p38  MAP  kinases all  play  roles  in  B  cell  signalling (reviewed  in  [143]). 
Generally,  ERK  MAPKs  have  been  classified  as  being  activated  by  growth  factor 
stimulation, whereas JNK and p38 are considered to be responsive to stress stimuli such 
as osmotic shock and radiation as well as cytokines [144]. Nevertheless, all of the MAPKs 
get activated by phosphorylation of their tyrosine/threonine activation motif, which differs 
between the subfamilies. For example, ERK1/2 share a TEY motif in their activation loop 
whereas the JNK and p38 family of MAP kinases are activated upon phosphorylation of 
their  TPY  or  TGY  motif,  respectively.  This  phosphorylation  is  carried  out  by  specific 
tyrosine-threonine kinases called MAPKK (MAPK kinase) or MEK which themselves are 
activated  by  a  family  of  serine-threonine  kinases  generically  termed  MAPKKK  (MAPK 
kinase kinase) or MEKK. Upstream activation of GTPases (guanine triphosphatases) like 
Ras or Rap-1, which are able to activate MAPKKK, in this way initiates the appropriate 
MAPK pathways (Fig.1.10). Another family of GTPases involved in MAPK activation are 
the  Rho-GTPases  (e.g.  Rac,  RhoA,  Cdc42).  The  guanine  nucleotide  exchange  factor 
(GEF) for those GTPases is Vav which can be recruited to the BCR by BLNK [145]. Rac1 
and Cdc42 have been shown to be involved in MAPK activation, especially the JNK and 
p38 pathways [146] by activating MEKK-1, MEK4 and MEK7 [147]. Once activated, the 
three  sub-classes  of  MAPKs  can  phosphorylate  various  different  substrates  including 
phospholipases, cytoskeletal proteins and transcription factors as well as the MK (MAPK 
activated protein kinases) family of proteins (formerly known as MAPKAP kinases) [143].  
 
1.5.3.1  The ERK1/ERK2 MAP kinase pathway 
ERK1/2 are ubiquitiously expressed at varying levels in different tissues and cells, 
with  multiple  stimuli  activating  the  ERK1/2  cascade  such  as  serum,  growth  factors, 
cytokines, stress as well as some ligands for G protein-coupled receptors (GPCRs) [144]. 
Initiation of signalling by these stimuli leads to activation of small GTP-binding proteins 
such as Ras or Rap followed by activation of ERK1/2-specific MAPKKK, such as various 
Raf isoforms, Mos, MEKK1-3 and Tpl-2 [148]. Thus, following BCR ligation, ERK can be  
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activated in a Ras and Raf-1-dependent manner. Firstly, the adaptor transducer, Shc is 
recruited  to  the  phosphorylated  ITAMs  of  Igα/Igβ  where  upon  Syk-mediated 
phosphorylation, Shc is able to recruit Grb2-Sos complexes [149] (Fig.1.9). Sos is a GEF 
which catalyses the exchange of GDP for GTP on Ras leading to its activation. Similarly, 
BLNK is another adaptor protein that is able to recruit the Grb2-Sos complex therefore 
representing an additional pathway of Ras activation other than via Shc recruitment [150]. 
The  next  step  in  the  signalling  cascade  is  the  derepression  of  Raf  by  activated  Ras 
thereby inducing its kinase activity [151]. The targets of Raf, and other ERK1/2 specific-
MAPKKKs, are MEK1 and 2 [152,153], dual-specific threonine/tyrosine kinases, which are 
in turn activated by phosphorylation of two serine or threonine residues in their activation 
loop [148]. MEK1/2 then activates ERK1/2 by phosphorylation of the TEY motif thereby 
allowing ERK1/2 to phosphorylate and activate its relevant downstream targets which have 
been shown to include signal transducers such as protein kinases like RSK1-3 (90 kD 
ribosomal  S6  kinase),  MAPKAPkinase-2,  or  MAP  kinase-interacting  kinase  (Mnk)  1/2, 
membrane or cytoplasmic proteins such as cytosolic phospholipase A2 (cPLA2), Ral-GDS 
(Ral-guanine nucleotide dissociation stimulator) or heat shock factor transcription factor 1 
(hsp1)  as  well  as  the  transcription  factors  c-Jun,  c-Fos,  ATF-2  and  Elk-1  (reviewed  in 
[144]). A more in depth overview of the relevance of ERK MAP kinase signalling in B cells 
can be found in Chapter 3.  
 
1.5.3.2  The p38 MAP kinase pathway 
The p38 MAP kinase family consists of the four related proteins p38α, p38β, p38γ 
(formerly  ERK6  or  SAPK3)  and  p38δ  (SAPK4).  Like  the  other  members  of  the  MAPK 
family, p38 molecules are activated downstream of a kinase cascade consisting of several 
MAPKKKs such as MEKK1-4, MLK2/3 (mixed lineage kinase), DLK (dual leucine zipper-
bearing  kinase),  ASK1  (activator  of  S-phase  kinase),  Tpl2  and  Tak1  (TGFβ-activated 
kinase 1), which in turn activate MAPKK such as MEK3 and 6, as well as MEK4. MEK3 
and 6 specifically activate p38 whereas MEK4 is able to phosphorylate and activate p38 
and JNK [154]. Some of the known targets of p38 are cPLA2, p53, the transcription factors 
ATF1,  EF2A,  Elk-1,  NF-κB  and  Ets-1  as  well  as  MKs  such  as  MSK1/2  (mitogen-  and 
stress-activated protein kinase), MNK1/2, and MK2/3 [143]. p38 plays a critical role in the 
regulation  of  immunity  as  exemplified  by  the  fact  that  p38  is  activated  downstream  of 
inflammatory mediators such as cytokines, chemokines or LPS [155]. Furthermore, it is 
involved in the regulation of T cell differentiation and apoptosis as well as many functional 
responses  in  macrophages  and  neutrophils  such  as  respiratory  burst  and  chemotaxis 
[155]. By contrast, in B cells p38 does not seem to play such an important role as the  
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major  MAPK  activated  by  BCR  signalling  appears  to  be  ERK.  Nevertheless,  p38  is 
involved in signalling pathways initiated by the ligation of other important receptors on B 
cells  such  as  CD40,  IL-4  receptor  or  BAFF  receptor.  Thus,  in  the  case  of  CD40  p38 
activation seems to be mediated downstream by NF-κB, whereas p38 signalling via the IL-
4 receptor is mediated by STAT6 (signal transducer and activator of transcription 6) [156]. 
IL-4 together with CD40 stimulates the proliferation of B cells and induces the expression 
of MHC II as well as class-switching to IgG1 and IgE [156]. Thus, p38 plays an important 
role in regulating in TH2-type humoral immune responses. 
 
1.5.3.3  The JNK MAP kinase pathway 
The  JNK  family  of  proteins  consists  of  three  isoforms  –  JNK1,  JNK2  and  JNK3 
however, due to alternative splicing mechanisms these three isoforms yield a total of 12 
different possible JNK proteins [157]. Similarly to the above-described pathways for ERK 
and  p38  activation,  JNK  is  also  activated  by  consecutive  phosphorylation  of  upstream 
MAPKKKs and MAPKKs. Some of the known MAPKKKs for JNK are MEKK1-4, MLK1-3, 
DLK,  Tpl2,  ASK  and  Tak  which  phosphorylate  MEK4  and  MEK7  [158].  The  exact 
mechanisms activating the MAPKKKs are not fully elucidated yet, but adaptor proteins 
such as Crk or TRAFs (TNF-receptor associated factor), as well as small GTP-binding 
proteins like Rho appear to be involved [159]. One of the major substrates of JNK is the 
molecule  that  gave  it  its  name,  c-Jun  which  together  with  c-Fos  forms  the  active 
transcription  factor  AP-1.  JNK  phosphorylates  c-Jun  thereby  increasing  its  activity  and 
possibly also its stability [160,161]. Further targets of JNK include the transcription factors 
ATF-2, Elk-1, p53 and NFAT4 and the anti-apoptotic molecule Bcl-xL [159]. The functional 
outcome  of  JNK  activity  varies  depending  on  numerous  factors  such  as  cell  type  and 
activation of other signalling cascades. For example, JNK has been implicated in induction 
of  apoptosis  [162]  as  well  as  survival  [163],  depending  on  the  cell  type  and  context. 
Indeed, in the human B cell line B104 it was shown to be linked to apoptosis
 downstream 
of  BCR  ligation  [164]  whereas  it  was  found  to  be  activated  downstream  of  positive 
signalling  in  naïve  B  cells  [165].  Similarly,  whilst  JNK  was  found  to  be  activated  by 
apoptotic  signalling  via  the  BCR  in  the  murine  immature  B  cell  line  WEHI-231,  JNK 
activation  was  more  pronounced  downstream of  CD40-mediated rescue signal  in  such 
cells  [166]. As the functional  outcome  of JNK  activation  in  these  experiments was  not 
always analysed, these studies left unanswered questions about the function of JNK in B 
cells some of which have since been addressed by animal models using mice deficient for 
JNK or its upstream regulators. For example, studies using T cells from JNK-deficient mice 
indicated that this kinase is not necessary for effective IL-2 production or proliferation; on  
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the  contrary,  lack  of  JNK  actually  increased  the  levels  of  IL-2  and  proliferation.  JNK 
however was found to be necessary for the production of the TH1 effector cytokine IFNγ 
and JNK-deficiency consequently impaired the TH1 differentiation of T cells in vitro due to 
the lack of IFNγ-mediated suppression of TH2 differentiating cytokines [167]. By contrast, T 
cells  lacking  MEK4,  the  upstream  activator  of  JNK,  but  potentially  also  that  of  p38, 
displayed impaired proliferation upon CD28 costimulation [168]. Moreover, MEK7-deficient 
T  and  B  cells  showed  increased  proliferation  downstream  of  growth  factor  or  antigen-
receptor  stimulation  [169].  These  studies  therefore  emphasise  the  complexity  of  JNK 
signalling and its’ multiple roles in T and B cell signalling and demonstrate the need for 
further investigation to reconcile the contradictory results. 
 
1.5.4  Integration of signalling cascades 
The major signalling cascades utilised by B cells downstream of the BCR are not 
simply activated in a linear fashion but interact at many levels, regulating each other by 
cross-talk. Thus, activation of Ras downstream of the BCR can activate ERK [170] and PI3 
kinase signalling [171]. Interestingly, these two pathways seem to be further connected at 
several additional levels. For example, PI3 kinase can positively and negatively regulate 
the  Ras/Raf  cascade.  Thus,  PI3  kinase  can  potentially  activate  Raf  through  a  p21-
activated  kinase  (PAK)-dependent  mechanism  thereby  influencing  ERK  activation 
downstream of Raf [172] whilst on the other hand PI3 kinase can inhibit ERK signalling by 
inducing  the  phosphorylation  of  Raf  in  an Akt-dependent  manner  [173]. Moreover,  PI3 
kinase itself can be negatively regulated by ERK-mediated phosphorylation of GAB1 [174], 
thereby potentially connecting these two pathways by a complex series of positive and 
negative feedback loops. In addition, PKCξ is recruited via its PH domain to the plasma 
membrane where it gets activated by Ras [130] and then phosphorylates NF-κB, thereby 
enhancing  its  transcriptional  activity  [131].  Further  emphasising  the  link  between  PI3 
kinase  and  survival,  PLCγ2  is  another  major  signalling  pathway  downstream  of  BCR-
ligation and it is also connected to both the PI3 kinase and ERK cascades. Thus, it has 
been  shown  in  various  studies  that full  initiation  of  calcium  signalling  depends  on  PI3 
kinase activity [94]. As mentioned before, this partial dependency of PLCγ2 activation on 
PI3 kinase is due to the recruitment of Btk to the plasma membrane by PI-(3,4,5)-P3 via its 
PH domain [122]. The ERK cascade is also linked to PLCγ2 as evidenced by the finding 
that deletion of PLCγ2 downregulates ERK activation [175]. One potential point of signal 
integration  between  ERK  and  PLCγ2  could  be  the  activation  of  PKCβ2  and  PKCθ  by 
PLCγ2-dependent  mechanisms  such  as  production  of  DAG  and  initiation  of  calcium 
signalling.  This  is  because  PKCβ2  and  PKCθ  have  recently  been  implicated  in  
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phosphorylation and activation of RasGRP3, a GEF for Ras. Furthermore, RasGRP3 itself 
can be activated by DAG-binding, challenging the typical linear model of PLCγ2 activation 
followed  by  production  of  DAG  and  activation  of  PKC  and  its  downstream  targets. 
Therefore, RasGRP3 activation, through downstream activation of Ras, potentially links 
DAG production, PKC activation and the ERK pathway [176].  
A major integrative junction of BCR signalling lies in the regulation of transcription 
factors as evidenced by reports that the three major signalling pathways activated by the 
BCR are all involved in the regulation of various transcription factors such as Elk-1, ATF, 
NF-κB, NFAT and AP-1. For example, NF-κB is an important transcription factor in B cells 
as  it  regulates  survival  and  studies  using  various  different  knock-out  mice for  relevant 
signalling molecules such as the PI3 kinase subunit p85α, Btk, BLNK, PLCγ all showed 
impaired activation of NF-κB indicating that optimal activation of NF-κB requires both PI3 
kinase and PLCγ signalling [131,177]. Similarly, AP-1 is another important transcription 
factor  which  is  regulated  by  more  than  one  BCR-dependent  signalling  cascade.  For 
example, AP-1 comprises a family of transcription factors consisting of dimers comprising 
various  combinations  of  two  subunits  of  the  Jun,  Fos  and  ATF  family  of  proteins. 
Depending on the precise subunits, AP-1 dimers can induce various cellular responses 
such as proliferation or apoptosis. Thus, in B cells it was shown that both JNK and ERK 
are needed for AP-1 dependent transcription of miR-155, and its primary transcript, B-cell 
integration cluster (BIC) which is involved in B-cell maturation and antibody production in 
response to antigen [178,179]. Moreover, AP-1 dependent upregulation of the cyclin D 
levels  necessary  for  survival  and  proliferation  requires  integrated  signalling  via  several 
transcription factors in B cells. This is because c-Jun which regulates expression of cyclin 
D1, is itself regulated by stable Jun/Fos AP-1 dimers, which are promoted by the ability of 
ERK to induce Fos upregulation via activation of Elk-1 [178]. Elk-1 is a member of the Ets 
family of transcription factors which can be regulated by all three MAPK cascades as well 
as calcium signalling [180]. Thus, phosphorylation of Elk-1 by ERK, JNK or p38 leads to 
the activation of Elk-1 which in turn can regulate the expression of its target genes such as 
c-Fos [180] which is able to regulate c-Jun expression, emphasising the complexity and 
the multiple levels of signal integration downstream of the BCR. 
 
1.5.5  Co-receptors on B cells  
The BCR is not the only receptor regulating B cell activity. B cells express additional 
receptors such as CD19, CD40 and FcγRIIb which can positively or negatively influence 
the function and outcome of signalling by modulating signalling thresholds downstream of 
the BCR.  
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1.5.5.1  CD19 
CD19 is a transmembrane glycoprotein that is expressed by B cells from the early 
pre-B  cell  stage  onwards  until  it  is  downregulated  upon  plasma  cell  differentiation 
[181,182]. During follicular B cell development, upregulation of CD19 can be detected at 
the mature B cell stage and B-1 B cells generally express higher levels of CD19 relative to 
follicular B cells [182]. Although CD19 levels seem to be developmentally regulated they 
do not however seem to be influenced by activation by stimuli such as LPS, anti-IgM or IL-
4 [181,183]. On the surface of B cells, CD19 can be found in a complex with CD21 and 
CD81 (Fig.1.11) and this complex is an important mediator of B cell activation, as CD19-
deficient  B  cells  display  reduced  activation  upon  BCR  ligation.  This  is  because  the 
CD19/CD21(CR2)/CD81 complex binds to soluble fragments of complement proteins such 
as C3b and C3d which bind to pathogen surfaces. Thus, B cells expressing BCR specific 
for antigens of such pathogens can be activated by the simultaneous binding of antigen to 
the  BCR  and  engagement  of  the  CD19  co-receptor  complex  through  binding  of  C3 
fragments  [184].  Thus,  although  development  of  B  cells  per  se  does  not  seem  to  be 
affected by lack of CD19, B cell proliferation, expansion and differentiation are severely 
compromised in CD19-deficient mice. Furthermore, the humoral response and germinal 
centre  formation  in  CD19-deficient  mice  is  reduced  as  well  [182,185,186]  due  to  the 
increased signalling threshold in the absence of CD19-signalling. Costimulation of B cells 
by  BCR  and  CD19  due  to  the  presence  of  complement-targeted  pathogens  therefore 
provides a mechanism for enhancing B cell responses.  
Signalling  downstream  of  CD19  is  initiated  by  Lyn-mediated  phosphorylation  of 
tyrosines in its’ cytoplamic tail which creates SH2 binding sites allowing the recruitment 
and  activation  of  various  signalling  molecules  [187]  such  as  Lyn  (and  other 
phosphotyrosine  kinases),  the  GEF  protein  Vav  as  well  as  the  PI3  kinase  regulatory 
subunit  p85.  CD19  activation  thereby  amplifies  the  signalling  initiated  by  BCR  by 
enhancing activation of PLCγ2 by PTKs [187], the PI3 kinase pathway by localising p85 to 
the membrane [188] and recruitment of Vav [189] to potentially activate MAPK pathways 
via Rac1 or Cdc42. Moreover, such Vav-dependent activation of Rho can also stimulate 
phosphatidylinositol-4-phosphate-5-kinase which produces PI-(4,5)-P2 thereby maintaining 
the levels of substrate required for prolonged PLCγ activation [89].  
 
1.5.5.2  CD40 
CD40 is a glycoprotein expressed not only by B cells but also by dendritic cells and 
monocytes as well as endothelial and epithelial cells [190]. Its ligand, CD154 (CD40L) is  
  26 
mainly expressed on activated TH cells, but it is also found on a small population of CTL 
cells, γδ T cells as well as mast cells, basophils and eosinophils. Furthermore, CD40L 
expression can be induced in B cells, NK cells, macrophages and dendritic cells under 
certain conditions, for example on phorbol ester/ionomycin-stimulated human B cells [190]. 
The important role of CD40-CD40L interaction was originally perceived due to studies in 
humans showing that the immune deficiency X-linked hyper-IgM syndrome can be caused 
by  mutations  in  the  gene  encoding  CD40L.  Patients  suffering  from  X-linked  hyper-IgM 
syndrome  display  elevated  levels  of  IgM  in  their  circulation  accompanied  by  reduced 
expression of class-switched isotypes such as IgG [191]. Further confirmation came from 
animal models with induced mutations or deletions of the CD40 or CD40L gene, showing 
similar deficient immune responses as seen in humans [190]. These deficiencies reflect 
that CD40 plays a pivotal role in B cells by activating their proliferation, differentiation and 
antibody production as well as rescuing B cells from apoptosis. It is involved in induction of 
class-switching,  selection  and  maturation  of  memory  cells  and  can  regulate  the 
differentiation of plasma cells [190].  
CD40 is part of the TNF-receptor-family and signals through TRAFs. Several TRAFs 
(TRAF  1,  2,  3,  5  and  6)  as  well  as  JAK3  have  been  found  to  associate  with  CD40. 
Recruitment  and  activation  of  the  different  TRAF  molecules  initiates  varying  signalling 
outcomes such as activation of NF-κB, PI3 kinase, MAPKs and PLCγ2 [192] (Fig.1.12). 
Thus,  TRAF2  is  involved  in  activation  of  NF-κB  [193],  whereas  TRAF6  links  to  ERK 
activation in both a Ras-dependent and -independent manner [194]. TRAF3, on the other 
hand, has been found to be important both for p38 and JNK activation downstream of 
CD40 in a human B cell line [195]. CD40 signalling is generally considered to be important 
for  regulating  survival  and  proliferation  of  B  cells  although  it  can  transduce  apoptotic 
signals in some human B cell lymphoma cell lines. Consistent with this, it induces the NF-
κB-dependent upregulation of anti-apoptotic Bcl-2 family members such as Bcl-xL and Bcl-
2, thereby inhibiting the induction of apoptosis and actively promoting cell cycle progress 
by reducing the levels of the Cdk inhibitor, p27. Moreover, the expression and activation of 
Cdk4 (cyclin-dependent kinase) and Cdk6 are upregulated by CD40 signalling allowing 
cells to escape growth arrest from G1 and drive entry into S phase. c-Myc, another NF-κB-
regulated  protein,  has  also  been  shown  to  be  upregulated  upon  CD40  ligation  further 
supporting its role in promoting cell cycle progression [196]. Additionally, NF-κB-dependent 
upregulation  of  FLIP  (FLICE-like  inhibitory  protein),  an  inhibitor  of  apoptosis,  further 
strengthens the “survival” programme induced by CD40 [197]. 
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1.5.5.3  FcγRIIb 
FcγRIIb is a low affinity receptor for the Fc portion of IgG. Cross-linking the BCR and 
FcγRIIb  inhibits BCR-mediated  activation  and  proliferation of  B cells by  inhibiting  BCR 
coupling to calcium mobilisation, Akt and MAPK activation [73]. This inhibitory mechanism, 
which reflects cognate immune complex-mediated co-ligation of the BCR and FcγRIIb, is 
widely believed to be important in the homeostatic regulation of B cell responses as it 
ensures that B cell responses are switched off as soon as enough antibodies to deal with 
the pathogen are circulating. That such FcγRIIb-mediated signalling is important in the 
downregulation  of  cognate  antibody  responses  was  finally  proven  with  the  analysis  of 
FcγRIIb  knockout  mice  which  showed  augmented  antibody  production  in  reaction  to 
immunisation with immune complexes when compared to FcγRIIb-expressing mice [198]. 
FcγRIIb belongs to the family of Fcγ receptors which bind to the Fc portion of IgG. In 
the murine system there are four classes of Fcγ receptors: FcγRI, FcγRII, FcγRIII and 
FcγRIV. These different sub-classes of Fcγ differ in their binding affinities. For example, 
FcγRIV  preferentially  binds IgG2b  whereas  FcγRIIb  has  highest affinity for IgG1  [199]. 
FcγRI is a high affinity receptor whereas FcγRIIa and FcγRIIIa are of lower affinity and 
only able to bind IgG if it is present in immune complexes [199] (Table 1.1). FcγRIIb is 
widely expressed on cells such as macrophages, neutrophils and mast cells but it is the 
only Fcγ receptor expressed on murine B cells [199]. Recently, there have been studies 
postulating expression of FcγRIIa, an activating Fcγ receptor containing an ITAM, on the 
surface of peripheral human B cells and B leukemia cells [200,201]. However, as detection 
was carried out with antibodies against the extracellular domain, which is very similar in 
FcγRIIa and FcγRIIb, these proposed findings have still to be confirmed. 
Whilst most other Fcγ receptors stimulate activating signals, FcγRIIb is an inhibitory 
receptor, both in humans and in mice. FcγRIIb comprises a single chain glycoprotein that 
contains an immuno-receptor tyrosine based inhibition motif (ITIM) domain, defined by the 
consensus sequence I/V/L/SxYxxL/V, in its cytoplasmic tail. This ITIM was shown to be 
indispensable  for  the  inhibitory  function  of  FcγRIIb,  which  is  dependent  on  the 
phosphorylation  of  the  ITIM-tyrosine  upon  BCR/FcγRIIb  co-ligation.  Recently  however, 
new  evidence  has  suggested  that  there  is  a  second  docking  motif  which  might  be 
necessary for recruitment of the 5’ inositol phosphatase SHIP (SH2 domain containing 
inositol  5’  phosphatase),  the  key  molecule  required  for  FcγRIIb-mediated  negative 
signalling. This motif is located in the C-terminal region of FcγRIIb and also needs to be 
tyrosine-phosphorylated  to  be  activated.  This  motif  does  not  directly  bind  SHIP,  but 
recruits the adapter molecules Grb2 and Grap (Grb2-like
 accessory protein) which help 
stabilise  the  binding  between  SHIP  and  the  ITIM  [202].  Human  B  cells  also  express  
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FcγRIIb which like the mouse homologue, recruits SHIP upon tyrosine-phosphorylation of 
its ITIM. Moreover, and again similar to the mouse receptor, the C-terminal region is also 
needed  to  ensure  optimal  SHIP  phosphorylation  and  activation  although  the  phospho-
tyrosine-motif has not been detected in the human receptor [203].  
At the proximal signalling level the co-ligation of BCR and FcγRIIb induces Lyn to 
tyrosine-phosphorylate  the  ITIM  in  the  cytoplasmic  portion  of  FcγRIIb  (Fig.1.13).  The 
importance of Lyn in this process is supported by studies showing that knocking-out Lyn in 
mice increases BCR-mediated induction of MAPK cascades and proliferation [204]. The 
main signal transducer recruited to the phosphorylated ITIM is SHIP and, as stated above, 
this was found to be indispensable for negative regulation carried out by FcγRIIb [205]. 
SHIP  signalling  affects  PI3  kinase,  Ras-ERK  MAP  kinase  and  calcium-dependent 
signalling [206,207]. For example, the downregulation of PI3 kinase activated signalling 
cascades  by  SHIP  is  due  to  its  ability  to  convert  PI-(3,4,5)-P3  to  PI-(3,4)-P2.  This 
counteracts  PI3 kinase which  produces the  PI-(3,4,5)-P3  required for  many  PH-domain 
mediated signals such as Akt [208]. Recent studies indicating that PI-(3,4)-P2 generation 
could also lead to Akt activation made it very unlikely, however, that SHIP was the only 
mechanism for Akt deactivation. Thus, the finding that PTEN is also activated by FcγRIIb 
and BCR co-ligation potentially provided an additional regulatory molecule to ensure that 
BCR signalling is effectively abrogated [209]. This is because PTEN, which is a 3’ inositol 
phosphatase, directly antagonises the effects of PI3 kinase by decreasing the levels of 
both  PI-(3,4,5)-P3  and  PI-(3,4)-P2  available  for  recruiting  PH-domain  containing  signal 
transducers and therefore further reduces Akt activation. 
The influence FcγRIIb signalling has on the mobilisation of calcium within cells is 
less well understood. Inositol-(1,3,4,5)-tetraphosphate (IP4) is also a potential target for 
dephosphorylation  by  SHIP  and  IP4  is  known  to  be  an  activator  of  membrane  Ca
2+ 
channels [210]. Reduction of the IP4 concentration may therefore disturb the calcium flux 
through these channels changing its distribution pattern in the cell [211]. Calcium is an 
important second messenger whose concentration determines the activation of molecules 
like  calmodulin/calcineurin  and  consequently  the  transcription  factor  NFAT  [212]. 
Alternatively, SHIP/PTEN mediated PI-(3,4,5)-P3 degradation not only prevents Akt from 
associating with the membrane but also Btk and PLCγ which are required for sustained 
coupling of the BCR to an increase in intracellular calcium levels. This might therefore 
present a second mechanism by which SHIP and/or PTEN suppress calcium mobilisation 
after BCR/FcγRIIb co-ligation. 
As illustrated above, the ERK MAP kinase pathway is a key proliferative signalling 
cascade initiated upon BCR activation. Upon BCR stimulation Shc and Grb2/Sos form a  
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complex, enabling Sos to exchange GDP for GTP on Ras, thereby activating it. Ras in 
consequence  recruits  Raf  to  the  membrane  resulting  in  its  activation  and  leading  to 
phosphorylation and activation of MEK1/2, the immediate upstream regulator of ERK1/2. 
SHIP directly competes for Shc binding, sequestering it from interacting with Sos/Grb2 and 
hence inhibiting the activation of Ras downstream signalling [213]. In addition, SHIP uses 
a second mechanism to decrease ERK MAPK signalling via the recruitment and activation 
of p62 Dok which interacts with RasGAP (Ras GTPase activating protein) to enhance the 
GTPase activity of Ras and render Ras inactive [214]. Additionally, BCR/FcγRIIb ligation 
recruits  PAC-1  (phosphatase  of  activated  cells-1),  an  ERK-specific  dual  specificity 
phosphatase, inducing dephosphorylation and thereby inactivation of previously activated 
ERK, thereby further reducing active ERK levels in the cell [209]. 
Interestingly, the induction of apoptosis upon FcγRIIb ligation in the absence of BCR 
involvement  (non-cognate  immune  complexes)  appears  to  induce  signalling  pathways 
independent of the ITIM sequence. Indeed, such apoptotic signals can be blocked by the 
recruitment of SHIP that normally occurs upon BCR/FcγRIIb colligation [215]. These ITIM-
independent  signaling  mechanisms  have  been  partially  elucidated  and  shown  to  be 
dependent on the depolarisation of the mitochondrial membrane with resultant release of 
cytochrome  C  and  activation  of  caspases  3  and  9.  Moreover,  under  these  conditions, 
FcγRIIb needs to be tyrosine phosphorylated to recruit two c-Abl family kinases, c-Abl and 
Arg, to couple to this apoptotic pathway, in an as yet to be defined manner [216]. It is 
thought that this ITIM/SHIP-independent pathway induced by ligation of FcγRIIb by non-
cognate  immune  complexes,  plays  a  role  in  the  maintenance  of  peripheral  tolerance. 
However, the in vivo relevance of this process, which is only seen in B cells, has yet to be 
elucidated. 
Thus, FcγRIIb is a negative regulator of B cell responses playing an important role in 
downregulating ongoing immune responses after the successful removal of the pathogen. 
Such  downregulation  of  the  immune  response  is  necessary  to  maintain  the  balance 
between the beneficial and detrimental effects of the inflammatory process and maintain B 
cell homeostasis. 
 
 
 
1.6  The role of ubiquitination in cell signalling 
 
Ubiquitin  is  a  small  molecule  of  only  76  amino  acids,  which  can  be  attached  to 
proteins thereby influencing their stability, localisation and function. The best characterised  
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function  of  posttranslational  modification  by  ubiquitin  is  the  targeting  of  proteins  for 
degradation  by  the  proteasome.  In  this  way,  ubiquitination  plays  a  crucial  role  in  the 
regulation  of  cell  cycle  progression,  proliferation  and  signal  transduction.  Recently, 
however,  it  has  become  apparent  that  ubiquitination,  dependent  on  the  length  of  the 
ubiquitin chain and specific linkages between ubiquitin molecules, can influence cellular 
processes independently of proteasomal degradation.  
 
1.6.1  Linking ubiquitin to target proteins 
Linking ubiquitin to its target protein is a three-step process. The first step is the 
activation  of  a  C-terminal  glycine  residue  of  ubiquitin.  This  step  is  carried  out  by  an 
enzyme called E1 and uses up energy in the form of ATP. E1 then binds to activated 
ubiquitin via a thiolester linkage, releasing AMP in the process (Fig.1.14). Consequently, 
activated ubiquitin is transferred from E1 to an E2 ubiquitin-conjugating enzyme, the next 
enzyme in the cascade. This enzyme then forms a complex with an E3 ubiquitin ligase and 
the target protein whereby the activated ubiquitin gets transferred to an ε-amino group of a 
lysine of  the  substrate protein  [217]. Depending on  the  E3  ligase, this  last  step  either 
involves direct transfer of ubiquitin from E2 to the substrate, or transfer via E3 to the target 
protein [217]. The specificity of the ubiquitination system is conferred by E3 ligases, as 
these enzymes govern the recruitment of ubiquitin-loaded E2 enzymes to their specific 
target proteins [217].  
Both mono- and poly-ubiquitination exist and these distinct modifications most likely 
control differential functional outcomes. Furthermore, several residues in proteins can be 
tagged  by  mono-ubiquitination,  a  process  termed  multi-ubiquitination  [218].  Generally, 
poly-ubiquitination, by linkage of multiple ubiquitins via their lysine 48 residues, targets 
proteins for degradation by the 26S proteasome complex [219] leading to the release of 
peptides  and  re-usable  ubiquitin.  Linkages  of  ubiquitin  molecules  to  each  other  on 
residues other than lysine 48 have been classified as atypical and have been shown to 
have several different functional effects. Thus, poly-ubiqutiniation via lysine 63 has been 
implicated in the regulation of the NF-κB pathway as well as receptor endocytosis and 
DNA repair [220]. The differential outcomes of the various ubiquitin-modifications is most 
likely due to binding of proteins containing different forms of ubiquitin binding domains 
(UBDs) which are thought to be able to preferentially bind to specific forms of ubiquitin 
linkages.  Although  these  poly-ubiquitin  chains  are  all  made  up  of  the  same  subunit, 
ubiquitin, the  linkage seems  to  influence the  confirmation  of the  chain,  explaining  how 
UBDs can distinguish between lysine 48 and lysine 63 mediated linkage [220]. Likewise, 
recent  studies  suggest  an  important  role  for  the  other  form  of  ubiquitination,  mono- 
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ubiquitination, in receptor endocytosis and histone modification [221]. Thus, Cbl has been 
shown  to  mono-ubiquitinate  receptor  tyrosine  kinases  targeting  them  to  the  lysosomal 
compartment  and  thereby  regulating  activation  of  signalling  downstream  of  RTK 
dependent receptors [222]. Adding another layer of complexity to the ubiquitination system 
are DUBs (deubiquitinating enzymes) which can remove ubiquitin from proteins making 
ubiquitination a reversible process [223]. For example, in murine lymphocytes, cytokine 
stimulation leads to the upregulation of several DUBs indicating that these enzymes might 
play a role in the responses initiated by cytokine stimulation [224].  
 
1.6.2  E3 ligases and their role in the immune system 
There are many studies implicating various E3 ligases in signalling regulating the 
responses of immune cells such as T and B cells. Among the E3 ligases associated with 
the immune system, Itch and Cbl are probably the best studied. Initial interest in the E3 
ligase  Itch  arose  after  the  finding  that Itch-deficient  mice  develop  a  late  onset type  of 
autoimmune disease [225]. More detailed anlysis of these mice indicated a role of Itch in T 
cell  biology  as  Itch-deficient  T  cells  were  found  to  be  hyperresponsive  concerning 
proliferation and IL-2 production upon engagement of CD3. It was then found that Itch 
ubiquitinates JunB and c-Jun leading to their degradation and hence lack of Itch leads to 
increased  stability  of  these  transcription  factors,  production  of  AP-1  and  consequent 
production  of  IL-2  and  T  cell  proliferation  [226].  The  physiological  outcome  of  Itch 
deficiency in T cells is therefore a reduced sensitivity of Itch
-/- TH2 cells to the induction of 
tolerance [227].  
The  Cbl family  of  E3  ligases  has  been  reported  to  play  multiple  roles  in  cellular 
signalling although some of these appear to depend on the adaptor protein function of Cbl 
and are independent of its’ E3 ubiquitin ligase activity. For example, a major ubiquitin-
dependent  function  of  Cbl  is  the  downregulation  of  RTKs  downstream  of  several 
immunoregulatory  receptors  such  as  CSF-1,  stem  cell  factor  (kit)  and  macrophage-
stimulating  protein  (MSP)  [228].  Similarly,  Cbl  can  ubiquitinate  non-receptor  tyrosine 
kinases such as Syk, Fyn and Lyn and target them for degradation [228]. Consistent with 
this, mice lacking Cbl-b were shown to develop spontaneous autoimmune disease [229] 
and both T and B cells from these mice were found to be hyperresponsive to antigen-
receptor stimulation [229,230]. Moreover, such Clb-b deficient T cells displayed a reduced 
need for CD28 costimulation for the production of IL-2 indicating that Cbl-b plays a role in 
the negative regulation of CD28 signalling [230]. A similar role for Cbl in the regulation of 
human T cell activation has recently also been demonstrated as lower levels of c-Cbl were 
shown to correlate with increased CD3/CD28-dependent activation [231].  
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Further  important  immunoregulatory  signalling  pathways  which  are  regulated  by 
ubiquitination-dependent  processes  are  the  Notch  and  NF-κB  cascades.  For  example, 
Notch signalling is important in the development of T cells as well MZ B cell differentiation. 
Itch and c-Cbl are able to ubiquitinate Notch, which in case of c-Cbl leads to the lysosomal 
degradation of Notch resulting in the downregulation of Notch levels and hence signalling 
[232,233]. Likewise, ubiquitination plays multiple roles in the regulation of NF-κB signalling. 
The  best  known  function  of  ubiquitination  in  the  NF-κB  pathway  is  probably  the 
ubiquitination  of  IκB  with  a  lysine  48  linked  poly-ubiqutin  chain  which  targets  it  for 
degradation via the proteasome. However, other forms of ubiquitination such as lysine 63-
linked chains also play important roles. Thus, both NEMO, the regulatory subunit of IKK, 
and its activating kinase Tak1 require poly-ubiquitination via lysine 63-linked ubiquitin for 
their activation [234]. Similarly, RIP (receptor-interacting protein), another component of 
NF-κB signalling downstream of TNFα, is modified by a lysine 63-linked ubiquitin chain, 
protecting it from degradation [235]. Moreover, some reports have investigated the role of 
ubiquitination  in  regulation  of  B  cell  signalling,  including  modification  of  important 
molecules  such  as  Igβ  and  Syk  [236,237].  The  role  of  ubiquitination  and  specific  E3 
ligases in B cell signalling is therefore addressed in more detail in Chapter 3.  
 
1.7  Regulation of the cell cycle 
 
The cell cycle constitutes a highly regulated sequence of events that orchestrates 
the processes underlying cell division. In order to divide, cells have to undergo a growth 
phase during which they increase their cytoplasmic volume followed by DNA duplication 
and mitosis. The cell cycle (Fig.1.15) is divided into four phases. After entering the cell 
cycle  from  the  quiescent  state  (G0),  cell  growth  takes  place  (G1  phase)  before  DNA 
replication (S phase) and another shorter growth phase (G2) after which the cells separate 
into two daughter cells (M phase), each inheriting a full set of chromosomes. To ensure 
that cells only proliferate in response to appropriate extrinsic and intrinsic signals, there 
are  checkpoints  at  both  the  G1-S  and  G2-M  boundaries.  Overcoming these  restriction 
points depends on the integrated signals the cells receive from their environment such as 
growth factor availability and cell culture density or alternatively, from signals created due 
to DNA damage. 
The different phases of the cell cycle and entry into them are primarily regulated by 
the  action  of  cyclin-dependent  kinases  (Cdk).  Cdks  are  proline-directed  kinases  which 
require  binding  to  cyclins  for  full  activation  [238]  and  each  phase  of  the  cell  cycle  is 
governed by different Cdk/cyclin complexes. Thus, the first cyclins to be expressed after  
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growth factor stimulation are the D-type cyclins [239] which form complexes with Cdk4 or 
Cdk6. Due to the constitutive expression of Cdk4 and Cdk6, regulation of these complexes 
therefore depends on cyclin D availability which is regulated both at the transcriptional and 
protein  level  [240,241].  The  major  target  of  the  cyclin  D/Cdk4/6  complex  is  the 
phosphorylation of Rb (Retinoblastoma) family proteins including Rb, p107 and p130 [242] 
(Fig.1.15). This is because hypophosphorylated Rb proteins bind to the transcription factor 
E2F  thereby  blocking  its  transactivation  ability  [243],  whilst  Cdk/cyclin  D-mediated 
phosphorylation  of  Rb  proteins  at  serine  780  leads  to  the  release  of  E2F  and  its 
consequent binding to the family of DP proteins [244], allowing these complexes to act as 
transcriptional activators of genes such as cyclin E necessary for G1-S phase transition 
(reviewed in [245]). Indeed, cyclin E is upregulated in mid to late G1 phase [246] and the 
resultant cyclin E/Cdk2 complexes are required for the further hyperphosphorylation of Rb 
at serines 807/811 [247] that is necessary for complete S phase entry and initiation of DNA 
replication  [248].  Moreover,  additional  targets  of  phosphorylation  by  the  cyclin  E/Cdk2 
complex are the Cdk inhibitor (CKI) p27 and cyclin E itself, leading to their degradation, 
[249,250].  Cyclin  A,  an  alternative  partner  for  Cdk2,  is  then  expressed  at  the  G1/S 
boundary and is required for S phase transition  and control of DNA replication [251,252]. 
The  last  cyclin/Cdk  complex  that  requires  to  be  activated  before  cell  cycle  completion 
consists of cyclin B1 and Cdc2 (Cdk1). Although Cyclin B1 gets upregulated in late S and 
G2 phases, the complexes remain inactive due to inhibitory phosphorylation [253]. This 
phosphorylation  is  removed  by  the  phosphatase  Cdc25  to  allow  activation  of  cyclin 
B1/Cdc2 complexes and M phase entry [253]. Cyclin B1/Cdc2 activity is needed for entry 
into M phase due to its phosphorylation of targets such as lamins, nuclear proteins and 
microtubule proteins that are necessary for the reorganisation of the cellular architecture 
[254].  Thus,  phosphorylation  of  key  target  proteins  regulate  events  such  as  the 
establishment  of  the  bipolar  spindle,  breakdown  of  the  nuclear  lamina  as  well  as  cell 
rounding, processes essential to mitosis [254]. An associated and important function of 
cyclin B1/Cdc2 is the regulation of DNA replication, transcription and translation during M 
phase by phosphorylation of proteins regulating termination of these processes [255]. The 
sequential  activation  of  cyclin/Cdk  complexes  therefore  ensures  correct  entry  and 
progression through the cell cycle. It is therefore not surprising that multiple regulatory 
mechanisms cooperate in order to guarantee their appropriate cell cycle control. 
 
1.7.1  Regulation of cyclin/Cdk activity  
Cyclin/Cdk  activity  is  further  regulated  by  a  complex  network  of  posttranslational 
modifications of the Cdks. For example, phosphorylation of cyclin/Cdks by Cdk activating  
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kinase (CAK; reviewed in [256]), which itself is a cyclin/Cdk complex composed of cyclin H 
and Cdk7 [257] (Fig.1.16), changes the confirmation of Cdks thereby allowing their full 
activation. Such CAK-mediated phosphorylation can be removed by the dual specificity 
serine/tyrosine  phosphatase  KAP  (CDK  associated  phosphatase)  leading  to  the 
inactivation of cyclin/Cdk complexes [258]. Moreover, whilst phosphorylation of inhibitory 
sites on Cdk2 and Cdc2 by serine/threonine kinases Wee1 and Myt1 provide additional 
mechanisms  to  abrogate  CDK  activity  [259,260],  these  inhibitory  modifications  can  be 
counteracted  by  phosphatases  of  the  Cdc25  family  such  as  Cdc25B  which 
dephosphorylates and therefore activates Cdc2 [261]. Interestingly, Cdc25 phosphatases 
are  themselves  targets  for  activation  by  Cyclin/Cdk  complexes  creating  a  positive 
feedback loop [262]. 
Temporally regulated expression and degradation of CKI represents an additional 
layer of regulation. At present, seven CKI have been described and these can be divided 
into two families: the Ink4 family (p15, p16, p18 and p19) and the Cip/Kip family (p21, p27 
and p57), reflecting their slightly different inhibitory mechanisms (Fig.1.16). Thus, whereas 
the Ink4 family proteins bind to Cdk4/6 to inhibit their binding to their cyclin partner, the 
Cip/Kip proteins have been shown to bind cyclin/Cdk complexes and directly inhibit their 
activity  (reviewed  in  [263]).  Like  the  cyclins  and  Cdks,  CKI  are  regulated  at  the 
transcriptional,  translational  and  posttranslational  level,  phosphorylation  again  being  an 
important  modification.  For  example,  phosphorylation  plays  an  important  role  in  the 
inhibition  of  p27  which  acts  to  regulate  arrest  of  cells  in  G1.  Thus,  cyclin  E/Cdk2 
complexes phosphorylate p27 at threonine 187 thereby targeting it for ubiquitination and 
degradation by the proteasome [264]. 
Indeed, phosphorylation of other proteins involved in cell cycle regulation, such as 
cyclin D1 and E2F, targets them for ubiquitination by specific E3 ligases and consequent 
proteasome-mediated degradation. Thus, both, p27 and E2F are ubiquitinated by the SCF 
(Skp2)  E3  ligase  complex  [264,265]  and  consistent  with  this,  one  of  the  mechanisms 
utilised by the transcription factor, c-Myc to promote cell cycle progress is the upregulation 
of Cul1 expression. Cul1 is part of the SCF complex and an increase of Cul1 and thereby 
SCF complexes increases the ubiquitination and degradation of p27, revealing another 
level of cell cycle control mediated through activation of E3 ligases [266].  
 
1.7.2  c-Myc and its role in cell cycle regulation 
c-Myc is a transcription factor which plays multiple roles in various cellular processes 
such  as  proliferation,  differentiation,  growth  and  adhesion  (reviewed  in  [267])  and  its 
importance has been underlined by many studies implicating an oncogenic role for c-Myc  
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in human cancers [268]. Functional c-Myc forms heterodimers with its binding partner Max 
through a basic-region/helix-loop-helix/leucin-zipper (bHLHZip) binding domain [269]. This 
domain acts not only as a protein-protein interaction platform but also as the DNA binding 
site for its canonical CACGTG responsive element sequence [270]. Max was found to be 
required not only for c-Myc binding to this canonical DNA sequence but also for binding to 
other non-canonical binding sites to which the complex is recruited by other proteins [271]. 
After  binding  to  DNA,  c-Myc/Max  complexes  can  act  as  transcriptional  activators  or 
repressors depending on the co-factors involved [272]. Indeed, it has been estimated that 
c-Myc might be involved in the regulation of up to 15% of the genes in the genome [273], 
although  to  date,  only  a  small  percentage  of  the  potential  targets  of  c-Myc-mediated 
transcriptional regulation have been investigated. Nevertheless, it has been shown that the 
potential of c-Myc to drive proliferation is partly due to its ability to activate the transcription 
of genes such as Cdk4 and cyclin D2 and to repress the expression of cell cycle inhibitors 
such as p15, p27 and p21 [274-278]. 
 
1.8  Apoptosis 
 
Cellular necrosis constitutes the accidental and passive death of cells resulting from 
environmental  influences  such  as  mechanical  pressure,  heat  or  toxins.  By  contrast, 
apoptosis is an actively induced and highly regulated mechanism of cell death that is a 
pivotal process in development as well as maintenance of cellular homeostasis in many 
organisms.  Apoptosis  is  of  special  importance  in  the  immune  system  as  it  regulates 
processes like negative and positive selection during lymphocyte development as well as 
removal  of  activated  T  and  B  cells  at  the  end  of  an  immune  response.  However,  the 
majority  of  our  understanding  of  this  controlled  cell  death  mechanism  has  come  from 
studies  using  Caenorhabditis  elegans,  the  organism  in  which  the  role  of  caspases 
(cysteine-aspartic acid proteases) was first discovered. Caspases are a family of cysteinyl 
aspartate proteases which are usually present in the cell in an inactive pro-caspase form. 
Cleavage of pro-caspases preferentially happens at the C-terminal end of a X-X-X-Asp 
motif leading to the activation of the caspase. Caspases themselves then cleave various 
substrates such as ICAD/DFF45, the inhibitor of caspase-actived DNAse (CAD), thereby 
activating this DNAse leading to fragmentation of genomic DNA, a hallmark of apoptosis 
[279,280].  Moreover,  caspases  cleave  and  thus  inactivate  PARP  (poly(ADP-ribose) 
polymerase) and DNA-PK (DNA-dependent protein kinase), two molecules that usually act 
to maintain the integrity of genomic DNA. Caspases are also responsible for cleaving and 
activating pro-apoptotic Bcl-2 family members such as Bid thereby driving mitochondrial  
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disruption.  Additionally,  caspases  contribute  to  the  disassembly  of  the  cytoskeleton  by 
cleaving lamin, fodrin and gelsolin [280] with the overall outcome of caspase activation 
being the “orderly” disassembly of the cells. A major feature of the controlled break-down 
of cells is the creation of apoptotic bodies which are membrane bound cellular fragments 
that prevent plasma membrane breakdown and unwanted release of intracellular proteins. 
The apoptotic bodies are recognised and taken up by phagocytes such as macrophages 
or neutrophils without causing activation of these cells thereby averting unnecessary and 
potentially harmful inflammation [281]. 
Mammalian  cells  utilise  two  major  apoptosis-inducing  pathways:  the  extrinsic 
pathway through “death receptor” ligation or the intrinsic pathway functioning at the level of 
the mitochondria. 
 
1.8.1  The extrinsic apoptotic pathway 
The extrinsic pathway is initiated by ligation and signalling through so called “death 
receptors”. These include Fas (CD95) and its ligand FasL (CD178), the “death receptors” 
DR4 and 5 and their ligand TRAIL (TNF-related apoptosis inducing ligand) as well as the 
TNF-receptor and TNFα [279]. A feature that all of these death receptors share is the 
death  domain  (DD)  [279]  which  recruits  downstream  effectors  of  the  prototypic  death 
receptor signalling pathways (Fig.1.17). For example, the initial event in Fas signalling is 
the binding of FasL to its receptor which induces the trimerisation of Fas molecules in the 
membrane. This in turn will lead to the recruitment of the DISC (death-inducing signalling 
complex),  a  multimeric  complex  consisting  of  Fas,  the  adaptor  protein  FADD  (Fas-
associated death domain) as well as inactive pro-caspase 8 [282]. FADD is a common 
adaptor protein shared amongst all the death receptor pathways which interacts with Fas 
through  its  DD.  The  binding  of  FADD  to  Fas  initiates  a  conformational  change  which 
exposes the death effector domain (DED) of FADD allowing it to recruit pro-caspase 8 
[282]. Following recruitment to the Fas receptor complex, pro-caspase 8 is activated by 
self-cleavage and in turn cleaves pro-caspases 3, 6 and 7. These effector caspases then 
execute the apoptosis process by cleaving their substrates including DNA repair enzymes, 
structural proteins as well as endonuclease inhibitors [279]. The other important substrate 
of caspase 8 is Bid, a pro-apoptotic member of the Bcl-2 family of proteins. Caspase 8 
cleaves Bid creating the truncated form which can then translocate to the mitochondria 
and induce the intrinsic pathway of apoptosis [282]. This cross-regulation of the extrinsic 
and intrinsic pathway seems to be crucial in hepatocytes, but is apparently less important 
in lymphocytes [282].  
  37 
The importance of apoptosis in the regulation of many pivotal processes such as cell 
homeostasis makes it necessary to tightly control its initiation. There are multiple levels of 
regulation in the “death receptor” signalling pathways including transcriptional regulation of 
Fas and FasL expression, expression of Fas isoforms lacking the transmembrane or DD 
domain and production of soluble FasL [279]. Another major regulatory mechanism is the 
expression of FLIP, an inhibitor of caspase 8 activation. FLIP displays a similar structure to 
caspase 8 and performs its inhibitory function by binding to the DISC complex thereby 
hampering its ability to recruit and activate caspase 8 [283]. 
It is known that B cells can express Fas on their surface and be killed by Fas-ligation 
induced  apoptosis  [284]  but  the  physiological  importance  of  Fas  signalling  in  B  cells 
depends on the maturation stage of the cells. Thus, whilst Fas does not seem to play a 
major role in developing B cells and negative selection of immature B cells [285], it is 
involved  in  the  deletion  of  low  affinity-BCR  expressing  B  cells  in  the  germinal  centre 
reaction  which  have  not  successfully  undergone  affinity-maturation  of  their  antigen 
receptors [286]. 
 
1.8.2  The intrinsic apoptotic pathway 
The key event in the intrinsic pathway is the disruption of the mitochondrial outer 
membrane potential culminating in the permeabilisation of the mitochondria and this is 
termed  MOMP  (mitochondrial  outer  membrane  permeabilization).  It  can  be  induced  by 
various different events, such as viral infection, DNA damage or removal of growth factors 
and activation of this intrinsic pathway appears to be mainly regulated by the Bcl-2 family 
of  proteins.  This  family  consists  of  pro-  and  anti-apoptotic  members  which  have  been 
classified according to the number and combination of Bcl-2 homology (BH) domains in 
their structure. For example, the anti-apoptotic family members Bcl-xL, Bcl-2, Bcl-w Mcl-1 
and A1 share up to 4 BH domains (BH1-4) whereas the pro-apoptotic molecules of the 
“Bax, Bak” or “multi-BH domain’’ family (Bax, Bak and Bok) contain 3 BH domains. The 
other pro-apoptotic family are the BH3-only proteins (Bid, Bad, Bik, Hrk, Bim, Noxa, Puma 
and Bmf) which, as their name implies, only contain the BH3 domain (reviewed in [285]). 
The  two  pro-apoptotic  molecules  Bax  and  Bak  are  the  major  transducers  of  MOMP 
(Fig.1.18); how exactly these two molecules induce MOMP is still not fully elucidated yet, 
but  it  is  thought  that  they  might  cause  the  formation  of  pores  in  the  mitochondrial 
membrane. Ultimately, the leakage through the mitochondrial membrane will lead to the 
release  of  molecules  usually  retained  in  the  space  between  the  inner  and  outer 
mitochondrial membrane [285], the most important of these mediators are cytochrome C 
and DIABLO (also called Smac). Thus, upon release into the cytosol, cytochrome C binds  
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to APAF-1 (apoptotic peptidase activating factor 1) initiating formation of the apoptosome, 
a heptameric protein ring made up of cytochrome C and APAF-1 molecules, that activates 
pro-caspase  9  [287].  By  contrast,  the  release  of  DIABLO  constitutes  an  apoptosome-
independent pathway leading to apoptosis in that DIABLO sequesters caspase inhibitors 
such as X-linked inhibitor of apoptosis proteins (XIAP), a family of proteins that bind and 
inhibit caspases such as caspase 9 and 3. Thus, through binding of DIABLO, XIAP will 
release the caspase it was bound to allowing it to be activated [285].  
The precise events regulating activation of Bax and Bak are not fully known but there 
are currently two major models of the mechanisms involved (Fig.1.19). The first model 
suggests  that  Bax  and  Bak  can  directly  interact  with  BH3-only  proteins,  which  in  turn 
activate Bax and Bak [288]. Alternatively, the second model argues that Bax and Bak are 
normally bound to anti-apoptotic Bcl-2 family members until induction of apoptosis and 
hence activation of BH3-only proteins leads to the displacement and activation of Bax and 
Bak [285]. What both models have in common is the need for the presence and activity of 
BH3-only proteins and this explains why the expression and activation of these proteins is 
highly regulated and only induced upon detection of apoptotic signals. For example, Noxa, 
Puma  and  Bim  expression  is  upregulated  downstream  of  DNA  damage,  growth  factor 
deprivation and ER stress and the increase in expression of these molecules is achieved 
by  the  activation  of  transcription  factors  such  as  p53  or  FOXO3A  [289-293].  Post-
translational modifications, proteolysis or release from complexes provide other additional 
important regulatory mechanisms controlling the activity of Bcl-2 family members [285]. 
Moreover,  for  example,  upregulation  of  Bcl-xL  can  protect  WEHI-231  cells  from  BCR-
induced apoptosis [294] and so in the end, the overall balance between pro- and anti-
apoptotic signalling decides the fate of the cell. 
 
1.8.3  Caspase-independent execution of apoptosis 
Caspases and their role in the execution of apoptosis have long been the major 
focus, but in recent years it has become obvious that other proteases can play important 
roles  in  the  final  stages  of  apoptosis.  The  two  classes  discussed  in  this  context  are 
calpains  and  cathepsins.  Calpains  are  calcium-dependent  cysteine  proteases  that  are 
active at neutral pH whereas cathepsins generally prefer an acidic environment, such as 
the  lysosomes,  for  optimal  function.  However,  upon  activation  of  apoptotic  signalling 
cathepsins have been found to be released into the cytosol. Thus, cathepsin D release into 
the cytosol precedes the oxidative stress-induced apoptosis of fibroblasts [295]. Moreover, 
another cathepsin isoform, cathepsin B was found to be released into the cytosol upon 
TNFα-mediated induction of apoptosis in hepatocytes [296]. Calpains and their precise  
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effector functions in apoptosis are still not well studied but some that are known include a 
role in cell fusion and motility by remodelling the cytoskeleton, degradation of cell cycle 
regulators,  degradation  of  filamin,  talin,  and  spectrin  and  modulation  of  signalling 
molecules such as PKC [297]. A role for calpains in apoptosis has been shown in many 
different cells and systems such as ionomycin-induced apoptosis of a human carcinoma 
cell line [298], dexamethasone-induced apoptosis in thymocytes [299], drug-induced death 
of  HL-60  cells  due  to  calpain-mediated  cleavage  of  Bax  [300]  and  radiation-induced 
apoptosis of the Burkitts' Lymphoma cell line BL30A [301]. Moreover, it seems that the 
calpain and caspase system are not necessarily exclusive to each other but rather seem to 
be  cross-regulatory  as shown  by  the  inactivation  of  the  calpain  inhibitor  calpastatin  by 
caspases during Fas-induced apoptosis in Jurkat and U937 cells [302]. Calpain in turn is 
able to cleave pro-caspase 3 and 9 thereby activating them in a caspase-independent 
fashion [303]. 
Like calpains, cathepsins have been implicated in various systems of apoptosis in a 
range of cell types and in addition, cathepsin B has been shown to be able to induce 
chromatin condensation, a morphological feature of apoptosis in a cell-free system [304]. 
Thus,  under  conditions  of  TNFα-induced  apoptosis  of  hepatocytes,  cathepsin  B  was 
shown  to  be  released  from  lysosomes  in  a  caspase  8-dependent  manner,  resulting  in 
cytochrome C release from mitochondria. Such cytochrome C release as well as caspase 
activation  and  resultant  apoptosis  were  markedly  reduced  in  cells  from  cathepsin  B-
deficient mice [296]. Likewise, inhibition of cathepsin B has been reported to reduce p53-
induced apoptosis in myeloid leukemic cells [305] and it was similarly shown to be involved 
in the intrinsic apoptotic pathway induced by Bacillus Calmette-Guérin (attenuated Myco-
bacterium  bovis)  in  cancer  cell  lines  [306].  Moreover,  studies  in  this  laboratory  have 
demonstrated  the  involvement  of  cathepsin  B  in  BCR-induced  apoptosis  of  WEHI-231 
cells, although in this system cathepsin B, rather than caspases, seems to be the main 
executioner-protease [307]. Besides cathepsin B, another isoform, cathepsin D, has also 
displayed the potential to cleave molecules important in the last stages of apoptosis. Thus, 
in neutrophils cathepsin D cleaves and thereby activates caspase 8 under inflammatory 
conditions and might therefore play an important role in neutrophil apoptosis and hence 
resolution of inflammation [308]. 
 
1.9  Aims and Objectives 
 
The core aim of this study was to characterise the differential signalling mechanisms 
underlying tolerance induction employed by B cells at distinct stages of development. In  
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particular, the primary objective was to investigate the signals that regulate commitment to, 
and  rescue  from,  negative  selection  of  immature  B  cells  in  the  bone  marrow  (central 
tolerance). In addition, it was planned to compare these signals with those of a mechanism 
involved in peripheral tolerance: specifically, the homeostatic regulation of mature B cells 
provided by FcγRIIb-mediated negative feedback inhibition of B cell activation. Finally, it 
was  proposed  to  investigate  whether  defects  in  the  latter  homeostatic  mechanism  of 
peripheral tolerance played a contributing role to the autoimmune responses of patients 
with autoimmune inflammatory diseases such as rheumatoid arthritis and systemic lupus 
erythematosus. 
 
1.10  Figures and Tables 
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Figure 1.1 Structural features of antibodies 
Antibodies consist of four chains, two heavy (55-70kD) and two light chains (~24kD) linked 
by  disulphide  bonds.  Both  heavy  and  light  chains  are  composed  of  constant  (C)  and 
variable (V) regions which contain multiple immunoglobulin (Ig) domains. Antibodies can 
further be divided into their Fc and Fab regions. Antibody binding is conferred by the Fab 
region which contains the V regions of the heavy and light chains. These opposing regions 
create the antibody binding cleft, the site of antigen binding. The Fc portion binds to Fc-
receptors  which  initiate  signalling  leading  to  various  responses  such  as  activation, 
inhibition or degranulation of various immune cells, depending on the cell class, antibody 
isotype as well as Fc-receptor isoforms. 
There  are  five  antibody  isotypes:  IgA,  IgD,  IgE,  IgG  and  IgM.  These  isotypes  differ 
concerning the number of Ig domains in their constant region as well as their ability to form 
multimeric structures. Each isotype has a defined set of functions increasing the versatility 
of B cell responses. 
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Figure 1.2 Somatic V(D)J recombination 
Somatic  recombination  of  immunoglobulin  heavy  and  light  chains  differs  slightly. 
Recombination  of  the  heavy  chain  is  achieved  by  two  separate  recombination  events 
joining firstly the  D  and  the  J  segments followed  by  joining  the V segment to the D-J 
segment. Due to the lack of D segments, light chain rearrangement is achieved by a single 
recombination event which joins a V segment with a J segment. 
Following somatic recombination the genes are transcribed and spliced to join up the parts 
encoding the variable region with the exons encoding the constant region. Finally, the RNA 
is translated into heavy or light chain proteins which are then assembled to yield functional 
antibodies. 
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Figure 1.3 Basic structure of the BCR 
The BCR consists of an antigen-binding component – the membrane bound Ig molecule – 
and the signal-transducing units Igα and Igβ. The Ig molecule is made up of two heavy and 
light chains which are composed of constant and variable regions, the latter containing the 
so-called CDRs (complementarity-determining regions). CDRs are areas of high variabilty 
where most mutations occur during somatic hypermutation. The Ig molecule itself is not 
able  to  signal  and  therefore  needs  Igα  and  Igβ.  Those  proteins  both  contain  ITAMs 
(immunoreceptor tyrosine-based activation motif), which confer their signalling ability.  
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Figure 1.4 B-2 B cell development 
The development of B cells is characterised by changes in surface receptor expression 
and  Ig  gene  rearrangement  which  allows  the  identification  of  different  developmental 
stages. The first stage at which cells can be identified as being committmed to the B cell 
lineage is the pre-pro-B cells stage at which little or no immunoglobulin (Ig) rearrangement 
occurs. The transition from progenitor CLP (common lymphoid progenitor) to committed B 
cell  is  dependent  on  multiple  transcription  factors  including  Pax5,  EBF  and  PU.1. 
Rearrangement  of  the  heavy  chain  is  first  induced  at  the  pre-pro  B  cell  stage,  but 
functional heavy chain is not expressed until the pre-B cells stage. Rearranged µ heavy 
chain is expressed on the surface in combination with λ5 and VpreB (surrogate light chain) 
to  yield  the  pre-BCR.  This  receptor  is  associated  with  Igα  and  Igβ  (CD79a/b)  on  the 
surface of the cell and signalling via the pre-BCR induces heavy chain allelic exclusion and 
initiates  light  chain  rearrangement.  Surface  expression  of  functional  µ  heavy  and  light 
chain complexes (IgM) is a characteristic feature of the immature B cell stage. Up to this 
point, B cell development has been Ag-independent, however from the immature B cell 
stage onwards the clonal selection processes are Ag-dependent. Immature B cells which 
survive  negative  selection  are  released  from  the  bone  marrow  into  the  circulation  to 
migrate to  the  secondary  lymphoid  organs. The  initiation  of  IgD  expression  on  B  cells 
indicates  their  development  into  transitional  B  cells  which  need  BCR-  and  BAFF-
dependent signalling to progress to their next developmental stage, mature naïve B cells. 
A mature B cell then has two main developmental possibilities after activation – becoming 
an antibody secreting plasma cell or a memory B cell. 
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Figure 1.5 Structure of the pre-BCR and BCR 
At  the  pre-B  cell  stage  rearranged  µ  heavy  chain  in  combination  with  λ5  and  VpreB 
(surrogate light chain) are expressed on the surface associated with Igα and Igβ compared 
to conventional light chains in the mature BCR. A functional pre-BCR is necessary to allow 
the B cells reach their next developmental stage. The association of the rearranged heavy 
chain with the surrogate light chain substitutes provides a mechanism to ensure that only 
B cells expressing a correctly folded heavy chain can develop any further.  
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Figure 1.6 The germinal centre reaction 
During a T cell-dependent response naïve mature B cells will migrate from the T cell rich 
areas of secondary lymphoid organs into the follicular mantle (1) where they start forming 
the  dark  zone  of  the  germinal  centre.  They  undergo  rapid  proliferation,  downregulate 
surface Ig expression and undergo somatic hypermutation (2). After having mutated their 
Ig  the  cells  stop  dividing,  express  their  new  receptor  and  migrate  into  the  light  zone 
following a chemokine gradient (3). Follicular dendritic cells in the light zone retain antigen 
and  present  it  to  all  the  B  cells,  but  only  centrocytes  with  high  affinity  receptors  are 
selected and allowed to survive whereas low affinity or self-reactive BCR-expressing cells 
undergo  apoptosis.  The  positively  selected  centrocytes  interact  with  TH  cells  thereby 
receiving CD40-mediated signals leading to isotype switching and development into either 
memory B cells or plasma cells (4).  
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Figure 1.7 B cell development 
B cells are divided into three subsets – follicular B cells, B-1 B cells and marginal zone 
(MZ) B cells. The development of these separate lineages has not been fully elucidated, 
but a general model has been proposed based on recent findings. Follicular B cells and 
MZ B cells, the so called B-2 B cells, both appear to originate from the same bone marrow 
precursor. The development of follicular and MZ B cells is thought to divide into the two 
subsets at the T2 transitional B cells stage. Follicular B cells will recirculate through lymph 
nodes and the spleen whereas MZ B cells are mainly sessile and stay in the marginal zone 
of the spleen. Separate B-1 B cell progenitors have recently been identified, placing this 
subset in its own developmental pathway diverging from B-2 B cells as early as the pro-B 
cell stage. 
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Figure 1.8 Tolerance checkpoints in B cell development 
Activation of autoreactive B cells can play an important role in autoimmune diseases. In 
healthy  humans  these  pathogenic  cells  are  either  absent  or  kept  in  an  inactive  state. 
Studies in humans and mice have found that self-reactive cells are depleted from the B 
cell pool at multiple points during the development. Thus, the percentage of autoreactive 
clones is reduced before cells enter the immature B cell stage and again after having left 
the bone marrow and hence before they develop into mature naïve cells. Not only are self-
reactive B cells depleted but they are also prevented from entering certain developmental 
stages. Self-reactive B cells have been found to be excluded from the IgM
+ memory cell 
pool and the GC reaction. Moreover, these cells might not develop into plasma cells and 
even though autoreactive IgG
+ memory B cells are present in healthy humans, they are 
prevented from producing pathogenic autoantibodies. 
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Figure 1.9 BCR ligation initiates three major signalling cascades 
Upon BCR ligation, three major signalling pathways are initiated: the PI3 kinase, PLCγ and 
MAP kinase pathways. PI3 kinase catalyses the phosphorylation of inositol lipids like PI, 
PI-(4)-P and PI-(4,5)-P2 thereby producing PI-(3)-P, PI-(3,4)-P2 and PI-(3,4,5)-P3 (PIP3), 
molecules  normally  present  in  the  cell  at  very  low  levels  and  whose  concentration 
increases  after  PI3  kinase  activation.  PIP3  is  able  to  recruit  PH  (pleckstrin  homology) 
domain-containing proteins, such as PLCγ, Btk, Vav, PDK1/2 and Akt, to the membrane 
where they can be activated. PLCγ is recruited to the BCR-ITAMs, possibly by BLNK, to 
bring it into close proximity with Btk and Syk. This leads to PLCγ phosphorylation and 
activation  and  subsequent  downstream  signalling.  PLCγ  produces  DAG  and  IP3,  two 
important  second  messengers  that  activate  protein  kinase  C  (PKC)  and  increase 
intracellular  calcium  levels,  respectively.  The  ERK  MAP  kinase  signalling  cascade 
becomes activated due to the recruitment of Sos (son of sevenless), a guanine nucleotide 
exchange factor which  catalyses  the  exchange  of  GDP for GTP on Ras  leading  to  its 
activation. The next step in this signalling cascade is the derepression of Raf by activated 
Ras  thereby  inducing  its  kinase  activity.  Raf  is  a  MAPKK  and  therefore  able  to 
phosphorylate MEK1/2 which in turn activate ERK1/2.  
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Figure 1.10 The MAPK signalling cascade 
The MAP kinases (MAPK) are serine/threonine protein kinases which regulate multiple 
cellular  responses  including  proliferation,  apoptosis  and  differentiation.  They  can  be 
separated into three groups: The extracellular signal-regulated kinases (ERK MAP kinase), 
the c-Jun N-terminal kinases (also known as stress activated protein kinases (JNK/SAPK) 
and  the  p38  MAP  kinases.  Activation  of  the  MAP  kinases  is  achieved  by  sequential 
activation  of  upstream  kinases  MAPKKK  (MAPK  kinase  kinase)  and  MAPKK  (MAPK 
kinase)  ultimately  leading  to  the  phosphorylation  of  MAPKs  on  tyrosine  and  threonine 
residues  located  in  a  T-X-Y  motif,  the  X  being  different  in  each  MAPK  group.  Active 
MAPKs phosphorylate and thereby activate transcription factors such as Elk-1, c-Myc and 
c-Jun  and  numerous  other  cytoplasmic  and  nuclear  substrates  like  cPLA2.  Another 
important class of proteins regulated by MAPK-dependent phosphorylation are the MAPK-
activated protein kinases (MK) such as MAPKAPs and MNKs. 
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Figure 1.11 CD19 signalling 
CD19 is expressed at the surface of B cells as a receptor complex together with CD21 and 
CD81.  Binding  of  ligand  to  the  CD21/CD81/CD19  receptor  complex  will  lead  to 
phosphorylation of tyrosine residues in CD19 allowing it to recruit and activate PI3 kinase 
as well as Vav which in turn induce Akt and PLCγ2 signalling. Therefore, CD19 contributes 
to the activating signals and hence lowers the signalling threshold of the BCR. 
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Figure 1.12 CD40 signalling in mature B cells 
Ligation of CD40 with CD154 initiates the recruitment of TRAFs to the cytoplasmic portion 
of  the  receptor.  TRAFs  2,  3,  5  and  6  can  then  activate  multiple  signalling  pathways 
including the PLCγ2, PI3 kinase and MAPK pathways. The overall outcome of all these 
signals is the inhibition of apoptosis through NF-κB-dependent upregulation of Bcl-xL and 
FLIP,  and  the  initiation  of  cell  cycle  progression  by  downregulating  levels  of  p27  and 
upregulating Cdk4/6.  
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Table 1.1 The family of Fcγ receptors 
Murine and human cells express a variety of different activatory and inhibitory Fc receptors 
for  the  IgG  subclass  of  antibodies.  There  are  some  major  differences  between  Fcγ 
receptors expressed in mice and humans such as the lack of FcγRIIA and C in mice and 
the expression of FcγRIV on murine but not human cells. The expression of Fcγ receptors 
in  mice  and  humans  can  be  found  on  many  cell  lineages  such  as  macrophages, 
neutrophils, eosinophils, B cells and NK cells. 
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Figure 1.13 BCR-mediated sigalling is inhibited by co-ligation of FcγRIIb 
FcγRIIb is the low affinity receptor for the Fc portion of IgG. Cross-linking of BCR and 
FcγRIIb  inhibits  BCR-mediated  activation  and  proliferation  of  B  cells.  At  the  proximal 
signalling level, the co-ligation of BCR and FcγRIIb induces Lyn to tyrosine-phosphorylate 
the ITIM in the cytoplasmic portion of FcγRIIb. The main signal transducer recruited to the 
phosphorylated  ITIM  is  SHIP.  SHP-1  and  -2  are  also  recruited  by  FcγRIIb  but  do  not 
appear  to be  essential  for  negative  signalling.  By  contrast,  SHIP  signalling appears  to 
effect  negative  signalling  by  dephosphorylating  PIP3  and  consequently  reducing 
recruitment  of  pro-survival  and  proliferation-promoting  PH-domain  containing  proteins. 
Furthermore, FcγRIIb also recruits PTEN (inositol 3’ phosphatase) to further antagonise 
PI3 kinase signalling. The ERK MAPK cascade is also inhibited by FcγRIIb signalling due 
to the direct inhibition of Shc/Gbr2 interaction by SHIP as well as recruitment of p62 Dok 
which  activates  RasGAP  thereby  reducing  Ras  activation.  Additionally,  BCR/FcγRIIb 
ligation  recruits PAC-1,  an ERK-specific  dual phosphatase, inducing  dephosphorylation 
and  thereby  inactivation  of  ERK.  FcγRIIb  signalling  has  also  been  found  to  decrease 
calcium signalling, but the underlying signalling mechanisms are not yet fully elucidated. 
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Figure 1.14 Ubiquitination and proteasomal degradation 
Ubiquitination of target proteins consists of three major steps:  
1.  The  initial  activation  of  ubiquitin  is  catalysed  by  E1  enzymes  in  a  process  that 
requires  energy  in  the  form  of  ATP.  The  activated  ubiquitin  molecule  is  then 
transferred onto the E1 enzyme itself via a thioester linkage. 
2.  The ubiquitin is then transferred from E1 to the ubiquitin-conjugating enzyme E2 by 
trans-thio-esterification. 
3.  The  last  step  in  the  process  involves  the  E3  enzyme  which  functions  as  the 
substrate recognition unit of the complex. The E3 ligase forms a complex with E2-
bound ubiquitin as well as the target protein allowing the transfer of ubiqutin to a 
lysine of the target protein. 
If  no  further  modification  occurs  the  protein  is  classified  as  mono-ubiquitinated.  But 
following this initial step the ubiquitin can also be linked to further ubiquitins creating poly-
ubiquitination. The outcome of conventional polyubiqutination via lysine 48 is proteasome-
dependent degradation of the protein whereas other forms of poly-ubiquitination (such as 
via  lysine  63)  or  multi-monoubiquitination  can  target  substrates  for  endocytosis  and 
lysosomal degradation as well as influencing their signalling properties by changing their 
transduction interaction partners. 
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Figure 1.15 The cell cycle 
The cell cycle consists of four major stages. Cells enter the cell cycle at the G1 phase and 
following growth and given the right signals, will enter S phase in which they will replicate 
their DNA, followed by another growth phase in the G2 phase. The last step is mitosis (M 
phase) and the division of the DNA and cellular contents between two daughter cells. The 
so called restriction point during arrest in G1 is mainly regulated by activation of cyclin/Cdk 
complexes which hyperphosphorylate the Retinoblastoma (Rb) proteins thereby releasing 
the transcription factor E2F. This will initiate transcription of genes necessary for entry and 
progress  through  S  phase.  Each  stage  of  the  cell  cycle  is  highly  regulated  to  stop 
damaged  cells  from  entering  the  cell  cycle  and  allowing  the  proper  progression  and 
completion of the previous stages before entry into the next one. One level of regulation is 
provided  by  the  Ink  and  Cip/Kip  cell  cycle  inhibitors  which,  by  inhibiting  cyclin/Cdk 
complexes, can stop progresssion of cells through the cell cycle at various stages. 
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Figure 1.16 Regulation of the cell cycle 
(A)  The  cell  cycle  is  divided  into  four  phases.  After  entering  the  cell  cycle  from  the 
quiescent state (G0) the cells’ initial growth takes place during G1 phase. This is followed 
by DNA replication (S phase) and another shorter growth phase (G2) after which the cells 
separate into two daughter cells (M phase) with each inheriting a full set of chromosomes. 
Checkpoints at the G1-S boundary and G2-M boundary ensure that cells only progress 
through cell cycle and divide under appropriate conditions and in the absence of DNA 
damage. Such checkpoints involve regulation by Cdk/cyclin complexes. 
(B) Activation of Cdk/cyclin complexes is regulated at multiple levels. Phosphorylation by 
CAK activates Cdks whereas Wee1 and Myt phosphorylate inhibitory sites on Cdk2 and 
Cdc2. Phosphatases of the Cdc25 family counteract Wee and Myt1 by dephosphorylating 
the inhibitory residues. The Cdk inhibitors are divided into two classes: The Ink4 family of 
proteins inhibit the assembly of cyclin D and Cdk4/6, the Cip/Kip family inhibitors block the 
activity of pre-assembled cyclin/Cdk complexes. 
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Figure 1.17 Extrinsic pathway of apoptosis - Fas/FasL signalling 
Ligation of the Fas receptor by its ligand FasL induces the oligomerisation of Fas initiating 
the  assembly  of  the  DISC  which  consists  of  the  Fas  associated  FADD  proteins  and 
consequently  recruits  pro-caspase  8.  Interactions  between  Fas  and  FADD  are  via  the 
proteins  death  domains  (DD),  whereas  FADD  recruits  pro-caspase  8  using  its  death 
effector  domain  (DED).  Following  recruitment  to  this  complex,  pro-caspase  8  is  then 
activated by autocleavage. FLIP is a specific inhibitor of DISC assembly due to its similar 
structure to pro-caspase 8, allowing it to compete for DED binding and thereby displacing 
pro-caspase 8. Active caspase 8 can activate effector caspases 3, 6 and 7 which in turn 
cleave multiple targets to induce the hallmark changes of apoptosis including chromatin 
condensation, nuclear shrinkage and cytoskeletal collapse. Caspase 8 also cleaves Bid to 
create active truncated Bid (tBid) which localises to the mitochondria thereby initiating the 
intrinsic mitochondrial apoptosis pathway.  
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Figure 1.18 Intrinsic/mitochondrial pathway of apoptosis 
Pro-apoptotic stimuli induce the activation of Bax and Bak and these two pro-apoptotic Bcl-
2  family  members  then  lead  to  pore-formation  at  the  mitochondria  and  initiation  of 
mitochondrial  outer  membrane  permeabilization  (MOMP).  Consequently,  mitochondrial 
proteins,  such  as  cytochrome  C  and  DIABLO/Smac  are  released.  In  the  cytoplasm 
cytochrome C can form complexes together with APAF-1. These oligomers, the so called 
apoptosome, activate pro-caspase 9 and subsequently effector caspases. One of the other 
molecules released from the mitochondria, DIABLO, carries out its pro-apoptotic function 
by blocking the binding of XIAP to caspases 3 and 9 thereby releasing them from inhibition 
and hence allowing them to cleave their substrates to induce disassembly of the major 
cellular structures required to induce apoptosis. 
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Figure 1.19 Models for the regulation of apoptosis by Bax-Bak Bcl-2 family proteins 
Currently, the precise mechanism of apoptosis transduced by the Bax-Bak Bcl-2 family 
members  is  not  known  but  there  are  two  major  models  to  explain  their  role  in  the 
regulation of mitochondrial stability and apoptosis. Model 1 proposes that apoptotic stimuli 
will lead to the upregulation of BH3-only proteins which will then be able to directly activate 
Bax and Bak, resulting in the disruption of the mitochondrial membrane and consequent 
generation of the apoptosome. In this model, the upregulation of BH3-only proteins and 
direct activation of Bax and Bak would be able to overcome the positive effects of anti-
apoptotic Bcl-2 family members present in the cell. By contrast, Model 2 suggest that anti-
apoptotic Bcl-2 family members are bound to Bax and Bak in viable cells thereby stopping 
them from being activated and translocated to the mitochondria. In this case, apoptotic 
signalling BH3-only proteins are upregulated and can then compete for binding to anti-
apoptotic Bcl-2 proteins subsequently releasing Bax and Bak which can relocalise to the 
mitochondria and initiate the apoptotic process. 
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2  Materials and Methods 
 
2.1  Cell culture reagents, antibodies and inhibitors 
 
All  cell  culture  reagents  were  purchased  from  Invitrogen  Life  Technologies.  All  other 
reagents  were  obtained  from  Sigma-Aldrich  unless  otherwise  stated.  For  a  full  list  of 
antibodies used, refer to Table 2.1, but to target particular receptors on murine B cells, the 
following  antibodies  were  used  as  follows.  For  functional  studies,  AffiniPure  F(ab’)2 
fragments  of  goat  anti-mouse  IgM  (H+L)  antibodies  (Jackson  ImmunoResearch 
Laboratories) were used at 50 µg/ml to cross-link the BCR on mature B cells. By contrast, 
intact AffiniPure rabbit anti-mouse IgG+IgM (H+L) antibodies (Jackson ImmunoResearch 
Laboratories) were used at 75 µg/ml to cross-link the BCR and FcγRIIb on mature B cells. 
However, for Western Blotting studies, the BCR was ligated by a rat anti-mouse IgM (clone 
B7.6, made in house) mAb at 50 µg/ml, FcγRIIb was ligated by a rat anti-mouse FcγRIIb 
(clone 2.4G2, made in house) mAb at 50 µg/ml, and donkey anti-rat IgG (H+L) antibodies 
(Jackson ImmunoResearch Laboratories) at 75 µg/ml were used to cross-link the rat mAbs 
and hence the BCR and FcγRIIb. Blocking Fas/FasL interactions was achieved by adding 
5  or  10  µg/ml  armenian  hamster  anti-FasL  (anti-CD178)  antibody  (BioLegend)  to  the 
cultures  with  armenian  hamster  IgG  used  as  an  isotype-specific  control  antibody 
(BioLegend). The rat anti-mouse IgM (clone B7.6) antibody was also used to cross-link the 
BCR on WEHI-231 cells at concentrations between 0.0001 and 10 µg/ml. To antagonise 
the anti-IgM-mediated growth arrest signal in WEHI-231 cells, rat anti-mouse CD40 (clone 
FGK 45, made in house) mAb was used at 10 µg/ml. Unless otherwise specified, cell 
signalling inhibitors were used at the following concentrations. The MEK-specific inhibitor 
PD98059 (Calbiochem) and the PI3 kinase-specific inhibitor LY294002 (Calbiochem) were 
used  at  previously  established  optimal  concentrations  (10  µM  and  1  µM,  respectively) 
[309,310]. Likewise, the Caspase-8 Inhibitor II (Z-IETD-FMK) (Calbiochem) was used at 10 
µM whereas the proteasome inhibitor Z-Leu-Leu-Leu-al (MG132) (Sigma) was used at 0.5 
µM. 
 
2.2  Animals 
 
Mice on a BALB/c background, were used to isolate primary splenic B cells. These 
mice were maintained at the Central Research Facility (CRF), University of Glasgow. The 
mouse model of Systemic Lupus Erythematosus, MRL/MpJ-Fas
lpr,
 and its’ parental strain  
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MRL/MpJ,  were  kept  at  the  Joint  Research  Facility  (JRF),  University  of  Glasgow  and 
managed by Mairi McGrath, Dr. Angela Morton and myself. 
 
2.3  WEHI-231 immature B cell line 
 
The murine B cell lymphoma, WEHI-231 (obtained from ECACC) was cultured in 
RPMI-1640 medium supplemented with 5% foetal calf serum (FCS), 100 U/ml penicillin, 
100 mg/ml streptomycin, 50 mM b-mercaptoethanol and 2 mM L-glutamine at 37°C in a 5% 
(v/v)  CO2  atmosphere  at  95%  humidity.  WEHI-231.7  JM  cells  were  transfected  by 
electroporation  with  the  pSFFV-Neo  plasmid  containing  either  the  human  bcl-xL  gene 
(BclXL WEHI-231) or empty vector as control (Neo WEHI-231). Stable transfectants were 
selected  for  the  acquisition  of  neomycin  resistance  by  growth  in  the  presence  of  the 
antibiotic  G418  (500  mg/ml,  Promega)  and  were  a  kind  gift  from  Dr.  C.  B.  Thompson 
(University  of  Pennsylvania).  Stable  transfectants  were  cultured  in  RPMI-1640  media 
supplemented  with  5%  FCS,  100  U/ml  penicillin,  100  mg/ml  streptomycin,  50  mM  β-
mercaptoethanol,  2  mM  L-glutamine  and  500  mg/ml  G418  at  37°C  in  a  5%  (v/v)  CO2 
atmosphere at 95% humidity. 
 
2.4  B cell purification from mouse spleens 
 
Primary B cells were prepared from murine spleens using the anti-CD43-magnetic 
bead negative-selection method of Miltenyi Biotec. This method takes advantage of the 
fact that the CD43 antigen is expressed on nearly all leukocytes, except for immature and 
mature  naive  B  cells.  Negative  selection  of  CD43-positive  cells  therefore  removes  all 
unwanted  cells  without  manipulating  the  B  cells  themselves.  To  avoid  non-specific 
labelling and increase survival of cells all procedures were carried out at 4° C. 
Briefly,  spleens  were  removed and  washed  in  RPMI-1640  media  and  then  dissociated 
through nitex. The resultant single cell suspension was centrifuged (450 g, 10 min, 4 °C) 
and the pellet resuspended in 9 ml of red blood cell removal buffer (0.168 M NH4Cl, pH 
7.2). The suspension was incubated on ice for 7 min to permit red blood cell lysis and lipid 
precipitation. The supernatant was removed, carefully layered over 1 ml FCS in a fresh 
tube and centrifuged again (450 g, 10 min, 4 °C). The pellet was resuspended in 9 ml dead 
cell removal buffer (20 mM HEPES, DPBS (8 mM Na2HPO4, 1.5 mM KH2PO4, 140 mM 
NaCl, 0.3 mM KCl, 0.7 mM CaCl2, 0.5 mM MgCl2, pH 7) supplemented with 0.12 M sorbitol 
and 20 mM glucose and filtered through dead cell removal columns (absorbent cotton wool  
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plugged, short-form, glass pasteur pipettes, wetted with 1 ml RPMI/5% FCS) into 1 ml 
FCS. The cells were centrifuged (450 g, 7 min, 4 °C) and resuspended in 50 ml ice-cold 
MACS buffer (phosphate buffered saline (PBS), 0.5% BSA, 2 mM EDTA) counted and 
pelleted again. The pellet was resuspended in ice-cold MACS buffer (2 x 10
8 cells/ml), 
incubated for 25 min at 4 ºC with anti-CD43 (Ly-48) beads (100 ml anti-CD43
+ beads/ 2 x 
10
8 cells) and passed through a pre-separation filter. The cells were applied to a CS-type 
negative selection magnetic column (Miltenyi Biotec) in a strong magnetic field. Purified 
mature B cells (CD43-negative) were eluted from the column by washing with 50 ml ice-
cold  MACS  buffer.  The  cells  were  centrifuged,  the  pellet  resuspended  in  RPMI-1640 
medium supplemented with 5% FCS, 100 U/ml penicillin, 100 mg/ml streptomycin, and 2 
mM L-glutamine. Live B cells were then counted by trypan blue exclusion. To assess the 
purity of the purified B cells a small aliquot of cells was stained for B220 (CD45R) as 
described in section 2.9.1 and expression of this surface marker analysed by FACS (FACS 
Calibur, BD). 
 
2.5  PBMC (peripheral blood mononuclear cells) purification and culture 
 
Human  peripheral  blood  samples  were  collected  at  the  Rheumatology  Clinic 
(Glasgow Royal Infirmary) and informed consent was obtained from patients and healthy 
controls prior to research use. Venous blood (10-25 ml) was collected in heparinised tubes 
and  either  used  straight  away  or stored at  4° C for  a maximum  of 12 h. PBMCs  were 
isolated by Histopaque-1077 purification. In short, 9 ml blood diluted 1 in 2 with PBS was 
layered over 5 ml Histopaque in a 15 ml centrifuge tube. After 30 min centrifugation (430 g, 
21° C)  the  opaque  layer  containing  the  PBMCs  was  tra nsferred  into  a  fresh  tube  and 
washed 3 times with PBS. PBMCs were cultured in RPMI-1640 media containing 5% FCS, 
100 U/ml penicillin, 100 µg/ml streptomycin, 2 mM L-glutamine at 37° C in a 5% (v/v) CO 2 
atmosphere  at  95%  humidity.  Cells  were  stimulated  using  the  appropriate  stimuli  as 
indicated in the figure legends.  
 
2.6  Purification of human B cells from peripheral blood 
 
Several  purification  procedures  were  established  in  an  attempt  to  ensure  the 
enrichment  of  B  cells  from  human  peripheral  blood  without  their  activation.  After 
purification, human B cells were cultured in RPMI-1640 media containing 5% FCS, 100 
U/ml  penicillin,  100  µg/ml  streptomycin,  2  mM  L-glutamine  at  37° C  in  a  5%  (v/v)  CO 2  
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atmosphere  at  95%  humidity.  Cells  were  stimulated  using  the  appropriate  stimuli  as 
indicated in the figure legends.  
 
2.6.1 Positive selection of CD19
+ B cells using magnetic microbeads 
The  PBMC-pellet  was  resuspended  in  80  µl  MACS  buffer  (PBS  containing  0.5% 
FCS, 2 mM EDTA) per 10
7 cells and incubated with 20 µl anti-CD19 microbeads (Miltenyi 
Biotec) for 15 min at 4° C. The cells were washed on ce with 1-2 ml MACS buffer and the 
pellet was resuspended in 500 µl MACS buffer (up to 10
8 cells). The cell suspension was 
filtered  through  pre-separation  filters  (Miltenyi  Biotec)  and  loaded  on  the  equilibrated 
positive selection column (MS column) followed by three wash steps with 500 µl MACS 
buffer. The cells were eluted by removing the column from the magnet and flushing with 1 
ml MACS buffer. The purity (typically 85-95%) of the cells was assessed by staining with 
anti-CD20-PE antibody and FACS analysis (FACS Calibur, Becton Dickinson) (Fig 2.1). 
 
2.6.2 Purification of B cells by negative selection using human B cell 
isolation kits 
PBMCs were resuspended in 40µl MACS buffer (PBS containing 0.5% FCS, 2 mM 
EDTA) and incubated with 10 µl biotin-antibody cocktail consisting of either anti-CD2, -
CD14, -CD16, -CD36, -CD43, and -CD235a antibodies (Human B cell Kit, Miltenyi Biotec) 
or  anti-CD2,  -CD14,  -CD16,  -CD27,  -CD36,  -CD43,  and  -CD235a  antibodies  (Naïve 
Human B cell Kit, Miltenyi Biotec) per 10
7 cells for 10 min at 4° C. After the addition of 30  µl 
MACS buffer and 20 µl anti-biotin microbeads per 10
7 cells the suspension was incubated 
for another 15 min at 4° C. The cells were then washed with 5-10 ml MACS buffer and the 
pellet was resuspended in 500 µl MACS buffer (up to 10
8 cells). The cell suspension was 
filtered through pre-separation filters (Miltenyi Biotec) and then loaded on an equilibrated 
LS-column and washed 3 times with 3 ml MACS buffer. The flow through was collected 
and the purity of the eluted cells was assessed by staining with anti-CD19-FITC and anti-
CD20-PE  antibodies  and  FACS  analysis  (Fig.  2.2).  Only  about  18%  of  the  PBMC 
population are CD19-FITC positive cells before the purification. Although this percentage 
increased during the purification process (31.8% human B cell isolation kit, 52.5% naïve 
human B cell isolation kit) (Fig. 2.2), a high percentage of other cell classes (T cells and 
monocytes), as shown by anti-CD3 and anti-CD14 staining, could still be detected after 
one round of such B cell enrichment (Fig. 2.3). 
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2.6.3 High speed FACS sorting of CD19
+, CD20
+ B cells 
Peripheral blood was collected by  venipuncture in tubes with 200 µl  heparin and 
PBMC  were  prepared  as described  above.  PBMC  were then either single-stained  with 
anti-CD20-PE, anti-CD19-FITC for positive selection protocols or a mixture of anti-CD3-
APC, anti-CD14-FITC and anti-CD56-PE for negative selection of T cells, monocytes and 
natural killer cells. The cells were stained in 100 µl FACS buffer (PBS containing 0.5% 
FCS,  2  mM  EDTA)  containing  the  antibodies  (all  at  1:50  dilution)  for  15  min  at  room 
temperature. After two washes with 1 ml FACS buffer, the cells were subjected to FACS 
sorting using a FACSAria machine (BD). Positive selection of B cells proved superior in 
terms of purity of the B cells (~ 98.8% CD20-specific, ~99.3% CD19-specific) compared 
with that of populations obtained following negative selection of B cells (~87.8%) (Fig. 2.4). 
However, the B cells generated by all of the protocols showed low viability.  
 
2.7  Purification of antibodies from hybridoma cell lines 
 
Cells (B7.6 clone – rat IgG1; FGK45 clone – rat IgG2a, 2.4G2 clone – rat IgG2b) 
were cultured in RPMI-1640 medium supplemented with 10% FCS, 100 U/ml penicillin, 
100 mg/ml streptomycin, 2 mM L-glutamine and 50 mM β-mercaptoethanol. The antibody-
rich tissue culture supernatants were collected and the relevant Ab purified using protein 
G-sepharose  columns  filled  with  1  ml  protein  G-sepharose  beads  (immunoglobulin 
capacity >20 mg/ml, Pierce) and washed with binding buffer (0.2 M NaH2PO4.2H2O, 0.2 M 
Na2HPO4.2H2O, pH 7.0). Tissue culture supernatant was loaded onto the column at 4
oC 
and the column was washed with binding buffer to elute unbound protein. Immunoglobulin 
was then eluted in 0.5 ml fractions using elution buffer (0.1 M glycine, pH 2.7) into tubes 
containing 0.5 ml 1M Tris base-HCl (pH 8) to raise the pH to neutral levels. The protein 
concentration of each fraction was determined using spectrophotometry to measure the 
absorbance at 280 nm (an optical density of 1.4 was approximately equivalent to 1 mg/ml 
of protein). The protein-rich fractions were pooled and dialysed exhaustively in PBS at 
4° C. The resultant purified Abs were filter-sterili sed and stored at -20
oC. 
 
2.8  Functional assays 
 
2.8.1 DNA synthesis assay 
To be able to divide, cells have to replicate their DNA. Thus, if cells are cultured in 
the presence of radio-labelled bases, such as thymidine, these are incorporated into their 
DNA with the levels of signal being proportional to the amount of DNA synthesised. The  
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most common label used to detect DNA synthesis is [
3H]-labeled thymidine which can be 
detected by scintillation counting. Thus, for the measurement of DNA synthesis, cells (10
5 
cells/well human B cells, 5 x10
5 cells/well mature mouse B cells, 10
4 cells/well WEHI-231) 
were  cultured  in  triplicate  in  round  bottom  microtitre  plates  in  RPMI-1640    media 
supplemented with 2 mM L-glutamine , 1 mM sodium pyruvate, 1% nonessential amino 
acids, 50 mM β-mercaptoethanol, 100 U/ml penicillin, 100 mg/ml streptomycin, 5% FCS in 
the  presence  of  the  indicated  stimuli  at  37°C  in  a  5%  (v/v)  CO2  atmosphere  at  95% 
humidity. [
3H] thymidine (0.5 mCi/ well, Amersham) was added 4 (murine B cells) or 8 h 
(human B cells) before cell harvesting with an automated cell harvester (Perkin Elmer). 
Incorporated label was analyzed by liquid scintillation analysis (Microbeta Trilux, Perkin 
Elmer). Data are presented as cpm +/- SD. 
 
2.9  FACS analysis 
 
2.9.1 Staining for surface markers 
Aliquots of cells (10
5-10
6 per sample) in 5 ml polystyrene tubes (Falcon, BD) were 
washed with 200  l cold FACS buffer at 450 g for 5 min at 4° C. Cells were re-suspended 
in  200   l  Fc  receptor  (FcR)  blocking  buffer  (anti-CD16/32,  clone  2.4G2,  hybridoma 
supernatant,  10%  mouse  serum,  0.1%  sodium  azide)  containing  the  appropriate 
fluorochrome-conjugated or biotinylated primary Abs for 15-30 min in the dark at room 
temperature. Anti-CD16/32 binds to FcγRII/III and the immunoglobulin in mouse serum 
binds to FcγRI, and so the FcR blocking buffer blocks non-specific binding of Ab to such 
FcR-bearing cells. Details of the Ab clones, their specificities and isotype controls used are 
provided  in  Table  2.1. Cells  were  then  washed  with  1  ml FACS  buffer  as before and, 
where appropriate, biotinylated Abs were detected following incubation with fluorochrome-
conjugated streptavidin (BD) for 15-30 min in the dark at room temperature. Finally, cells 
were washed again in FACS buffer re-suspended in 100-300  l FACS buffer for analysis 
using a FACS Calibur (BD) and Flowjo software (version 8.8.6, TreeStar). Two or three-
colour analysis was performed on a minimum of 10,000 events. 
 
2.9.2 Cell cycle analysis by DNA content 
Propidium iodide (PI) is a fluorescent dye that is able to intercalate into DNA in a 
stochiometric fashion enabling determination of the DNA content of cells. Thus, following 
permeabilisation  of  human  B  cells  with  70%  ethanol  for  15  min  on  ice,  cells  were 
centrifuged and the pellet resuspended in 100 µl PI stain solution (PBS containing 0.5%  
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FCS, 2 mM EDTA, 50 µg/ml PI, 50 µg/ml RNAse A) and incubated at 4° C for 30 min. 
FACS buffer (100 µl) was added and the cells filtered through nitex to remove clumps and 
analysed  by  FACS.  However,  due  to  strong  autofluorescence  after  ethanol  treatment, 
WEHI-231 cells and murine B cells were stained following a different protocol. Thus, these 
cells were harvested and washed twice in ice-cold FACS buffer before being resuspended 
in 200 µl PI stain (0.1% (w/v) sodium (tri) citrate, 0.1% (v/v) triton-X-100, 50 µg/ml PI, 50 
µg/ml RNase A) for 45 min on ice. After addition of a further 200 ml of FACS buffer, cells 
were passed through nitex and analysed for PI fluorescence by FACS (FACS Calibur, BD). 
Data were analysed by setting gates that identify the G0/G1 peak which represents 
2n DNA, the cells that are in G2/M phase containing 4n DNA (double the fluorescence 
intensity) and the S phase located between the G0/G1 and G2/M peaks. Cells containing 
sub-diploid  DNA  show  lower  fluorescence  than  the  G0/G1  peak  and  represent  the 
apoptotic fraction (Fig.2.5). 
 
2.9.3 DiOC6 staining of mitochondrial potential 
DiOC6  is  a  cationic  lipophilic  dye  that  is  incorporated  into  the  mitochondrial 
membrane  in  a  manner  that  is  directly  proportional  to  the  mitochondrial  membrane 
potential (MMP). Cells were stained in a solution of 2.5 µM DiOC6 (Molecular Probes) in 
FACS buffer for 30 min at RT. Before analysis by FACS, the cells were washed twice with 
1 ml FACS buffer and passed through nitex to remove cell clumps. The profiles obtained 
were used to set gates to divide cells into those with high (healthy) or low (apoptotic) MMP 
(Fig. 2.6). 
 
2.9.4 CFSE staining of cell division 
CFSE is a cell-permeable dye that becomes trapped inside cells following labelling 
and consequent binding to intracellular proteins. During each cell division therefore, the 
amount of cellular dye is halved and this can be detected as a shift to lower fluorescence 
intensity  by  FACS  analysis  Thus,  each  50%-reduction  of  the  fluorescence  signal 
represents one division (Fig. 2.7). Briefly, prior to this analysis, cells (10
5/sample) were 
resuspended in PBS containing 0.1% BSA and loaded with 2.5 µM CFSE for 10 min at 
37° C. The cells were then washed with 10 ml cold culture medium followed by a wash step 
with 10 ml warm medium followed by culture with the appropriate stimuli. The cells were 
analysed for CFSE-staining (intensity) by FACS analysis of cells in the FL-1 channel. The 
dilution  of  CFSE  in  the  cells  was  then  analysed  using  Flowjo  software  creating  gates 
correlating  with  the  number  of  cycles  of  proliferation  (generations)  the  cells  have 
undergone. As it has been found in this and other laboratories that murine B cells do not  
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generate discrete division peaks, the feasibility of the method was independently validated 
in  this  laboratory  by  Dr.  Angela  Morton  utilising  a  T  cell  transfer  model.  Thus,  in  vivo 
antigen-stimulation of CFSE-labeled transferred T cells displayed CFSE dilution showing 
proliferation upon stimulation compared to unstimulated T cells (Fig. 2.7).  
 
2.9.5 FACS-based caspase activation assay 
This assay (BioVision) utilises a cell-permeable version of the pan-caspase inhibitor 
VAD-FMK conjugated to FITC which irreversibly binds to activated caspases and hence 
allows the detection of such activated caspase in cells. Briefly, cells were plated out (10
6 
cells/well) with the appropriate treatments and incubated for up to 24 h. Cells were then 
transferred into FACS tubes and incubated with 1 µl FITC-VAD-FMK at 37°C/5% CO2 for 
45  min.  The  cells  were  then  washed  twice  with  300  µl  wash  buffer  (supplied  by 
manufacturer) and the pellet was resuspended in 200 µl FACS buffer. The labelled cells 
were analysed by FACS by measuring the fluorescence intensity in the FL-1 channel.  
 
2.10  Signalling assays 
 
2.10.1  LSC (Laser Scanning Cytometry) 
A key method for the in situ analysis of signalling pathways in immune cells has 
been established in this laboratory and involves Laser Scanning Cytometry (LSC) analysis 
of  immunofluorescently-stained  cytospins  or  tissue  [311].  The  use  of  LSC  to  analyse 
stained cells allows quantification and imaging of cell signalling molecules at the single cell 
level  and  within  their  physiological  niche  in  tissue.  Unlike  FACS,  which  only  allows 
detection of positive cells and their fluorescence intensity, the LSC also allows analysis of 
the subcellular localisation of the molecules. This can be very important especially for the 
analysis  of  signalling  pathways  as  the  localisation  often  determines  the  activity  of  a 
molecule.  
 
2.10.1.1  LSC data collection 
Detection of cytocentrifuged cells by LSC involves the use of analysis  “contours” 
(Fig. 2.8A, figure reproduced with kind permission [312]). The primary contour, also called 
the threshold contour, is commonly set on cell nuclei which were stained with a dye that 
binds  DNA,  such  as  DAPI.  To  exclude  detection  of  artefacts  such  as  cell  debris,  the 
minimum detection area  was set to 30 µm
2, allowing nuclei of 30 µm
2 or above to be 
scanned. In order to define the outer edge of the cell and hence allow the calculation of the 
total fluorescence within the cell, the integration contour was then set 10 pixels outside the  
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threshold contour (1 pixel equates to 0.5  m). Furthermore, a peripheral contour was set 
between  the  threshold  and  integration  contours  enabling  the  detection  of  fluorescence 
emitted in the periphery of the cell (Fig. 2.8A). The background fluorescence outside the 
cells  was  measured  by  setting  two  background  contours.  This  value  was  then 
automatically deducted from all measured fluorescence values.  
Before  scanning  each  batch  of  slides  the  detector  gain  voltages  (PMTs)  were 
adjusted in order to optimise fluorescence excitation with the maximum value of 75 for the 
number of saturated pixels. Furthermore, appropriate data collection protocol (.PRO) and 
display (.DPR) files were set up for each experiment [311]. The next step was to set the 
threshold  value  to  a  value  between  5500  and  7500  fluorescence  units  to  ensure  the 
optimal detection of the cells as setting the threshold too high might exclude cells with low 
or medium DAPI staining from the analysis. A very low threshold, on the other hand, can 
lead  to  the  erroneous  detection  of  multiple  cells  as  a  single  event  (Fig.  2.8B,  figure 
reproduced with kind permission [312]). Finally, the slide area was then scanned and the 
data file saved for analysis. 
 
2.10.1.2  Cell cycle analysis by LSC 
It has been shown previously that LSC can be used for the efficient examination of 
the cell cycle status of individual cells [313-315] as it determines both the content and 
concentration of DNA at the same time. Therefore, by plotting Max Pixel (the most highly 
fluorescent pixel value in the cell) against Integral (sum of all fluorescence in the cell) 
values of the nuclear staining, such as DAPI, the different cell cycle stages can easily be 
identified (Fig. 2.9, figure adapted with kind permission from [312]). This is because DAPI 
Max  Pixel  values  correlate  with  concentration  of  the  cellular  chromatin  (condensation) 
whereas the DAPI Integral value correlates with the absolute levels of DNA content. For 
example, cells in S phase (green gate) can be identified by their increased DNA content. 
However, cells in the other mitotic stages (G2/M phase) which also contain high amounts 
of DNA can be differentiated due to the higher level of chromatin condensation (max pixel; 
yellow gate). By contrast, cells arrested at the G1/G0 stage (red gate) of the cell cycle 
contain half the amount of DNA (2n DNA) compared to cells in G2/M (4n DNA) and can 
therefore  be  identified  by  the  lower  DNA  content,  as  detected  by  lower  DAPI  Integral 
values. Cells undergoing apoptosis (blue gate) contain subdiploid DNA content due to their 
fragmented DNA placing them below cells in G1/G0 on the scattergram. New daughter 
cells  (purple  gate)  represent  cells  which  have  recently  undergone  mitosis  and  can  be 
identified due to their small nuclei with still highly condensed DNA. Representative images 
of cells in each stage of the cell cycle were captured using the xy re-location feature of  
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LSC  to  confirm  that  the  cells  in  the  various  cell  cycle  gates  were  morphologically 
consistent with their cell cycle stage as detected on the scattergram [312] (Fig. 2.9).  
 
2.10.1.3  Immunofluorescence staining 
Cytospins were generated by centrifuging cells (0.75 x 10
5) onto glass slides at 40 g 
for  4  min.  The  following  staining  protocol  was  carried  out  at  room  temperature  with 
incubation being performed in a darkened, humidified chamber. Firstly, the cells were fixed 
with 4% formaldehyde in PBS for 15 min and washed with PBS for 5 min, followed by 
incubation with permeabilisation buffer (2% FCS, 2 mM EDTA pH 8.0, 0.1% w/v saponin in 
PBS) for 5 min. Blocking of non-specific binding was performed after three washes with 
PBS (10 s each) with blocking/antibody-dilution buffer (PBS containing 1% BSA, 0.1% w/v 
saponin) for 10-15 min. The cells were then incubated with primary antibody (appropriate 
dilutions  listed  in  Table  2.1)  or  the  equivalent  dilution  of  an  appropriate  IgG 
isotype/irrelevant antibody control for 30 min. Cells were then washed and incubated for 
25  min  with  the  appropriate  HRP  (horse  radish  peroxidase)  -  labeled  anti-Ig  antibody 
(diluted 1:100, Cell Signaling Technology, NEB) followed by another three washes with 
TNT buffer (100 mM Tris base, pH 7.5, 150 mM NaCl, 0.05% Tween-20) before Alexa 
Fluor® 488 tyramide (diluted 1:100, Invitrogen) was added for 10 min. After three washes 
with TNT buffer the cells were stained with 300 nM DAPI (in PBS, 0.1% saponin) for 4 min, 
washed with TNT buffer three times and left to air-dry for 5 min and covered with mounting 
medium (Vector). Pictures were acquired using a laser scanning microscope (Compucyte) 
and quantitatively analysed using Wincyte software version 3.6 (Compucyte). 
 
2.10.2  WideScreen
TM EpiTag
TM ERK pathway assay 
This assay allows simultaneous analysis of multiple signalling molecules and their 
phosphorylation  status  in  a  single  sample.  Briefly,  the  cells  are  lysed  and  the  cellular 
proteins  are  extracted  before  digestion  with  proteases  to  create  peptides.  Antibodies 
specific for particular peptide epitopes are then used to detect molecules of interest. The 
principle of the assay is therefore the same as for other bead-array multiplex assays in that 
the different capture antibodies are bound on beads which emit fluorescence of distinct 
wavelengths and hence allow differentiation of beads coated with antibodies specific for 
the  different  target  peptides.  In  addition,  fluorescently  labeled  detection  antibodies  are 
used to label peptides bound to beads which are then analysed on a Bio-Plex (BioRad) 
machine.  Thus,  whilst  the  beads  are  recognised  due  to  their  specific  emission,  the 
intensity of bound detection antibody can also be measured to yield information on the 
amount of bound peptide relative to defined peptide standards and hence enabling the  
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absolute quantitation of protein in each sample. 
The  EpiTag
TM  assay  (Merck)  was  used  to  detect  phosphorylated  B-Raf  (p-B-
RafS446) with ERK2 as the internal reference control protein. Phosphorylation at S446 
stops auto-inhibition of B-Raf enhancing its activity [316]. The protocol was carried out 
using reagents supplied by the manufacturer and according to their instructions. Briefly, 
0.5  x  10
7  cells/stimulation  were  cultured  for  the  indicated  time  in  the  presence  of 
appropriate stimuli. The cells were then washed twice with ice-cold PBS and lysed by the 
addition  of  100   l  supplemented  lysis  reagent  (lysis  reagent,  1x  phosphatase  inhibitor 
cocktail, 0.5 U/ l benzonase nuclease) and incubation at room temperature for 5 mins with 
occasional vortexing. Subsequently, the samples were transferred to microcentrifuge tubes 
and  incubated for  an  additional  20 min  at  4° C.  Foll owing  this  incubation,  5   l  of  each 
sample were set aside to perform quantitation of the total protein amount by BCA protein 
assay (Pierce) and the remainder of the sample was stored at -70° C until further use. The 
concentration  of  the  samples  was  then  adjusted  to  1  mg/ml  and  100   l  aliquots  were 
digested as follows. Firstly, the lysates were denatured by the addition of 2 mM of the 
reducing agent TCEP (Tris(2-carboxyethyl)phosphine) and incubation at 95° C for 5 min 
before centrifugation of the sample at 12,000 g for 10 min and transfer of the supernatants 
into  fresh  tubes.  Following  alkylation  of  the  supernatant  by  the  addition  of  10  mM  α-
Iodoacetamide  (30  min  at  room  temperature),  proteins  were  digested  with  5.7  mU 
Endopeptidase Lys-C at 37° C overnight. The samples  were then adjusted to 400  l by the 
addition of 287  l Assay Diluent. The detection of p-B-Raf and ERK2-derived peptides was 
carried out by analysis on a Bio-Plex machine (BioRad) according to the manufacturer’s 
instructions.  Briefly,  dilutions  of  the  provided  standard  solutions  were  prepared  by 
consecutive 1 in 3 dilutions in titration buffer (25% lysis reagent, 75% assay diluent). The 
provided  filter  plate  was  pre-wetted  with  100   l  assay  diluent  per  well  and  the  liquid 
aspirated with a vacuum manifold. The capture beads were vortexed and 50  l pipetted in 
each well followed by the addition of either 50  l of the standard dilutions or 50  l of the 
samples which had been further diluted 1 in 4 in titration buffer before addition to the plate. 
After 2 h incubation on a platform shaker the beads were washed three times with wash 
buffer  and  100   l  Biotin-coupled  detection  antibody  was  added.  The  plate  was  then 
incubated for a further hour at room temperature on a platform shaker followed by three 
washes with wash buffer and the addition of 100  l of Streptavidin-PE solution. The plate 
was incubated for 30 min at room temperature after which time the beads were washed 
three times with wash buffer and resuspended in 120  l Assay diluent. Finally, 100 events 
per sample were acquired on a Bio-Plex (BioRad) machine on low gain RP1-setting. 
  
  72 
2.11  PCR 
 
2.11.1  mRNA isolation and reverse transcription 
Total mRNA was isolated from purified B cells or WEHI-231 cells using an RNeasy 
Mini Kit (Qiagen) following the manufacturer’s instructions and the mRNA was stored at -
20° C until further use. Optional DNAse I digestion  was carried to digest possible genomic 
DNA impurities. To this end, DNAse I, amplification grade (Invitrogen), was used as per 
the  manufacturer’s  instructions.  In  short,  the  RNA  sample  was  digested  at  room 
temperature  with  1  unit  DNAse  I  for  15  min  and  then  the  enzyme  was  inactivated  by 
addition of 2.5 mM EDTA and incubation at 65° C for  10 min. Those pretreated samples 
were  then  used  for  reverse  transcription  with  the  Superscript  II  Reverse  Transcriptase 
system  (Invitrogen)  to  transcribe  mRNA  into  cDNA  following  the  manufacturer’s 
instructions. Briefly, between 500 ng and 5 µg of mRNA were incubated with Oligo(dT) 
primers (500 µg/ml) and dNTP mix (10 mM each) at 65°C for 5 min. After the addition of 
0.1 M DTT and 5 x First Strand buffer, the mixture was heated for 5 min at 42° C and 200 
Units of Superscript enzyme were added. The reaction was carried out at 42° C for 50 min 
followed by 15 min at 70° C to inactivate the enzyme . Alternatively, DNAse-digested RNA 
was  transcribed  into  cDNA  using  the  “High  Capacity  cDNA  Reverse  Transcription  Kit” 
(Applied Biosystems) following the manufacturer’s instructions. Thus, between 500 ng and 
5  µg  of  mRNA  were  incubated  with  random  primers,  4  mM  dNTPs  and  50  units 
MultiScribe
TM Reverse Transcriptase for 10 min at 25° C followed  by 120 min at 37° C and a 
final step at 85° C for 5 s. 
 
2.11.2  Real-time PCR by TaqMan® 
Primers  and  probes  (Table  2.2)  were  designed  using  PrimerExpress  software 
(Applied  Biosystems)  and  purchased  from  VH  Bio.  In  some  cases  pre-designed 
primers/probe  supplied  in  the  form  of  Endogenous  Control  Kits  or  Taqman®  Gene 
Expression  Assays  (Applied  Biosystems)  were  used.  TaqMan®  real-time  PCR  was 
performed using a 2 x mastermix (Eurogentec) which contains dNTPs/dUTPs, Hot Gold 
Star  enzyme,  MgCl2,  UNG,  stabilizers  and  the  Rox  passive  reference.  The  probes 
contained  a  reporter  dye  (FAM)  attached  to  the 5’ end  and  a  quencher  dye  (TAMRA) 
attached to the 3’ end (Table 2.1). The PCR reactions were performed in the ABI-prism 
7700  Sequence  Detector  or  the  7900HT  Fast  Real-Time  PCR  System  (Applied 
Biosystems).  The  reactions  were  performed  in  10  µl  total  volume  containing  the  1  x 
mastermix, 200 nM primers and 900 nM probes. Amplification was performed using the  
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following  conditions:  2  min  at  50° C,  10  min  at  95°C ,  followed  by  a  total  of  45  two-
temperature cycles (15 s at 95° C and 1 min at 60° C) .  
 
2.12  Western Blotting, ”pull-down”-based assays and subcellular fractionation 
 
2.12.1  Whole cell lysates 
Mature B cells or WEHI-231 cells (10
7 cells/stimulation) were stimulated as indicated. 
The cells were then washed in PBS and the reactions were terminated by the addition of 
100 ml of ice-cold modified RIPA lysis buffer (50 mM Tris buffer, pH 7.4 containing 150 mM 
sodium chloride, 2% (v/v) NP 40, 0.25% (w/v) sodium deoxycholate, 1 mM EGTA, 10 mM 
sodium  orthovanadate,  0.5  mM  phenylmethylsulfonylfluoride,  10   g/ml  chymostatin,  10 
 g/ml leupeptin, 10  g/ml antipain, 10  g/ml pepstatin A and 10  g/ml aprotinin). After 
resuspending the pellet, the cells were solubilised for 30 min on ice before centrifugation of 
lysates at 16,000 g for 15 min. The resulting supernatants (whole cell lysate) were stored 
at -20
oC before being used for Western Blot analysis. 
 
2.12.2  Nuclear extraction 
An  Active  Motif  Nuclear  Extract  kit  was  used  to  produce  nuclear  and  cytosolic 
fractions. The protocol was followed as per the manufacturer’s instructions (overview in 
Fig.2.10). Briefly, cells (10
7) were incubated with the appropriate stimuli at 37°C in a 5% 
(v/v) CO2 atmosphere at 95% humidity. Samples were washed with 5 ml of PBS containing 
phosphatase inhibitors to terminate any cellular reactions, and then centrifuged for 5 min 
at 400 g. The pellets were resuspended in 500  l of hypotonic buffer by pipetting and then 
incubated on ice for 15 min. Following this, 25  l of detergent (supplied with kit) was added 
and  the  samples  were  vortexed  on  the  highest  setting  for  10  s.  Samples  were  then 
centrifuged at 14,000 g for 30 s and the supernatant removed. This supernatant contains 
the cytosolic fraction and can be stored at -80 °C for further use. The pellet was then 
resuspended  in  50   l  of  complete  lysis  buffer  (containing  DTT  and  protease  inhibitor 
cocktail) and vortexed for 10 s. The samples were then left on ice for 30 min and after a 
further vortexing centrifuged at 14,000 g for 10 min. The resultant supernatant contains the 
nuclear fraction and was stored at -80 °C. 
 
2.12.3  Mitochondrial fractionation 
An Active Motif Mitochondrial Fractionation kit was used to produce mitochondrial, 
nuclear  and  cytosolic  fractions  using  a  slightly  modified  version  of  the  manufacturer’s  
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instructions as follows (overview in Fig.2.10). Briefly, cells (0.5-1 x 10
8) were incubated 
with the appropriate stimulations at 37°C in a 5% (v/v) CO2 atmosphere at 95% humidity. 
To terminate reactions, samples were washed with 2 ml of PBS and centrifuged for 5 min 
at 400 g. The pellets were resuspended in 1 ml of ice cold 1x cytosolic buffer by pipetting 
and then incubated on ice for 15 min. Following this, the cell suspension was transferred to 
a pre-chilled homogeniser and lysed by the application of 40 strokes. The samples were 
then centrifuged at 400 g for 20 min to sediment cell debris, the supernatant transferred 
into a fresh tube and centrifuged at 800 g for 10 min. The supernatant, containing the 
mitochondria, was again centrifuged (8000 g for 20 min) after which the supernatant was 
transferred into a fresh tube (cytosolic fraction) and the pellet washed in 100 µl cytosolic 
buffer (8000 g, 10 min). The pellet was resuspended in 100 µl complete mitochondria lysis 
buffer,  incubated  on  ice  for  15  min  and  vortexed  for  10  s  to  produce  a  solubilised 
mitochondrial fraction. 
 
2.12.4  Subcellular fractionation 
To  obtain  cytoplasmic,  membrane/organelle,  nuclear  and  cytoskeletal  fractions  a 
Cellular  Protein  Fractionation  kit  (Perkin  Elmer)  was  used.  This  kit  utilises  different 
detergents  to  extract  proteins  from  various  subcellular  compartments  due  to  their 
differential  solubility.  The  experiments  were  carried  out  as  per  the  manufacturer’s 
instructions except for slight changes of cell numbers and buffer volumes (overview  in 
Fig.2.10). Briefly, cells (5 x 10
6) were incubated with appropriate stimulations at 37°C in a 
5% (v/v) CO2 atmosphere at 95% humidity. For some experiments, samples were counted 
again after harvesting and cell numbers were adjusted to match the sample with the lowest 
cell count. All buffers were supplemented with protease inhibitors immediately before use. 
Briefly, samples were washed with 2 ml of wash buffer twice (centrifuged at 400 g for 5-10 
min) and the resulting pellet was resuspended in 200 µl ice-cold cytoplasmic buffer. The 
samples were then incubated at 4°C for 10 min on an orbital rotator. The insoluble fraction 
was pelleted by centrifugation at 1000 g for 10 min (4°C) and the supernatant transferred 
to  a  fresh  tube  (cytoplasmic  fraction).  The  pellet  was  resuspended  in  200  µl  chilled 
membrane/organelle buffer and the samples were incubated for further 30 min at 4°C on 
an orbital rotator. The insoluble fraction was again collected by centrifugation (6000 g, 
4°C)  and  the  supernatant,  representing  the  membrane/organelle-enriched  fraction,  was 
transferred to a fresh tube. To acquire the nuclear fraction, the insoluble material from the 
membrane/organelle enrichment was resuspended in 100 µl nuclear buffer followed by 
incubation  at  4°C  for  10  min  on  an  orbital  rotator.  The  cytoskeletal  fraction  was  then  
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pelleted by centrifugation (6800 g, 10 min, 4°C) and the supernatant tranferred to a fresh 
tube (nuclear fraction). The cytoskeletal fraction was resuspended in 100 µl of cytoskeletal 
buffer.  
 
2.12.5  Rap-1 activity assay 
A Rap-1 activation kit (Upstate Biotechnology) was used to determine the activity of 
Rap-1 in WEHI-231 cell samples. Briefly, cells (1.25 x10
7) were harvested after stimulation 
and washed twice with cold TBS (50 mM Tris-HCl pH 7.4, 150 mM NaCl). Cells were 
incubated with 500 µl lysis buffer and the released DNA sheared by passing the lysate 
through a syringe needle. The lysate was cleared by centrifugation (5 min, 13,000 g) and 
50  µl  Ral-GDS-RBD  (Ras-binding  domain  of  the  Ral  guanine  nucleotide  dissociation 
stimulator) agarose slurry added. After 45 min incubation at 4° C the beads were washed 
three  times  with  500  µl  lysis  buffer  (30  s,  13,000  g).  The  agarose  beads  were  then 
resuspended in 40 µl 2x reducing SDS-PAGE loading buffer (NuPAGE system, Invitrogen) 
and boiled for 5 min. Samples were analysed by SDS-PAGE gel electrophoresis followed 
by Western Blotting using anti-Rap-1 antibodies. 
 
2.13  SDS-PAGE gel electrophoresis 
 
The  protein  concentration  of  whole  cell  lysates  or  nuclear,  cytoplasmic  or 
mitochondrial  fractions  was  assessed  by  either  the  BCA  protein  assay  (Pierce)  or  the 
Bradford assay (BioRad). The BCA protein assay is more suited for whole cell lysates 
whereas  the  different  detergents  used  for  the  cytoplasmic,  nuclear  and  mitochondrial 
fractions made it necessary to use the Bradford assay. Equal protein amounts (whole cell 
lysates) or cell equivalents (using the Perkin Elmer Cellular Protein Fractionation kit) of 
samples were resolved using the XCell SureLock Mini-Cell kit with NuPAGE Novex high-
performance  pre-cast  Bis-Tris gels  and  NuPAGE buffers  and  reagents  (all supplied  by 
Invitrogen). The appropriate volume of 4 x NuPAGE LDS (Lithium Dodecyl Sulfate) sample 
buffer and 10 x NuPAGE reducing agent were added prior to heating samples to 70
oC for 
10 min and samples were resolved using NuPAGE Bis-Tris gels (10%, 12% or 4-12%) with 
NuPAGE MOPS or MES running buffer (supplemented with NuPAGE antioxidant) at 200 V 
for 50 min following the manufacturers instructions. The gel was then transferred onto a 
nitrocellulose  membrane  (Amersham)  using  NuPAGE  transfer  buffer  with  20%  (v/v) 
methanol at 30 V for at least 1 h. 
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2.14  Western Blotting 
 
Following transfer, nitrocellulose membranes were washed once in TBS/Tween (0.5 
M  NaCl  and  20  mM  Tris  pH7.5  with  0.1%  (v/v)  Tween-20)  and  blocked  for  1  h  in 
TBS/Tween containing 5% non-fat milk protein. Membranes were then incubated with the 
appropriate  primary  detection  antibody  overnight  at  4
oC.  All  antibodies  were  diluted  in 
TBS/Tween  with  5%  BSA.  Following  incubation  with  primary  antibody,  nitrocellulose 
membranes were washed (5 x 5 min) with TBS/Tween and incubated in the appropriate 
HRP-conjugated secondary antibody containing 5% non-fat milk protein for 1 h at room 
temperature. Nitrocellulose membranes were then washed (5 x 5 min) with TBS/Tween 
and  protein  bands  were  visualised  using  the  ECL  detection  system.  Nitrocellulose 
membranes were incubated in a mixture of equal volumes of ECL solution A (2.5 mM 
luminol, 0.4 mM p-coumaric acid and 100 mM Tris pH 8.5) and ECL solution B (0.002% 
hydrogen peroxide  and 100 mM  Tris  pH8.5) for 1  min  before  exposing  membranes to 
Kodak X-Ray film. Nitrocellulose membranes were sometimes stripped and re-probed with 
an alternative primary antibody. Membranes were stripped at room temperature for 1 h in 
stripping  buffer  (100  mM  2-mercaptoethanol,  2%  SDS  and  62.5  mM  Tris  pH  7). 
Nitrocellulose  membranes  were  washed  thoroughly  in  TBS/Tween  and  checked  for 
residual signal before re-starting the Western Blotting protocol. 
 
2.15  Cloning of Rap-1A WT, Rap-1A G12V and Rap-1A S17N into pcDNA3.1 (-) Zeo, 
pIRES2-AcGFP1 and pLVX-IRES-ZsGreen1 vectors 
 
2.15.1  Transformation of chemically competent bacteria 
One Shot® TOP10 competent Escherichia coli (E. coli; Invitrogen) cells were transformed 
with appropriate plasmids (Table 2.3) as per the manufacturer’s instructions. Briefly, 0.1 - 
0.5 µg plasmid or 5 µl ligation-reaction were added to 50 µl One Shot® cells and mixed by 
gentle tapping. Subsequently, the reactions were incubated on ice for 30 min. Following 
this incubation, the cells were heat-shocked at 42°C for 30 s before being placed on ice. 
Following  the  addition  of  250  µl  pre-warmed  SOC  media  (2%  (w/v)  tryptone,  20  mM 
MgSO4, 0.5% (w/v) yeast extract, 8.6 mM NaCl, 2.5 mM KCl, 20 mM glucose, Sigma), the 
vials were shaken at 3 g for 60 min at 37° C in an Innova 4400 incubator shak er (New 
Brunswick  Scientific  (UK)  Ltd.,  St.  Albans,  Herts,  UK).  Each  transformation  was  then 
spread  on  separate  Luria  broth  (LB) agar plates  containing 100   g/ml  ampicillin  or 50 
 g/ml kanamycin which were incubated at 37° C overnig ht. 
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2.15.2  PCR amplification of Rap-1A WT, Rap-1A G12V and 
RapS17N 
In order to sub-clone Rap-1A WT, Rap-1A G12V and Rap-1A S17 into the pLVX-
IRES-ZsGreen1 vector, the cDNA had to be amplified by PCR to introduce convenient 
restriction sites (Eco RI/Xba I). The pcDNA3.1 constructs (Missouri S&T cDNA Resource 
Center) were used as template DNA for the following PCR reaction. In short, 50 ng of the 
vector were mixed with Taq DNA Polymerase buffer (Invitrogen), 0.5 µM of the forward 
primer  pcDNA3.1-Rap  FW  and  the  reverse  primer  pcDNA3.1-Rap  RV  (for  sequence 
details see Table 2.3B), 0.2 mM dNTP mix (New England Biolabs), 1.5 mM MgCl2 and 
1.25 units of Taq DNA Polymerase (Invitrogen) and the volume adjusted with sterile dH2O 
to  50  µl.  Amplification  was  performed  using  the  following  conditions:  3  min  at  95° C, 
followed by a total of 35 three-temperature cycles (30 s at 94° C, 30 s at 55° C and 1 min at 
72° C) and 10 min at 72° C. The PCR was then separate d on an agarose gel (1% (w/v) 
agarose  in  Tris-Acetate-EDTA  (TAE)  buffer  with  667  ng/ml  of  the  fluorescent  DNA-
intercalating dye, ethidium bromide). Subsequently, the appropriate PCR fragments were 
cut out of the gel and DNA was purified according to the manufacturer’s instructions using 
a Gel Extraction Kit (Qiagen). 
 
2.15.3  Restriction digest 
The vectors (1 µg per reaction) or PCR-fragments (16.8 µl of the 50 µl PCR reaction) 
were  digested  by  the  addition  of  restriction  enzyme  buffer  (Promega),  10  units  of  the 
appropriate restriction enzyme (see Table 2.3C), 0.2 µl BSA solution (Promega) and sterile 
dH2O to a total volume of 20 µl per reaction. The digest was carried out at 37° C for 1 h. 
Following  this  incubation,  the  digested  DNA  was  separated  on  an  agarose  gel,  as 
described above, and bands comprising either vector fragments or inserts were cut out 
and the DNA purified by gel extraction. 
 
2.15.4  Ligation reaction 
Appropriate  vector  fragments  and  inserts/PCR  fragments  (see  Table  2.3C)  were 
ligated  in  the  following  reaction:  5  µl  digested  vector  and  12.6  µl  digested  insert/PCR 
fragment were mixed with T4 DNA ligase buffer (New England BioLabs), 160 units T4 
DNA ligase (New England BioLabs) and incubated for 1 h at room temperature. Aliquots (5 
µl)  of  this  ligation  reaction  were  then  transformed  into  TOP10  E.coli  as  previously 
described and the bacteria were spread on LB agar plates containing 100  g/ml ampicillin 
or 50  g/ml kanamycin which were incubated at 37° C overnig ht. 
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2.15.5  Screening for positive clones 
To screen for bacteria expressing plasmids containing the desired inserts (Rap-1A 
WT, Rap-1A G12V and Rap-1A S17), single bacterial colonies were picked and used to 
inoculate 5 ml LB cultures containing 100  g/ml ampicillin or 50  g/ml kanamycin. The 
bacteria were allowed to grow over night at 37° C, shaking at 5 g. Following this incubation, 
the  cells  were  centrifuged at  6000  g for  3 min and  plasmid  DNA  was  extracted using 
Plasmid  Mini  Kits  (Qiagen).  The  plasmids  were  then  digested  with  the  appropriate 
restriction  enzymes  (see  Table  2.3C),  as  described  above.  Finally,  plasmids  that 
harboured  fragments  of  the  desired  size  were  chosen  and  the  inserts  sequenced 
(Geneservice). Plasmids with the correct sequence were then purified on a larger scale, as 
described below, and stored at -20° C until further use. 
 
2.15.6  Purification of plasmid DNA 
The plasmids were purified using HiSpeed Plasmid Midi Kits (Qiagen, Crawley, UK) 
as per the manufacturer’s instructions. Briefly, single bacterial colonies were picked and  
used to inoculate a starter culture of 5 ml LB broth containing 100  g/ml ampicillin or 50 
 g/ml kanamycin. The cultures were incubated at 37° C with vigorous shaking (5 g) for 6-8 
h before being diluted 1:500 in 100 ml LB broth containing ampicillin or kanamycin and 
cultured at 37° C with vigorous shaking for 16 h. Th e bacterial cells were then harvested by 
centrifugation at 6000 g at 4° C for 20 min and re-suspended in 6 ml buffer  P1 (all buffers 
and components supplied with kit). To lyse the cultures, 6 ml of buffer P2 was added and 
the cultures were mixed gently and incubated at 37°C for 5 min followed by the addition of 
6 ml chilled P3 buffer. Next, the cultures were mixed and poured immediately into the 
barrels of QIAfilter cartridges and incubated at room temperature for 10 min. The plungers 
were then inserted into the QIAfilter cartridges and the cultures were filtered into HiSpeed 
tips (previously equilibrated with 4 ml buffer QBT) and the HiSpeed tips were washed with 
20 ml buffer QC before the relevant DNA was eluted with 5 ml buffer QF and collected in 
15 ml tubes. DNA was then precipitated by addition of 3.5 ml isopropanol and incubation at 
room  temperature  for  5  min.  This  mixture  was  then  filtered  through  a  QIAprecipitator 
before the DNA was washed with 2 ml 70% ethanol. The membrane was then dried by 
forcing air through the QIAprecipitator and the DNA was eluted with 0.5 ml sterile dH2O 
and collected into a 1.5 ml tube. To ensure a maximum yield the elution was repeated 
using the same filter and sample. Finally, the DNA concentration was determined by an 
Eppendorf BioPhotometer (Eppendorf). 
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2.16  Transfection of WEHI-231 cells 
 
The relevant vectors (10 µg; see table 2.3A and Fig. 2.11-12 for information on the 
vectors) were digested with 10 units of Pvu I (pcDNA3.1/pcDNA3.1 Zeo-based vectors) or 
Cla I (pIRES2-AcGFP1-based vectors) (New England Biolabs) for 2 h at 37°C to linearise 
them.  The  DNA  was  then  purified  using  a  PCR  purification  kit  (Qiagen)  following  the 
manufacturer’s instructions and the linearised vector stored on ice until further use. For 
some experiments the vectors (5 µg) were used in a non-linearised form. 
WEHI-231 cells were split 24 h prior to transfection. Before transfection the cells 
(5x10
6) were washed once with electroporation media (RPMI-1640 containing 20% FCS) 
and resuspended at a concentration of 2x10
7 cells/ml. The linearised vector was cooled in 
a cuvette on ice for 5 min and then mixed with the cells followed by another incubation (10 
min) on ice. Following optimisation, electroporation was carried out at 1000 µFarads and 
140 V. After the cells had been left on ice for a further 10 min they were transferred into 
complete  media  (RPMI-1640,  2  mM  L-glutamine,  100  U/ml  penicillin,  100  mg/ml 
streptomycin,  20%  FCS,  1%  non-essential  amino  acids,  1  mM  sodium  pyruvate)  and 
incubated for 48 h at 37°C to recover.  
Alternatively, cells were transfected using the Nucleofector® Kit L (Amaxa). Briefly, 
cells (2x10
6) were washed once with complete media (RPMI-1640 , 2 mM L-glutamine , 
100 U/ml penicillin, 100 mg/ml streptomycin, 5% FCS, 1% non-essential amino acids, 1 
mM  sodium  pyruvate)  and  resuspended  in  100  µl  Nucleofector  solution  L.  Following 
addition of 5 µg of the relevant vector, the cells were transferred into cuvettes (Amaxa) and 
electroporation  was  carried  out  using  the  advised  pre-set  programme  (C-005)  on  the 
Nucleofector™  II  (Amaxa).  The  cells  were  then  transferred  into  complete  media  and 
incubated at 37°C for 48 h.  
Irrespective of the protocol used for transfection the cells were washed through FCS 
once after the recovery phase and resuspended in complete media supplemented with 
varying concentrations of G418 (Promega) or Zeocin (Invitrogen) to select for neomycin- or 
zeocin-resistant gene expression. 
 
2.17  Generation of lentiviral particles and transduction of HT-1080 cells 
 
Lentiviral-based transduction can be used to stably introduce DNA into the genome 
of various cell types [317]. To this end, a lentiviral expression vector containing the gene of 
interest is co-transfected with plasmids expressing the packaging components needed for  
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the assembly of the virus. The cells used for the production of virions are a 293T-based 
packaging cell line (Lenti-X 293 T cells, Clontech) which produces infectious virions after 
transfection  with  the  above-mentioned  vectors  and  releases  them  into  the  supernatant 
which can then be used to transduce the target cells. In this study, pLVX-IRES-ZsGreen1 
was chosen as the parental vector in which the gene of interest was inserted. This vector 
encodes the ZsGreen1 protein which, when excited by a 488 nm laser, fluoresces green 
and  can  be  detected  by  FACS  analysis  (FL-1  channel).  The  gene  of  interest  and  the 
ZsGreen1 gene are connected by an IRES (internal ribosome entry site) sequence. Thus, 
both genes are transcribed as a single mRNA and then simply translated as separate 
proteins at the ribosome. ZsGreen1 therefore acts as a marker protein and expression of 
ZsGreen1 should directly correlate with the expression of the protein of interest. 
 
2.17.1  Production of lentiviral particles in Lenti-X 293 T cells 
Lenti-X 293 T cells were maintained in Dulbecco’s Modified Eagle’s Medium (DMEM) 
containing 4 mM L-glutamine, 4.5 g/L glucose, 1 mM sodium pyruvate, 1.5 g/L sodium 
bicarbonate, and 10% FCS. One day before transfection, the cells were washed once in 
DMEM media containing 10% tetracycline-free FCS and 4 x 10
6 cells were plated out in a 
10  mm  cell  culture  dish.  The  tetracycline-free  FCS  ensures  the  efficient  production  of 
virus-particles, as the packaging system utilises Tet-Off transactivation to drive high-level 
expression  of  the  viral  packaging  proteins.  Tetracycline  present  in  the  media  would 
therefore  reduce  the  expression  of  these  proteins  and  potentially  decrease  viral  titres. 
Transfection of Lenti-X 293 T cells was carried out 12-24 h after plating out the cells using 
the  Lenti-X  HT  Packaging  System  (Clontech)  and  following  the  manufacturer’s 
instructions.  Briefly,  15   l  of  the  Lenti-X  HT  packaging  mix  (contains  the  plasmids 
encoding proteins needed for packaging), 3  g of the various pLVX-IRES-ZsGreen1-based 
vectors  (for  vector  information  see  Table  2.3)  and  sterile  water  (to  make  up  the  total 
volume to 438  l) were mixed with 62  l Lentiphos 1 solution and then 500  l Lentiphos 2 
solution  was  added  drop-wise  while  vortexing.  The  solution  was  incubated  at  room 
temperature for 5 to 10 min to allow the formation of DNA precipitates. After this time the 
solution was added drop-wise to the Lenti-X 293 T cells which were then incubated at 
37° C/5% CO 2 for 8-16 h. Following the replacement of the media, cells were left for an 
additional  48  h.  The  virus-containing  supernatant  was  then  harvested,  aliquoted  and 
stored at -80° C until further use. 
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2.17.2  Transduction of HT-1080 cells with lentiviral particles 
HT-1080  cells  are  a  cell  line  which  is  easily  transduced  by  lentiviruses.  It  can 
therefore be used to test the transduction efficiency of lentiviral particles produced by the 
Lenti-X 293 T packaging cell line. HT-1080 cells were grown in DMEM containing 2 mM L-
glutamine, 4.5 g/L glucose, 1 mM sodium pyruvate, 1.5 g/L sodium bicarbonate, and 10% 
FCS. For transduction, HT-1080 cells (2 x 10
5 cells/well) were seeded into 6-well plates in 
2 ml complete media 12 - 24 h before transduction with the virus-containing supernatants. 
The cells were then transduced by incubating them with 600  l supernatant for 12 h. After 
replacing the media the cells were incubated for an additional 48 h after which they were 
analysed by FACS to detect ZsGreen1 expression.  
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Belgium 
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c/o AXXORA (UK) Ltd. 
P.O. Box 6757 Bingham 
Nottingham NG13 8LS 
 
Amaxa AG 
Nattermannallee 1 
50829 Cologne 
Germany 
 
Amersham/GE Healthcare UK Ltd 
Amersham Place 
Little Chalfont 
Buckinghamshire HP7 9NA 
 
Applied Biosystems 
Lingley House 
120 Birchwood Boulevard 
Warrington WA3 7QH 
 
 
 
 
 
BD Biosciences 
21 Between Towns Road 
Cowley 
Oxford OX4 3LY 
 
BioLegend distributed by 
Cambridge BioScience Ltd. 
24-25 Signet Court 
Newmarket Road 
Cambridge CB5 8LA 
Bio-Rad Laboratories Ltd. 
Bio-Rad House 
Maxted Road 
Hemel Hempstead 
Hertfordshire HP2 7DX 
 
 
BioVision distributed by 
Cambridge BioScience Ltd. 
24-25 Signet Court 
Newmarket Road 
Cambridge CB5 8LA 
 
Calbiochem 
c/o CN Biosciences 
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Padge Road 
Beeston 
Nottingham NG9 2JR 
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Cell Signaling Technology 
New England Biolabs (UK) Ltd. 
73 Knowl Piece,Wilbury Way 
Hitchin 
Hertfordshire SG4 OTY 
 
 
Takara Bio Europe/Clontech 
2 Avenue du President Kennedy 
78100 Saint-Germain-en-Laye 
France 
 
CompuCyte Corporation 
385 University Avenue, 
Westwood 
MA 02090, USA 
 
ECACC 
Health Protection Agency Culture 
Collections 
Health Protection Agency 
Centre for Emergency Preparedness 
and ResponsePorton Down 
Salisbury 
SP4 0JG 
 
 
Eppendorf UK Limited 
Endurance House 
Chivers Way 
Histon 
Cambridge CB24 9ZR 
 
 
Eurogentec Ltd. 
Old Headmasters House 
Unit 1, Building 1 
Forest Business Centre 
Fawley Road, Fawley  
Southampton 
Hampshire SO45 1FJ 
 
Invitrogen Ltd 
Fountain Drive 
Inchinnan Business Park 
Paisley PA4 9RF 
 
Jackson Immunoresearch 
Laboratories 
c/o Stratech Scientific Ltd. 
Unit 7 Acorn Business Centre 
Oaks Drive, Newmarket 
Suffolk CB8 7SY 
 
Kodak Ltd 
Kodak House 
Station Road 
Hemel Hempstead 
Herfortshire HP1 1JU 
 
Merck Serono Ltd 
Bedfont Cross 
Stanwell Road 
Feltham 
Middlesex TW14 8NX 
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Miltenyi Biotec Ltd. 
Almac House 
Church Lane 
Bisley 
Surrey GU24 9DR 
 
Pierce/Perbio Science UK Ltd. 
Unit 9, Atley Way 
North Nelson Industrial Estate 
Cramlington 
Northumberland NE231WA 
 
PerkinElmer Life and Analytical 
Sciences  
Via Tiepolo, 24 
20052 Monza (Milano) 
Italy 
 
Promega UK Ltd 
Delta House 
Southampton Science Park 
Southampton 
Hampshire 
SO16 7NS 
 
 
 
 
 
 
 
QIAGEN Ltd. 
QIAGEN House 
Fleming Way 
West Sussex RH10 9NQ 
Santa Cruz Biotechnology Inc. 
c/o Insight Biotechnology Limited 
PO Box 520 
Wembley HA9 7YN 
 
Sigma-Aldrich Company Ltd 
Fancy Rd 
Poole 
Dorset BH12 4QH 
 
Vector Laboratories Ltd 
Accent Park 
Bakewell Road 
Orton Southgate 
Peterborough PE2 6XS 
 
VH Bio Ltd. 
Unit 11B Station Approach 
Team Valley Trading Estate 
Gateshead NE11 0ZF 
 
Upstate 
c/o Millipore Ltd. 
Units 3&5 The Courtyards 
Hatters Lane 
Watford WD18 8YH
2.18  Figures and Tables 
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Table 2.1 Antibodies  
(A) List of antibodies used for FACS based analysis 
(B) List of antibodies used for the stimulation of cells 
(C) List of antibodies used for Western Blotting 
(D) List of antibodies used for Immunofluorescent staining 
If applicable, optimised dilutions are listed. 
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Figure 2.1 Assessment of purity of CD19
+ MACS-sorted cells 
To assess the purity of the enriched human B cell population, the cells were stained with 
anti-CD20-PE and analysed via FACS relative to an unstained sample. The percentage of 
CD20
+ cells was assessed by gating on live cells judging by their FSC/SSC distribution (A) 
followed by setting a gate on the CD20-expressing cells in the FL-2 channel (B).  
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Figure 2.2 Assessment of B cells purified by negative selection using commercial B 
cell isolation kits 
PBMCs (A) and cells purified by either the B cell isolation kit (B) or naïve B cell isolation kit 
(C) were stained for CD19 expression and analysed by FACS. The percentage of CD19-
positive cells was assessed by gating on live cells judging by their FSC/SSC distribution as 
described  in  figure  2.1  followed  by  setting  a  gate  on  the  CD19-expressing  cells  as 
detected in channel FL-1 by anti-CD19-FITC antibodies and by using unstained cells as a 
negative control.  
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Figure 2.3 T cell and monocyte contamination after B cell enrichment 
B  cells  purified  using  the  B  cell  isolation  kit  were  stained  for  CD3  (A)  or  CD14  (B) 
expression and analysed by FACS. The percentage of CD3
+ or CD14
+ cells was assessed 
by gating on live cells judging by their FSC/SSC distribution as described in figure 2.1 
followed by setting a gate on the CD3-APC (FL-4 channel) or CD14-FITC (FL-1 channel) 
expressing cells using unstained cells as a negative control.  
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Figure 2.4 Purification of B cells by high speed FACS sorting  
Cells  from  a  healthy  individual  were  collected  and  PBMCs  were  purified  by  density 
centrifugation. The cells were stained  with either anti-CD20-PE or anti-CD19-FITC and 
selected for fluorescence-positive cells. To purify B cells by negative selection, PBMCs 
were stained with anti-CD3-APC, anti-CD14-FITC and anti-CD56-PE and the unstained 
cells were selected. The purity of the CD20- (A), CD19- (B) or negatively-selected cells (C) 
was assessed by staining for either CD20 or CD19 expression. Unstained cells were used 
to set the gates determining the percentage of CD20-PE positive cells detected in the FL-2 
channel in the CD19-sorted population or the CD19-FITC positive cells (FL-1 channel) in 
the CD20-sorted and negatively selected populations.  
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Figure 2.5 FACS determination of cell cycle status by analysis of PI-stained cells 
WEHI-231 cells were stained with PI and analysed by FACS using histograms for the FL-3 
(A;  linear  )  and  FL-2 (B;  log) fluorescence  to gate  on  apoptotic cells (subdiploid DNA 
content), cells in G0/G1 phase of the cell cycle (2n DNA), cells in G2/M phase (4n DNA) or 
cells in S phase (DNA content between 2n and 4n).  
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Figure  2.6  Analysis  of  mitochondrial  membrane  potential  (MMP)  using  DiOC6 
fluorescence 
WEHI-231 cells were stained with DiOC6 (2.5 µM) and analysed by FACS. Gates were set 
using FL-1 fluorescence histograms in order to identify populations of cells with high or low 
levels of DiOC6 fluorescence. Anti-IgM treated WEHI-231 (B) cells show an increase in the 
percentage of cells expressing lower DiOC6 fluorescence compared to untreated cells (A) 
indicating that these cells have dissipated their mitochondrial membrane potential which is 
an early sign of apoptosis.  
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Figure 2.7 Analysis of cellular proliferation using the cell division stain, CFSE 
To  assure  the  technical  feasibility  of  CFSE  dilution  as  a  method  for  the  detection  of 
proliferation BALB/c recipients were immunised s.c. with OVA (100  g) in 100  l PBS/50% 
CFA 24 h after adoptive transfer of CFSE-labelled Ag-specific Tg TcR (KJ1.26
+) T cells. 
On day 5 after immunisation, inguinal lymph nodes were harvested from unimmunised (A) 
and immunised (B) mice and the CFSE staining in Ag-specific CD4
+ T cells was assessed 
by flow cytometry. Control mice (unimmunised) were injected s.c. with 100  l PBS (Figure 
adapted with kind permission from [312]). 
Purified human B cells were stained with CFSE before culturing them with F(ab’)2 anti-
IgM/IgG for 48 h (D). A sample of the cells before culture (C) was used to set multiple 
gates using FlowJo software. The gates were set to each represent one round of division 
starting with gate 0 representing undivided cells. 
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Figure 2.8 The principle of LSC cell detection 
LSC analysis employs a series of contours (A) such as the threshold contour which is 
commonly set on nuclei. Furthermore, the integration and peripheral contours are used to 
define different parts of the cell. The integration contour is based on the size of the cell or 
detection  of  a  cell  surface  marker,  as  it  defines  the  outer  edge  of  the  cell.  The  inner 
peripheral contour is set one pixel out from the threshold contour and the outer peripheral 
contour is set one pixel in from the integration contour, allowing definition of the periphery 
of the cell. Detection of a cell is determined by the nuclear fluorescence it emits which has 
to be above a certain threshold set by the user (B). The correct setting of the threshold is 
important as a high threshold enables to detect individual cells, whereas a low threshold 
might  lead  to  the  detection  of  multiple  cells  as  one  event.  Figure  taken  with  kind 
permission from [312]. 
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Figure 2.9 Analysis of cell cycle progression by LSC 
Nuclei of cytocentrifuged cells were stained with DAPI and analysis carried out by LSC by 
plotting the Max Pixel value (depicting chromatin condensation) along the x-axis and the 
Integral value (representing DNA content) along the y-axis of the scattergram. The plotted 
cells  were  then  gated  according  to  their  xy-position  on  the  scattergram,  which  allows 
identifying cells in S phase (green gate) by their increased DNA content. Moreover, cells in 
the other mitotic stages (G2/M phase) which also contain high amounts of DNA can be 
differentiated due to a higher level of chromatin condensation (yellow gate). Cells arrested 
at the G1/G0 phase (red gate) of the cell cycle contain half the amount of DNA (2n DNA) 
compared to cells in G2/M (4n DNA) and can therefore be identified by the lower DNA 
content, as detected by lower DAPI Integral values. Cells undergoing apoptosis (blue gate) 
contain subdiploid DNA content due to their fragmented DNA placing them below cells in 
G1/G0 on the scattergram. Representative images of cells validating each stage of the cell 
cycle were captured using the slide xy-re-location feature of LSC and are shown here. 
Figure adapted from [312]. 
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Table 2.2 Primers and probes 
The table shows the sequences of the primers and probes used for quantitative RT-PCR 
or TaqMan® real-time PCR and the covalently attached dyes and quenchers. 
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Figure 2.10 Protocols used for cellular fractionations 
Three different commercially available kits were used to produce subcellular fractions. 
(A) Nuclear fractionation (nuclear/cytosolic fractions) using a kit from Active Motif. 
(B) Mitochondrial fractionation using a kit from Active Motif. 
(C) Cytoplasmic,  membrane/organelle,  nuclear  and  cytoskeletal  fractions  were 
obtained utilising a Cellular Protein Fractionation kit from Perkin Elmer. 
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Table 2.3 Table of vectors used for transfection of WEHI-231 
(A) List of vectors used in this study for the transfection of WEHI-231 B cells 
(B) Primers  used  for  the  amplification  of  Rap-1  coding  region  from  pcDNA3.1-based 
vectors 
(C) Parental  plasmids  and  cloning  sites/enzymes  used  for  the  cloning  of  the  listed 
constructs 
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Figure 2.11 Vector map of pcDNA3.1 (+) and pcDNA3.1 (-) Zeocin 
(A) pcDNA3.1 (+) and (B) pcDNA3.1 (-) Zeocin both contain a human cytomegalovirus 
(CMV) promoter which permits high level expression of the gene of interest. They encode 
a multiple cloning sites (MCS) in forward or reverse orientation and pcDNA3.1 (+) harbours 
a neomycin resistance gene whereas pcDNA3.1 (-) Zeocin contains the gene encoding a 
zeocin  resistance  gene.  These  antibiotic  resistance  genes  allow  stable  transfection  of 
mammalian  cells  following  selection  by  culturing  with  the  antibiotics  G418  or  Zeocin, 
respectively. Expression of the resistance genes is controlled by the SV40 early promoter 
and the SV40 early polyadenylation signal. The presence of a pUC origin of replication 
allows  replication  and  growth  in  E.  coli  and  the  ampicillin  resistance  gene  enables 
selection of the plasmid in E. coli. Vector maps are courtesy of Invitrogen.  
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Figure 2.12 Vector map of pIRES2-AcGFP1 and pLVX-IRES-ZsGreen1 
Both (A) pIRES2-AcGFP1 as well as (B) pLVX-IRES-ZsGreen1 contain a multiple cloning 
site (MCS) and an Internal Ribosomal Entry Site (IRES) of the encephalomyocarditis virus 
followed  by  green  fluorescent  protein  (GFP)  of  Aequorea  coerulescens  or  green 
fluorescent protein from Zoanthus sp (ZsGreen1), respectively. This allows the bicistronic 
expression of the gene of interest and the marker proteins GFP or ZsGreen1. High level 
expression  of  the  gene  of  interest  is  ensured  by  the  human  cytomegalovirus  (CMV) 
promoter.  pIRES2-AcGFP1  harbours  a  neomycin  resistance  gene  which  allows  stable 
transfection of mammalian cells following selection with the antibiotic G418. Expression of 
the resistance genes is controlled by the SV40 early promoter. pLVX-IRES-ZsGreen1 on 
the other hand does not encode a mammalian resistance gene. The presence of a pUC 
origin  of  replication  in  both  vectors  allows  replication  and  growth  in  E.  coli  and  the 
ampicillin or kanamycin resistance gene enables selection of the plasmid in E. coli. pLVX-
IRES-ZsGreen1 is a HIV-based vector which has been optimised for the production of 
lentiviral  particles.  Thus,  it  contains  the  woodchuck  hepatitis  virus  posttranscriptional 
regulatory element (WPRE) which promotes RNA processing events and nuclear export of 
viral  RNA.  Furthermore,  the  Rev-response  element  (RRE)  increases  viral  titres  by 
enhancing the transport of unspliced RNA from the nucleus. Vector maps are courtesy of 
Clontech. 
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3  Signalling involved in negative selection of immature B cells 
 
3.1  Introduction 
 
The  immune  system  generates  an  extremely  diverse  repertoire  of  antigen-
specific  B  cells.  The  drawback  of  this  diversity  is  the  potential  to  produce  (cross)-
reactivities  against  host  components.  Thus,  because  of  their  potential  to  initiate 
immune responses against self-molecules, B cell development and maturation is tightly 
regulated  to  ensure  tolerance  against  self.  For  example,  B  cells  have  to  undergo 
negative selection during the immature B cell stage which ensures the deletion of the 
majority of autoreactive clones in the bone marrow. Thus, whereas ligation of the BCR 
on mature B cells initiates activatory signals, on immature B cells it leads to either 
receptor  editing,  anergy  or  deletion  by  apoptosis  [36].  However,  the  differential 
signalling mechanisms employed by mature and immature B cells to effect the distinct 
functional outcomes have still not been fully elucidated. Indeed, the majority of signals 
utilised downstream of the BCR in mature and immature B cells appear to be very 
similar. For example, as with mature B cells, the BCR of immature B cells can couple to 
the ERK MAPK, PI3 kinase and PLCγ pathways. 
Nevertheless, it is possible that differences between BCR signalling in mature 
and immature B cells might reflect differential expression levels, kinetics or localisation 
of such signalling elements. Furthermore, there is increasing evidence that there are 
some major differences in the expression and/or nature of downstream mediators of 
the above mentioned pathways in mature and immature B cells. Thus, immature B cells 
express cPLA2, a phospholipase which is not expressed by mature B cells [318] and 
hence,  the  ligation  of  the  BCR  leads  to  the  activation  of  cPLA2  and  consequent 
induction of apoptosis in immature, but not mature, B cells. Similarly, another class of 
phospholipase,  phospholipase  D  (PLD)  is  activated  differentially  in  mature  and 
immature B cells [319]. For example, in mature, but not immature, B cells BCR-ligation 
induces  activation  of  a  phosphatidyl-inositol  specific  PLD  isoform  which  can  create 
phosphatidic acid which is converted to DAG potentially feeding into the activation of 
PKC enzymes [319]. The lack of this activating PLD-dependent pathway in immature B 
cells  might  therefore  contribute  to  their  inability  to  proliferate  upon  BCR-ligation. 
Moreover, whilst the initiation of calcium mobilisation is not impaired in immature B 
cells, the hydrolysis of PIP2 by PLCγ is reduced [320] also resulting in lower production 
of DAG than the levels required for the stronger activation of PKCs observed in mature 
B cells. Consistent with this, differential BCR-dependent activation of PKCs is thought 
to provide another crucial difference as defective PKC activation has been implicated in 
driving  BCR-induced  apoptosis  of  immature  B  cells  [321,322].  For  example,  it  was  
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shown  that  enforced  activation  of  PKCβ  can  inhibit  BCR-induced  apoptosis  of 
transitional immature B cells and that blocking PKCβ activation in mature follicular B 
cells makes them more prone to die by apoptosis after BCR-ligation [322]. Consistent 
with this, the downstream effector of PKCβ involved in the survival of immature B cells 
is thought to be NF-κB. Indeed, PKCs can activate NF-κB which in turn increases the 
expression of survival factors such as c-Myc, Bcl-xL and Bcl-2 [131,323]. 
Moreover, c-Myc also plays an important role in the regulation of the cell cycle, 
specifically  in  the  progression  through  G1  and  into  S  phase.  It  is  therefore  not 
surprising that reduction of c-Myc was found to be linked to initiation of growth arrest 
and apoptosis in  immature B cells or  immature B cell  lines such as the WEHI-231 
lymphoma [324]. Furthermore, constitutive expression of c-Myc in B cells expressing 
an  autoreactive  BCR  led  to  an  increase  of  autoreactive  clones  appearing  in  the 
periphery  of  a  double  transgenic  mouse  model  system.  These  mice  express  a 
transgene encoding a BCR specific for hen-egg lysozyme (HEL) as well as another 
transgene resulting in the ubiquitous expression of HEL thereby turning HEL into a neo 
self-antigen. In the absence of c-Myc overexpression the peripheral B cells in these 
mice  are  anergic  due  to  constant  exposure to  the  neo  self-antigen  HEL  [325]. The 
increase of HEL-specific and hence autoreactive clones seen in mice overexpressing 
c-Myc therefore argues for a role of c-Myc in the regulation of negative selection in 
immature B cells [326].  
Such  differential  BCR-signalling  between  mature  and  immature  B  cells  might 
partly  be  due  to  a  difference  in  the  assembly  of  the  initial  BCR-related  signalling 
complex.  Indeed,  in  recent  years  many  studies  have  revealed  the  importance  of 
membrane organisation in signalling. These studies proposed that efficient assembly of 
signalling  complexes  at  the  membrane  depends  on  so-called  lipid  rafts  which  are 
sterol-  and  sphingolipid-enriched  domains. In  mature  B  cells,  BCR  ligation  leads  to 
rapid  localisation  of  the  BCR  into  these  lipid  rafts  and  initiation  of  signalling  [327]. 
Immature B cells however, were found to display a reduced ability to re-localise their 
BCR into lipid rafts upon antigenic stimulation [328] and this has been proposed to be 
due to lower levels of cholesterol in immature B cells [329]. Differential raft formation 
could  therefore  potentially  influence  the  assembly  of  the  signalling  complex 
downstream of BCR-ligation thereby changing the signalling initiated at different stages 
of B cell development. 
In addition to these intrinsic signalling differences, the bone marrow environment 
has also been identified as having an influence on the fate decisions of immature B 
cells. For example, the bone marrow was found to contain Thy-1
dull DX5
pos cells which 
appear to be responsible for directing the response of autoreactive immature B cells 
towards receptor editing rather than apoptosis. Thus, lack of these cells increases the  
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number  of  immature  B  cells  undergoing  apoptosis  in  mixed  bone  marrow  cultures 
compared to cultures containing this cell subset [330]. The lack of these cells in the 
periphery in vivo could therefore explain the preferential induction of receptor editing in 
the bone marrow compared to BCR-dependent induction of apoptosis, which is the 
predominant response of transitional immature cells in the periphery. 
 
3.1.1 ERK MAP kinase signalling regulates proliferation and 
apoptosis in B cells 
Activation of the ERK MAPK cascade is important in the regulation of mature B 
cell proliferation [331] and can be initiated by BCR-ligation and to a lesser extent by 
CD40 signalling [332]. However, activation of ERK has also been implicated in BCR-
induced apoptosis and growth arrest by studies showing that cross-linking the BCR on 
WEHI-231 cells causes rapid upregulation of ERK activation [333]. Subsequently, work 
from this laboratory showed that ERK can play a dual role in determining functional 
responses of the immature B cell line, WEHI-231, linking it to apoptosis as well as 
proliferation. Thus, sustained cyclic activation of ERK was found to be necessary to 
maintain the spontaneous proliferation of WEHI-231 cells. By contrast, cross-linking of 
the antigen receptors on such WEHI-231 B cells stimulated a strong transient ERK 
activation (< 4h) but abrogated the cyclic activation of ERK, resulting in growth arrest 
and apoptosis [307,310]. The link between this strong transient ERK activation and 
apoptosis was provided by cPLA2, a known substrate of ERK. Thus, upon BCR-ligation 
cPLA2 is upregulated and activated by ERK-mediated phosphorylation, followed by its 
translocation to the mitochondria where it catalyses the production of arachidonic acid 
causing  the  mitochondrial  membrane  potential  to  dissipate  [307]  (Fig.3.1).  Such 
disruption of mitochondrial integrity leads to loss of cellular ATP and initiation of an 
intrinsic mitochondrial apoptosis pathway which was found to be caspase-independent. 
Instead, the main executioner protease seems to be cathepsin B which is activated 
downstream of BCR-ligation. In confirmation of a role for this protease in such BCR-
induced  apoptosis,  cell  death  could  be  prevented  by  the  cathepsin  B  inhibitor  EST 
[307].  
The  positive  role  for  sustained  cycling  ERK  activation  in  the  survival  and 
proliferation of WEHI-231 cells has been confirmed with several pieces of evidence. 
For example, BCR-induced as well as pharmacological (olomoucine) - induced growth 
arrest correlates with abrogation of the cyclic ERK activation [310]. Moreover, even in 
the presence of apoptotic BCR-signalling, CD40-ligation, a known rescue signal from 
growth arrest and apoptosis, re-instates the sustained cyclic activation of ERK. More 
direct evidence for a role of such ERK activation in CD40-mediated rescue from growth 
arrest  was  obtained  by  using  pharmacological  inhibition  of  ERK  with  MEK-specific  
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inhibitors PD98059 or UO126. Thus, inhibition of cyclic ERK activation downstream of 
CD40 ligation abrogated the ability of such signalling to rescue cells from BCR-induced 
growth arrest [310]. Finally, inhibition of ERK activation in otherwise untreated WEHI-
231  cells  reduced  their spontaneous  proliferation  and  increased  levels  of  apoptosis 
indicating a role for ERK in the survival as well as the spontaneous proliferation of 
these cells [310].  
 
3.1.2 The role of CD40 signalling 
CD40 signalling plays a pivotal role in B cell biology regulating their proliferation, 
activation,  survival  and  maturation-dependent  effector  functions  such  as  class-
switching and development of plasma cells [190]. Moreover, it has been shown that 
CD40  can  rescue  immature  B  cells  from  BCR-induced  apoptosis  and  prevent 
spontaneous death of mature B cells [334]. Ligation of CD40 appears to antagonise 
BCR-mediated  apoptosis  by  initiating  signals  which  stabilise  the  mitochondrial 
membrane thereby avoiding ATP depletion and apoptosis [307]. A key mechanism is 
the CD40-dependent upregulation of anti-apoptotic Bcl-2 family members such as Bcl-
xL, Bcl-2 or A1 [335-338]. Previous work in our laboratory underpins the important role 
of Bcl-xL  in CD40-mediated rescue from apoptosis. For example, overexpression of 
Bcl-xL in WEHI-231 cells was sufficient to mimic CD40 signalling in protecting these 
cells from BCR-induced apoptosis by preventing the dissipation of the mitochondrial 
membrane potential and subsequently activation of the executioner protease cathepsin 
B  [294].  This  protection  from  apoptosis  was  achieved  by  two  Bcl-xL-dependent 
mechanisms (Fig.3.1). Firstly, Bcl-xL, by locating to the mitochondria itself, stabilises 
the mitochondrial membrane and secondly, it inhibits the translocation of cPLA2 to the 
mitochondria.  The  finding  that  Bcl-xL  overexpression  also  protected  cells  from 
apoptosis induced by treatment with exogenous arachidonic acid (AA) implies that Bcl-
xL  can  stabilise  the  mitochondria  in  BCR-dependent  apoptosis,  at  least  in  part,  by 
counteracting the effects of AA produced by cPLA2 [294].  
As mentioned above, CD40 not only prevents BCR-induced apoptosis but also 
rescues WEHI-231  cells  treated  with  anti-IgM from growth  arrest  and restores  their 
proliferation [310]. However, in this case, overexpression of Bcl-xL was not sufficient to 
mimic the effects of CD40-ligation. Indeed, BCR stimulation of Bcl-xL-expressing WEHI-
231 cells caused similar levels of growth arrest as seen in untransfected wild-type cells. 
These results, in conjunction with the need for (Bcl-xL-independent) restoration of cyclic 
ERK  activation  for  CD40-dependent  rescue  from  growth  arrest,  implicated  the 
existence of at least two independent pathways mediating rescue from apoptosis and 
growth arrest. Thus, CD40-mediated upregulation of Bcl-xL is crucial in the prevention 
of apoptosis but does not affect growth arrest whereas the ERK-dependent pathway is  
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involved in rescue from BCR-dependent growth arrest but not apoptosis [294,310]. The 
exact mechanisms regulating CD40-dependent restoration of cyclic ERK have still to 
be  delineated  but  preliminary  data  suggests  that  production  of  prostaglandins  and 
leukotrienes  is  involved  in  proliferation  of  WEHI-231  cells.  Thus,  inhibitors  of 
cycloxygenase 2 (Cox2) and lipoxygenase (Lox), the enzymes converting arachidonate 
to prostaglandins and leukotrienes, respectively, promote growth arrest. Interestingly, 
expression of PGE2, a product of Cox2 which can potentially have growth promoting 
effects [339], is reduced upon BCR signalling and restored by CD40-ligation in WEHI-
231  cells  [294].  Additionally,  pharmacological  inhibition  of  Cox2  and  Lox  abrogated 
cyclic activation of ERK in CD40-stimulated WEHI-231 cells providing a more direct link 
between  prostaglandin/leukotriene  synthesis  and  CD40-mediated  regulation  of  ERK 
levels [294]. Therefore, CD40-signalling might restore cyclic ERK activation and hence 
proliferation through a novel PGE2-dependent pathway.  
 
3.1.3  Regulation of ERK MAP kinase activation 
The ERK MAPK cascade can be regulated by several mechanisms. For example, 
negative feedback regulation can act at multiple levels with ERK phosphorylating and 
thereby inhibiting some of its own upstream regulators such as MEK1/2 [340] and Raf 
[341].  In  addition,  ERK  activation  of  the  downstream  serine/threonine  kinase  RSK2 
leads to the phosphorylation of the Ras-GEF Sos, preventing it from interacting with 
Grb-2 and translocating to the plasma membrane, resulting in a consequent reduction 
of Ras activation [342]. Moreover, ERK can regulate some of its negative regulators, 
such  as  the  dual-specificity  phosphatase  1  (DUSP1,  also  known  as  MKP-1),  a 
phosphatase  which  can  dephosphorylate  and  hence  inactivate  ERK.  Thus,  ERK-
mediated  phosphorylation  of  DUSP1  contributes  to  its  stabilisation  [343]  thereby 
creating another negative feedback loop causing downregulation of ERK activation. All 
these  mechanisms  might  therefore  contribute  to  avoiding  uncontrolled  ERK  MAPK 
responses.  
 
3.1.3.1  Scaffold proteins 
An additional level of regulation is provided by scaffold proteins which are able to 
bind two or more components of the same signalling cascade bringing them into close 
contact. Therefore, these scaffold proteins can act to control the substrate specificity of 
a pathway, target the signalling complex to various subcellular localisations or link the 
cascade to a specific upstream regulator [344]. The best studied scaffold protein for the 
ERK cascaded is kinase suppressor of Ras (KSR) [345] which can bind Raf, MEK and 
ERK  [344].  Depending on  the  expression  levels  of  KSR,  binding  to  ERK  has  been 
shown to have different outcomes. Thus, at optimal levels, KSR increases activation of  
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ERK  whereas  an  excess  of  KSR  over  its  ligands  inhibits  ERK  [346,347].  The 
importance  of  KSR  in  vivo  was  confirmed  by  a  study  using  KSR1-deficient  T  cells 
which showed a defect in their activation [348]. Another ERK-specific scaffold protein is 
MEK  partner-1  (MP-1),  a  positive  regulator  of  ERK  which  enhances  the  B-Raf-
mediated phosphorylation of MEK1 [349].  
 
3.1.3.2  MAPK phosphatases 
A major mechanism of ERK inhibition is the direct dephosphorylation of the T-X-Y 
motif in the activation loop of the MAPKs. There are three types of phosphatases able 
to catalyse such dephosphorylation of MAPKs: tyrosine phosphatases, serine/threonine 
phosphatases and dual-specificity (threonine/tyrosine) phosphatases [350]. 
For example, upon activation by protein kinase A, the tyrosine protein phosphatase 
hematopoietic PTP (HePTP) can keep ERK1/2 in a dephosphorylated state causing 
reduced activity of ERK1/2 [351]. Indeed, HePTP has been shown to inhibit ERK1/2, as 
well  as  p38,  following  its  activation  downstream  of  the  TCR  [352].  Such 
dephosphorylation does not only influence ERK activity but also regulates its nuclear 
translocation.  Hence,  HePTP-dependent  dephosphorylation  of  ERK2  inhibited  its 
localisation  to  the  nucleus  in  K562  myelogenous  leukaemia  cells  [353].  Two  other 
tyrosine  phosphatases,  PTP-SL  and  STEP  were  shown  to  have  similar  effects  on 
ERK2 in Cos-7 and HEK-293 cells, inhibiting the activation and nuclear translocation of 
ERK2 by dephosphorylation [354]. 
Several serine/threonine protein phosphatases have been identified that regulate 
the activity of ERK, JNK and p38 by direct dephosphorylation or by targeting upstream 
activators  of  these  MAPKs  [355].  Protein  phosphatase  2A  (PP2A)  is  one  such 
serine/threonine phosphatase involved in the regulation of the ERK pathway. It has 
been shown to influence ERK activation by interacting with its upstream modulators 
such as Shc, Raf-1 or MEK1/2. For example, PP2A can dephosphorylate and inhibit 
Raf-1  and  MEK  downstream  of  the  PDGF  receptor  in  NIH-3T3  cells  leading  to 
suppression of ERK [356]. Moreover, in vitro PP2A was shown to dephosphorylate not 
only MEK1/2 but also ERK1/2 itself [357] and in PC12 cells inactivation of the early 
transient  ERK  signal  was  achieved  by  PP2A-mediated  dephosphorylation  [358]. 
Overexpression  of  a  dominant-negative  form  of  PP2A  in  mouse  brain  caused  an 
increase in MEK1/2 phosphorylation thereby providing an in vivo model confirming the 
activity of PP2A as an important regulator of the ERK MAPK cascade [358]. 
DUSP can dephosphorylate threonine and tyrosine residues and can therefore 
directly  dephosphorylate  the  T-X-Y  motif  in  MAPKs  causing  their  inactivation  [359]. 
Besides regulating the phosphorylation status of MAPK, some of these phosphatases  
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have also been implicated in determining the localisation of their targets, for example, 
MKP-3 was found to localise ERK1/2 in the cytoplasm [360].  
MKPs, which can be regulated at both the transcriptional as well as their enzyme 
activity level, play an important role in feedback-type regulation of MAPKs [361]. For 
example,  induction  of  MKP-1  and  -2  expression  is  enhanced  by  ERK-dependent 
mechanisms resulting in downregulation of ERK activity by dephosphorylation of the 
TEY  activation  motif  [361].  Similarly,  ERK-mediated  phosphorylation  and  thereby 
stabilisation of MKP-1 can also lead to reduced ERK activation [343]. However, there 
are also reports supporting the existence of positive feedback loops due to increased 
ERK-dependent  degradation  of  dual-specificity  phosphatases  [362].  Dual-specificity 
phosphatases can regulate all three families of MAPK: ERK, JNK and p38. Indeed, 
each phosphatase has a different set of substrates allowing the selective inhibition of a 
defined  subset  of  MAPKs  and  therefore responses  in  the  cells  [352].  For  example, 
PAC-1 is a selective phosphatase for ERK and p38 whereas MKP-1 can interact with 
all three MAPKs and MKP-2 preferentially dephosphorylates ERK and JNK [363,364]. 
PAC-1 is of particular interest, as it is regulated in immune cells upon activation. 
It was identified originally as a mitogen-inducible gene in human T cells [365] and was 
consequentially found to be highly upregulated in activated immune system cells such 
as B and T cells [366] implicating a role for PAC-1 in the regulation of immune cells 
[367]. Interestingly, the upregulation of PAC-1 expression in activated immune cells 
depends  on  ERK,  further  underpinning  the  important  role  of  negative  feedback 
mechanisms in the MAPK cascades [365,366]. For example, ERK, which is activated 
by  TCR-ligation  in  Jurkat  cells,  in  turn  increases  expression  of  PAC-1  thereby 
terminating ERK activation [368]. Interestingly, p53 was recently identified as another 
transcriptional regulator of PAC-1, inducing an increase in its expression which was 
found  to  be  necessary  for  p53-mediated  apoptosis,  possibly  by  inhibiting  ERK 
activation [369]. A study using PAC-1-deficient mice has shown that this phosphatase 
may also play a role in regulating auto-immune responses. Perhaps surprisingly, lack 
of  PAC-1  reduced  the  inflammatory  responses  in  an  antibody-mediated  model  for 
arthritis. This study therefore highlighted the complexity of the MAPK signalling network 
as PAC-1 deficiency increased the activity of JNK but subsequently reduced activation 
of  ERK  implicating  the  existence  of  regulatory  cross-talk  between  the  three  MAPK 
pathways [367]. Thus, PAC-1 could be one of the major regulators of MAPK activation 
in immune system cells. 
 
3.1.4  The role of ERK MAPK in cell cycle regulation 
As  stimulation  with  mitogens,  which  cause  cell  cycle  progression  and 
subsequently proliferation, is often associated with ERK activation it is therefore not  
  107 
surprising that ERK has been implicated in the regulation of cell cycle. The initial link 
between  ERK  activation  and  cell  cycle  progression  came from  studies  showing  the 
correlation  between  ERK1/2  activation  and  induction  of  DNA  synthesis  [370].  More 
directly, inhibition of ERK1 by overexpressing an inactive mutant or ERK1-antisense 
RNA  in  fibroblasts  reduced  ERK  activation  causing  decreased  proliferation  [371]. 
Similarly,  pharmacological  inhibition  of  MEK1/2,  the  upstream  activators  of  ERK1/2, 
can reduce proliferation in many cell types such as fibroblasts, smooth muscle cells, 
hepatocytes and immune system cells including T and B cells [372,373]. Indeed, it was 
subsequently  shown  that  ERK1/2  was  active  in  G1  and  its  activity  needed  to  be 
sustained until late G1 phase to guarantee entry into S phase [374].  
At  the  molecular  level  activated  ERK1/2  seems  to  have  multiple  functions 
impacting on the cell cycle including the control of transcription, translation and cell 
cycle  regulators  [372].  Thus,  inhibition  of  ERK1/2  was  found  to  reduce  the 
phosphorylation of the translation initiation factor eIF4E which is a substrate of MNK1/2 
suggesting that their ERK1/2 dependent activation might be involved in the regulation 
of translation [375-377]. Additionally, ERK1/2 could potentially also influence translation 
through modifying the mTOR signalling pathway which regulates ribosome biogenesis 
and initiation of translation [378]. mTor is regulated by inhibition through the tuberous 
sclerosis complex 1 (TSC1)/TSC2 heterodimer. Two studies have recently reported the 
involvement  of  ERK1/2  in  regulating  mTOR,  either  directly  or  indirectly  through 
activation of RSK1 to phosphorylate TSC2 and thus reducing the inhibitory activity of 
the complex [379,380]. 
As mentioned above, ERK1/2 plays a crucial role in the transition from G1 to S 
phase. One of the known mechanisms by which ERK1/2 regulates this transition is the 
induction of cyclin D1 expression [372]. The mechanisms of this ERK1/2 – cyclin D1 
signalling axis have not yet been fully delineated but it has been suggested to involve 
AP-1-dependent  transcriptional  upregulation  of  cyclin  D1  [240,372].  Additionally, 
however, ERK has also been implicated in the regulation of the nuclear export of cyclin 
D1  mRNA  to  allow  its  translation  at  the  ribosomes  [381].  Finally,  ERK1/2-mediated 
phosphorylation and stabilisation of c-Myc provides another link between cell survival 
and cell cycle progression and ERK1/2 activation.  
 
3.1.5  Regulation of c-Myc expression 
The importance of c-Myc in regulating processes such as proliferation and cell 
growth makes it necessary to tightly regulate its expression and activity. Thus, c-Myc is 
subject  to  regulation  at  the  transcriptional,  translational  and  post-translational  level 
[382,383], the latter being the most extensively studied. For example, c-Myc protein  
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stability  depends  on  its  posttranslational  modifications  such  as  phosphorylation, 
ubiquitination and possibly acetylation (reviewed in [384]).  
The role of phosphorylation was the first to be detected and characterised and is 
still the focus of much attention. In particular, two of the N-terminal phosphorylation 
sites at threonine 58 and serine 62 have been analysed in detail as it has been found 
that they influence c-Myc protein stability and possibly trans-activation potential [384-
387] (Fig.3.2). For example, it has been shown by several groups that phosphorylation 
of  T58  by  glycogen  synthase  kinase  3  (GSK3)  [388]  renders  c-Myc  prone  to 
ubiquitination  by  F-box  protein  Skp2  or  Fbw7-containing  SCF  complex  E3  ligases 
[389,390].  Whereas  Fbw7-mediated  ubiquitination  of  c-Myc  is  followed  by  its 
degradation by the proteasome, Skp2 signalling appears to play a more complex role in 
the regulation of c-Myc as it also influences its transactivation capacity. Indeed, Skp2 
has  been  found  to  co-localise  with  c-Myc  at  its  target  promoters  and  increases  its 
transcriptional  activation  possibly  by  recruiting  proteasome  subunits  which  were 
recently found to  play  a  role  in  RNA  polymerase  II  transcription  [389]. By  contrast, 
phosphorylation of S62 increases c-Myc stability through as yet unknown mechanisms 
and  little  is  known  about  the  kinases  which  carry  out  the  phosphorylation  [384]. 
Nevertheless, the consensus sequence surrounding S62 makes it a likely target for 
modification by proline directed kinases such as ERK MAPK which has been shown to 
phosphorylate  c-Myc  at  position  S62  in  vitro  [386].  It  is  of  interest  that  T58 
phosphorylation only occurs after prior phosphorylation at position S62 [386] further 
complicating  the  regulatory  mechanisms  underlying  c-Myc  stabilisation  and 
degradation. The interaction of the c-Myc binding partner, Max with other bHLHZip – 
domain  containing  proteins  such  as  Mad  or  Mnt  provides  another  regulatory 
mechanism as these complexes act as transcriptional repressors being able to bind the 
same sequence as the c-Myc/Max complexes [391,392]. 
 
3.1.6  The small GTPase, Rap 
Rap (Ras proximity) belongs to the Ras superfamily of small GTPase proteins 
which includes five subgroups: the Ras, Rho, Rab, Arf and Ran families [393]. Rap 
belongs to the Ras-like small G proteins which include the three Ras family members 
H-Ras, Ki-Ras, N-Ras and the five members of the Rap family: Rap-1A, Rap-1B, Rap-
2A, Rap-2B, and Rap-2C [394]. The Rap-1 and Rap-2 isoforms are 60% identical and 
are mainly regulated by the same GEFs and RapGAPs but Rap-2 displays a lower 
sensitivity for RapGAPs allowing it to remain in an active state for longer. This has led 
to suggestions that Rap-1 and Rap-2, if activated in the same cell, might function as a 
molecular switch between fast (Rap-1) and slow (Rap-2) Rap activation/deactivation 
[395].   
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3.1.6.1  Regulation of Rap activity 
Activation of Rap is achieved by the exchange of GDP for GTP which is carried 
out by GEF proteins including C3G, Epac1, Epac2, RasGRP2, PDZ (PSD-95/Dgl/ZO-
1)-GEF1, PDZ-GEF2, CalDAG-GEF and PLCε (reviewed in [393]; Fig.3.3). Binding of 
GEF  to  Rap  decreases  its  affinity  for  GDP  and  promotes  its  replacement  by  GTP, 
which is found in excess in the cell [394]. Binding of GTP induces a conformational 
change which exposes the effector binding loop allowing the recruitment of different 
Rap effectors. Different GEFs have been found to activate Rap downstream of a range 
of signals such as cytokines and chemokines, growth factors, cell adhesion molecules 
and  antigen-receptors  in  B  and  T  cells  [396].  Moreover,  activation  of  Rap  can  be 
achieved by different mechanisms depending on the expression of specific GEFs as 
well as the type of regulatory adaptor complex formed. For example, C3G (Crk SH3-
domain-binding  guanine-nucleotide  releasing  factor,  where  SH3  stands  for  Src 
homology  region  3  domain),  which  is  an  ubiquitously  expressed  GEF  in  many  cell 
types, is activated downstream of RTK (Fig.3.3). Thus, binding of C3G to its adaptor 
Crk allows recruitment to the plasma membrane where RTKs facilitate phosphorylation 
and hence activation of C3G on tyrosine 504 [397]. The phosphotyrosine docking sites 
needed  for  the  recruitment  of  Crk/C3G  can  be  provided  by  phosphorylation  of 
scaffolding  proteins  such  as  Cbl,  Cas  or  Gab1  [398-400].  The  importance  of  the 
adaptor proteins and the complexes they form with Rap-1 downstream of RTK-induced 
signalling  is  emphasised  by  the fact that  inhibition  of  complex  formation  blocks the 
activation of Rap-1 [400].  
By contrast, CalDAG-GEF 1 is regulated by calcium binding whereas CalDAG-
GEF 3 needs to bind DAG for activation. These RapGEFs therefore likely connect the 
PLC pathway with Rap activation [401]. Moreover, a recent addition to the RapGEF 
family of proteins, the Epac proteins, depend on cyclic AMP (cAMP) for activation and 
have thus been implicated in the transduction of signals through GPCRs [402]. Thus, 
different stimuli induce activation of Rap by initiating varied signals such as elevation of 
cAMP, calcium or phosphotyrosine kinase activity, all of which can cause the activation 
of different types of GEFs (Fig.3.3). 
Inactivation of Rap is achieved by RapGAPs which enhance the intrinsic Rap 
GTPase activity leading to the hydrolysis of GTP to GDP and subsequent inactivation 
of Rap [403]. There are two major groups of RapGAPs: The RapGAP family (including 
RapGAP1 and 2) and the SPA-1 family of proteins (SPA-1, SPA-1-like (SPA-L) 1 (also 
called SPAR), SPA-L 2, and SPA-L 3) which all share the catalytic GAP-related domain 
(GRD)  [396]  (Fig.3.3).  SPA-1  is  the  family  member  expressed  most  abundantly  in 
lymphohematopoietic tissues whereas for example SPAR is more highly expressed in  
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epithelial  tissues  and  brain  [404,405].  RapGAPs  do  not  need  post-translational 
modifications such as phosphorylation to be activated as they are constitutively active 
and therefore expression levels appear to be the major determinant of their activity in 
the cell [396]. 
 
3.1.6.2  Functions of Rap 
Rap has been implicated in a range of cellular responses including regulation of 
integrin expression and signalling, T cell anergy and neuronal cell differentiation [396]. 
Interestingly, activation of Rap can have distinct cellular effects depending on the cell 
type and/or stimuli. For example, Rap-1 was initially discovered as a factor that could 
suppress the K-Ras-mediated transformed phenotype of fibroblasts [406] which led to 
the initial hypothesis that Rap-1 antagonises Ras mediated signals by binding to Raf-1 
and hence sequestering it away from Ras and consequently inhibiting Ras-mediated 
activation of ERK. Indeed, this seems to be the mechanism by which Rap-1 inhibits 
activation  of  ERK  in  in vitro  anergised T  cells. Thus,  cross-linking  of  the  TCR/CD3 
complex in the absence of CD28 costimulation increases the recruitment and activation 
of Rap-1 at the TCR signalling complex whereas costimulation via CD28 blocks such 
Rap-1 activation [407,408]. Consistent with this, it has been shown subsequently by in 
situ  immunofluorescence  staining  that  upregulation  of  Rap-1  and  reduction  of  ERK 
activation is also a hallmark of in vivo anergised antigen-specific T cells [409] and that 
T cells with an anergic phenotype in vivo display Rap-1 activation [410]. These studies 
therefore confirm the relevance of Rap-1-dependent inhibition of ERK activation in the 
regulation of T cell dependent immune responses.  
By contrast, in neuronal cell lines, Rap-1 was found to activate the ERK pathway. 
It was shown that such activation of ERK was achieved in a B-Raf dependent manner 
[411]. Here Rap-1 binds and activates B-Raf, another Raf isoform known to effectively 
phosphorylate and thereby activate MEK1/2 and hence ERK1/2. Therefore, it is now 
thought that Rap-1 can either activate or inhibit the ERK cascade depending on cell 
type and expression of different Raf isoforms (Raf-1 or B-Raf). An interesting study by 
Dillon et al provides supporting evidence for this hypothesis in peripheral T cells which 
generally do not express B-Raf. In those cells Rap-1 functions as a negative regulator 
of ERK by binding Rap-1 and inhibiting Raf-1/Ras interactions. However, by creating 
mice expressing B-Raf in peripheral T cells, they showed that Rap-1 was then able to 
activate  ERK  in  a  B-Raf-dependent  manner  reducing  the  sensitivity  of  these  cells 
towards induction of anergy [412].  
Rap-1 is also involved in the regulation of integrin-mediated adhesion of various 
immune system cells such as lymphocytes and macrophages [413,414] by affecting the 
activity and clustering of integrins [415]. Indeed, in T cells Rap-1 is needed for the  
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activation of LFA-1 and synapse formation with antigen-loaded APCs [416,417]. Rap-1 
utilises various effector proteins to achieve this regulation of integrins. For example, 
Rap-1 recruits RapL which in turn binds to the α-chain of the αLβ2 integrin, activating it 
and  increasing  its  interaction  with  ICAM  [415].  Alternatively,  Rap-1-mediated 
recruitment of RacGEFs links Rap-1 to the control of cell spreading [415]. Thus, Rap-1 
is a versatile signalling molecule which can regulate diverse cellular processes such as 
proliferation,  differentiation  or  cellular  adhesion  depending  on  the  cell  type  and 
expression of Rap-1-specific upstream or downstream regulatory molecules (Fig.3.3). 
 
3.1.6.3  The role of Rap activation in B cells 
Rap-1 and Rap-2 have been shown to be activated downstream of the BCR in B 
cells [418,419] and previous studies have indicated that Rap-1 can potentially regulate 
multiple  signalling  pathways  including  the  ERK,  p38  [420,421]  and  PI3  kinase/Akt 
pathways [422]. Interestingly, it has been suggested that, for example in chicken DT40 
B cells, the B-Raf/Rap-dependent activation of ERK might be more important than the 
Raf-1/Ras cascade [170]. 
Rap-1A and Rap-1B deficient mice have been instrumental in further analysing 
the role of Rap in B cell development and activation. For example, Rap-1B was found 
to be the dominant form of Rap-1 in B cells [423] and Rap-1B-deficiency was shown to 
reduce the absolute number of pre-pro-B cells as well as immature B cells in the bone 
marrow.  Similarly,  in  the  periphery,  numbers  of  MZ  B  cells  were  reduced  as  were 
mature  follicular  B  cells  in  lymph  nodes.  Moreover,  Rap-1B-deficient  B  cells  were 
shown to display impaired adhesion and chemotaxis in vivo [424] as well as reduced 
SDF-1 (CXCL13)-induced migration and homing to lymph nodes [423]. These latter 
defects  can  be  explained  by  the  need  for  Rap  for  integrin  activation  and  therefore 
adhesion. Indeed, Rap has not only been shown to be important for integrin activation 
but also for reorganisation of the actin cytoskeleton upon BCR and integrin-mediated 
stimulation [425]. Moreover, Rap is required for the BCR-ligation mediated formation of 
the  immune-synapse  as  well  as  the  F-actin-dependent  extension  of  membrane 
processes  upon  BCR-ligation  and  cell  spreading  [426].  By  contrast,  proliferation  of 
splenic B cells was not influenced by Rap-1B-deficiency thereby indicating that Rap-1B 
does not play a role in the expansion of mature B cells.  
Unlike Rap-1B, Rap-1A does not seem to be crucial for T or B cell development 
but,  similarly  to  Rap-1B,  plays  a  role  in  adhesion  of  various  cell  types  such  as 
macrophages and chemotaxis of T, B and myeloid cells [427]. Taken together these 
studies show that Rap-1A and Rap-1B functions are partly redundant but some effects 
appear  to  be  specific  for  one  isoform  or  the  other.  Indeed,  mice  conditionally 
expressing a dominant-negative Rap-1 mutant Rap-1A17, which is able to inhibit all the  
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Rap  family  proteins,  displayed  a  significant  reduction  of  pre-B  cells,  immature  and 
mature B cells [428] causing a more severe phenotype in these mice compared to mice 
deficient for single isoforms and hence indicating that more than one Rap protein may 
be involved in the regulation of development. Interestingly, Rap signalling also seems 
to  be  involved  in  the  selection  of  the  BCR  repertoire  of  B  cells.  Thus,  Ishida  and 
colleagues have reported an increase of anti-dsDNA antibody-producing B-1a B cells 
as well as the development of lupus-like nephritis in mice deficient for the Rap-1-GAP, 
SPA-1. It seems that developing B cells with higher active Rap levels display a change 
in their V(D)J recombination and thereby receptor repertoire [429]. Thus, upregulation 
of  Rap  activity  due  to  the  lack  of  inhibition  by  SPA-1  increases  the  number  of 
autoreactive  B  cells  developing  in  these  mice  indicating  a  role  for  SPA-1  in  the 
maintenance of tolerance.  
 
3.1.7  The role of the Cbl family of E3 ubiquitin ligases in B cells 
Ubiquitination  of  proteins  involved  in  signalling  cascades  can  influence  their 
activity, protein stability and localisation and thereby change the signalling outcome 
downstream  of  various  receptors  [430]  (see  section  1.6).  The  members  of  the  Cbl 
family of E3 ubiquitin ligases have been implicated in regulation of immune responses 
by influencing T and B cell signalling [431]. In mammals there are three Cbl isoforms: 
c-Cbl, Cbl-b and Cbl-c, but only c-Cbl and Cbl-b are expressed in haematopoietic cells 
[228]. Cbl proteins contain a tyrosine kinase-binding (TKB) domain [432] as well as a 
Zinc-binding RING finger domain which confers the E3 ubiquitin ligase activity of Cbl 
[433]. The TKB allows Cbl to bind to phospho-tyrosine residues in multiple PTKs and 
other  signalling  proteins  [228].  Cbl  itself  is  also  tyrosine-phosphorylated  by  PTKs 
associated with the TCR, EGFR, IL-7, IL-4 and IL-2 receptors and this phosphorylation 
influences its adaptor function and E3 ligase activity [228]. 
There  are  two  major  mechanisms  by  which  Cbl  regulates  receptor  signalling. 
Firstly,  Cbl  can  ubiquitinate  receptors  themselves  such  as  the  EGFR  leading  to 
internalisation and degradation of the receptor [434,435]. Additionally, Cbl ubiquitinates 
downstream  signalling  mediators  such  as  Syk,  Fyn,  Lck  and  Lyn  [228].  Generally 
ubiquitination will target the proteins for proteasomal degradation as seen for c-Cbl-
mediated ubiquitination and degradation of Syk in B cells [236] (see Chapter 1, section 
1.6).  But  in  some  cases  ubiquitin-modification  changes  the  capacity  of  proteins  to 
interact with their usual binding partners. Thus, Cbl-b-dependent ubiquitination of the 
PI3 kinase subunit p85 does not induce degradation but inhibits its recruitment to CD28 
or TCR [436,437]. Similarly, ubiquitination of CrkL, an adaptor protein involved in the 
recruitment of Rap, impairs the interaction with C3G [438]. Cbl therefore can potentially 
regulate various signalling pathways, some of which are known to be important in B  
  113 
cells. Initial studies carried out in chicken B cells indeed showed that c-Cbl and Cbl-b 
regulate BCR signalling [439,440] and Cbl-b was found to downregulate Syk following 
BCR stimulation in a ubiquitination-dependent fashion [441]. A study by Kitaura et al 
has recently confirmed a role for c-Cbl and Cbl-b in the regulation of B cells in vivo. 
They used B cell-specific c-Cbl/Cbl-b-doubly-deficient mice to analyse the role of these 
proteins  in  B  cell  development  and  activation  [442].  The  c-Cbl/Cbl-b-deficient  mice 
displayed major changes in B cell development leading to an increase of B cells in the 
periphery  and  reflecting  an  increase  in  T1,  MZ  as  well  as  B-1  B  cell  numbers. 
Compared to wild-type littermates, the mice also expressed more IgM and detectable 
levels  of  anti-dsDNA  and  ANA  antibodies  and  some  animals  developed  SLE-like 
autoimmune disease [442]. This inability to regulate autoreactive B cells might be partly 
due  to  reduced  ability  of  c-Cbl/Cbl-b-deficient  B  cells  to  be  anergised  resulting  in 
increased levels of activated self-reactive B cells.  
Similarly, both Cbl isoforms were shown to also play an  important role in the 
negative  regulation  of  T  cell  activation.  Thus,  T  cells  from  mice  deficient  for  Cbl-b 
produced IL-2 and proliferated upon stimulation via CD3 without any need for CD28 
costimulation. Cbl-b was consequently found to be involved in the negative regulation 
of signalling through the TCR and CD28 by ensuring the need for CD28 costimulation 
to overcome a certain signalling threshold [230]. The decreased need for costimulation 
and  subsequent  hyperresponsiveness  of  these  T  cells  made  Cbl-b-deficient  mice 
susceptible not only to the induction of autoimmune diseases such as experimental 
autoimmune encephalomyelitis [230] but also spontaneous autoimmune disease [229]. 
Mice deficient for both c-Cbl and Cbl-b in T cells also develop autoimmune disease due 
to  hyperreactive  T  cells  [443].  Thus,  Cbl-mediated  negative  regulation  of  antigen-
receptor signalling seems to influence pivotal processes including positive selection of 
T  cells  in  the  thymus,  activation  threshold  of  peripheral  T  cells  as  well  as  B  cell 
tolerance mediated by anergy [431]. 
 
3.2  Aims 
 
Negative selection of immature B cells expressing self-reactive specificities plays 
an  important  role  in  preventing  the  development  of  autoimmune  diseases.  It  is 
therefore  vital  to  characterise  the  signalling  pathways  that  lead  to  the  induction  of 
growth arrest and apoptosis in immature B cells upon BCR stimulation. 
The WEHI-231 B cell lymphoma expresses high levels of IgM as well as
 no/low 
levels of IgD, FcγR, and MHC class II on their surface, a phenotype similar to immature 
B cells. This cell line has therefore been used extensively as a model system for BCR-
induced growth arrest and apoptosis of immature B cells [444,445]. Thus, cross-linking  
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of the BCR on WEHI-231 cells by treatment with anti-IgM antibodies leads to growth 
arrest in G1 phase of the cell cycle and apoptosis in a manner which models anergy 
and clonal deletion during negative selection of immature B cells in the bone marrow. 
Furthermore, and similarly to primary immature B cells, WEHI-231 cells can be rescued 
from growth  arrest  and apoptosis  by  TH  cell-derived  signals  such  as  ligation  of  the 
CD40 receptor [334]. WEHI-231 cells therefore represent an exploitable in vitro model 
for the dissection of signalling pathways underlying BCR-mediated negative selection 
which can then be translated and validated in primary immature B cells. 
 
The specific aims and objectives of this investigation were: 
·  to  investigate  the  signalling  mechanisms regulating  ERK  activation  in 
immature B cells and how these are modulated during BCR-mediated 
growth  arrest  and  apoptosis  and  rescue  via  CD40  signalling.  In 
particular,  it  was  planned  to  focus  on  the  roles  of  B-Raf,  Rap-1  and 
SPA-1 in ERK signalling and consequent immature B cell fate. 
·  to characterise the downstream effectors of ERK, such as c-Myc, and to 
investigate their role in directing immature B cell fate. 
·  to further explore the role of other signalling pathways and regulatory 
mechanisms such as ubiquitination in BCR-induced growth arrest and 
apoptosis of WEHI-231 cells.  
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3.3   Results 
 
3.3.1 Induction of growth arrest and apoptosis in WEHI-231 cells 
In order to assess the negative selection response to BCR stimulation, WEHI-231 
cells  were  stimulated  with  increasing  concentrations  of  anti-mouse  IgM  antibody  to 
mimic  crosslinking  of  the  BCR  by  high  affinity/avidity  antigen.  Proliferation  was 
assessed  not  only  by  determination  of  DNA  synthesis  using  a  [
3H]  thymidine 
incorporation assay but also by analysis of the percentage of cells in the different cell 
cycle stages following quantitation of DNA content by PI staining. Thus, dose response 
experiments were performed that showed that increasing concentrations of anti-IgM 
repressed  proliferation  (Fig.3.4A).  This  growth  arrest  could  be  reversed  by 
simultaneous  treatment  of  the  cells  with  agonistic  anti-CD40  antibody  (Fig.3.4B)  as 
indicated by the restoration of proliferation. 
Cell  cycle  analysis  of  living  cells  confirmed  these  results.  Thus,  treatment  of 
WEHI-231 cells with anti-IgM for 48 or 72 hours dramatically decreased the percentage 
of cells in G2-M phase and S phase with a compensatory increase in the percentage of 
cells  arrested  in  G1-G0  (Fig.3.5).  However,  analysis  of  all  the  cells  in  the  culture 
revealed that G1-G0 arrest only partially accounted for the loss of proliferation as by 
48-72 h there was also a dramatic increase in the percentage of cells with subdiploid 
DNA content, a hallmark of apoptosis (Fig.3.6). 
Furthermore,  it  was  shown  that  BCR-ligation  led  to  the  dissipation  of  the 
mitochondrial membrane potential (MMP), detected as a decrease of the percentage of 
cells with high DiOC6 fluorescence intensity (Fig.3.6E). DiOC6 is a dye that integrates 
into the mitochondrial membrane in a stoichiometric fashion correlating with the MMP. 
A decrease of the levels of DiOC6-staining therefore indicates the disintegration of the 
cells MMP, a hallmark of the intrinsic apoptosis pathway. Both BCR-mediated growth 
arrest and apoptosis, as well as dissipation of the MMP, could be counteracted by the 
simultaneous stimulation of the cells with anti-CD40 antibody (Fig.3.5 and 3.6). 
Collectively,  therefore,  these  results  showed  that  both  growth  arrest  and 
apoptosis contributed to the decrease in proliferation of WEHI-231 cells following BCR 
ligation  and  that  WEHI-231  immature  cells  provided  an  in  vitro  model  not  only  for 
dissecting the BCR signals responsible for growth arrest and apoptosis during negative 
selection but also those directing rescue by CD40-mediated TH-derived signals.  
 
3.3.2 Regulation of ERK activation during BCR-mediated negative 
selection and rescue via CD40 
Previous  research  in  this  laboratory  has  shown  that  differential  ERK  signals 
determine distinct important cell fate decisions of the immature B cell line WEHI-231.  
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Thus, depending on the strength and duration of ERK activation, WEHI-231 immature 
B cells can either survive and proliferate or undergo growth arrest and apoptosis [310]. 
Thus,  as  shown  previously,  cyclic  activation  of  ERK  accompanies  the  robust 
spontaneous  proliferation  of  cultured  WEHI-231  cells  for  up  to  at  least  32  hours 
(Fig.3.7A).  By  contrast,  stimulation  of  the  cells  with  anti-IgM  induced  the  transient 
upregulation  of  ERK  phosphorylation  during  the  first  2-4  hours  after  stimulation 
followed by a sustained downregulation for at least 32 hours (Fig.3.7B). This reduction 
of ERK activation was mirrored by that of its putative downstream effector of survival 
and proliferation, c-Myc, as expression of this protein also displayed an initial increase 
in the early phase of BCR stimulation followed by strong downregulation during the rest 
of the analysed time course. By contrast, simultaneous stimulation of the BCR and 
CD40 restored both the levels of activated ERK and c-Myc expression (Fig.3.7D) and 
the cyclic activation pattern seen in untreated cells (Fig.3.7A and D). Consistent with its 
anti-apoptotic  effects,  ligation  of  CD40  in  the  absence  of  BCR  stimulation  did  not 
induce the early activation of ERK as seen after BCR-ligation but did generally tend to 
enhance ERK phosphorylation and c-Myc levels throughout the time course (Fig.3.7C). 
To corroborate these data at the single cell level the activation of ERK, in terms 
of expression of dually-phosphorylated (T202/Y204) ERK, was imaged and quantitated 
by laser scanning cytometry. Image analysis showed that pERK showed a focused, 
punctate staining in the perinuclear region and, in agreement with the above Western 
Blot  data  and  our  previous  studies  [310],  quantitative  LSC  analysis  of  the 
immunofluorescence  staining  of  WEHI-231  cells  treated  with  anti-IgM  showed  a 
reduction in the percentage of cells expressing pERK, as well as the level of pERK 
expressed in the cells at 48 h due to cross-linking of the BCR which was reversed upon 
CD40-mediated  rescue  from  growth  arrest  (Fig.3.8).  c-Myc  expression  detected  by 
immunofluorescent staining was predominantly located, as expected, in the nucleus. 
Moreover, quantitative analysis by LSC showed that it was expressed in fewer cells 
and at a lower level after BCR-ligation, confirming the results demonstrated by Western 
Blotting (Fig.3.8). Moreover, mimicking TH-cell help by ligation of CD40 restored the 
expression of c-Myc even in the presence of BCR-ligation (Fig.3.8). 
 
3.3.3 Activation of ERK correlates with progression through the 
cell cycle 
The cell cycle is controlled very tightly to ensure the timed entry and exit through 
cell cycle phases. Proteins regulating the cell cycle are therefore often expressed only 
during certain stages of the cell cycle and are downregulated once the next phase is 
entered.  The  correlation  of  protein  expression  and  cell  cycle  stage  can  therefore 
indicate  a  positive  or  negative  regulatory  role  of  the  analysed  proteins.  In  order  to  
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directly  correlate  protein  expression  levels  with  cell  cycle  stage,  cells  were 
cytocentrifuged  and  immunofluorescently  stained  and  then  analysed  by  LSC.  The 
advantage of LSC analysis is that this method allows the direct correlation between cell 
cycle status and protein expression on a single cell basis. Firstly, to determine the 
different cell cycle phases in WEHI-231 cells, BCR- and/or CD40-stimulated cells were 
stained  with  DAPI  to  determine  their  DNA  content  and  chromatin  condensation 
(Fig.3.9). It was shown that such LSC-based analysis produced broadly similar results 
as FACS analysis of PI staining detecting an increase in cells arrested in G1 phase and 
a decrease of new daughter cells and cells in mitotic phases (G2/M and S phase) after 
treatment with anti-IgM at this time point (Fig.3.9C). 
Activation  of  ERK  has  been  shown  to  be  important  for  the  proliferation  and 
survival of B cells [310] and it is known to be a prerequisite for G1/S phase transition 
and hence cell cycle progression in other cell systems such as fibroblasts [446]. The 
LSC-based  analysis  of  cell  cycle  status  was  therefore  utilised  to  investigate  the 
possible correlation between pERK (active ERK) and cell cycle progression. Indeed, in 
confirmation of previous results [310], higher levels of ERK activation were found in 
cells in G2/M or S phase whereas lower levels of pERK were associated with growth 
arrested or apoptotic cells (Fig.3.10). Moreover, the percentage of pERK expressing 
cells was generally higher in mitotic cells compared to growth arrested/apoptotic cells 
(Fig.3.10).  Interestingly,  new  daughter  cells  which  represent  cells  having  recently 
undergone  mitosis,  express  relatively  low  levels  of  pERK,  most  likely  due  to  their 
quiescent state (Fig.3.10). Taken together these results further confirm the connection 
between proliferation and ERK activation directly linking high levels of ERK activation 
with mitosis. 
 
3.3.4 Rap/B-Raf signalling as a target of BCR-mediated negative 
selection? 
It  has  been  shown  by  this  laboratory  that  whilst  BCR  signalling  leads  to  the 
suppression of sustained, cycling ERK activation, activation of Ras, one of the major  
upstream  regulators  of  the  ERK  cascade,  was  essentially  unaffected  [373].  Thus, 
downregulation of Ras activity did not appear to be the mechanism underlying BCR-
mediated suppression of ERK activation. Interestingly, however, activation of MEK1, 
the ERK-specific MAPKK in BCR signalling, which is constitutively active in proliferating 
WEHI-231  cells,  was  found  to  display  a  cyclic  pattern  after  BCR  stimulation  [447], 
suggesting  that  a  Ras-independent  pathway  contributes  to  the  full  activation  of  the 
MEK/ERK cascade in spontaneously proliferating WEHI-231 immature B cells and that 
BCR-mediated  downregulation  of  this  pathway  might  be  responsible  for  the 
suppression of ERK activity.   
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Since  Rap-1  has  also  been  reported  to  activate  MEK  via  B-Raf  [411],  it  was 
decided  to  investigate  the  potential  of  Rap-1/B-Raf  signalling  as  targets  in  BCR-
induced growth arrest. Rap-1 is a small GTPase and therefore only active if bound to 
GTP  [422]  and  thus,  Western  Blotting  using  an  anti-Rap-1  antibody  detects  Rap 
expression  independent  of  its  activation  status.  Nevertheless,  to  assess  if  all  the 
components of the Rap/B-Raf cascade are expressed in WEHI-231 cells and to further 
examine any stimulation-induced changes, Rap, B-Raf and Raf-1 levels were detected 
by Western Blotting. Rap-1, B-Raf and Raf-1 were found to be expressed in WEHI-231 
cells under all conditions tested and the levels of Rap-1 and Raf-1 did not appear to be 
substantially reduced by BCR-ligation or indeed correlate with the differential levels of 
pERK  observed  in  control  and  BCR-stimulated  WEHI-231  B  cells  (Fig.3.11A-D). 
Concerning Rap-1 expression, these results were further confirmed by LSC analysis of 
immunofluorescence  staining  of  Rap-1  expression  in  individual  cells  showing  no 
changes of the percentage or overall level of Rap-1 expression (Fig.3.11E). However, 
Raf-1  expression  appeared  to  be  upregulated  by  CD40  signalling,  results  perhaps 
consistent with the finding that ERK activation is generally found to be higher in these 
cells across the full time course. Rather unexpectedly, Rap-1 expression was found to 
be somewhat reduced in cells stimulated via the BCR and CD40 at later time points 
(Fig.3.11D). Most interestingly, however, was the finding that whilst B-Raf appeared to 
be highly expressed constitutively in control or CD40-stimulated WEHI-231 B cells, its 
expression appeared to be regulated in a cyclic manner in BCR-stimulated cells which 
was essentially reversed by CD40 signalling (Fig.3.11). 
Next,  the  relative  activities  of  these  ERK  pathway  regulators  were  assessed 
under the various cell fate conditions. Firstly, preliminary studies using the EpiTag
TM 
assay  which  detects  phosphorylated  B-Raf  were  performed.  B-Raf  is  constitutively 
phosphorylated  on  serine  446  [448]  and  this  phosphorylation  is  an  indication  of 
activation as it stops auto-inhibition of B-Raf by decreasing the binding of the regulatory 
and catalytic domain of B-Raf. Thus, even though this position is phosphorylated in the 
basal state, activation of receptors can enhance the phosphorylation of B-Raf at serine 
446 to further increase the spontaneous activity of B-Raf [316]. Consistent with the 
proposal that BCR-signalling may abrogate Rap-1/B-Raf coupling to ERK, treatment 
with  anti-IgM  abrogates  the  expression  of  pB-Raf  observed  in  control  cells  at  4  h. 
However, there were no significant differences at later time points indicating that this 
mechanism is likely to be insufficient to explain either the sustained cyclic levels of 
pERK in untreated WEHI-231 cells or the full BCR-mediated suppression of ERK and 
its’ rescue afforded by CD40 signalling (Fig.3.11F).  
To  further  analyse  the  impact  of  the  different  treatments  on  the  potential 
activation of molecules involved in the Rap-1/ERK signalling cascade, levels of active  
  119 
Rap-1 were determined. To this end a commercially available Rap-1 activity assay kit 
was used. The principle of this assay exploits the fact that GTP-Rap-1, but not GDP-
Rap-1,  is  able  to  bind  the  Ras-binding  domain  of  the  Ral  guanine  nucleotide 
dissociation stimulator (RalGDS-RBD) [449] and hence only the active Rap-1 can be 
purified  by  binding  to  RalGDS-RBD-conjugated  agarose  beads  and  analysed  by 
subsequent  Western  Blotting  using  an  anti-Rap-1  antibody.  Using  this  approach, 
stimulation of WEHI-231 cells with anti-IgM antibody was shown to substantially reduce 
the levels of active Rap-1 over the period where ERK activity is suppressed whereas 
simultaneous treatment with anti-CD40 could partially reverse this effect (Fig.3.12A-D). 
These results were confirmed by LSC analysis of immunofluorescence staining using a 
recombinant  Ral-GDS-RBD-GST  construct  to  track  activated  Rap  in  individual  cells 
(Fig.3.12E). Here BCR stimulation of WEHI-231 cells was found to decrease overall 
expression  levels  as  well  as  the  percentage  of cells  expressing  active  Rap  at  high 
levels 24 hours post-stimulation (Fig.3.12F/G). Similar to the data acquired by Western 
Blotting, CD40-costimulation partially rescued the cells from downregulation of active 
Rap, slightly increasing the percentage of cells containing high levels of active Rap 
(Fig.3.12F/G). Taken together these results indicate that BCR-signalling in WEHI-231 
cells  decreases  the  levels  of  active  Rap  which  could  contribute  to  the  observed 
reduced  activation  of  MEK  and  hence  ERK.  CD40-ligation,  which  is  known  to  re-
establish cyclic ERK activation and proliferation in BCR-stimulated cells, was found to 
partially reverse the decrease of active Rap. This could be one of the mechanisms 
CD40 utilises to prevent growth arrest. 
 
3.3.5 SPA-1 expression is regulated by BCR-mediated signalling 
In order to shed some light on the possible mechanisms by which BCR-signalling 
could inactivate Rap-1, the role of the RapGAP, SPA-1, [405,450] was investigated. 
SPA-1 indeed appears to be upregulated both at the protein and at the transcriptional 
level in WEHI-231 cells after BCR stimulation (Fig.3.13A and D/E). Furthermore, anti-
CD40  induces  a  significant  downregulation  of  SPA-1  mRNA  and  protein  levels  and 
reverses  the  effects  of  BCR-ligation  reducing  SPA-1  levels  even  below  the  levels 
observed in untreated cells, findings perhaps consistent with the rescued levels of ERK 
activation found in these cells (Fig.3.13A and D/E). As previously reported, SPA-1 was 
mainly found in the nucleus and cytoplasm [451]. Its cytoplasmic localisation allows 
SPA-1 to regulate the activity of Rap whereas nuclear SPA-1 might carry out different, 
so far ill-defined, functions (Fig.3.13B).  
Many  of  the  negative  regulators  of  the  ERK  MAPK  cascade,  such  as  MAPK 
phosphatases  can  be  themselves  regulated  by  feedback  loops  [452].  Therefore,  in 
order to determine the effect of ERK activation on SPA-1 expression in spontaneously  
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proliferating  WEH-231  B  cells,  these  cells  were  treated  with  the  pharmacological 
inhibitor  of  MEK,  PD98059  (Fig.3.13C).  Perhaps  surprisingly,  inhibition  of  sustained 
cycling ERK activation did not affect SPA-1 mRNA expression. Rather, inhibition of PI3 
kinase  appeared  to  mimic  the  effects  of  BCR-ligation  concerning  SPA-1  mRNA 
expression,  as  treatment  of  cells  with  a  specific  PI3  kinase  inhibitor  (LY294002) 
increased SPA-1 RNA levels (Fig.3.13D-E). No further increase in SPA-1 mRNA levels 
could  be  detected  following  co-culture  of  the  cells  with  the  MEK  and  PI3  kinase 
inhibitors. 
Supporting  evidence  for  a  role  for  PI3  kinase  in  the  regulation  of  SPA-1 
expression  was  provided  by  experiments  utilising WEHI-231 cells  stably  expressing 
RasV12,  RasV12S35  and  RasV12C40  [453]  which  are  constitutively  active  Ras 
mutants  either  activating  both  the  PI3  kinase  and  ERK  cascades  (RasV12),  or 
selectively the ERK (RasV12S35) or PI3 kinase (RasV12C40) cascade [171,454]. 
Although,  as  previously  mentioned,  it  had  been  shown  by  this  laboratory  that 
activation of Ras was not substantially modulated by BCR-ligation, overexpression of 
constitutively  active  Ras  mutants  which  prevented  BCR-mediated  downregulation  of 
ERK signalling was able to rescue WEHI-231 cells from growth arrest at least in the 
first 24 hours following BCR stimulation [373] (Fig.3.14) and as such provide a useful 
tool for the dissection of the role of differential effects of Ras activation. 
Interestingly, although SPA-1 mRNA levels were essentially the same in empty 
vector control cells and all of the Ras-mutant cells at time zero, levels of SPA-1 mRNA 
were slightly lower in unstimulated cells transfected with either RasV12 or RasV12C40 
compared to empty vector- or RasV12S35-transfected cells after 24 hours in culture 
(Fig.3.14C). Similarly, the increase of SPA-1 mRNA observed upon BCR-ligation was 
found to be reduced in cells transfected with either RasV12 or RasV12C40 compared 
to empty vector- or RasV12S35-transfected cells (Fig.3.14C). These results suggested 
that  Ras-dependent  PI3  kinase  but  not  Ras-mediated  ERK  activation  is  efficient  at 
suppression  of  SPA-1  transcription  and  supported  the  previous  findings  using 
pharmacological inhibition which showed pronounced effects of PI3 kinase but not ERK 
inhibition on SPA-1 mRNA levels (Fig.3.13D/E). Interestingly, expression of these Ras 
constructs was not effective at suppressing growth arrest at later timepoints (48 hours) 
[447], further supporting the hypothesis that Ras-independent signalling is a target of 
BCR-mediated growth arrest, especially during the later stages of the response.  
Collectively, these results indicate that, in untreated and therefore proliferating 
WEHI-231  cells,  PI3  kinase  signalling  suppresses  the  transcription  of  SPA-1  which 
could  increase  levels  of  active  Rap  and  hence  ERK.  Consistent  with  this,  BCR 
stimulation of immature B cells has been reported to reduce PI3 kinase signalling [455] 
and  therefore,  this  could  potentially  lead  to  the  loss  of  SPA-1  suppression  and  an  
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increase  in  SPA-1  levels.  Thus,  these  elevated  levels  of  SPA-1  might  be  partly 
responsible for the BCR-mediated downregulation of Rap and hence ERK. 
 
3.3.6 PAC-1  mRNA  expression  is  regulated  by  BCR-mediated 
signalling 
PAC-1  is  a  DUSP  which  dephosphorylates  ERK  and  thereby  inactivates  it 
[365,368]. It was previously shown to be upregulated at the protein level and recruited 
to ERK-containing complexes following BCR stimulation in WEHI-231 cells [310]. The 
mechanisms  involved  in  such  upregulation  have  not  yet  been  defined  and  so  the 
regulation of PAC-1 mRNA expression was therefore now examined in WEHI-231 cells. 
It was shown that anti-IgM stimulation appeared to increase the expression of PAC-1 
mRNA in a cyclical manner with an early peak within 2 h followed by a later peak 
between 8-24 h (Fig.3.15). Similarly to that observed for SPA-1 expression, an inverse 
PAC-1 expression pattern was found in cells treated with either anti-CD40 (or indeed 
anti-IgM in combination with anti-CD40) as PAC-1 expression was downregulated in 
those cells to levels below those detected in untreated cells (Fig.3.15). As mentioned 
before,  negative  and  positive  feedback  loops  often  modulate  DUSP-mediated 
regulation  of  MAPK  pathways.  It  was  therefore  perhaps  not  surprising  to  find  that 
inhibition of PI3 kinase or, to a lesser extent, ERK increased the expression of PAC-1 
at  the  mRNA  level,  to  a  similar  extent  as  that  observed  following  BCR-ligation 
(Fig.3.15).  Interestingly,  this  enhancement  was  only  apparent  some  12-16  h  after 
addition  of  inhibitors  but  functionally,  this  would  mimic  the  period  in  which  BCR 
signalling had also downregulated ERK activation. Whilst these data indicate that both 
ERK and PI3 kinase pathways can independently suppress the transcription of PAC-1, 
co-culture  with  both  inhibitors  appears  to further  enhance  PAC-1  mRNA  production 
suggesting that these may interact and perhaps even cross-regulate each other. 
To potentially corroborate these data, PAC-1 mRNA expression levels were also 
investigated in the WEHI-231 B cell lines expressing the mutant constructs of RasV12. 
Here, PAC-1 mRNA expression was found to be comparable in all 4 lines at time zero, 
but was found to be lower in cells expressing any of the active forms of Ras compared 
to empty vector cells after 24 h of culture (Fig.3.15C). Moreover, and supportive of the 
pharmacological  inhibitor  data,  cells  transfected  with  any  of  the  three  Ras  mutants 
displayed reduced upregulation of PAC-1 due to BCR-ligation (Fig.3.15C) confirming 
that Ras-mediated activation of either of the ERK and PI3 kinase pathways reduces the 
expression of PAC-1 and thereby enhances ERK signalling. 
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3.3.7 Differential subcellular localisation of Rap-1 and ERK 
It  is  becoming  increasingly  evident  that  the  functional  outcome  of  signalling 
pathways is not only dependent on the expression levels and activation status of the 
proteins but also on their subcellular localisation as this determines the upstream and 
downstream  interaction  partners. Thus,  preliminary  experiments  were  carried  out  to 
investigate  whether  Rap-1,  pERK  and  ERK  signals  were  differentially  localised  in 
spontaneously  proliferating  cells  in  comparison  to  those  undergoing  BCR-mediated 
negative selection and rescue via CD40. Thus, the expression of Rap-1, pERK and 
ERK  was  further  analysed  in  cytoplasmic,  membrane/organelle  (including 
mitochondrial), nuclear and cytoskeletal fractions (Fig.3.16).  
At both timepoints analysed (1 and 24 hours) Rap-1 was most strongly expressed 
in  the  membrane/organelle  fraction  consistent  with  reports  indicating  it  shuttles 
between  the  plasma  membrane  and  endosomal  membranes  [456].  However, 
substantial amounts of Rap-1 could also be detected in the cytoplasmic and nuclear 
fraction both at the early and later timepoints. At the later timepoint (24 hours) Rap-1 
was also found in the mitochondrial fraction and BCR-ligation appeared to increase the 
translocation  of  Rap-1  to  the  mitochondria  (Fig.3.16C)  where  it  has  been  shown 
previously to be able to influence mitochondrial function [457]. Interestingly, whilst Rap-
1 expression in the membrane and cytoplasmic fractions appeared to be reduced in 
BCR-stimulated samples relative to those from spontaneously proliferating cells, it was 
found to be enhanced in the nuclear fractions under conditions of negative selection at 
1  h  suggesting  that  such  differential  localisation  of  this  signalling  element  may 
contribute  to  the  functional  outcome  of  BCR-ligation.  Moreover,  for  all  conditions 
tested, whilst relatively higher levels of Rap-1 were detected in the nucleus compared 
to  the  cytoplasm  at  1  h,  an  inverse  pattern  of  Rap-1  expression  in  these  cellular 
compartments was observed at 24 h. Similarly, localisation to the cytoskeleton could 
only be detected at the 1 h timepoint (Fig.3.16). Sustained Rap-1 signalling at later 
timepoints  might  therefore  be  originating  from  different  subcellular  compartments 
compared  to  the  early  signal  (1  hour).  This  could  potentially  change  the  signalling 
outcome as it has been described before that activation of downstream effectors of the 
Rap-1 cascade depends on its localisation [458,459].  
Activated ERK (pERK) was predominantly found in the cytoplasmic and nuclear 
fractions 1 hour after stimulation with low level expression of pERK1 but not pERK2 
detected in the membrane/organelle fraction (Fig.3.16). The enhanced ERK activation 
routinely observed in BCR-stimulated cells at this time point (Fig.3.7) was reflected in 
all fractions analysed indicating that this was a global effect and not restricted to a 
particular location and/or group of downstream substrates. The selective activation of 
ERK1  observed  in  the  membrane  fractions  (and  in  all  but  the  cytoskeletal  fraction  
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derived from spontaneously proliferating cells) was intriguing as essentially equivalent 
levels of ERK1 and ERK2 were expressed in these fractions indicating localisation-
specific  activation  of  this  isoform  (Fig.3.16).  Moreover,  given  the  relatively  high 
expression of ERK1/2 protein in the cytoplasmic/cytoskeletal compared to the nuclear 
and membrane fractions, the ERK activation observed in the membrane and nuclear 
fractions  under  these  conditions  was  particularly  strong.  The  organelle/membrane 
fraction  contains,  amongst  others,  mitochondria  and  the  expression  of  pERK  in  a 
purified mitochondrial fraction was therefore analysed. However, neither expression of 
ERK  nor  its  activation  was  observed  in  this  cellular  compartment  (Fig.3.16C).  The 
membrane/organelle  fraction  further  also  contains  endosomes.  The  importance  of 
endocytosis as  well as  signalling from endosomes has been underlined by multiple 
studies [460,461]. For example, MEK partner-1 (MP-1) is a small scaffold protein which 
localises  MEK/ERK  to  late  endosomes  where  it  binds  to  MEK1  and  ERK1  thereby 
enhancing the activation of this pathway [349]. Interfering with the localisation of MP-1 
to endosomes reduced the sustained activation of the ERK cascade rather than early 
signalling which appeared to take place at the membrane [349,462]. Thus, signalling 
from  this  compartment  might  provide  an  amplification  mechanism  to  maintain  high 
levels of ERK activation. 
After 24 hours pERK was mostly found in the membrane/organelle and nuclear 
fractions whereas expression in the cytoplasm could not be detected anymore despite 
ERK protein still being strongly expressed in this fraction (Fig.3.16). Consistent with the 
whole cell lysate samples, pERK expression is highest in fractions from cells which had 
their BCR cross-linked in the presence of CD40 signalling but not in cells treated with 
anti-IgM only (Fig.3.16). Rather surprisingly, however, the high levels of ERK activation 
detected in whole cell lysates of spontaneously proliferating WEHI-231 cells were not 
found in any of the analysed subcellular fractions. It is possible that ERK activation in 
these cells, which is most likely initiated by growth factor signalling, takes place in a 
fraction of the cells  which gets lost during the fractionation process. It  would be of 
interest to identify the localisation of activated ERK in these spontaneously proliferating 
cells, as the reduced overall activation of ERK in BCR-stimulated cells could be due to 
the inability of ERK to localise to this, as yet not identified, cellular compartment. This 
might  also  reflect  the  other  unexpected  finding  reputed  above  of  the  preferential 
activation of ERK1, rather than ERK2, in most compartments 1 hour after stimulation 
(Fig.3.16). This is in stark contrast to the favoured activation of ERK2 detected in whole 
cell  lysates.  Thus  again,  this  discrepancy  between  the  pattern  found  in  whole  cell 
lysates and the subcellular fractions might be due to the loss of a particular cellular 
compartment during the experimental procedure. These results are intriguing as ERK1 
and ERK2, although they are highly homologous and can compensate for each other  
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concerning  many  ERK-dependent  responses  [463],  carry  out  some  non-overlapping 
functions [464,465]. The differential levels of activation of these two isoforms as well as 
their varying localisation could therefore indicate that ERK1/2 direct different signalling 
outcomes during BCR-mediated growth arrest and apoptosis. 
Finally,  detection  of  marker  proteins  such  as  VDAC-1  (marker  protein  for 
mitochondria – membrane/organelle fraction) and HDAC-1 (marker protein for nuclear 
fraction)  was  used  to  validate  the  subcellular  fractionation.  Thus,  HDAC-1  although 
found to be weakly expressed in all fractions, was strongly enriched in the nuclear 
fraction,  as  expected  (Fig.3.16).  By  contrast,  VDAC-1  expression,  a  marker  for 
mitochondria, was found to be enriched not only in the membrane/organelle fraction but 
also  in  the  cytoskeletal  fraction  (Fig.3.16)  possibly  indicating  carry  over  from  the 
membrane/organelle  fraction  to  the  cytoskeletal  fraction.  Collectively,  the  data 
described in this section shows that subcellular fractionation and analysis by Western 
Blotting could provide a useful tool to identify interesting changes in the localisation of 
signal  transducers  under  conditions  of  positive  and  negative  signalling.  However,  a 
second method, such as immunofluorescent staining, should be used to confirm the 
biochemical data or clarify any inconsistencies. 
 
3.3.8 Overexpression of Rap-1 in WEHI-231 cells 
The  data  described  above  provides  circumstantial  evidence  that  Rap  activity 
might contribute to ERK activation in spontaneously proliferating WEHI-231 cells. Thus, 
to  directly  address  this,  the  effects  of  over-expressing  different forms of  HA-tagged 
Rap-1A  (constitutively  active/dominant  negative  forms)  in  WEHI-231  cells  were 
assessed relative to empty vector controls.  
The BCR-mediated growth arrest response of cells transfected with Rap-1A WT 
did not differ greatly from the response seen in cells expressing either the constitutively 
active  form  (Rap-1A  G12V)  or  the  dominant  negative  form  (Rap-1A  S17N)  of  the 
protein or indeed the empty vector control at 48 h. The rescue from anti-IgM induced 
growth  arrest  by  stimulation  of  the  CD40  signalling  cascade  was  not  differentially 
influenced  by  expression  of  any  of  these  mutant  proteins,  but  rather  all  of  them 
prevented the full CD40-mediated rescue observed in the cells expressing the empty 
vector (Fig.3.17A).  
WEHI-231 cells transfected with Bcl-xL (WEHI-231- Bcl-xL) are protected against 
BCR-induced apoptosis but not growth arrest [294]. These cells therefore provide a 
useful tool to study BCR-induced growth arrest independent of the apoptosis response, 
which is abrogated due to the overexpression of Bcl-xL. Transfection of WEHI-231-Bcl-
xL  cells  with  the  constructs  encoding  the  above  mentioned  forms  of  Rap-1A  could 
therefore  give  further  insight  into  the  mechanisms  regulating  growth  arrest  
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independently from apoptosis. Therefore, WEHI-231-Bcl-xL cells were transfected with 
pcDNA3.1(-)Zeocin vectors encoding the previously described Rap-1A mutants. The 
pcDNA3.1(-)Zeocin  vector  encodes  a  resistance  gene  which  allows  the  positive 
selection  of  successfully  transfected  cells  in  media  containing  the  antibiotic  Zeocin 
enabling  selection  of  double-transfectants.  Thus,  after  transfection  with  the  above-
mentioned  vectors  and  positive  selection  in  Zeocin-containing  media,  the  functional 
responses such as anti-IgM induced growth arrest, CD40-mediated rescue from growth 
arrest as well as induction of apoptosis were analysed in the transfected cells. The 
cells expressing the Rap-constructs underwent growth arrest to a very similar extent as 
these containing the empty vector at 24 hours (Fig.3.17B). Moreover, in these WEHI-
231  Bcl-xL  cells  CD40-mediated  rescue  from  BCR-induced  growth  arrest  was  not 
influenced  by  expression  of  Rap-1A  or  any  of  the  Rap-1A  mutants  at  24  hours 
(Fig.3.17B). Moreover, analysis of the cell cycle stage of the cell populations showed 
only minor differences. Due to the overexpression of Bcl-xL only a very small proportion 
of WEHI-231- Bcl-xL cells undergo BCR-mediated apoptosis (Fig.3.18). Nevertheless, 
more of the cells transfected with Rap-1A WT, Rap-1A G12V and in particular Rap-1A 
S17N appeared to initiate apoptosis upon BCR-ligation compared to the empty vector-
transfected control cells. However, none of the G0/G1 or mitotic responses observed in 
cells expressing the Rap constructs (Fig.3.18) indicated that Rap greatly influenced the 
responses of these cells to BCR stimulation.  
To  investigate  the  possibility  that  despite  the  selection  procedures,  inefficient 
transfection or expression of the molecules was the reason for the observed lack of 
changes of the response of transfected cells, expression of the HA-tag in WEHI-231- 
Bcl-xL cells transfected with pcDNA3.1(-)Zeocin vectors, containing various forms of 
Rap, was assessed. Indeed, it was shown that even after selection in Zeocin containing 
media the expression of HA-tagged Rap-1A proteins could not be detected (Fig.3.19A). 
The positive signal detected in control fibroblast transfected with an HA-tagged PCKα 
construct  further  proved  that  the  inability  to  detect  the  expression  of  HA-tagged 
proteins in the WEHI-231-Bcl-xL cells was not due to a lack of antibody-binding or any 
other  experimental  difficulties  (Fig.3.19A).  Additionally,  transfected  WEHI-231-Bcl-xL 
cells displayed the same levels of Rap-1 expression as empty control vector- or un-
transfected  cells  further  confirming  the  lack  of  overexpression  of  the  transfected 
proteins (Fig.3.19A). 
Due to these difficulties and to further assess the cause of the lack of expression 
it was decided to transfect WEHI-231 cells using pIRES2-AcGFP1-vectors encoding 
various forms of Rap-1A which should lead to the expression of the marker protein 
GFP upon successful transfection. Indeed, GFP-positive cells could be detected 24 h 
after transfection of WEHI-231 cells (Fig.3.19B). However, the efficiency of transfection  
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was  very  low.  Furthermore,  stability  of  transfected  clones  was  an  issue,  as  GFP-
expression and hence expression of the genes of interest was found to be transient 
even  in  the  presence  of  the  selection  antibiotic  G418.  Thus,  expression  of  GFP 
declined rapidly and was lost by 11 days post-transfection (Fig.3.19B-C). To try and 
overcome  the  technical  difficulties  hindering  stable  transfection  of  WEHI-231  cells, 
various  constructs,  methods  of  transfection  and  selection  conditions  were  tested 
(summarised in Fig.3.19C-ii/iii). However, stably transfected lines were not achieved 
under any of the tested conditions. 
In view of the experimental problems in creating stable Rap-1A-expressing lines 
using conventional transfection methods, another method for creating stable clones, 
lentiviral transduction, was tested. Production of infective lentiviral particles was shown 
to  be  effective,  as  virus  generated  from  transfected  HEK293  T  cells  was  able  to 
transduce  HT-1080  cells  leading  to  the  production  of  the  marker  protein  ZsGreen1 
which could be detected by FACS (Fig.3.20A). Furthermore, it was possible to detect 
high expression of the HA-tagged Rap-1A proteins in lysates of these transduced cells 
(Fig.3.20B). Lentiviral transfection therefore provides a promising method of choice for 
future experiments investigating Rap-1-dependent signals in WEHI-231 cells. 
 
3.3.9 The role of the ERK cascade in the regulation of c-Myc 
c-Myc is an important transcription factor involved in cell cycle progression and 
thereby cell proliferation. It is known that BCR cross-linking on the WEHI-231 B cell line 
leads  to  a  transient  induction  of  c-Myc  mRNA  and  protein  levels  followed  by  a 
sustained  downregulation  [466,467].  By  contrast,  CD40  ligation,  which  is  known  to 
rescue WEHI-231 cells from growth arrest and apoptosis, was found to stabilise c-Myc 
levels [468]. In agreement with such results stimulation of WEHI-231 cells with anti-IgM 
resulted  in  downregulation  of  c-Myc  protein  levels  within  4  hours  reducing  them  to 
below baseline levels for at least 32 hours (Fig.3.21). By contrast, and in keeping with 
its  ability  to  promote  cell  survival,  CD40-ligation  on  its  own  enhanced  c-Myc  and 
ameliorated the downregulation of c-Myc induced by such BCR stimulation (Fig.3.21). 
Moreover, in unstimulated cells, c-Myc expression displayed a cyclic pattern over time, 
similar to previously observed with phosphorylated ERK (Fig.3.7). c-Myc expression 
therefore  seems  to  mirror  the  pattern  observed  for  phosphorylation  and  hence 
activation  of  ERK  in  either  unstimulated,  BCR-  or  BCR/CD40-stimulated  WEHI-231 
cells. Perhaps consistent with this, phosphorylation including that in response to ERK 
has  been  implicated  as  an  important mechanism  in  the regulation  of  c-Myc  protein 
levels. Thus, phosphorylation of the protein at residue serine 62 stabilises the protein, a 
mechanism that is probably used to promote c-Myc-driven progression through the cell 
cycle [469,470]. By contrast, phosphorylation of c-Myc on threonine 58 by GSK3 has  
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been  shown  to  lead  to  the  protein  phosphatase  2A  (PP2A)-dependent 
dephosphorylation  of  serine  62  which  destabilises  the  protein  leading  to  its 
ubiquitination  and  degradation  by  the  proteasome  [469].  In  confirmation  with  the 
putative role the phosphorylation of these specific residues plays in the stabilisation of 
c-Myc,  the  stabilised  form,  pc-MycS62,  was  found  to  be  downregulated  by  BCR-
mediated inhibition of ERK (Fig.3.21). In order to furthermore address whether BCR-
mediated  downregulation  of  c-Myc  and  pc-MycS62  reflected  GSK3-mediated 
phosphorylation of T58 followed by ubiquitination and degradation, the expression of 
pc-MycT58 was also analysed (Fig.3.22). At first sight, the finding that expression of 
this phosphorylated form of c-Myc was abrogated within 4-8 h of BCR stimulation was 
rather surprising but given that protein expression of c-Myc was not detectable in these 
cells suggests that c-Myc had already been degraded by this point and any such peak 
of T58 phosphorylation targeting c-Myc for ubiquitination would have occurred between 
2-4 h. Consistent with this proposal, analysis of the profiles of pc-MycT58 expression in 
the spontaneously proliferating cells reveals that peaks of expression occurs prior to 
downregulation of c-Myc expression resulting in a cyclic pattern of c-Myc expression 
(Fig.3.22).  These  results  were  corroborated  by  analysis  using  an  antibody  that 
recognises  c-Myc  which  is  either  dually-phosphorylated  at  Ser62  and  Thr58  (pc-
MycT58/S62) or phosphorylated at Thr58 but not at Ser62 alone and is therefore only 
able to detect c-Myc targeted for ubiquitination by Fbw7 [471] (Fig.3.22). Similarly, this 
antibody  also  detected  major  peaks  of  phosphorylated  c-Myc  prior  to  the  general 
downregulation of c-Myc levels (Fig.3.22).  
As it has been reported in other systems that ERK can regulate c-Myc stability by 
phosphorylating it at serine 62 [384,386], the potential role of ERK signalling in the 
regulation  of  c-Myc  stability  was  assessed  by  treating  spontaneously  proliferating 
WEHI-231 cells with the MEK inhibitor, PD98059, which inhibits ERK activation and 
results in growth arrest and apoptosis of such cells [310,447]. Furthermore, LY294002, 
a specific PI3-Kinase inhibitor, was used in order to compare the effects of inhibiting 
this key regulator of c-Myc stability (by inhibition of GSK3 [388]) as it has previously 
been reported by the Harnett group and others that BCR-signalling suppresses PI3 
kinase activity in WEHI-231 cells [373,455]. These data showed that repeated addition 
of the MEK inhibitor led to inhibition of ERK activation throughout the time course with 
substantial  downregulation,  comparable  or  greater  than  that  seen  following  BCR-
ligation observed at 2 h and from 8 h onwards (Fig.3.23). In general, inhibition of PI3 
kinase  was  not  effective  at  inhibiting  early  ERK  activation  but  in  agreement  with 
previous  findings  [373]  it  inhibited  ERK  activation  at  later  time  points  (>20  h)  and 
therefore  this  may  reflect  induction  of  growth  arrest  and  therefore  secondary 
inactivation  of  ERK  through  unknown  mechanisms  (Fig.3.23).  Consistent  with  their  
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proposed  roles  in  stabilising  c-Myc  expression  both  inhibitors  were  also  shown  to 
reduce  c-Myc  expression  (Fig.3.23  and  3.24A-D)  and  similar  to  BCR-ligation  also 
reduced levels of pc-MycT58/S62 consistently (Fig.3.25A-D).  
To determine if different stimulations not only changed the protein levels of c-Myc 
but  also  its  subcellular  localisation,  nuclear  and  cytoplasmic  fractions  of  WEHI-231 
cells were prepared and tested for c-Myc expression. BCR- or CD40-ligation or the 
combination of both did not appear to lead to translocation of c-Myc or pc-MycT58/S62 
into the cytoplasm as virtually no protein could be detected in the cytoplasm 4 hours 
after stimulation (Fig.3.24E and 3.25E). This indicates that c-Myc acts in the nucleus 
and  that  its  activity  is  determined  by  its  overall  expression  levels  rather  than 
translocation events. Corroboration of these Western Blot-based results was achieved 
by  immunofluorescent  staining  which  showed  that  both  c-Myc  and  pc-MycS62  co-
localised with the DAPI-stained nuclei (Fig.3.24/25F-i). Moreover, by analysing c-Myc 
expression  using  LSC,  it  was  found  that  not  only  did  BCR  stimulation  reduce  the 
percentage of cells expressing c-Myc but it also reduced the overall expression level of 
c-Myc in these cells (Fig.3.24F). Additionally and in confirmation of Western Blotting-
based  assays,  pharmacological  inhibition  of  ERK  and  PI3  kinase  also  reduced  the 
percentage  of  cells  expressing  c-Myc  as  well  as  their  levels  of  c-Myc  expression 
(Fig.3.24F). By contrast, CD40-mediated rescue from growth arrest was found to fully 
reverse the effects of BCR-ligation by enhancing the levels of c-Myc detected in cells 
and increasing the proportion of cells expressing c-Myc (Fig.3.24F). Similarly to the 
results described for c-Myc, the stabilised form of c-Myc, pc-MycS62, was found to be 
expressed  by  a  smaller  proportion  of  cells  after  BCR  stimulation  in  comparison  to 
untreated, proliferating WEHI-231 cells at 12 and 20 hours (Fig.3.25F). Moreover, the 
levels of pc-MycS62 expressed by such cells were found to be reduced upon induction 
of  BCR-mediated growth  arrest  at  the  earlier  timepoints.  Although,  at 32  hours  the 
levels of pc-MycS62 in cells treated with anti-IgM were broadly equivalent to that of the 
control  cultures  (Fig.3.25F),  this  presumably  reflects  the  cyclic  nature  of  c-Myc 
expression in proliferating cells as indicated by the Western Blot analysis (Fig.3.7A). 
Pharmacological  inhibition  of  ERK  and  PI3  kinase  signalling  was  as  effective  at 
suppressing the expression of the stabilised form of c-Myc as BCR-ligation (Fig.3.25F), 
further  confirming  the  important  role  of  these  cascades  in  stabilising  c-Myc  protein 
levels. Moreover, and in accordance with its ability to enhance the survival of WEHI-
231  cells,  CD40-ligation  markedly  increased  the  levels  of  pc-MycS62  detected 
(Fig.3.25F),  restoring  the  expression  of  stabilised  c-Myc  in  BCR-stimulated  cells  to 
levels detected in untreated, proliferating WEHI-231 cells (Fig.3.25F). 
Due to its role in the regulation of proliferation and hence potential for oncogenic 
transformation of cells [472], c-Myc is highly regulated not just at the post-translational  
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but also at the transcriptional level. Thus, to determine if the BCR-mediated decrease 
of  c-Myc  observed  at  the  protein  level  was  partly  due  to  a  downregulation  at  the 
transcriptional  level,  c-Myc  mRNA  expression  was  determined  in  spontaneously 
proliferating  WEHI-231  cells  or  anti-IgM  and/or  anti-CD40  stimulated  cells.  c-Myc 
mRNA  expression  was  indeed  found  to  follow  a  cyclical  pattern  in  spontaneously 
proliferating WEHI-231 B cells, similar to those observed with the protein levels of c-
Myc (Fig. 3.26A-i). Likewise, stimulation of BCR-signalling led to a transient increase of 
c-Myc expression peaking at around 2 hours after stimulation (Fig. 3.26A/B) followed 
by sustained downregulation of c-Myc mRNA levels over a period of 24 hours, which 
was reversed by activating the CD40 signalling cascade (Fig.3.26A/B). In contrast to 
their inhibitory effects on c-Myc protein expression (Fig.3.24), inhibitors of ERK and PI3 
kinase  did  not  however  downregulate  c-Myc  mRNA  levels  to  the  same  extent  as 
treatment  with  anti-IgM,  indicating  that  both  the  ERK  and  PI3  kinase  signalling 
cascades  acted  to  mainly  regulate  c-Myc  at  the  post-translational  rather  than  on  a 
transcriptional level (Fig.3.26A-B). In confirmation of these findings, mRNA levels of c-
Myc were also found not to be protected by the expression of the active Ras mutants 
(Fig.3.26C)  which  enhance  the  activation  of  the  ERK  and  PI3  kinase  signalling 
cascades.  By  contrast,  overexpression  of  the  active  Ras  mutants  diminished  the 
downregulation of c-Myc at the protein level after BCR-ligation (Fig.3.26D). These data 
therefore further support the idea that regulation of c-Myc downstream of ERK and PI3 
kinase cascades seems to be mainly due to regulation at the protein level. 
c-Myc is an important regulator of the cell cycle, as it controls the entry into S 
phase  and  consistent  with  this  BCR-mediated  growth  arrest  correlates  with  the 
reduction of c-Myc levels in WEHI-231 cells. Therefore, to prove the direct correlation 
between  c-Myc  levels  and  cell  cycle  status  of  cells,  it  was  decided  to  utilise  LSC 
analysis  to  gate  on  cells  with  different  c-Myc  or  pc-MycS62  expression  levels  and 
determine their distribution in terms of cell cycle stage (Fig.3.27A). Thus, it was found 
that cells with very low c-Myc or pc-MycS62 expression levels were mostly apoptotic 
cells and cells arrested in G1 phase, whereas the cells with higher levels of c-Myc and 
c-Myc pSer62 expression were generally found to be in the mitotic G2/M phase of the 
cell cycle (Fig.3.27B/C). Although c-Myc expression is mainly needed to overcome the 
restriction point during G1 growth arrest, the finding that few cells in G0/G1 expressed 
c-Myc probably reflects that these are cells arrested in G0/G1 rather than transiting 
through the cell cycle. The relatively low levels of c-Myc/ pc-MycS62 detected in cells in 
the S phase (Fig.3.27B/C) on the other hand are not surprising as it has been shown 
before that progression through S phase is not hampered by the lack of c-Myc and that 
the need for elevated c-Myc expression is not as stringent during S phase [473,474]. 
Expression of c-Myc/c-Myc pSer62 was also found to be relatively low in freshly divided  
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new daughter cells (Fig.3.27B/C) which most likely reflects their resting state, as they 
have to induce growth prior to re-entering the cell cycle at the G1 phase.  
As shown above, inhibition of the ERK and PI3 kinase cascades reduces the 
activation of ERK as well as the overall expression of c-Myc (Fig.3.23). In confirmation 
of previous results [310,373], such pharmacological inhibition of ERK or PI3 kinase 
gradually induced growth arrest of WEHI-231 cells between 12 and 32 hours after the 
addition of the inhibitors (Fig.3.28). Thus, both inhibitors increased the percentage of 
cells arrested in G0/G1 and diminished the proportion of cells in the mitotic phases of 
cell cycle (G2-M and S phase) in a similar manner to that following of BCR-ligation 
(Fig.3.28A).  A  more  detailed  analysis  revealed  that  such  effects  on  cell  cycle 
progression directly correlated with the levels of c-Myc as well as its stabilised form c-
Myc-pSer62.  Thus,  the  higher  the  expression  of  c-Myc  or  pc-MycS62  in  these 
populations of cells, the fewer cells were found in G0/G1 growth arrest (Fig.3.28B). 
Collectively,  these  data  suggest  that  the  direct  correlation  between  growth  arrest 
induced  by  the  inhibition  of  ERK  and  PI3  kinase  activation  and  reduced  c-Myc 
expression indicates that BCR-mediated reduction of ERK and PI3 kinase signalling 
might contribute to growth arrest by abrogating c-Myc levels by interfering with c-Myc 
stabilisation. 
 
3.3.10  The role of CTCF in BCR-induced growth arrest 
The data presented so far suggests that BCR-mediated modulation of the ERK 
and  PI3  kinase  cascades  regulates  c-Myc  levels  mostly  through  post-translational 
modifications  rather  than  transcriptional  regulation.  However,  BCR-ligation  was  also 
found to inhibit c-Myc transcription and this is also likely to have contributed to the 
reduced protein expression observed. It was therefore decided to examine CTCF, a 
transcription factor that is known to repress transcription of the c-Myc gene [475] and 
has previously been shown to be upregulated after stimulating WEHI-231 cells with 
anti-IgM [476]. Consistent with this, CTCF overexpression has been shown to lead to 
the downregulation of c-Myc and upregulation of p19, p21, p27 and p53 and thereby to 
the induction of growth arrest [476]. 
Interestingly,  given  the  previously  demonstrated  expression  patterns  of  pERK 
and  c-Myc  (Fig.3.7),  CTCF  expression  also  appears  to  be  regulated  in  a  cyclical 
manner  at  both  the  mRNA  and  protein  level  in  spontaneously  proliferating  cells 
(Fig.3.29). Moreover, expression at the protein level is enhanced throughout the time 
course following BCR-ligation and reduced by signalling via CD40 (Fig.3.29). Whilst the 
effects of BCR signalling were not replicated at the transcriptional level suggesting a 
role for stabilisation of CTCF protein expression, CD40 signalling did tend to suppress 
CTCF mRNA production. (Fig.3.29). Thus, increased expression of CTCF upon BCR- 
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ligation might contribute to the transcriptional repression of c-Myc. Like many other 
transcription  factors,  the  activity  of  CTCF  can  be  influenced  by  post-translational 
modifications such as phosphorylation. In the case of CTCF, phosphorylation at certain 
serines in its C-terminus attenuate its suppressive capacity [477]. It therefore remains 
to be determined if, rather than changing the overall level of CTCF, BCR-signalling 
might change CTCF activity more dramatically by changing its phosphorylation status.  
 
3.3.11  BCR stimulation regulates expression and activation 
of key regulators of cell cycle control 
Cell cycle progression of WEHI-231 cells has been reported to depend on the 
downregulation  of  inhibitors  like  p27  or  p19  [335,476].  p27  especially  seems  to  be 
crucial in the regulation of G1 growth arrest due to its ability to inhibit cyclin D/Cdk4/6 
complexes as well as cyclin E/Cdk2 complexes thus hampering the entry into S phase 
[478].  Consistent  with  this,  c-Myc  induces  the  upregulation  of  an  SCF-E3  ligase 
complex which ubiquitinates p27 thereby targeting it for degradation [479] and relieving 
such suppression of cyclin/Cdk activity. Moreover, c-Myc increases the expression of 
cyclins and hence further enhances the activity of cyclin/Cdk complexes [480]. Thus, 
BCR-mediated  reduction  of  c-Myc  levels  could  suppress  cyclin/Cdk-mediated 
phosphorylation of Rb proteins and release of E2F which is necessary for S phase 
entry. 
In confirmation of previous reports [481], p27 protein expression was shown to be 
increased within 16 h of BCR-ligation, and due to pharmacological inhibition of ERK as 
well as PI3 kinase pathways (Fig.3.30) correlating with the initiation of growth arrest 
induced by these stimuli/inhibitors. In confirmation of its pro-survival function, CD40-
signalling reduced the expression of p27 and rescue from growth arrest achieved by 
CD40 costimulation correspondingly reduced the levels of p27 (Fig.3.30). Moreover, 
similarly to the pattern observed for pERK and c-Myc expression, p27 also seems to be 
expressed in a cyclical manner in spontaneously proliferating WEHI-231 cells. These 
data  therefore  indicate  that  in  WEHI-231  cells  p27  represents  an  important  switch 
between  proliferation  and  cell  cycle  arrest.  BCR-mediated  reduction  of  levels  of 
activated  ERK  might  be  linked  to  increased  p27  expression  through  multiple 
mechanisms. Thus, ERK has been shown to directly phosphorylate p27, targeting it for 
ubiquitination and degradation [482]. Additionally, c-Myc dependent regulation of p27 
levels  might  be  another  mechanism  linking  activation  of  ERK  and  cell  cycle 
progression. It is therefore proposed that BCR-mediated signalling increases the levels 
of  p27  thereby  reducing  activation  of  cyclin/Cdk  complexes.  This  will  decrease  the 
phosphorylation of Rb and hence ultimately lead to growth arrest.  
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p53 is another important cell cycle regulator which stops cells from dividing if 
there is for example, any damage to their DNA. The main mechanisms by which p53 
achieves  cell  cycle  arrest  is  the  upregulation  of  p21,  a  cell  cycle  inhibitor  which 
suppresses the activation of Cdk1 and Cdk2 [483]. Moreover, p53 plays an important 
role in regulation of apoptosis and was found to induce apoptosis by upregulating pro-
apoptotic proteins such as Puma, Noxa and Bax, as well as directly interacting with 
Bcl-2 family members at the mitochondria [484-486]. Preliminary data by this group 
indicated that p53 might play a role in FcγRIIb-mediated apoptosis and or growth arrest 
in  mature  B  cells  [309].  Thus,  p53  might  also  potentially  regulate  growth 
arrest/apoptosis  at  other  B  cell  developmental  stages,  such  as  immature  B  cells. 
Therefore, the regulation of p53 downstream of BCR-signalling in the immature B cell 
line WEHI-231  was  analysed.  Due  to  its  important  role  in the cell  cycle  it  is  highly 
regulated,  especially  at  the  protein  level.  Indeed,  detection  of  protein  levels  of  p53 
showed  an  increase  of  the  levels  upon  BCR-ligation  at  24  hours  and  even  more 
pronounced at 48 hours after stimulation (Fig.3.31A). This increase of p53 protein was 
counteracted by the simultaneous stimulation of CD40-signalling (Fig.3.31A). However, 
there were no significant changes at the mRNA level indicating that p53 expression 
under these conditions is mainly regulated at the protein level (Fig.3.31B).  
Rb proteins and their binding partners, the E2F proteins, represent the principal 
regulatory element controlling entry into S phase [487]. Hyperphosphorylation of Rb 
disrupts the  binding  of Rb  to  E2F  leading to the  release  of this transcription factor 
enabling it to trans-activate transcription of genes needed for cells to overcome the G1-
restriction point [487] (see section 1.7). Phosphorylation of Rb proteins is a gradual 
process and phosphorylation at multiple positions is necessary to fully abrogate Rb 
binding to E2F. Cyclin D/Cdk4/6 complexes phosphorylate Rb at serine 780 during the 
earlier stages of G1 followed by phosphorylation of serines 807/811 by cyclin E/Cdk2 
complexes  [247,488].  Thus,  the  presence  of  hyperphosphorylated  Rb  proteins 
indicates the progression of a cell through G1/S transition. The ERK MAPK pathway 
appears to be involved at multiple stages in the control of Rb phosphorylation as ERK 
signalling can directly, as well as indirectly through its regulation of c-Myc, increase the 
expression of cyclin D and reduce levels of the cell cycle inhibitor p27 [482,489,490]. 
Activation  of  the  ERK  cascade  can  therefore  enhance  the  activity  of  cyclin/Cdk 
complexes leading to the hyperphosphorylation of Rb proteins.  
Thus,  as  predicted,  phosphorylation  of  Rb  on  the  serine  residues  780  and 
807/811  was  found  to  be  substantially  reduced  following  BCR  stimulation  or 
pharmacological  inhibition  of  the  ERK  and  PI3-Kinase  pathways  (Fig.3.30).  The 
expression of the other molecules involved in the proliferation and survival of WEHI-
231 cells, such as pERK, c-Myc and p27, has been shown to be cyclical over time.  
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Thus, unsurprisingly, the expression of phosphorylated Rb followed a similar pattern 
indicating a connection between the mechanisms regulating pERK, c-Myc, p27 and Rb 
(Fig.3.30 and 3.32/33). CD40-mediated rescue from growth arrest not only restored the 
levels of phosphorylated Rb but it also enhanced it at the later timepoints (12 hours 
onwards), an effect also seen in cells solely stimulated through CD40 (Fig.3.30 and 
3.32/33). However, at first sight, LSC analysis of pRbS780 expression only partially 
corroborated the Western Blotting data. Thus, although levels of pRbS780 were found 
to be increased due to CD40 signalling, the decrease of phosphorylated Rb upon BCR 
stimulation could not be detected by immunofluorescent staining as the percentage of 
pRbS780 expressing cells, as well as the expression intensity were found to be above 
the levels found in untreated, proliferating WEHI-231 cells (Fig.3.32E). However, this 
discrepancy may simply reflect the fact that Western Blotting for phosphorylated Rb 
allows analysis of not only the strength of the signal, but also of the relative distribution 
of  the  different  pRb  forms.  Thus,  phosphorylated  Rb  appears  as  multiple  bands  of 
increasing size reflecting the sequential hyperphosphorylation of Rb and it is mainly 
these  higher  molecular  weight  bands  which  are  downregulated  upon  BCR-ligation 
(Fig.3.32A/B) and which may not be detected by LSC analysis which does not involve 
protein denaturation and cannot detect changes of protein size due to phosphorylation 
rather than overall expression differences. This problem however was not encountered 
concerning detection of pRb S807/811 as the BCR-mediated downregulation observed 
by  Western  Blotting  analysis  was  also  confirmed  by  LSC  analysis  of 
immunofluorescent staining (Fig.3.33E).Thus, a lower percentage of cells stimulated 
through  the  BCR  expressed  hyperphosphorylated  RbS807/811  and  the  cells  which 
expressed it did so at a reduced level (Fig.3.33Ei/ii). Moreover, in agreement with the 
results shown by Western Blotting, CD40 signalling not only efficiently increased the 
percentage of pRbS807/811-expressing cells as well as the level of expression but also 
prevented the BCR-mediated downregulation of pRbS807/811 (Fig.3.33Ei/ii). 
As mentioned previously, phosphorylation of Rb plays a crucial role during G1/S 
transition, whereas hypophosphorylation will ultimately lead to growth arrest during G1. 
Thus, to confirm the direct correlation between cell cycle progress and phosphorylation 
of Rb proteins, cells stained for pRbS780 and pRbS807/811 were analysed concerning 
their cell cycle status. As expected, higher expression levels of pRbS780 as well as 
pRbS807/811 correlated with cells being located in the mitotic phases of the cell cycle 
(Fig.3.32/33F),  whereas  a  higher  percentage  of  cells  expressing  lower  levels  of 
hyperphosphorylated  Rb  were  arrested  in  the  G0/G1  phase  of  the  cell  cycle  or 
undergoing apoptosis as detected by supdiploid DNA content (Fig.3.32/33F).  
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3.3.12  Ubiqitination and proteasomal degradation 
Ubiquitination  plays  an  important  role  in  regulating  many  cellular  processes 
including the cell cycle. Thus, phosphorylation of cell cycle regulators such as p27 and 
c-Myc at specific regulatory sites targets these proteins for ubiquitination followed by 
degradation  [250,387].  Consistent  with  this,  BCR-mediated  growth  arrest  correlates 
with the downregulation of c-Myc as well as stabilisation and reduced degradation of 
p27 (Fig.3.28 and 3.30). Changes in the ubiquitination status of these crucial molecules 
could therefore reflect commitment to growth arrest and apoptosis of WEHI-231 cells. 
Indeed,  preliminary  data  suggests  that  ubiquitination  and  expression  of  certain  E3 
ubiquitin ligases might play a role in directing both BCR-driven negative selection and 
CD40-mediated  rescue.  Firstly,  when  the  global  ubiquitination  pattern  of  whole  cell 
lysates of WEHI-231 cells treated with anti-IgM and/or anti-CD40 was examined, it was 
found that the pattern observed in anti-IgM treated cells differed markedly from cells 
stimulated  with  CD40  or  untreated  cells  (Fig.3.34)  as  stimulation  through  the  BCR 
strongly increased the total amount of ubiquitinated proteins (Fig.3.34B).  
To  further  study  whether  these  differential  profiles  are  due  to  BCR-signalling 
pathways  utilising  ubiquitination  to  target  key  signalling  elements  for  proteasomal 
degradation,  the  effect  of  a  cell-permeable  reversible  proteasome  inhibitor,  MG132, 
was tested in WEHI-231 cells. Inhibition of the proteasome was found to induce growth 
arrest and apoptosis independent of any further stimulation, underlining the importance 
of proteasomal degradation in housekeeping functions needed for survival (Fig.3.34E-
F). These non-specific effects of MG132 were found to strongly affect cells from around 
8-12 hours after addition of the inhibitor and hence restricted the scope and timescale 
of  analysis  during  these  experiments.  Thus,  it  was  decided  to  mainly  analyse 
timepoints before 20 hours or “trap” substrates of varying kinetics by restricting addition 
of MG132 to 1 hour before the cells were harvested.  
Blocking proteasomal degradation by inhibiting the proteasome should lead to an 
accumulation of ubiquitinated proteins. Thus, as expected, treatment of the cells with 
an optimised dose of MG132 increased the level of ubiquitinated proteins as detected 
by Western Blotting (Fig.3.35). This analysis further showed that, at least in the first 12 
h of culture, inhibition of the proteasome converted the profile seen in untreated cells to 
a phenotype more similar to that observed in cells stimulated via the BCR (Fig.3.35). 
These  results  perhaps  suggest  that  in  spontaneously  proliferating  cells  there  is  a 
dynamic process of ubiquitination and degradation of negative regulatory elements that 
perhaps allows expression and activation of the cyclical signals promoting survival and 
proliferation.  Moreover,  the  finding  that  many  of  the  same  bands  appear  to  be 
ubiquitinated in control and BCR-treated cells, but to a lesser degree (Fig.3.35), may 
suggest that an additional level of regulation may be afforded by a dynamic balance of  
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E3  ligase-mediated  ubiquitin-based  targeting  of  positive  signalling  elements 
counteracted  by  de-ubiquitination.  Thus,  in  the  case  of  BCR-mediated  negative 
selection,  it  is  possible  that  this  balance  is  skewed  in  favour  of  the  ubiquitination 
system and downregulation of de-ubiquitination enzymes (DUBs).  
Thus to assess the impact of the E3 ligase/DUB balance on negative selection of 
B cells, the effect of proteasome inhibition on p27 and c-Myc expression levels was 
examined. These elements were selected as BCR-mediated modulation of their protein 
stabilisation has been implicated by this study as a regulatory mechanism and both 
molecules  have  previously  been  shown  to  be  regulated  by  ubiquitin-mediated 
degradation through the proteasome [250,387]. As indicated previously (Fig.3.7), whilst 
c-Myc  expression  exhibits  a  cyclical  profile  in  spontaneously  proliferating  cells,  its’ 
expression is upregulated in the first 4 h following stimulation via the BCR before being 
profoundly downregulated, findings consistent with commitment of these cells to BCR-
mediated growth arrest and apoptosis. Expression of c-Myc was found to be enhanced 
following proteasome inhibition in not only the negatively-selected but particularly the 
spontaneously proliferating WEHI-231 B cells, at least in the first 4 h following addition 
of  MG132  (Fig.3.35).  Moreover,  inhibition  of  the  proteasome  partially  inhibited  the 
BCR-mediated downregulation of c-Myc levels even after 8 hours (Fig.3.35A). These 
results therefore suggested that the regulation of c-Myc protein stability under these 
conditions and at these early timepoints was achieved by the ubiquitin-proteasomal 
targeting  mechanism  through  phosphorylation  of  threonine  58,  as  reported  in  other 
systems [387]. Accordingly, phosphorylation of c-Myc on threonine 58 was found to be 
strongly upregulated 2 hours after BCR-ligation (Fig.3.22B). Collectively, these results 
therefore indicate that a BCR-mediated increase of phosphorylation of this inhibitory 
position  triggers  ubiquitination  and  hence  targeting  of  c-Myc  to  the  proteasome 
followed by its degradation.  
The cell cycle inhibitor p27 controls the stability of cyclin/Cdk complexes through 
directly  binding  these  proteins  [263].  Mitotic  stimulation  of  cells  induces  signalling 
cascades which lead to the phosphorylation of p27 on threonine 187 by cyclin/Cdk 
kinases [250,491]. This facilitates the recognition and binding of p27 by the SCF E3-
ubiquitin  ligase  complex  thereby  initiating  the  ubiquitination  of  p27  and  finally 
degradation by the proteasome [479]. Apart from the earliest time point, inhibition of 
proteasomal degradation with MG132 only marginally increased p27 levels detected in 
spontaneously  proliferating  WEHI-231  cells  (Fig.3.35).  Moreover,  inhibition  of 
degradation  had  no  major  effects  on  the  already  enhanced  levels  of  p27  in  BCR-
stimulated  cells  (Fig.3.35).  Taken  together  these  results  indicate  that  decreased 
proteasomal  degradation  is  not  a  major  mechanism  controlling  the  BCR-mediated 
increase of p27. Moreover, the suppression of p27 levels needed to allow WEHI-231  
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cells to spontaneously proliferate does not seem to reflect an increase of proteasomal 
degradation of p27. The increase of p27 levels observed after BCR-ligation is therefore 
more  likely  due  to  upregulation  of  p27  transcription,  a  mechanism  which  has  been 
previously reported to play a major role in the induction of BCR-mediated growth arrest 
of WEHI-231 cells [481]. 
To  further  investigate  the  proposal  that  c-Myc  is  regulated  by  modification 
through  ubiquitination,  a  specific  ubiquitin-pull-down  matrix  was  used.  This  method 
allows the extraction of ubiquitinated proteins which can then be analysed further by, 
for example, Western Blotting. Thus, c-Myc was found to be present in the fraction of 
ubiquitinated proteins (Fig.3.36A). At first sight it appeared that BCR-ligation did not 
increase the amount of ubiquitinated c-Myc, rather it seemed to reduce the levels of c-
Myc.  However,  due  to  the  late  timepoint  (24  hours)  chosen  for  this  analysis,  this 
change seems to be due to the lower overall levels of c-Myc rather than ubiquitination-
dependent  changes  of  c-Myc  levels,  which  appear  to  take  place  soon  after  BCR-
ligation (2-8 hours) (Fig.3.35).  
Ubiquitination  seems  to  be  involved  in  the  regulation  of  many  of  the  major 
signalling proteins regulating growth and survival of WEHI-231 cells. Therefore, it was 
decided to examine the effect of proteasomal inhibition on the dynamic regulation of 
ERK  activation,  one  of  the  major  pathways  controlling  the  fate  of  WEHI-231  cells. 
Interestingly, ubiquitination and hence degradation of proteins seems not to be a major 
mechanism involved in the BCR-mediated reduction of ERK activation as MG132 did 
not  substantially  enhance  or  inhibit  either  the  transient  upregulation  or  subsequent 
downregulation of pERK (Fig.3.36B). Unexpectedly, the heightened activation of ERK 
usually observed at the later timepoints (8 hours) after costimulation of the BCR and 
CD40 was hampered by the inhibition of proteasomal degradation (Fig.3.36B-ii). Thus, 
these results might argue for the sustained presence of a negative regulator of the ERK 
cascade  which  under  normal  circumstances  is  targeted  for  degradation  by  the 
proteasome  through  CD40-mediated  signalling  thereby  lifting  the  suppression  and 
enhancing  ERK signalling.  Blocking  proteasomal  degradation could  therefore  hinder 
the  degradation  of  this  unknown  negative  regulator  and  stabilise  it  leading  to  the 
observed reduction of ERK activation.  
Having established a connection between ubiquitination/proteasomal degradation 
and regulation of signalling pathways involved in BCR-mediated growth arrest, it was 
decided to analyse the expression of some E3 ubiquitin ligases previously implicated in 
the regulation of B cell responses (reviewed in [492]). Thus, preliminary experiments 
were carried out to examine the expression of Cbl-b, c-Cbl, Itch and Grail, all of which 
have  been  identified  as  negative  regulators  of  B  and/or  T  cell  signalling  [492]. 
Interestingly,  it  was  observed  that  Cbl-b,  an  E3  ubiquitin  ligase  implicated  in  the  
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regulation of B cell and T cell signalling, was itself highly regulated by proteasome-
dependent  degradation  as  shown  by  an  increase  in  Cbl-b  levels  in  MG132-treated 
samples compared to untreated cells (Fig.3.37A). Moreover, analysis of expression of 
Cbl-b at the protein and mRNA levels indicated that Cbl-b was upregulated upon BCR-
ligation at both the protein and mRNA levels whereas co-ligation of CD40 protected the 
cells  from  Cbl-b  upregulation  (Fig.3.37B/C).  As  previously  mentioned,  Cbl-b  can 
influence  BCR-signalling  through  different  mechanisms.  Hence,  a  BCR-mediated 
increase of Cbl-b could decrease Syk levels following its ubiquitination by Cbl-b [441]. 
Furthermore,  Cbl-b  could  interfere  with  Rap-1  signalling  as  it  has  been  shown  to 
ubiquitinate adaptor proteins involved in recruiting Rap-1 [438]. The overall outcome of 
this  BCR-mediated  increase  of  Cbl-b  levels  could  therefore  potentially  contribute  to 
negative signalling induced by BCR-ligation. 
These promising findings led us to analyse the expression of further E3 ubiquitin 
ligases implicated in regulation of immune cell signalling such as c-Cbl, Itch and Grail. 
Due to difficulties in qRT-PCR primer/probe design, mRNA expression data could only 
be acquired for c-Cbl but not for Itch or Grail. c-Cbl mRNA levels, similar to Cbl-b, were 
upregulated from  8  hours  onwards  after  BCR-ligation  (Fig.3.38A). This  upregulation 
could again be prevented by simultaneous CD40 signalling. These changes in mRNA 
expression, however, did not fully translate into changes at the protein level although c-
Cbl was most highly expressed in anti-IgM treated cells and this was suppressed by 
CD40-mediated signalling (Fig.3.38B). Similarly, analysis of the expression of Itch and 
Grail  appeared  to  show  degradation  following  co-ligation  of  the  BCR  and  CD40 
(Fig.3.38B).  Indeed,  Grail  was  found  to  be  present  in  different  forms  (possible 
degradation products) and stimulation with anti-CD40 antibodies led to an increase in 
the smaller sized fragments detected (Fig.3.38B). It has been shown in T cells that 
degradation of Grail allows increased T cell proliferation and diminishes the induction of 
anergy. Thus, an increase of the levels of these E3 ligases due to upregulation or 
inhibition of their degradation could contribute to negative signalling mediated by the 
BCR in WEHI-231 cells.  
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3.4  Discussion 
 
The adaptive immune system has evolved to allow recognition of and protection 
against  an  essentially  infinite  variety  of  pathogens.  However,  this  generation  of 
diversity in terms of the numbers of different antigen receptors also permits the creation 
of  self-reactive  specificities,  necessitating  the  development  of  selection  processes 
deleting self-reactive cells from the repertoire. In the case of B cells, this has led to the 
evolution of a number of checkpoints throughout development at which autoreactive 
cells are blocked from further progression and activation. Negative selection of self-
reactive immature B cells in the bone marrow represents one of the major checkpoints 
and provides a mechanism of central tolerance. At this stage, strong BCR-mediated 
signals induce either receptor editing, anergy or apoptosis to drive clonal tolerance. 
Defects disturbing this checkpoint have been shown to increase the proportion of self-
reactive B cells in the periphery, hence potentially increasing the risk of activating these 
cells  and  inducing  autoimmune  inflammation.  Therefore,  identifying  the  signals 
underlying  negative  selection  might  provide  interesting  information  to  counter  the 
development of autoimmune disease by targeting the regulation of this mechanism. For 
example,  in  this  chapter  signals  regulating  the  ERK  MAPK  cascade  have  been 
examined allowing further insight into the pathways utilised to induce BCR-mediated 
negative selection of immature B cells and hence potentially identify novel therapeutic 
targets. 
 
3.4.1 Rap and the RapGAP SPA-1 are regulated by BCR-mediated 
signals 
This laboratory has previously shown that sustained cyclic activation of ERK is 
necessary for proliferation of WEHI-231 cells (Fig.3.7) and BCR-mediated abrogation 
of this ERK signal induces growth arrest and apoptosis [310]. However, the signals 
linking  ERK  activation  to  cell  survival  and  cell  cycle  progression  were  not  fully 
elucidated in this model. Nevertheless, some of the pathways involved in the regulation 
of  such  ERK  activation  have  been  partly  identified.  These  data  indicated  that 
downregulation of Ras activity due to BCR-ligation is not the only mechanism leading 
to reduced ERK activation. Thus, for example, whilst the Ras/Raf-1 pathway has been 
shown  to  couple  to  ERK  activation  in  B  cells,  preliminary  data  showed  that  similar 
levels of Ras activation occurred in untreated and anti-IgM treated cells [373]. Perhaps 
consistent with this, other studies indicated that overexpression of Ras protected cells 
from growth arrest for up to 24 hours. After this time though, constitutively active Ras 
was not sufficient any more to prevent growth arrest and apoptosis [447]. Therefore,  
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other molecules which could potentially activate ERK downstream of the BCR were 
examined to identify their involvement in the induction of growth arrest.  
Ras is the prototypical G protein activating the MEK/ERK signalling cascade, but 
it is not the only small GTPase involved in ERK signalling in B cells. Although initially 
identified as a potential activator of ERK in neuronal cells another GTPase, Rap, has 
been proposed to regulate ERK activation via a B-Raf-dependent pathway in B cells 
[411,493]. Thus, in chicken DT40 B cells B-Raf is the main MAPKKK regulating ERK 
phosphorylation  and  activation  downstream  of  the  BCR,  indicating  a  role  for  Rap-
dependent activation of ERK in mature B cells [170]. Here, Rap was also found to be 
regulated  by  BCR-ligation  (Fig.3.12),  in  that  BCR  stimulation  reduced  the  levels  of 
activated Rap below the levels detected in untreated and hence proliferating WEHI-231 
cells and such suppression of Rap activity correlates with the BCR-mediated reduction 
in cyclic ERK signalling. Interestingly, simultaneous engagement of CD40 reversed the 
negative effects of BCR-ligation partly restoring levels of active Rap (Fig.3.12). It has 
been reported that Ras and Rap-1 mediate transient and sustained activation of ERK, 
respectively. Thus, interfering with Rap-1 activation in PC12 cells causes the loss of 
sustained  ERK  activation  usually  seen  upon  stimulation  with  nerve  growth  factor. 
Blocking Ras activation on the other hand only affected the transient early activation of 
ERK [493]. Furthermore, computational simulations and experimental validations have 
further strengthened this model of a biphasic ERK activation dependent on the two 
different GTPases Ras and Rap [494]. It can be inferred that a similar system might be 
deployed  to  regulate  ERK  activation  in WEHI-231  cells.  Hence,  the  sustained  ERK 
activation observed in spontaneously proliferating WEHI-231 cells would depend on 
Rap-1 rather than Ras activity. 
The upstream regulators responsible for the activation of Rap in WEHI-231 cells 
have not been examined yet, but in order to identify the pathways involved it would be 
interesting to analyse the levels of Rap-specific GEFs such as C3G and the effects of 
BCR-ligation  on  their  expression.  For  example,  signalling  through  the  BCR  could 
potentially recruit proteins to interfere with the complexes formed by Rap, its GEFs and 
adaptor proteins such as CrkL, Cbl and Grb2. Indeed, this complex is a good candidate 
for  recruitment  and  activation  of  Rap  in  B  cells  as  it  has  been  shown  that  these 
molecules interact upon BCR-mediated activation of Rap in mature B cells [495,496]. 
Interestingly, it has been shown in this chapter that BCR-ligation upregulates Cbl-
b  (Fig.3.37)  which  has  been  implicated  in  the  regulation  of  C3G,  CrkL  and  Rap 
complex formation and hence Rap activation. For example, it has been shown in T 
cells that Cbl-b can ubiquitinate CrkL and influence its ability to interact with its binding 
partner C3G. Thus, Rap activation was found to be enhanced in Cbl-b deficient T cells 
[438]. The observed BCR-mediated upregulation of Cbl-b expression in WEHI-231 cells  
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could  therefore  potentially  be  linked  to  reduced  Rap  activation.  However,  the 
subcellular localisation of Cbl-b and hence co-localisation with Rap or C3G and CrkL 
has not been examined in this study and it remains to be confirmed whether Cbl-b has 
a similar function in WEHI-231 cells as in T cells.  
Rap activation is not only determined by interaction with GEFs but also by its 
negative regulators, RapGAPs. One of the best studied RapGAPs in lymphoid cells is 
SPA-1, making it a likely candidate for the regulation of Rap in the WEHI-231 system. 
Indeed, whilst SPA-1 was found to be upregulated at the mRNA and protein level by 
BCR-signalling,  CD40-ligation  actively  suppressed  expression  of  SPA-1  (Fig.3.13). 
Thus,  negative  signalling  through  the  BCR  upregulates  signals  leading  to  the 
inactivation of Rap such as SPA-1 and potentially, Cbl-b. Consistent with this, a crucial 
role for Rap signalling in the survival of immature B cells has recently been identified 
for  the first  time  as  an  increased  proportion  of B  cells  from  SPA-1-deficienct  mice, 
which display high levels of Rap activation, showed signs of defects in receptor editing 
skewing their receptor repertoire towards auto-antigen-specificities ultimately leading to 
development of autoimmune disease in older SPA-1 deficient mice [429]. This study 
therefore emphasises the importance of regulated Rap/ERK signalling in immature B 
cells. 
The elements and signalling cascades regulating BCR-mediated transcription of 
SPA-1 have not been fully elucidated, but SPA-1 was originally identified as a gene 
upregulated in lymphocytes upon IL-2, ConA as well as antigen receptor stimulation 
[405]. Moreover, preliminary data in this chapter indicated that negative feedback loops 
are likely to play a role in the regulation of SPA-1 in immature B cells. For example, it 
has been shown that PI3 kinase activity is likely to be involved in the suppression of 
SPA-1 transcription as inhibition of PI3 kinase increased the levels of SPA-1 mRNA to 
a similar extent as BCR-ligation (Fig.3.13). Consistent with this, overexpression of Ras 
molecules constitutively activating the PI3 kinase cascade and/or the ERK cascade 
were found to generally downregulate SPA-1 levels (Fig.3.14). These data imply that 
PI3 kinase signalling, which can be detected in proliferating, activated cells, negatively 
regulates SPA-1 and hence increases Rap activation, which in turn can activate ERK to 
induce signalling that further strengthens the pro-survival programme.  
Another negative regulator of the ERK cascade, PAC-1, was also found to be 
transcriptionally regulated in a similar fashion to SPA-1. Thus, PAC-1 was found to be 
upregulated following inhibition of ERK and PI3 kinase signalling whilst overexpression 
of  constitutively  active  Ras  mutants  acted  to  decrease  the  levels  of  PAC-1 
(Fig.3.14/15), the latter finding being consistent with the ERK cascade being implicated 
in the regulation of PAC-1 mRNA levels in T cells [366]. However, whilst activation of T 
cells  was  found  to  induce  sustained  transcription  of  PAC-1  in  an  ERK-dependent  
  141 
fashion, BCR-signalling only transiently upregulated PAC-1 transcription. Thus, BCR 
stimulation increased PAC-1 expression at the very early timepoint (2 h) (Fig.3.15) and 
it can be envisaged that this reflected the strong but transient ERK signal triggered by 
the BCR at this time. However, at the later timepoints, it is not clear what signals are 
responsible for PAC-1 transcription required for BCR-mediated downregulation of the 
sustained  cyclic  ERK  activation.  By  contrast,  the  sustained  cyclic  moderate  ERK 
signalling presumably reflects cycles of PAC-1 upregulation and decay. 
In conclusion, positive signals such as PI3 kinase and ERK signalling appear to 
actively suppress the expression of negative regulators of the ERK cascade. On the 
other hand BCR-signalling acts to abrogate both these signalling cascades, releasing 
the  transcriptional  suppression  of  SPA-1  and  PAC-1.  These  molecules  therefore 
ensure the continuing inhibition of ERK signalling and in this way, the commitment of 
cells to growth arrest and apoptosis.  
 
3.4.2 Subcellular localisation of signalling molecules 
The localisation of signal transducers inside the cell can be as important as their 
levels  of  expression  or  activation  status,  due  to  the  different  potential  interaction 
partners present in the various subcellular compartments. Analysis of the levels of Rap-
1,  activated  ERK  and  SPA-1  showed  that  the  cellular  distribution  of  these  signals 
indeed changes depending on the time points and stimuli analysed. For example, as 
expected,  SPA-1  was  mainly  found  in  the  nucleus  and  cytoplasm  as  previously 
observed  [451].  Thus,  cytoplasmic  SPA-1  most  likely  regulates  the  activity  of  Rap 
whereas nuclear SPA-1 might carry out different, as yet unknown, functions. Relating 
to this, SPA-1 has recently been found in a complex with the chromatin binding protein 
Brd4 in the nucleus of HeLa cells [451]. Brd4 can influence assembly of transcription 
factor complexes and has been implicated in processes such as cell cycle control and 
DNA  replication  [497]  suggesting  that  SPA-1,  by  binding  Brd4  or  potentially  other 
nuclear  proteins,  could  influence  cellular  processes  independent  of  its  RapGAP 
function.  
Rap itself can also be found in different subcellular compartments as evidenced 
by its’ presence in cytoplasmic, nuclear, membrane/organelle, cytoskeletal as well as 
mitochondrial  fractions  of  WEHI-231  cells.  However,  Rap-1  levels  and  subcellular 
localisation were found to be similar in all the differently stimulated cell populations 
(Fig.3.16). Rather, the major change observed was in the localisation of Rap with time 
and hence cell fate status. Thus, independently of the various stimuli Rap expression 
was found to be diminished in the nuclear and cytoskeletal compartments following 
culture  for  24  hours  compared  to  the  levels  found  at  1  hour.  Rap  isoforms  have 
previously been found to localise to the ER [498], endosomes [499] and Golgi complex  
  142 
[500]  inducing  different  signalling  outcomes  depending  on  their  localisation.  For 
example, perinuclear activation of Rap by Epac does not result in the activation of the 
ERK cascade at this location as a result of C3G, as well as downstream components 
such  as  B-Raf,  not  being  localised  to  this  cellular  compartment  [458].  Interestingly, 
sustained Rap-1 and ERK activation in response to nerve growth factor stimulation has 
been observed at endosomes in PC12 cells rather than at the plasma membrane [459]. 
It is therefore possible that localisation of Rap to the endosomes could also reflect 
sustained Rap activation in the WEHI-231 system. Interestingly, given that Rap-1 was 
found in the mitochondrial fraction (Fig.3.16C), Rap-1 has also been found to localise 
to mitochondria in a renal tubular cell model of glucose induced apoptosis where it 
ameliorates mitochondrial dysfunction by interacting with Bcl-2 [457]. Whether Rap is 
activated at the mitochondria of WEHI-231 cells or interacts with Bcl-2 family members 
remains to be established. It should be borne in mind, moreover, that the general lack 
of change in Rap expression/subcellular localisation observed (Fig.3.16) might be due 
to the fact that detection of Rap-1 by Western Blotting does not differentiate between 
active and inactive  Rap-1. Thus, immunofluorescent staining for Rap-1 activation in 
combination  with  subcellular  marker  proteins  identifying  organelles  such  as 
mitochondria,  endosomes,  plasma  membrane  or  the  nucleus  would  clarify  if  Rap-1 
activation in various subcellular compartments is modulated due to BCR-ligation.  
That it is likely that detection of active Rap would render different results from 
looking at Rap expression levels, is supported by the analysis of levels of activated 
ERK compared to those of ERK protein expression. Thus, although ERK expression as 
such  does  not  change  in  the  cytoplasmic  or  nuclear  fraction,  activation  of  ERK 
increases dramatically 1 hour after BCR-ligation (Fig.3.16). Even more striking is the 
altered distribution of activated ERK at the later timepoint as at 24 hours after BCR 
stimulation, hardly any activation can be detected in the cytoplasm whereas pERK is 
still present in the membrane/organelle and nuclear fractions (Fig.3.16). 
In its inactive state ERK has been shown to be mainly localised in the cytoplasm 
where  it  is  retained  by  various  regulatory  molecules,  the  major  being  MEK.  Upon 
phosphorylation and hence activation, ERK can translocate to the nucleus whereas 
MEK  stays  in  the  cytoplasm  [501].  The  importance  of  such  nuclear  expression  of 
activated ERK has been underpinned by the finding that growth factor induced DNA 
replication, as well as cFos activation, is blocked by the forced retention of ERK in the 
cytoplasm  [502].  Although  nuclear  localisation  seems  to  be  the  major  pathway 
deployed  to  regulate  ERK-mediated  transcription,  other  downstream  signalling 
cascades  can  be  activated  in  different  compartments  of  the  cell.  For  example,  β-
arrestin  was  observed  to  associate  with  ERK  retaining  it  in  the  cytoplasm  and 
enhancing its activity. Thus, by preventing ERK from entering the nucleus [503], β- 
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arrestin complexing could provide a mechanism to potentially increase ERK activity in 
the cytoplasmic compartment, directing and allowing the phosphorylation and activation 
of  cytoplasmic  substrates  such  as  cPLA2  or  MAPK-activated  kinases.  Indeed,  this 
might be the case in the WEHI-231 cells as high levels of activated ERK were detected 
early on (1 h) in the cytoplasm of cells stimulated via the BCR (Fig.3.16), signalling 
which  has  previously  been  shown  to  be  key  to  activating  cPLA2  and  inducing 
apoptosis. BCR-signalling subsequently switches off sustained, cyclic ERK activation 
after this transient increase whereas simultaneous ligation of CD40 restores activation 
of ERK. Interestingly, the pool of activated ERK in the nucleus was diminished in BCR-
stimulated cells after 24 hours of culture. Thus, whilst both negative (BCR) and positive 
(BCR and CD40) signalling can induce the strong upregulation of active ERK observed 
in  the  cytoplasm  at  early  time  points,  only  positive  signalling  allows  the  sustained 
nuclear activation of ERK which may act, at least in part, to overcome BCR-mediated 
negative signalling by inducing counteracting survival mechanisms partly dependent on 
the nuclear function of ERK. Moreover, although the strong cytoplasmic ERK activation 
appears to be prerequisite for activating the cPLA2 apoptotic pathway, CD40 signalling 
blocks activation of cPLA2 despite also inducing high ERK activation. 
 
3.4.3 ERK-dependent regulation of c-Myc levels 
ERK is known to regulate proliferation of various cell types by impacting on the 
regulation of the cell cycle. For example, cyclin D1 in a complex with its Cdk binding 
partner  controls  S  phase  entry  and  cyclin  D1  upregulation  is  mediated  by  Fos-Jun 
transcription factors which in turn are activated by ERK [504]. Thus, increased levels of 
cyclin D1 therefore enhance the formation of active cyclin/Cdk complexes permitting 
the exit from G1 phase and hence cell cycle progression. Mitogenic signalling via the 
BCR in mature B cells induces cyclin D2 and to a lesser extent cyclin D3 expression 
rather than cyclin D1 [505] and B cells from cyclin D2-deficient mice displayed a lack of 
BCR-mediated proliferation confirming that this cyclin D isoform plays a crucial role in 
cell cycle progression [506]. Additionally, cyclin D2 has been shown, similarly to cyclin 
D1 in other cell types, to be regulated by ERK in mature B cells. Thus, inhibition of the 
MEK/ERK  cascade  blocked  cyclin  D2  expression  and  hence  phosphorylation  of  Rb 
[490]. 
However, the exact mechanism connecting such ERK activation with cyclin D2 
transcriptional regulation has not been experimentally determined. Nevertheless, there 
are  a  few  possible  candidates  which  could  potentially  link  ERK  and  cyclin  D2 
transcription. For example, one of the transcription factors able to regulate cyclin D2 
expression,  STAT5  [507],  has  been  shown  in  other  cellular  systems  to  be 
phosphorylated by ERK, increasing its activity [508]. Interestingly, cyclin D2 is also a  
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direct transcriptional target of c-Myc [480] as Myc/Max binding to its’ promoter was 
shown to enhance cyclin D2 expression [274]. Perhaps consistent with a role for c-Myc 
in  upregulating  cyclin  D2  in  B  cells,  in  this  present  study  it  was  shown  that 
pharmacological inhibition of ERK activation led to the downregulation of c-Myc protein 
levels  (Fig.3.23-25).  In  WEHI-231  cells,  this  appeared  to  reflect  ERK-mediated 
stabilisation of c-Myc protein levels rather than increase of c-Myc mRNA levels as c-
Myc transcription was not influenced to the same extent by pharmacological inhibition 
of ERK activation as c-Myc protein levels. This is perhaps not surprising as ERK has 
been shown to regulate c-Myc activity by phosphorylating the serine 62 residue in vitro 
which, if modified, increases the protein stability [387]. Consistent with this, it has now 
been  shown  in  this  study  that  inhibition  of  ERK  abrogated  the  levels  of  c-Myc 
phosphorylated  on  serine  62  hence  potentially  confirming the  link  of  ERK-mediated 
phosphorylation with the stabilisation of c-Myc in intact cells. Therefore, ERK could be 
connected to the regulation of cell cycle progression by increasing the level of c-Myc 
which in turn enhances cyclin D2 expression. Unlike pharmacological inhibition of ERK, 
BCR-signalling was found to not only reduce the protein levels of c-Myc but also its 
mRNA levels. Ligation of the BCR might therefore induce additional ERK-independent 
pathways to regulate c-Myc mRNA levels. The transcription factor CTCF, a repressor 
of c-Myc transcription [475], has been shown to be upregulated downstream of BCR 
stimulation (Fig.3.29) and so the BCR-mediated increase of CTCF could contribute to 
the reduction of c-Myc mRNA levels. 
Interestingly, pharmacological inhibition of PI3 kinase was also found to influence 
c-Myc expression (Fig.3.23), a finding that is consistent with the proposal that through 
the  activation  of  Akt  and  inactivation  of  GSK3,  PI3  kinase  signalling  can  directly 
increase  c-Myc  protein  stability  by  preventing  the  inhibitory  phosphorylation  of 
threonine  58.  However,  it  is  as  yet  not  clear  if  this  potential  direct  effect  on  c-Myc 
regulation is the only reason for reduced c-Myc levels upon inhibition of PI3 kinase 
signalling as ERK activation was found to be partly reduced in cells treated with the PI3 
kinase inhibitor suggesting a link between these two cascades. It therefore remains to 
be determined whether diminished c-Myc expression is due to inhibition of PI3 kinase 
signalling  or  secondary  abrogation  of  ERK  activation.  Independently  of  the  inhibitor 
used, c-Myc mRNA levels were not decreased to the same extent as by BCR-ligation 
(Fig.3.26) indicating that both cascades, ERK as well as PI3 kinase, regulate c-Myc 
predominantly at the protein level by stabilisation mechanisms. 
As  mentioned  before,  c-Myc  might  provide  one  of  the  links  between  ERK 
activation and cell cycle progression as it plays an important role in the regulation of 
the cell cycle machinery. Therefore, by taking advantage of LSC, it was directly tested 
whether  a  correlation  exists  between  expression  levels  of  important  cell  cycle  
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regulators such as c-Myc and the cell cycle stage. Thus, cells were firstly analysed for 
the expression of various molecules of interest by Western Blotting to confirm that they 
are indeed regulated by BCR-ligation. Following this, immunofluorescent staining to link 
cell cycle stage with the expression level of the molecules of interest, showed that 
increasing levels of not only pERK, but also of its downstream effector c-Myc as well as 
the phosphorylated (Ser62) and hence stabilised form of c-Myc, were linked to cell 
cycle  progression.  For  example,  growth  arrested  cells,  as  well  as  apoptotic  cells, 
displayed lower levels of pERK and c-Myc expression compared to cells found in the 
mitotic phases (G2/M and S phase) (Fig.3.10 and 3.27/28) of the cell cycle, findings 
consistent with reports that pERK and c-Myc expression is needed to overcome the 
restriction point and hence G1 growth arrest allowing successful entry into S phase 
[446,509]. Given that in WEHI-231 cells BCR stimulation suppresses sustained ERK 
activation which impacts on c-Myc protein stability, it is therefore perhaps not surprising 
to find a correlation between growth arrest/apoptosis and low levels of pERK/c-Myc 
expression.  Proliferation  on  the  other  hand  is  linked  to  elevated  levels  of  ERK 
activation  and  hence  c-Myc  levels  confirming  the  need  for  WEHI-231  cells  to 
upregulate c-Myc levels to enter into and successfully complete the cell cycle.  
 
3.4.4 BCR-mediated regulation of the cell cycle 
It has been established that ERK activation and c-Myc expression play a crucial 
role in determining the fate of WEHI-231 cells. How exactly the ERK/c-Myc cascade 
impacts  on  cell  cycle  progression  was  further  examined  by  analysing  downstream-
effectors involved  in cell cycle regulation. For example, p27 is a cell cycle  inhibitor 
which  acts  on  cyclin/Cdk  complexes  to  reduce  their  activation  [263].  p27  can  be 
regulated by various means such as transcriptional upregulation or post-translational 
modifications including phosphorylation [278,510]. p27 provides another potential link 
between an increase of c-Myc levels and enhanced progress through the cell cycle due 
to  the  ability  of  c-Myc  to  influence  the  rate  of degradation  of  p27. This  is  because 
components of the SCF-E3 ligase complex, which is responsible for p27 ubiquitination-
mediated degradation, are upregulated by c-Myc [511]. Moreover, c-Myc can directly 
suppress  p27  transcription,  thereby  further  decreasing  the  overall  levels  of  p27. 
Consistent with their effect on the induction of growth arrest, inhibitors of ERK or PI3 
kinase  activity  mimicked  BCR-signalling  in  increasing  the  protein  levels  of  p27 
(Fig.3.30), in a manner that correlated with the downregulation of c-Myc levels. In the 
case of BCR-ligation this might be partly due to increased transcription of p27 [481], 
however stabilisation of p27 due to reduced c-Myc levels in these cells might also play 
a  role  as  indicated  by  partial  rescue  of  p27  levels  during  inhibition  of  proteasomal 
degradation (Fig.3.35).  
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BCR-mediated upregulation of p53 (Fig.3.31) could represent another regulatory 
mechanism blocking the progress through the cell cycle as p53 signalling can enhance 
expression of p21, another cell cycle inhibitor regulating entry into S phase by blocking 
the activation of cyclin/Cdk complexes [512]. Alternatively, p53 could also target the 
putative ERK/c-Myc pathway by repressing c-Myc transcription [513,514]. For example, 
Mdm2 (murine double minute 2) is a ubiquitin ligase which binds to p53 and keeps it in 
an inactive state by binding and blocking its transactivation domain, as well as inducing 
p53 degradation [515,516]. Interestingly, it has been shown in hepatocytes that ERK is 
able  to  phosphorylate  Mdm2  at  serine  166  which  increases  Mdm2-dependent 
degradation of p53 [517]. Additionally, ERK signalling has been shown to induce the 
transcription of the Mdm2 gene as well as enhance the export of Mdm2 mRNA into the 
cytoplasm, thereby increasing its translation [518,519]. The reduced levels of active 
ERK in BCR-stimulated WEHI-231 cells could therefore lead to an increase in p53 and 
consequent downregulation of c-Myc by resulting in a decrease of Mdm2 expression 
and  activation.  Furthermore,  the  PI3  kinase-activated  Akt  also  phosphorylates  and 
activates  Mdm2  at  serine  166  [520]  and  therefore  reduced  levels  of  PI3  kinase 
activation,  observed  upon  BCR-ligation,  could  further  contribute  to  increased  p53 
levels. As well as being able to repress c-Myc transcription directly [513], p53 can also 
act to do this indirectly through upregulation of miR145 [514]. Taken together, BCR-
mediated events such as an increase of p27 and p53 prevent cells from overcoming 
the G1 restriction point and induce growth arrest or pro-apoptotic pathways contributing 
to BCR-mediated negative signalling.  
Mitotic stimulation of cells drives the transition through the G1 restriction point 
and entry into S phase with the major regulatory switch at this stage being the Rb/E2F 
module.  In  its  hypophosphorylated  state  Rb  is  bound  to  E2F  preventing  this 
transcription factor from transactivating S phase genes [487]. Hyperphosphorylation of 
Rb  by  cyclin/Cdk  kinase  complexes  modulates  the  binding  capacity  of  Rb  for  E2F, 
ultimately leading to release of E2F [487]. The presence of hyperphosphorylated Rb is 
therefore generally a sign for progression through G1 phase. Hence, as might have 
been predicted, phosphorylated Rb proteins (Ser 807/811 as well as Ser 780) were 
found at higher levels in spontaneously proliferating WEHI-231 cells compared to those 
displayed by cells undergoing BCR-mediated growth arrest (Fig.3.32/33). As sustained 
ERK  and  c-Myc  signalling  likely  feeds  into  the  upregulation  of  cyclin  D  levels,  the 
resultant  activated  cyclin/Cdk  complexes  would  then  phosphorylate  Rb  proteins 
contributing  to  the  entry  of  WEHI-231  B  cells  into  S  phase.  Stimulation  of  BCR-
signalling, on the other hand, abrogates such ERK activation and c-Myc expression 
ultimately  leading  to  reduced  phosphorylation  of  Rb  proteins  and  arrest  in  the  G1 
phase of cell cycle.   
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In line with its important role in cell cycle progress, hyperphosphorylation of Rb at 
Ser 780 as well as Ser 807/811 increased during the cell cycle  with highest levels 
being detected in the mitotic phases (Fig.3.32/33). These regulatory sites on Rb are 
phosphorylated by different cyclin/Cdk complexes, thus, for example, cyclin D1/Cdk4 
but not cyclinE/Cdk2 complexes are able to phosphorylate serine 780 [488]. However, 
there were no major differences in their pattern of expression as both forms of Rb were 
mainly found to be highly expressed in S and G2/M phases whereas hardly any cells 
arrested  in  G1  or  undergoing  apoptosis  expressed  hyperphosphorylated  Rb 
(Fig.3.32/33).  Thus,  BCR-ligation  on  WEHI-231  cells  induces  growth  arrest  and 
apoptosis by abrogating cyclic activation of ERK resulting in reduced levels of c-Myc 
and potentially impacting on cyclin D2 levels and consequently diminished levels of 
hyperphosphorylated Rb leading to growth arrest due to insufficient release of E2F and 
induction of S phase genes. 
 
3.4.5 Potential role for ubiquitination and E3 ubiquitin ligases in 
BCR-induced growth arrest 
There  are  many  ways  of  regulating  protein  levels  and  activity  in  a  cell. 
Ubiquitination provides a mechanism allowing the cell to rapidly change the levels of 
protein present by targeting such molecules for degradation and thereby modulating 
signalling  pathways  in  a  quick  and  reversible  manner.  It  was  therefore  examined 
whether ubiquitination plays a part in the pathways regulating the proliferative/growth 
arrest response of WEHI-231 cells. Indeed, initial experiments showed that the pattern 
of ubiquitinated protein expression by these cells changed following stimulation via the 
BCR suggesting that ubiquitination is indeed involved in BCR-mediated regulation of 
signal transducers (Fig.3.34). The availability of inhibitors of the proteasome makes it 
possible  to  analyse  the  contribution  of  ubiquitination-dependent  proteasomal 
degradation to cellular responses and regulation of protein levels. However, WEHI-231 
cells  proved  to  be  very  sensitive  to  the  toxic  side  effects  of  proteasome  inhibitors 
making  analysis  of  longer  term  signalling  difficult.  Nevertheless,  preliminary  results 
were still promising and provided some information on mechanisms regulating c-Myc 
levels  in  spontaneously  proliferating  WEHI-231  cells.  Thus,  protein  levels  of  c-Myc 
were  elevated  in  unstimulated  WEHI-231  cells  due  the  addition  of  MG132,  a 
proteasomal inhibitor, indicating a dynamic regulation of c-Myc expression even in the 
absence of external stimuli such as BCR-ligation (Fig.3.35) and could explain the cyclic 
pattern  of  c-Myc  expression  observed  in  proliferating  WEHI-231  B  cells.  Thus, 
stabilisation  of  c-Myc  by  post-translational  mechanisms  such  as  phosphorylation  of 
serine  62  by  ERK,  as  well  as  transcriptional  upregulation,  would  therefore  be 
counteracted by ubiquitin-mediated degradation allowing c-Myc to be maintained at a  
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steady-state  level.  This  tight  control  of  c-Myc  levels  is  certainly  very  important,  as 
mutated and hence de-regulated c-Myc has been detected in many tumours causing 
uncontrolled proliferation of cells [521]. 
The activation of ERK was also found to be potentially regulated by signalling 
involving  regulatory  mechanisms  controlled  by  proteasomal  degradation,  as  it  was 
shown that CD40-mediated rescue of BCR-dependent abrogation of ERK activation 
could be partially prevented by inhibition of the proteasome (Fig.3.36) suggesting that 
such rescue might therefore depend on the degradation of a negative regulator. CD40-
signalling is regulated by TRAF2, TRAF3 and TRAF6 and it has been shown in B cells 
that ubiquitination of TRAF3 is necessary to permit the CD40-mediated activation of 
JNK and p38 [522]. The CD40-dependent activation of ERK in B cells might therefore 
also  rely  on  the  ubiquitination  of  TRAF3  and  consequently,  proteasomal  inhibition 
therefore might block ERK activation. Alternatively, a TRAF6-dependent pathway could 
be targeted by blocking the proteasome as in HEK293 cells, CD40-mediated activation 
of ERK is achieved through Ras-independent signalling by TRAF6 [194]. Consistent 
with this, TRAF6 needs to be auto-ubiquitinated to allow full NF-κB signalling [523]. As 
a side effect of inhibition of the proteasome is the rapid depletion of free ubiquitin [524], 
the reduced availability of ubiquitin could therefore hinder auto-ubiquitination of TRAF6 
and hence reduce its activation and downstream signalling, potentially including the 
ERK cascade. 
Ubiquitination is carried out by an array of enzymes called ubiquitin ligases. E1 
and E2 ligases, the first two enzymes in the cascade are ubiquitously expressed in 
cells whereas E3 ubiquitin ligases confer the substrate specificity to the pathways (see 
section  1.6).  In  recent  years,  research  has  begun  to  unravel  the  various  roles  E3 
ubiquitin ligases play in the immune system. These enzymes function as part of many 
cascades involved in the regulation of immune cells, such as NF-κB signalling [525] 
and have been shown to control events proximal to the antigen receptors of T and B 
cells [492]. The Cbl family of proteins have attracted special attention due to their role 
in TCR- and BCR-signalling and indeed, both c-Cbl and Cbl-b have been identified as 
regulators of signalling events controlling T and B cell activation and proliferation [431]. 
Interestingly,  these  molecules  not  only  influence  signalling  pathways  via  their  E3 
ligase-mediated  ability  to  ubiquitinate  proteins,  but  also  by  functioning  as  adaptor 
molecules [526]. 
Data shown in this chapter indicates that Cbl-b and to a lesser extent c-Cbl are 
regulated  by  BCR-mediated  signalling.  Thus,  cells  stimulated  through  their  BCR 
displayed enhanced levels of Cbl-b and c-Cbl compared to spontaneously proliferating 
WEHI-231  B  cells  (Fig.3.37/38).  Cbl-b  can  potentially  regulate  BCR-signalling  by 
multiple  mechanisms  such  as  its  E3  ligase-mediated  ubiquitination  of  adaptor  
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molecules involved in the activation of Rap. Furthermore, Cbl-b could dampen BCR-
signalling by ubiquitination of Syk leading to its degradation [441]. Additionally, Cbl-b 
might also interfere with the PI3 kinase cascade as it has been shown in T cells that 
Cbl-b  enhances  the  polyubiquitination  of  the  PI3  kinase  subunit  p85  [436,437]  and 
hence inhibits its activation by preventing p85 recruitment to CD28. Thus, Cbl-b could 
similarly contribute to the reduced levels of PI3 kinase signalling detected upon BCR-
ligation  [455].  Moreover,  Cbl-b  might  negatively  regulate  Vav  [527]  as  it  has  been 
shown that Cbl-b deficient T cells have increased Vav activity and that loss of Cbl-b 
can restore some of the functions of Vav1-deficient T cells [230]. Upon BCR-signalling 
Vav is recruited and acts as a GEF for the Rho-family of GTPases including Rac1, 
RhoA and Cdc42 [146], to influence various cellular functions such as rearrangement 
of  the  actin  cytoskeleton,  thereby  regulating  capping  of  the  antigen  receptor,  and 
optimal calcium signalling as well as stimulation of PLCγ and PI3 kinase [146]. Cbl-b 
mediated  suppression  of  Vav  and  its  downstream  signalling  would  therefore further 
contribute to the suppression of activation of WEHI-231 B cells upon BCR-ligation. 
Itch and Grail are also E3 ubiquitin ligases which have been implicated in antigen 
receptor signalling [226,528]. Analysis of their expression levels displayed only minor 
changes upon BCR stimulation, however, degradation of Itch and Grail appeared to be 
increased upon CD40-signalling (Fig.3.38). Degradation of Grail has been shown to be 
regulated  by  otubain-1,  a  protein  which  can  be  transcriptionally  upregulated  by 
Akt/mTOR-mediated  signalling  [529].  Binding  of  otubain-1  is  thought  to  allow  auto-
ubiquitination  of  Grail,  targeting  it  for  the  proteasome  and  hence  degradation.  PI3 
kinase-dependent  effects  in  B  cells  have  been  shown  to  be  partially  mediated  by 
mTOR signalling, as inhibition of mTOR with rapamycin induces growth arrest of B 
cells [530]. Moreover, mTOR levels are positively regulated by PI3 kinase signalling 
[531]  and  thus,  CD40-mediated  increased  activity  of  Akt  and  hence  mTOR  would 
increase the expression of obutain-1 leading to Grail degradation. Although hardly any 
substrates  for  Grail  have  been  identified  yet,  RhoGDI  (Rho  guanine  dissociation 
inhibitor), has been shown to be ubiquitinated by Grail leading to the reduction of RhoA 
activity  in  T  cells  [532].  Interestingly,  RhoA  is  involved  in  the  regulation  of  PLCγ 
signalling  and  calcium  mobilisation  and  hence  proliferation  of  B  cells  [533].  Thus, 
CD40-mediated reduction of Grail levels could therefore contribute to the stabilisation 
of RhoA and calcium signalling further enhancing CD40-mediated pro-survival signals. 
 
3.5  Figures 
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Figure 3.1 Signalling pathways regulating apoptosis in WEHI-231 cells 
In WEHI-231 cells ligation of the BCR leads to a transient increase in ERK activation. 
Activated ERK in turn phosphorylates and activates cPLA2 which translocates to the 
mitochondria. cPLA2 catalyses the production of arachidonic acid at the mitochondria 
hence  inducing  dissipation  of  the  mitochondrial  membrane  potential.  Due  to 
mitochondrial malfunction the cellular ATP levels will be depleted. The final step in this 
apoptotic  pathway  is  the  activation  of  executioner  proteases  such  as  cathepsin  B. 
CD40 signalling is known to protect from BCR-mediated apoptosis. This protection is 
achieved  by  CD40-dependent  activation  and  nuclear  translocation  of  NF-κB.  This 
transcription factor enhances the expression of pro-survival molecules such as c-Myc 
and Bcl-xL. The anti-apoptotic Bcl-2 family member Bcl-xL is crucial to the inhibition of 
apoptosis and overexpression of Bcl-xL protects cells from BCR-mediated cell death. 
The anti-apoptotic function of Bcl-xL in this model is bipartite: it inhibits the localisation 
of  cPLA2  to  the  mitochondria  and  it  itself  translocates  to  these  organelles  where  it 
protects the integrity of the mitochondrial membrane. 
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Figure 3.2 Regulation of c-Myc protein levels 
Phosphorylation  is  an  important  post-translational  modification  of  c-Myc  proteins 
determining their stability. Thus, phosphorylation of T58 by glycogen synthase kinase 3 
(GSK3)  renders  c-Myc  prone  to  ubiquitination  followed  by  degradation  by  the 
proteasome. PI3 kinase signalling stabilises cyclic expression by inhibiting GSK3 and 
hence reduced phosphorylation of T58. Similarly, phosphorylation of S62 increases c-
Myc  stability  through  as  yet  unknown  mechanisms.  The  consensus  sequence 
surrounding S62 makes it a likely target for ERK MAP kinase which has indeed been 
shown to phosphorylate c-Myc at position S62 in vitro.  
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Figure 3.3 The Rap signalling cascade 
Extracellular stimulation activates Rap GEFs by different mechanisms. For example, 
cAMP will activate Epacs, whilst calcium and DAG are needed for the activation of 
CalDAGGEFs  and  C3G  is  activated  by  protein  tyrosine  kinases  (PTK).  GEFs  then 
catalyse  the  exchange  of  GDP  for  GTP  hence  activating  Rap.  Activated  Rap  has 
multiple functions depending on the cell type and upstream signalling involved. Thus, it 
can activate ERK through B-Raf dependent signals or inhibit it by sequestering Raf-1 
away  from  Ras.  The  regulation  of  ERK  and  another  MAPK,  p38,  makes  Rap  an 
important  part  of  signals  controlling  proliferation  and  survival.  Additionally,  Rap  has 
also been found to play a crucial role in regulating cell adhesion and motility through 
adaptor proteins such as RapL which can change integrin affinity and in turn signalling. 
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Figure 3.4 Ligation of the BCR on WEHI-231 induces growth arrest 
(A) WEHI-231 cells (10
4 cells/well) were cultured in triplicate in round bottom microtitre 
plates in complete medium in the presence of increasing concentrations of anti-IgM 
antibody (0-10 µg/ml) for 48 h. (B) WEHI-231 cells (10
4 cells/well) were cultured in the 
presence of 10 µg/ml anti-IgM antibody, 10 µg/ml anti-CD40 or the combination of both 
for  48  h.  Cells  were  harvested  4  h  after  the  addition  of  [
3H]  thymidine  and  the 
incorporated label analysed by liquid scintillation measurement. Data are represented 
as counts per minute (cpm) +/- standard deviation (SD) of triplicate values. Data are 
representative of at least five independent experiments. *** p<0.001 
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Figure 3.5 Ligation of the BCR on WEHI-231 cells induces growth arrest in G0/G1  
WEHI-231 cells (10
5 cells/well) were cultured in complete medium in the presence of 
10  µg/ml  anti-IgM  antibody,  10  µg/ml  anti-CD40  or  a  combination  of  the 
aforementioned  antibodies  for  48  h.  After  this  time  the  cells  were  harvested  and 
analysed for DNA content by staining with PI to assess the percentage live cells in 
G1/G0 phase (A), S phase (B) or G2/M phase (C) by excluding the subdiploid cells 
from the analysis. Cells stimulated with media only were included as a control. Data are 
representative of at least four independent experiments. 
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Figure  3.6  Ligation  of  the  BCR  on  WEHI-231  cells  induces  growth  arrest  and 
apoptosis 
(A-D)  WEHI-231  cells  (10
5  cells/well)  were  cultured  in  complete  medium  in  the 
presence of 10 µg/ml anti-IgM antibody, 10µg/ml anti-CD40 or a combination of the 
aforementioned  antibodies  for  48  h.  After  this  time  the  cells  were  harvested  and 
analysed for DNA content by staining with PI to assess the percentage of subdiploid 
cells representing cells undergoing apoptosis (A), cells in G1/G0 phase (B), cells in S 
phase (C) or G2/M phase (D). Cells stimulated with media only were included as a 
control.  
(E) To determine changes of the mitochondrial membrane potential (MMP) cells (10
6 
cells/ml) were stimulated with 10 µg/ml anti-IgM, 10 µg/ml anti-CD40 or 10 µg/ml anti-
IgM in combination with anti-CD40. Cells were then stained with DiOC6 and gates were 
set on DiOC6-bright (high MMP) cells. Data are expressed as percentage of cells with 
high MMP. Data are representative of at least four independent experiments. 
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Figure 3.7 BCR stimulation reduces cyclic ERK activation and c-Myc expression 
levels 
WEHI-231 cells (10
7 cells/stimulation) were stimulated with medium (untreated) (A), 1 
µg/ml anti-IgM (B), 10 µg/ml anti-CD40 (C) or the combination of both (D) for 0-32 h, as 
indicated. Expression of pERK (T202/Y204), c-Myc and total ERK was assessed by 
SDS-PAGE gel electrophoresis followed by Western Blotting (15 µg protein/lane). This 
experiment is representative of at least three independent experiments. 
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Figure  3.8  BCR  stimulation  reduces  pERK  and  c-Myc  expression  detected  by 
immunofluorescent staining and LSC analysis 
WEHI-231 cells (10
6 cells/well) were stimulated with 1 µg/ml anti-IgM, 10 µg/ml anti-
CD40  or  the  combination  of  both  for  48  h.  Cells  were  cytocentrifuged,  fixed, 
permeabilised and immunofluorescently stained for intracellular pERK (T202/Y204) or 
c-Myc  expression.  Expression  of  the  molecules  was  analysed  by  LSC  using  DAPI-
stained  nuclei  to  contour  on  single  cells.  (A)  Representative  immunofluorescence 
pictures (unstimulated control cells) are shown. Data are presented as (i) percentage 
or (ii) fluorescence integral of pERK (B) or c-Myc (C) expressing cells. Cells stimulated 
with media were included as a control. This experiment is representative of at least two 
independent experiments. 
 
  
  158 
Figure 3.9 Analysis of cell cycle progression of WEHI-231 cells after BCR-ligation 
by LSC 
(A) Cells (unstimulated control cells) are gated on according to their Max Pixel value 
(chromatin concentration/condensation) along the x-axis and their Integral value (DNA 
content) along the y-axis (as described in section 2.10.1.2, Fig. 2.9) identifying them as 
cells with subdiploid DNA content (apoptotic cells), cells in G1-G0 phase, G2-M phase, 
S phase or as new daughter cells. The cell cycle status of WEHI-231 cells (10
6 cells/ml) 
stimulated with media (B-i), 1 µg/ml anti-IgM (B-ii), 10 µg/ml anti-CD40 (B-iii) or the 
combination  of  both  antibodies  (B-iv) for  32  h,  was  analysed  following  staining the 
nuclei  with  DAPI.  The  percentage  of  cells  at  different  stages  of  the  cell  cycle  was 
determined by LSC (C). This experiment is representative of at least two independent 
experiments. 
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Figure 3.10 pERK expression correlates with cell cycle progress 
WEHI-231  cells  (10
6  cells/well)  were  cultured  for  48  h.  Cells  were  cytocentrifuged, 
fixed,  permeabilised  and  fluorescently  stained  for  intracellular  pERK  (T202/Y204) 
expression. Expression of pERK as well as DAPI staining was analysed by LSC. Cells 
with subdiploid DNA content (apoptotic cells), cells in G1-G0 phase, G2-M phase, S 
phase or new daughter cells (ND) were gated on as described in Figure 3.9. The pERK 
expression in each cell cycle stage was then analysed. (A) A dot plot depicting DAPI 
Max Pixel against DAPI Integral was used to gate on cells in different stages of the cell 
cycle. Separate histograms for the expression of pERK in each of these gates were 
then displayed. (B) Data are presented as pERK fluorescence integral of cells in each 
cell cycle stage or as (C-i) percentage of the cells that are pERK-expressing cells in 
each cell cycle stage or (C-ii) percentage of pERK-expressing cells in the total cell 
population that are in each cell cycle stage. 
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Figure 3.11 BCR ligation does not suppress the expression of Rap-1, B-Raf or 
Raf-1 in WEHI-231 cells 
(A-D) WEHI-231 cells (10
7 cells/stimulation) were stimulated with medium (untreated) 
(A), 1 µg/ml anti-IgM (B), 10 µg/ml anti-CD40 (C) or the combination of both antibodies 
(D) for 0-32 h, as indicated. Expression of Rap-1, B-Raf, Raf-1, pERK and total ERK 
was assessed by SDS-PAGE gel electrophoresis followed by Western Blotting (15 µg 
protein/lane).  This  experiment  is  representative  of  at  least  two  independent 
experiments. 
(E) WEHI-231 cells (10
6 cells/well) were stimulated with 1 µg/ml anti-IgM, 10 µg/ml anti-
CD40  or  the  combination  of  both  for  48  h.  Cells  were  cytocentrifuged,  fixed, 
permeabilised  and  immunofluorescently  stained  for  intracellular  Rap-1  expression. 
Rap-1 expression was analysed by LSC using DAPI-stained nuclei to contour on single 
cells. Data are presented as (i) percentage of Rap-1 expressing cells or (ii) the Rap-1 
fluorescence integral. This experiment is representative of at least two independent 
experiments. 
(F) WEHI-231 cells (0.5 x 10
7 cells/stimulation) were stimulated with 1 µg/ml anti-IgM, 
10 µg/ml anti-CD40 or the combination of both for 2, 4, 8 or 24 h and samples were 
prepared  as  per  manufacturer’s  instructions.  Unstimulated  cells  were  included  as  a 
control (media). Expression of phospho-B-Raf (pS446) and ERK2 was detected on a 
Bio-Plex  System  (Bio-Rad).  Data  are  displayed  as  the  ratio  of  phospho-B-Raf 
(pS446)/ERK2 expression, +/- the range of duplicate values.  
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Figure 3.12 Downregulation of Rap-1 signalling following BCR stimulation 
(A-D)  WEHI-231  cells  (1.25  x  10
7  cells/stimulation)  were  stimulated  with  medium 
(untreated) (A), 1 µg/ml anti-IgM (B), 10 µg/ml anti-CD40 (C) or the combination of 
both  (D)  for  4,  8  or  24  h,  as  indicated.  Levels  of  active  GTP-bound  Rap-1  were 
detected  using  a  Rap-1  activity  assay.  Active  Rap-1  specifically  binds  to  Ral  GDS-
RBD-agarose allowing to purify it and assess expression levels by Western Blotting. 
This experiment is representative of at least three independent experiments. 
(E-G) WEHI-231 cells (10
6 cells/well) were stimulated with 1 µg/ml anti-IgM, 10 µg/ml 
anti-CD40  or  the  combination  of  both  for  24  h.  Cells  were  cytocentrifuged,  fixed, 
permeabilised  and  immunofluorescently  stained  for  active  Rap-1  expression  using 
GST-labelled  recombinant  Ral  GDS-RBD  or  GST  as  a  control  (E).  Active  Rap 
expression was analysed by LSC using DAPI-stained nuclei to contour on single cells. 
(F) Histograms are shown for cells stained with the GST control (i), untreated cells (ii), 
cells stimulated with 1 µg/ml anti-IgM (iii), 10 µg/ml anti-CD40 (iv) or the combination 
of both antibodies (v). (G) Data are presented as (i) Rap fluorescence integral or (ii) % 
of cells expressing Rap at high levels (gate is shown in (F-ii) to (F-v)). This experiment 
is representative of at least two independent experiments. 
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Figure 3.13 SPA-1 expression is regulated by BCR-mediated signalling 
(A) WEHI-231 cells (10
7 cells/stimulation) were stimulated with medium, 1 µg/ml anti-
IgM,  10  µg/ml  anti-CD40  or  the  combination  of  both  antibodies  for  24  or  48  h,  as 
indicated.  Expression  of  SPA-1  and  β-actin  was  assessed  by  SDS-PAGE  gel 
electrophoresis followed by Western Blotting (45 µg protein/lane). This experiment is 
representative of at least three independent experiments. 
(B)  To  determine  SPA-1  expression  in  subcellular  fractions  and  whole  cell  lysates, 
WEHI-231 cells (10
7 cells/well) were stimulated with 10 µg/ml anti-IgM, 10 µg/ml anti-
CD40  or  the  combination  of  both  antibodies  for  24  h  and  nuclear  and  cytoplasmic 
fractions  as  well  as  whole  cell  lysates  were  prepared.  Mitochondrial  fractions  were 
prepared after stimulating 1 x 10
8 cells/well as described above. Cells stimulated with 
medium were included as a control. Expression of SPA-1 was assessed by SDS-PAGE 
gel electrophoresis of these fractions followed by Western Blotting (25 µg protein/lane 
of nuclear, cytoplasmic and mitochondrial fractions, 80 µg protein/lane of whole cell 
lysates). Gel loading was as follows: Lane 1 media, Lane 2 anti-IgM, Lane 3 anti-CD40, 
Lane 4 anti-IgM+anti-CD40. 
(C) WEHI 231 cells (10
7 cells/stimulation) were stimulated with media (untreated), 10 
µM PD98059, 1 µM LY294002 or the combination of the two inhibitors for 0-32 h, as 
indicated.  Expression  of  pERK  and  total  ERK  was  assessed  by  SDS-PAGE  gel 
electrophoresis followed by Western Blotting (15 µg protein/lane). 
(D-E) WEHI-231 cells (10
6 cells/ml) were stimulated with medium, 1 µg/ml anti-IgM, 10 
µg/ml  anti-CD40  or  the  combination  of  both  antibodies  for  0-48  h,  as  indicated  (i). 
WEHI-231  cells  were  stimulated  with  1  µg/ml  anti-IgM,  10  µM  PD98059,  1  µM 
LY294002 or the combination of the two inhibitors for 0-32 h (ii). Whole mRNA was 
isolated  and  transcribed  into  cDNA.  SPA-1  expression  levels  were  detected  by 
TaqMan®  quantitative  RT-PCR  using  HPRT  as  endogenous  control.  (D)  Data  are 
shown  as  mean  %  expression  relative  to  HPRT  +/-  SD  of  triplicate  values  of  a 
representative experiment. (E) Data shown are pooled from up to 4 experiments with 
individual time points representing the mean of SPA-1 expression relative to HPRT +/- 
SD of triplicate values in each independent experiment.  
  163 
Figure 3.14 Expression of constitutively-active Ras mutants protects WEHI-231 
cells from BCR-mediated growth arrest 
(A) WEHI-231 cells (10
4 cells/well) expressing the empty pcDNA3.1 vector, pcDNA3.1-
RasV12,  or  pcDNA3.1-RasV12  S35  vectors  were  stimulated  with  (i)  increasing 
concentrations of anti-IgM antibody (0-10 µg/ml) or (ii) with 10 µg/ml anti-IgM antibody, 
10µg/ml anti-CD40 or the combination of both for 24 h. Cells were harvested 4 h after 
the  addition  of  [
3H]  thymidine  and  incorporated  label  analysed  by  liquid  scintillation 
measurement.  (B)  WEHI-231  cells  (10
4  cells/well)  containing  the  empty  pcDNA3.1 
vector,  pcDNA3.1-RasV12,  or  pcDNA3.1-RasV12C40  vectors  were  cultured  and 
proliferation assessed as in (A). Data from individual experiments were normalised by 
expressing the mean [
3H] thymidine uptake values of treated cells as a percentage of 
those obtained with control cell cultures. The normalised values from 4 independent 
experiments were then pooled and expressed as means ± SEM. 
(C)  WEHI-231  cells  transfected  with  empty  pcDNA3.1  vector,  pcDNA3.1-RasV12, 
pcDNA3.1-RasV12C40 and pcDNA3.1-RasV12S35 (10
6 cells/ml) were stimulated with 
1 µg/ml anti-IgM or 10 µg/ml anti-CD40 and 1 µg/ml anti-IgM for 24 h. Cells stimulated 
in  the  presence  of  medium  alone  were  included  as  a  control.  Whole  mRNA  was 
isolated  and  transcribed  into  cDNA.  SPA-1  expression  levels  were  detected  by 
TaqMan® quantitative RT-PCR using HPRT as endogenous control. Data are shown 
as mean % expression relative to HPRT +/- SD of triplicate values. 
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Figure 3.15 BCR stimulation regulates PAC-1 mRNA levels 
(A-B) WEHI-231 cells (10
6 cells/ml) were stimulated with medium, 1 µg/ml anti-IgM, 10 
µg/ml  anti-CD40  or  the  combination  of  both  antibodies  for  0-48  h,  as  indicated  (i). 
WEHI-231 cells (10
6 cells/ml) were stimulated with 1 µg/ml anti-IgM, 10 µM PD98059, 1 
µM LY294002 or the combination of the two inhibitors for 0-32 h (ii). Whole mRNA was 
isolated  and  transcribed  into  cDNA.  PAC-1  expression  levels  were  detected  by 
TaqMan®  quantitative  RT-PCR  using  HPRT  as  endogenous  control.  (A)  Data  are 
shown  as  mean  %  expression  relative  to  HPRT  +/-  SD  of  triplicate  values  of  a 
representative experiment. (B) Data shown are pooled from up to 4 experiments with 
individual time points representing the mean of PAC-1 expression relative to HPRT +/- 
SD of triplicate values in each independent experiment. 
(C)  WEHI-231  cells  transfected  with  empty  pcDNA3.1  vector,  pcDNA3.1-RasV12, 
pcDNA3.1-RasV12C40 and pcDNA3.1-RasV12S35 (10
6 cells/ml) were stimulated with 
1 µg/ml anti-IgM or 10 µg/ml anti-CD40 and 1 µg/ml anti-IgM for 24 h. Cells stimulated 
in  the  presence  of  medium  alone  were  included  as  a  control.  Whole  mRNA  was 
isolated  and  transcribed  into  cDNA.  PAC-1  expression  levels  were  detected  by 
TaqMan® quantitative RT-PCR using HPRT as endogenous control. Data are shown 
as mean % expression relative to HPRT +/- SD of triplicate values. 
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Figure 3.16 Subcellular localisation of Rap-1 and pERK 
To determine Rap-1, pERK and ERK expression in various subcellular localisations 
WEHI-231 cells (5 x 10
6 cells/well) were stimulated with media or 1 µg/ml anti-IgM or 
10 µg/ml anti-CD40 in combination with 1 µg/ml anti-IgM for 1 h (A) or 24 h (B) and 
cytoplasmic,  membrane/organelle,  nuclear  and  cytoskeletal  fractions  were  prepared 
following the manufacturer’s instructions (Perkin Elmer, Cellular Protein fractionation 
Kit). Additionally, whole cell lysates were prepared at the same time. Cells stimulated 
with medium were included as a control. Expression of Rap-1, pERK, ERK as well as 
the  marker  protein  VDAC-1  and  HDAC-1  was  assessed  by  SDS-PAGE  gel 
electrophoresis  followed  by  Western  Blotting.  Gel  loading  was  as  follows:  Lane  1 
media, Lane 2 anti-IgM, Lane 3 anti-IgM+anti-CD40. 
(C)  The  subcellular  localisation  of  pERK,  Rap-1  and  ERK  signals  was  furthermore 
analysed using a different protocol of fractionation. Here WEHI-231 cells (10
7 cells/well) 
were stimulated with 10 µg/ml anti-IgM, 10 µg/ml anti-CD40 or the combination of both 
for  24  h  and  nuclear  and  cytoplasmic  fractions  as  well  as  whole  cell  lysates  were 
prepared.  Mitochondrial  fractions  were  prepared  after  stimulating  10
8  cells/well  as 
described above. Cells stimulated with medium were included as a control. Expression 
of pERK, Rap-1 and ERK was assessed by SDS-PAGE gel electrophoresis followed by 
Western  Blotting  (25  µg  protein/lane  of  nuclear,  cytoplasmic  and  mitochondrial 
fractions, 80 µg protein/lane of whole cell lysates). Gel loading was as follows: Lane 1 
media, Lane 2 anti-IgM, Lane 3 anti-CD40, Lane 4 anti-IgM+anti-CD40. 
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Figure  3.17  Induction  of  growth  arrest  in  WEHI-231  cells  transfected  with 
pcDNA3.1-Rap vectors 
(A)  WEHI-231  cells  (10
4  cells/well)  transfected  with  empty  pcDNA3.1  vector, 
pcDNA3.1-Rap-1A  WT,  pcDNA3.1-Rap-1A  G12V  or  pcDNA3.1-Rap-1A  S17N  were 
stimulated  with  rising  concentration  of  anti-IgM  antibody,  as  indicated,  (i)  or  with  1 
µg/ml anti-IgM or 1 µg/ml anti-IgM in combination with 10 µg/ml anti-CD40 (ii) and their 
DNA synthesis measured at 48 h. Cells were harvested 4 h after the addition of [
3H] 
thymidine  and  incorporated  label  was  analysed  by  liquid  scintillation  measurement. 
Data  represents  counts  per  minute  (cpm)  as  normalised  to  media  values  for  each 
group  +/-  SD  of  triplicate  values.  This  experiment  is  representative  of  at  least  two 
independent experiments. 
(B) WEHI-231- Bcl-xL cells (10
4 cells/well) transfected with either empty pcDNA3.1 Zeo 
vector, pcDNA3.1 Zeo-Rap-1A WT, pcDNA3.1 Zeo-Rap-1A G12V or pcDNA3.1 Zeo-
Rap-1A  S17N  were  stimulated  with  rising  concentrations  of  anti-IgM  antibody,  as 
indicated (i) or 1 µg/ml anti-IgM or 1 µg/ml anti-IgM in combination with 10 µg/ml anti-
CD40 (ii) and their DNA synthesis measured at 24 h. Cells were harvested 4 h after the 
addition of [
3H] thymidine and incorporated label was analysed by liquid scintillation 
measurement. Data represents counts per minute (cpm) as normalised to media values 
for each group +/- SD of triplicate values. This experiment is representative of at least 
two independent experiments. 
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Figure  3.18  Induction  of  growth  arrest  and  apoptosis  in  WEHI-231  cells 
transfected with pcDNA3.1-Rap vectors 
WEHI-231- Bcl-xL cells (0.5 x 10
6 cells/well) transfected with either empty pcDNA3.1 
Zeo vector, pcDNA3.1 Zeo-Rap-1A WT, pcDNA3.1 Zeo-Rap-1A G12V or pcDNA3.1 
Zeo-Rap-1A S17N were stimulated with rising concentration of anti-IgM antibody (0-1 
µg/ml) for 24 h, as indicated. The cell cycle stage was determined by staining the cells 
with PI followed by FACS analysis. Data are presented as percentage of subdiploid 
cells (A), cells in G1/G0 (B) or cells in the mitotic phases (G2/M and S phase) (C) of 
cell cycle. 
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Figure  3.19  WEHI-231  cells  were  not  stably  transfected  with  pcDNA3.1-Rap 
constructs 
(A)  WEHI-231-Bcl-xL  cells  (10
7  cells/stimulation)  transfected  with  either  empty 
pcDNA3.1 Zeo vector, pcDNA3.1 Zeo-Rap-1A WT, pcDNA3.1 Zeo-Rap-1A G12V or 
pcDNA3.1  Zeo-Rap-1A  S17N  were  lysed  with  RIPA  buffer  and  whole  cell  lysates 
prepared. MIEV and MIEV-PKCα-HA-tag transfected fibroblast-lysates were used as a 
negative or positive control for the HA-tag detection, respectively. Expression of HA-
tag,  Rap-1  and  ERK  was  assessed  by  SDS-PAGE  gel  electrophoresis  followed  by 
Western Blotting (40 µg protein/lane). Gel loading was as follows : Lane1 pcDNA3.1 
Zeo-Rap-1A WT transfected cells, Lane 2 pcDNA3.1 Zeo-Rap-1A G12V transfected 
cells,  Lane  3  pcDNA3.1  Zeo-Rap-1A  S17N  transfected cells,  Lane4  pcDNA3.1  Zeo 
(empty vector) transfected cells, Lane5 untransfected cells Lane 6 MIEV-transfected 
fibroblasts, Lane 7 MIEV-PKCα-HA-tag transfected fibroblasts. 
(B)  WEHI-231  cells  were  transfected  with  empty  pIRES2-AcGFP1  vector,  pIRES2-
AcGFP1-Rap-1A  WT,  pIRES2-AcGFP1-Rap-1A  G12V,  pIRES2-AcGFP1-Rap-1A 
S17N. (i) 24 h (Day 1) or (ii) 11 days after transfection cells were analysed for the 
expression  of  GFP.  (C-i)  Table  summarising  the  percentage  of  GFP-positive  cells 
detected 1, 5 or 11 days after transfection. (C-ii) Table summarising vectors, cells, 
concentrations of selection-antibiotic as well as methods of transfections tested during 
optimisation  experiments.  (C-iii)  Table  summarising  experiments  carried  out  to  test 
conditions for the production of stably transfected clones. 
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Figure  3.20  HA-tagged  Rap-1A  WT,  Rap-1A  G12V  and  Rap-1A  S17N  are 
expressed in the a lentivirus-based transduction system 
(A) HT-1080 cells were transduced or not with lentiviral particles encoding pLVX-IRES-
ZsGreen1-Rap-1A WT, -Rap-1A G12V or -Rap-1A S17N and analysed by FACS to 
detect ZsGreen1 expression after 72 h. (B) The HT-1080 cells described in (A) above 
were lysed in RIPA buffer and the expression of the HA-tag or total ERK was assessed 
by SDS-PAGE gel electrophoresis followed by Western Blotting (60 µg protein/lane). 
Gel loading was as follows: Lane1 untransduced cells, Lane2 pLVX-IRES-ZsGreen1-
Rap-1A  WT,  Lane3  pLVX-IRES-ZsGreen1-Rap-1A  G12V,  Lane4  pLVX-IRES-
ZsGreen1-Rap-1A S17N. 
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Figure  3.21  BCR-mediated  abrogation  and  CD40-dependent  rescue  of  c-Myc 
expression 
WEHI-231 cells (10
7 cells/stimulation) were stimulated with medium, 1 µg/ml anti-IgM, 
10  µg/ml  anti-CD40  or the  combination  of  both  antibodies for  0-32  h, as  indicated. 
Expression of pERK, c-Myc phospho-c-MycS62, ERK and β-actin was assessed by 
SDS-PAGE gel electrophoresis followed by Western Blotting (15 µg protein/lane). Gel 
loading was as follows: Lane1 media, Lane2 anti-IgM, Lane3 anti-CD40, Lane4 anti-
IgM+anti-CD40.  These  data  are  representative  of  at  least  two  independent 
experiments. 
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Figure 3.22 Ligation of the BCR on WEHI-231 cells regulates the levels of c-Myc 
WEHI-231 cells (10
7 cells/stimulation) were stimulated with medium (untreated) (A), 1 
µg/ml anti-IgM (B), 10 µg/ml anti-CD40 (C) or the combination of both antibodies (D) 
for 0-32 h, as indicated. Expression of pERK, c-Myc, phospho-c-MycT58/S62, phospho 
c-MycT58 and total ERK was assessed by SDS-PAGE gel electrophoresis followed by 
Western Blotting (15-45 µg protein/lane). This experiment is representative of at least 
three independent experiments. 
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Figure 3.23 c-Myc expression is regulated by the ERK and PI3 kinase signalling 
WEHI-231 cells (10
7 cells/stimulation) were stimulated with medium, 1 µg/ml anti-IgM, 
10  µg/ml  anti-CD40,  the  combination  of  both  antibodies,  10  µM  PD98059,  1  µM 
LY294002 or the combination of both inhibitors for 0-32 h, as indicated. Expression of 
pERK,  c-Myc,  ERK  and  β-actin  was  assessed  by  SDS-PAGE  gel  electrophoresis 
followed by Western Blotting (15 µg protein/lane). Gel loading was as follows: Lane1 
media, Lane2 anti-IgM, Lane3 anti-CD40, Lane4 anti-IgM+anti-CD40, Lane5 PD98059, 
Lane6 LY294002, Lane7 PD98059+ LY294002. These data are representative of at 
least two independent experiments. 
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Figure 3.24 c-Myc expression level is regulated by ERK and PI3 kinase signalling 
pathways 
(A-D) WEHI-231 cells (10
7 cells/stimulation) were stimulated with medium (untreated) 
(A), 10 µM PD98059 (B), 1 µM LY294002 (C) or 10 µM PD98059 in combination with 1 
µM LY294002 (D) for 0-32 h, as indicated. Expression of c-Myc, pERK and ERK was 
assessed  by  SDS-PAGE  gel  electrophoresis  followed  by  Western  Blotting  (15  µg 
protein/lane). (E) To determine c-Myc expression in subcellular localisations WEHI-231 
cells (10
7 cells/well) were stimulated with 1 µg/ml anti-IgM, 10 µg/ml anti-CD40 or the 
combination of both for 4 h and nuclear and cytoplasmic fractions were prepared. Cells 
stimulated with medium were included as a control. Expression of c-Myc was assessed 
by SDS-PAGE gel electrophoresis followed by Western Blotting (25 µg protein/lane). 
Gel loading was as follows: Lane 1 0 h, Lane 2 media, Lane 3 anti-IgM, Lane 4 anti-
CD40, Lane 5 anti-IgM+anti-CD40. (F) WEHI-231 cells (10
6 cells/well) were stimulated 
with 1 µg/ml anti-IgM, 10 µg/ml anti-CD40, the combination of both, 10 µM PD98059, 1 
µM LY294002 or the combination of the two inhibitors for 12, 20 or 32 h. Untreated 
cells were included as a control. Cells (0.75 x 10
5 cells/stain) were cytocentrifuged onto 
glass slides, fixed, permeabilised and immunofluorescently stained for intracellular c-
Myc expression which was analysed by LSC using DAPI-stained nuclei to contour on 
single  cells.  (i)  A  representative  image  of  CD40-stimulated  cells  is  shown  for  the 
immunofluorescent staining. Data are presented as (ii) percentage of c-Myc expressing 
cells or (iii) fluorescence integral of the cells. This experiment is representative of at 
least two independent experiments. 
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Figure 3.25 c-Myc phosphorylation is regulated by ERK and PI3 kinase signalling 
pathways 
(A-D) WEHI-231 cells (10
7 cells/stimulation) were stimulated with medium (untreated) 
(A), 10 µM PD98059 (B), 1 µM LY294002 (C) or 10 µM PD98059 in combination with 1 
µM  LY294002  (D)  for  0-32  h,  as  indicated.  Expression  of  phospho-c-MycT58/S62, 
pERK and ERK was assessed by SDS-PAGE gel electrophoresis followed by Western 
Blotting (15 µg protein/lane). (E) To determine phospho-c-MycT58/S62 expression in 
subcellular localisations WEHI-231 cells (10
7 cells/well) were stimulated with 1 µg/ml 
anti-IgM,  10  µg/ml  anti-CD40  or  the  combination  of  both  for  4  h  and  nuclear  and 
cytoplasmic fractions were prepared. Cells stimulated with medium were included as a 
control. Expression of c-Myc was assessed by SDS-PAGE gel electrophoresis followed 
by Western Blotting (25 µg protein/lane). Gel loading was as follows: Lane 1 0 h, Lane 
2 media, Lane 3 anti-IgM, Lane 4 anti-CD40, Lane 5 anti-IgM+anti-CD40. (F) WEHI-
231 cells (10
6 cells/well) were stimulated with 1 µg/ml anti-IgM, 10 µg/ml anti-CD40, the 
combination of both, 10 µM PD98059, 1 µM LY294002 or the combination of the two 
inhibitors for 12, 20 or 32 h. Untreated cells were included as a control. Cells (0.75 x 
10
5  cells/stain)  were  cytocentrifuged  onto  glass  slides,  fixed,  permeabilised  and 
immunofluorescently stained for intracellular phospho-c-MycS62 expression which was 
analysed  by  LSC  using  DAPI-stained  nuclei  to  contour  on  single  cells.  (i)  A 
representative  image  of  CD40-stimulated  cells  is  shown  for  the  immunofluorescent 
staining. Data are presented as (ii) percentage of phospho-c-MycS62 expressing cells 
or  (iii)  phospho-c-MycS62  fluorescence  integral  of  the  cells.  This  experiment  is 
representative of at least two independent experiments. 
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Figure 3.26 Transcriptional regulation of c-Myc expression 
(A-B) WEHI-231 cells (10
6 cells/ml) were stimulated with medium, 1 µg/ml anti-IgM, 10 
µg/ml  anti-CD40  or  the  combination  of  both  antibodies  for  0-48  h,  as  indicated  (i). 
WEHI-231  cells  were  stimulated  with  1  µg/ml  anti-IgM,  10  µM  PD98059,  1  µM 
LY294002 or the combination of the two inhibitors for 0-32 h (ii). Whole mRNA was 
isolated  and  transcribed  into  cDNA.  c-Myc  expression  levels  were  detected  by 
TaqMan®  quantitative  RT-PCR  using  HPRT  as  endogenous  control.  (A)  Data  are 
shown  as  mean  %  expression  relative  to  HPRT  +/-  SD  of  triplicate  values  of  a 
representative experiment. (B) Data shown are pooled from up to 4 experiments with 
individual time points representing the mean of c-Myc expression relative to HPRT +/- 
SD of triplicate values in each independent experiment. 
(C)  WEHI-231  cells  transfected  with  empty  pcDNA3.1  vector,  pcDNA3.1-RasV12, 
pcDNA3.1-RasV12C40 and pcDNA3.1-RasV12S35 (10
6 cells/ml) were stimulated with 
1 µg/ml anti-IgM or 10 µg/ml anti-CD40 and 1 µg/ml anti-IgM for 8 h. Cells stimulated in 
the presence of medium alone were included as a control. Whole mRNA was isolated 
and  transcribed  into  cDNA.  c-Myc  expression  levels  were  detected  by  TaqMan® 
quantitative RT-PCR using HPRT as endogenous control. Data are shown as mean % 
expression relative to HPRT +/- SD of triplicate values. 
(D)  WEHI-231  cells  or  cells  transfected  with  empty  vector,  pcDNA3.1-RasV12, 
pcDNA3.1-RasV12C40  and  pcDNA3.1-RasV12S35  cells  (0.5  x  10
7  cells/stimulation) 
were stimulated with 1 µg/ml anti-IgM or the combination of 1 µg/ml anti-IgM and 10 
µg/ml anti-CD40 for 24 h. Expression of c-Myc and total ERK was assessed by SDS-
PAGE  gel  electrophoresis  followed  by  Western  Blotting  (35  µg  protein/lane).  Gel 
loading was as follows: Lane 1 media, Lane 2 anti-IgM, Lane 3 anti-IgM+anti-CD40. 
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Figure 3.27 c-Myc expression level correlates with progression through the cell 
cycle 
WEHI-231  cells  (0.75  x  10
5  cells/stain)  were  analysed  for  expression  of  c-Myc  or 
phospho-c-MycS62  and  gates  were  set  according  to  the  intensity  of  the  c-Myc  or 
phospho-c-MycS62 signal. The cell cycle status of the population of cells of increasing 
expression  of  these  markers  was  then  assessed,  identifying  them  as  cells  with 
subdiploid DNA content (apoptotic cells), cells in G1-G0 phase, G2-M phase, S phase 
or  new  daughter  cells  as  previously  described  (section  2.10.1.2,  Figure  2.9).  (A) 
Representative  histogram  of  CD40-stimulated  cells  (32  h)  and  cell  cycle  plots  are 
shown. Data are presented as the percentage of cells in each cell cycle stage present 
in each region (fluorescence integral) of c-Myc (B) and phospho-c-MycS62 (C). 
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Figure  3.28  Growth  arrest  correlates  with  reduced  c-Myc  expression  and 
stabilisation 
WEHI-231 cells (10
6 cells/well) were stimulated with 1 µg/ml anti-IgM, 10 µg/ml anti-
CD40, the combination of both, 10 µM PD98059, 1 µM LY294002 or the combination of 
the two inhibitors for 12, 20 or 32 h. Untreated cells were included as a control. Cells 
(0.75 x 10
5 cells/stain) were cytocentrifuged onto glass slides, fixed, permeabilised and 
immunofluorescently stained for intracellular c-Myc and phospho-c-MycS62 expression 
as well as DAPI. (A) Cells were analysed by LSC to determine their cell cycle stage: 
G1-G0, S, G2-M phase and mitotic phases (S phase, G2-M phase and new daughter 
cells combined), as previously described (Figure 3.9). The data are presented as the 
percentage of cells in each cell cycle stage at 12, 20 and 32 h. (B) Furthermore, the 
correlation  between  the  fluorescence  integral  (expression  level)  of  (i)  c-Myc  or  (ii) 
phospho-c-MycS62 detected in each of the differently stimulated samples described 
above (32 h) (A) and the percentage of cells in each cell cycle stage in those samples 
was analysed. 
 
 
  
  178 
Figure 3.29 Regulation of CTCF expression upon BCR stimulation 
WEHI-231 cells (10
7 cells/stimulation) were stimulated with medium (untreated) (A), 1 
µg/ml anti-IgM (B), 10 µg/ml anti-CD40 (C) or the combination of anti-IgM and anti-
CD40 (D) for 0-32 h, as indicated. Expression of CTCF and β-actin was assessed by 
SDS-PAGE gel electrophoresis followed by Western Blotting (45 µg protein/lane). This 
experiment is representative of at least two independent experiments. 
(E) WEHI-231 cells (10
6 cells/ml) were stimulated with 1 µg/ml anti-IgM, 10 µg/ml anti-
CD40 or the combination of both for 4-48 h, as indicated. Whole mRNA was isolated 
and  transcribed  into  cDNA.  CTCF  expression  levels  were  detected  by  TaqMan® 
quantitative RT-PCR using HPRT as endogenous control. Data are shown as mean % 
expression relative to HPRT +/- SD of triplicate values. 
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Figure 3.30 Regulation of phosphorylation of Rb and p27 expression in WEHI-231 
B cells 
WEHI-231 cells (10
7 cells/stimulation) were stimulated with medium, 1 µg/ml anti-IgM, 
10  µg/ml  anti-CD40,  the  combination  of  both  antibodies,  10  µM  PD98059,  1  µM 
LY294002 or the combination of the two inhibitors for 0-32 h, as indicated. Expression 
of pERK, phospho-RbS780, phospho-RbS807/811 and ERK was assessed by SDS-
PAGE  gel  electrophoresis  followed  by  Western  Blotting  (15  µg  protein/lane).  Gel 
loading was as follows: Lane1 media, Lane2 anti-IgM, Lane3 anti-CD40, Lane4 anti-
IgM+anti-CD40, Lane5 PD98059, Lane6 LY294002, Lane7 PD98059+LY294002. This 
experiment is representative of at least two independent experiments. 
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Figure 3.31 p53 expression is regulated downstream of BCR-ligation 
(A) WEHI-231 cells (10
7 cells/well) were stimulated with 1 µg/ml anti-IgM, 10 µg/ml 
anti-CD40 antibody or the combination of both for 24 and 48 h and whole cell lysates 
were prepared. Cells stimulated with medium were included as a control. Expression of 
p53 was assessed by SDS-PAGE gel electrophoresis followed by Western Blotting (20 
µg protein/lane). 
(B) WEHI-231 cells (10
6 cells/ml) were stimulated with 1 µg/ml anti-IgM, 10 µg/ml anti-
CD40 or the combination of both antibodies for 4-48 h, as indicated. Whole mRNA was 
isolated and transcribed into cDNA. p53 expression levels were detected by TaqMan® 
quantitative RT-PCR using HPRT as endogenous control. Data are shown as mean % 
expression relative to HPRT +/- SD of triplicate values. 
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Figure 3.32 Regulation of phospho-Rb Ser780 expression in WEHI-231 cells 
(A-D) WEHI-231 cells (10
7 cells/stimulation) were stimulated with medium (untreated) 
(A), 1 µg/ml anti-IgM (B), 10 µg/ml anti-CD40 (C) or the combination of anti-IgM and 
anti-CD40 (D) for 0-32 h, as indicated. Expression of phospho-RbS780 and β-actin was 
assessed  by  SDS-PAGE  gel  electrophoresis  followed  by  Western  Blotting  (15  µg 
protein/lane).  This  experiment  is  representative  of  at  least  three  independent 
experiments. 
(E) WEHI-231 (10
6 cells/ml) cells were stimulated with medium, 1 µg/ml anti-IgM, 10 
µg/ml  anti-CD40  or  the  combination  of  both  for  32  h.  Untreated  cells  were 
cytocentrifuged, fixed, permeabilised and stained for phospho-RbS780 expression. (i) 
A  representative  picture  of  the  immunofluorescent  staining  of  unstimulated  cells  is 
shown. Data are presented as (ii) percentage of cells expressing phospho-RbS780 or 
(ii) fluorescence integral of phospho-RbS780 staining. 
(F) WEHI-231 cells (10
6 cells/ml) were stimulated as described above for 48 h. Cells 
were  cytocentrifuged,  fixed,  permeabilised  and  stained  for  phospho-RbS780 
expression as well as nuclear DNA content by DAPI staining. As described in Figure 
3.27 cells were then gated according to the intensity of the phospho-RbS780 signal 
and  their  cell  cycle  status  assessed,  identifying  them  as  cells  with  subdiploid  DNA 
content (apoptotic cells), cells in G1-G0 phase, G2-M phase, S phase or new daughter 
cells  as  previously  described  (section  2.10.1.2,  Figure  2.9).  Data  are  presented  as 
percentage  of  cells  in  each  cell  cycle  stage  present  in  each  region  (fluorescence 
integral). 
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Figure 3.33 Regulation of phospho-Rb Ser807/811 expression in WEHI-231 cells 
(A-D) WEHI-231 cells (10
7 cells/stimulation) were stimulated with medium (untreated) 
(A), 1 µg/ml anti-IgM (B), 10 µg/ml anti-CD40 (C) or the combination of anti-IgM and 
anti-CD40 (D) for 0-32 h, as indicated. Expression of phospho-RbS807/811 and β-actin 
was assessed by SDS-PAGE gel electrophoresis followed by Western Blotting (15 µg 
protein/lane).  This  experiment  is  representative  of  at  least  three  independent 
experiments. 
(E) WEHI-231 (10
6 cells/ml) cells were stimulated with medium, 1 µg/ml anti-IgM, 10 
µg/ml  anti-CD40  or  the  combination  of  both  for  32  h.  Untreated  cells  were 
cytocentrifuged, fixed, permeabilised and stained for phospho-RbS807/811 expression. 
(i) A representative picture of the immunofluorescent staining of unstimulated cells is 
shown. Data are presented as (ii) percentage of cells expressing phospho-RbS807/811 
or  (ii)  fluorescence  integral  of  phospho-RbS807/811  staining  after  deduction  of  the 
fluorescence integral of the isotype-stained sample. 
(F) WEHI-231 cells (10
6 cells/ml) were stimulated as described above for 48 h. Cells 
were  cytocentrifuged,  fixed,  permeabilised  and  stained  for  phospho-pRbS807/811 
expression as well as nuclear DNA content by DAPI staining. As described in Figure 
3.27  cells  were  then  gated  according  to  the  intensity  of  the  phospho-RbS807/811 
signal and their cell cycle status assessed, identifying them as cells with subdiploid 
DNA content (apoptotic cells), cells in G1-G0 phase, G2-M phase, S phase or new 
daughter  cells  as  previously  described  (section  2.10.1.2,  Figure  2.9).  Data  are 
presented  as  percentage  of  cells  in  each  cell  cycle  stage  present  in  each  region 
(fluorescence integral). 
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Figure 3.34 BCR signalling modulates the protein-ubiquitination pattern in WEHI-
231 cells 
(A-D) WEHI-231 cells (10
7 cells/stimulation) were stimulated with medium (untreated) 
(A), 1 µg/ml anti-IgM (B), 10 µg/ml anti-CD40 (C) or the combination of anti-IgM and 
anti-CD40 (D) for 0-32 h, as indicated. Expression of ubiquitin or β-actin was assessed 
by SDS-PAGE gel electrophoresis followed by Western Blotting (45 µg protein/lane). 
Data are representative of at least two independent experiments. 
(E) WEHI-231 cells (10
4 cells/well) were cultured in complete medium in the presence 
of 1 µg/ml anti-IgM antibody, 10 µg/ml anti-CD40 or the combination of both for 24 h. At 
0,  8  and  16  h,  0.5   M  MG132  or  DMSO  control  (%v/v)  was  added.  Cells  were 
harvested 4 h after the addition of [
3H] thymidine and the incorporated label analysed 
by liquid scintillation measurement. Data are represented as counts per minute (cpm) 
+/- SD of triplicate values. 
(F) WEHI-231 cells (0.5 x 10
6 cells/well) were cultured in complete media -/+ DMSO 
control (%v/v) (i) or 0.5  M MG132 (ii) for 24 h. Cells were harvested and stained with 
7-AAD which specifically labels dead cells and then analysed by FACS. Representative 
dot plots indicating % 7-AAD
+ (dead) cells are shown. 
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Figure  3.35  Influence  of  proteasome  inhibition  on  ubiquitinated-protein 
expression 
WEHI-231 cells (10
7 cells/stimulation) were treated with medium, 1 µg/ml anti-IgM, 0.5 
µM MG132 or the combination of anti-IgM and MG132 for (A) 2, 4, 8 h and (B) 12, 16 
and 20 h, as indicated. MG132 (0.5 µM) was added to the cultures at 0, 8 and 16 h. 
Expression  of  ubiquitin,  c-Myc,  p27  or  total  ERK  was  assessed  by  SDS-PAGE  gel 
electrophoresis followed by Western Blotting (35 µg protein/lane). Gel loading was as 
follows:  Lane  1  media,  Lane  2  media+MG132,  Lane  3  anti-IgM,  Lane  4  anti-
IgM+MG132. 
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Figure 3.36 Regulation of c-Myc and pERK  by ubiquitination and proteasomal 
degradation 
(A) WEHI-231 cells (10
7 cells/stimulation) were stimulated with medium, 1 µg/ml anti-
IgM, 10 µg/ml anti-CD40 or the combination of both antibodies for 24 h. One hour 
before harvesting, the cells were treated with 0.5 µM MG132 after which whole cell 
lysates  were  prepared.  In  order  to  pull-down  ubiquitinated  proteins  50  µg  of  each 
sample was treated with the Ubiqapture Q matrix (Biomol) as per the manufacturer’s 
instructions. Ubiquitin and c-Myc expression was analysed in the samples before (25 
µg  protein/lane)  and  after  ubiquitin-pull-down  (25  µl/lane)  by  SDS-PAGE  gel 
electrophoresis followed by Western Blotting. Gel loading was as follows: Lane1 media, 
Lane2 anti-IgM, Lane3 anti-CD40, Lane4 anti-IgM+anti-CD40. 
(B)  WEHI-231  cells  (10
7  cells/stimulation)  were  pre-treated  with  0.5  µM  MG132  or 
DMSO vector control for 1 h and then stimulated with medium, 1 µg/ml anti-IgM or 1 
µg/ml anti-IgM with 10 µg/ml anti-CD40 for 1, 2, 4 and 8 h and whole cell lysates were 
prepared.  Expression  of  pERK  or  ERK  was  assessed  by  SDS-PAGE  gel 
electrophoresis followed by Western Blotting (50 µg protein/lane). Gel loading was as 
follows: Lane 1 media, Lane 2 anti-IgM, Lane3 anti-IgM+anti-CD40. 
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Figure  3.37  Expression  of  Cbl-b  is  regulated  by  BCR  stimulation  at  both  the 
protein and mRNA level 
(A)  WEHI-231  cells  (10
7  cells/stimulation)  were  pre-treated  with  0.5  µM  MG132  or 
DMSO vector control for 1 h and then stimulated with medium, 1 µg/ml anti-IgM or 1 
µg/ml anti-IgM and 10 µg/ml anti-CD40 for 8 h and whole cell lysates were prepared. 
Expression  of  Ubiquitin,  Cbl-b  or  total  ERK  was  assessed  by  SDS-PAGE  gel 
electrophoresis followed by Western Blotting (50 µg protein/lane). 
(B) WEHI-231 cells (10
7 cells/stimulation) were treated with medium, 1 µg/ml anti-IgM, 
10 µg/ml anti-CD40 or the combination of both antibodies for 12 or 48 h. Expression of 
Cbl-b or ERK was assessed by SDS-PAGE gel electrophoresis followed by Western 
Blotting (90 µg protein/lane). 
(C) WEHI-231 cells (10
6 cells/ml) were stimulated with 1 µg/ml anti-IgM, 10 µg/ml anti-
CD40 or the combination of both for 0-48 h, as indicated. Whole mRNA was isolated 
and  transcribed  into  cDNA.  Cbl-b  expression  levels  were  detected  by  TaqMan® 
quantitative RT-PCR using HPRT as endogenous control. Data are shown as mean % 
expression  relative  to  HPRT  +/-  SD  of  triplicate  values.  This  experiment  is 
representative of at least two independent experiments. 
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Figure 3.38 c-Cbl, Itch and Grail expression is influenced by BCR-ligation 
(A) WEHI-231 cells (10
6 cells/ml) were stimulated with 1 µg/ml anti-IgM, 10 µg/ml anti-
CD40 or the combination of both antibodies for 0-48 h, as indicated before mRNA was 
isolated  and  transcribed  into  cDNA.  c-Cbl  expression  levels  were  detected  by 
TaqMan® quantitative RT-PCR using HPRT as endogenous control. Data are shown 
as mean % expression relative to HPRT +/- SD of triplicate values. This experiment is 
representative of at least two independent experiments. 
(B) WEHI-231 cells (10
7 cells/stimulation) were treated with medium, 1 µg/ml anti-IgM, 
10 µg/ml anti-CD40 or the combination of the two for 48 h. Expression of c-Cbl, Itch, 
Grail  or  total  ERK  was  assessed  by  SDS-PAGE  gel  electrophoresis  followed  by 
Western Blotting (90 µg protein/lane). 
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4  Signalling mechanisms underlying FcγRIIb mediated growth 
arrest and apoptosis 
 
4.1  Introduction 
 
4.1.1  Autoimmune disease  
Autoimmunity is the result of inappropriate responses of the immune system to self-
antigens  and  is  therefore  characterised  by  tissue  damage  caused  by  aberrant  hyper-
inflammatory processes. Over the last few decades the incidence of autoimmune diseases 
has risen dramatically, especially in the western/industrialised world and it is estimated 
that 4-5% of the human population suffer from some form of autoimmune disease. For 
example, in the United states about 90 people out of 100 000 per year will develop an 
autoimmune  disease  such  as Grave’s  disease,  rheumatoid  arthritis,  diabetes  or  uveitis 
[534]. 
Responses  elicited against self-antigens  can  lead to  damage  of  host tissue  by  a 
variety  of  mechanisms.  For  example,  autoreactive  B  cells  produce  antibodies  against 
molecules  expressed  by the  host, which  can  be  directly  harmful  by  binding  to  surface 
proteins and interfering with their normal function as in Myasthenia gravis [535]. Similarly, 
in  Grave’s  disease,  the  binding  of  the  antibody  to  its  antigen,  the  thyroid  stimulating 
hormone  receptor,  leads  to  activation  of  the  receptor  cascade  and  consequent 
overproduction of the  hormone [536].  Alternatively, if  the autoantibody  is specific for  a 
surface  antigen  on  circulating  cells  this  may  lead  to  the  opsonisation  of  these  cells 
followed by phagocytosis and initiation of Fc receptor-mediated macrophage activation, as 
seen  in  autoimmune  thrombocytopenia  purpura  [537].  Another  effector  function  of 
autoreactive  antibodies  can  be  the  formation  of  immune  complexes  that,  as  seen  in 
Systemic lupus erythematosus [538], can be deposited in small blood vessels in the kidney 
or  in  joints  where  they  initiate  complement  activation  and  production  of  inflammatory 
mediators,  leading  to  localised  inflammation  and  aggravation  of  antigen  release  with 
consequent further production of immune complexes. However, B cells are not the only 
potentially harmful cells. For example, diseases like insulin-dependent diabetes mellitus 
are  initiated  by  autoreactive  T  cells  which  mount  responses  against  pancreatic  β-cell 
antigen leading to the destruction of β-cells. 
Genetic susceptibility is also a major contributor to the development of autoimmune 
diseases:  indeed,  it  has  been  estimated  that  in  rheumatoid  arthritis  about  60%  of  the 
susceptibility is caused by genetic factors [539]. For example, some HLA-alleles are very  
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strongly associated with the disease indicating that presentation of specific peptides that 
bind  well  to  these  HLA  alleles  plays  a  role  in  the  disease  development.  Furthermore, 
various other genes encoding proteins with important regulatory functions in the immune 
system  like  PD-1,  FcγRIIb,  CD22,  SHIP  and  CTLA-4  (reviewed  in  [540])  have  been 
implicated  in  the  development  of  different  autoimmune  diseases.  Nevertheless,  the 
multigenic nature of many of the common autoimmune diseases makes the identification 
of susceptibility genes very difficult because of the low penetrance and the very complex 
interaction of the various susceptibility loci with each other. Beside genetic susceptibility, 
environmental factors and their influence should not be underestimated as infections are 
known to aggravate autoimmune diseases, and habits like smoking have been linked to 
susceptibility to autoimmune diseases such as RA [541]. 
 
4.1.1.1  Rheumatoid arthritis (RA) 
RA is a systemic, inflammatory autoimmune disease which mainly affects the joints 
leading to cartilage breakdown and bone destruction. Some patients also develop extra-
articular  manifestations  such  as  vasculitis,  pericarditis  or  glomerulonephritis  which 
contribute  to  the  increased  risk  of  premature  mortality  in  RA  patients.  The  disease  is 
defined  as  a  symmetric  polyarticular  arthritis  caused  by  chronic  inflammation  of  the 
synovium. The inflammatory cell mass develops into the so-called pannus which invades 
articular structures leading to their destruction. RA primarily affects the small diarthrodial 
joints of the hands and feet. It occurs in about 0.5-1% of the population with the mean 
onset of the disease in the 5
th decade of life. As in SLE, there is a higher prevalence in 
women  which  suggests  the  involvement  of  hormones  in  the  disease  pathogenesis. 
Moreover, twin and family studies suggest a 60% genetic susceptibility for RA. Candidate 
genes shown in some studies to be linked to RA include HLA-DRB1, one of the genes 
encoding MHC II, PTPN22 which encodes Lyp, a negative regulator of T cell activity and 
CTLA-4, a negative costimulatory surface receptor on T cells [540]. However, as RA is 
thought to be a multigenic disease caused by the contribution of multiple low-penetrance 
susceptibility loci it will need much larger studies to prove any further linkages [540]. 
At  the  cellular  level,  the  inflammation  of  the  joint  leads  to  massive  infiltration  of 
inflammatory  cells  such  as  T  cells,  B  cells  and  macrophages.  These  cells  can  form 
organised  structures  which  resemble  germinal  centres.  In  addition,  hyperplasia  of  the 
synovial membrane is caused by increased proliferation of macrophage- and fibroblast-like 
synoviocytes,  but  the  invading  cells  are  not  the  only  cause  of  destruction  in  the  joint. 
Indeed,  inflammation  induces  resident  cells  to  produce  degradative  enzymes  like  
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metalloproteinases, serine proteases and aggrecanases, all of which are able to digest 
extracellular matrix and thereby destroy joint structures (reviewed in [542]). 
Production of autoantibodies is a major feature of RA with rheumatoid factor (RF – 
antibodies  specific  for  the  Fc  portion  of  IgG)  and  ACPA  (anti-citrunillated  protein 
antibodies)  representing  the  best  studied  specificities  [543].  The  exact  role  of  these 
antibodies in pathogenesis of RA is still not fully elucidated yet but they can be detected in 
patients before disease onset [544] and it is therefore hypothesised that they might play a 
role in disease initiation. These antibodies are also detected in the synovium, the site of 
inflammation in RA, where they can form immune complexes with their antigens further 
enhancing inflammatory responses [545]. The efficacy of B-cell depleting therapies in RA 
has further confirmed the importance of B cells in RA pathogenesis [546]. 
 
4.1.1.2  Systemic lupus erythematosus (SLE) 
Systemic lupus erythematosus is a systemic autoimmune disease characterised by 
the production of autoantibodies against various antigens such as double stranded (ds)-
DNA,  single  stranded  (ss)-DNA,  snRNPs  (small  nuclear  ribonucleoproteins),  cardiolipin 
and phospholipids. The pathology of this disease varies widely between patients ranging 
from skin rash and joint pain to severe glomerulonephritis. There is a very high prevalence 
of the disease in women of childbearing age, the ratio of female to male patients being 8:1 
at this age. After the menopause this ratio drops to 2:1 implicating a role for hormones in 
disease development, which is underlined by mouse studies showing that treatment with 
estrogen increases the number of autoreactive B cells escaping deletion [547]. SLE affects 
less people than other inflammatory autoimmune diseases such as RA, occurring only in 
0.2% of the population (reviewed in [548]). 
SLE patients produce very high levels of anti-nuclear antigen (ANA) autoantibodies 
and such antibody-producing B cells from some patients have been shown to be clonally 
expanded  and  to  express  somatically  hypermutated  and  class-switched  self-reactive 
antibodies, all signs of an antigen specific response. Furthermore peripheral B cells from 
SLE  patients  have  been  shown  to  be  hyperactive  with  upregulated  expression  of 
costimulatory molecules such as CD154 and CD86 and increased activation of MAPKs 
[538,549,550].  The  pathological  role  of  such  autoantibodies  has  not  been  definitively 
demonstrated but there is evidence that they contribute to tissue damage seen in SLE 
patients.  Thus,  self-reactive  antibodies  are  able  to  form  immune  complexes  with  their 
antigen  in  the  circulation  and  are  deposited  in  organs  like  the  kidney,  the  joints  or 
vasculature.  Deposition  can  lead  to  complement  activation  and  hence  induction  of 
inflammatory processes accompanied by infiltration of inflammatory cells. In the absence  
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of  regulation  this  inflammation  produces  a  hyperresponse,  initiating  tissue  destruction 
[538]. Moreover, the importance of B cells in disease progression has been underpinned 
recently by the efficacy of a B cell-depleting antibody, Rituximab, in the treatment of SLE 
[551]. 
 
4.1.2  Effector functions of B cells in autoimmunity 
In the last few years it has become apparent that autoantibody production is not the 
only mechanism by which B cells can take part in harmful reactions against self. Thus, 
follicular  B  cells  can  also  function  as  secondary  APCs  being  very  efficient  at  binding, 
internalising and processing antigen. That this APC capacity of B cells can play a major 
role in the development and maintenance of inflammation in autoimmune diseases has 
been illustrated by several findings. For example, a study by Takemura and colleagues 
[552] showed that the survival of human CD4
+ T cell clones from RA patients in SCID mice 
depended on the presence of CD20-positive B cells. Further support came from another 
model  system  in  which  mice  that  do  not  secrete  antibody  (mIgM-mice)  were  used  to 
examine the role of B cells in a proteoglycan (PG) induced arthritis (PGIA) model and 
where  it  was  found  that  B  cell-deficient  and  mIgM-mice  were  both  resistant  to  the 
development of arthritis [77]. This study showed that serum transfer of autoantibodies led 
to the development of transient, mild arthritis proving that antibodies do indeed play a 
pathogenic role in the PGIA model. However, T cells from mIgM-mice were not able to 
induce severe arthritis upon transfer into a healthy host indicating that these T cells are not 
properly primed as antigen-specific B cells were needed to prime T cells adequately to 
allow them to induce severe arthritis in the host animals. By contrast, the combination of 
transferring  adequately  primed  T  cells  and  pathogenic  serum  induced  severe  arthritis 
underlining  the  importance  for  T  and  B  cell  interactions  in  the  pathology  of  such 
autoimmunity [77].  
B cells might also contribute to autoimmune disease pathogenesis by the production 
of cytokines like IL-12 or IL-6 [553,554]. For example, the latter has been shown to play a 
role in diseases such as RA and juvenile idiopathic arthritis and indeed, anti-IL-6 treatment 
seems to be a promising treatment option in RA and other autoimmune diseases [555]. 
However, B cells do not only contribute to the aggravation of disease. The discovery of 
regulatory B cells has shown that these IL-10 producing cells can ameliorate autoimmune 
pathogenesis in disease models for Multiple sclerosis, inflammatory bowel disease, SLE 
as well as RA [82] (see section 1.4).  
B-1  cells  produce  polyreactive  antibodies  including  low-affinity  self-reactive 
specificities, such as those found in increased numbers in some human diseases such as  
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Sjogren’s syndrome. Moreover, there is some evidence that B-1 cells are able to produce 
high  affinity  antibodies  against  self-antigens  [556]  and  such  B-1  cells  are  found  in 
increased numbers in the autoimmune strain NZB which develops lupus like disease [557] 
and  they  were  found  to  produce  autoantibodies  in  MRL/MpJ-Fas
lpr  mice,  another 
autoimmune-prone strain [558]. 
Some  studies  indicate  that  MZ  B  cells  might  play  a  pathogenic  role  in  some 
autoimmune  diseases  where,  for  example  in  Grave’s  disease,  cells  with  a  MZ  B  cell 
phenotype have been found in infiltrates at the site of inflammation [559]. Additionally, MZ 
B cells have been found in increased number in lupus-prone autoimmune mice and these 
cells  were  shown  to  contribute  to  the  production  of  anti-DNA  antibodies  [560,561]. 
Likewise, MZ B cells are similar to B-1 cells in that they are generally polyreactive with a 
restricted antibody diversity. MZ B cells mostly do not re-circulate and are found in the MZ 
of the spleen where, due to their location, they are able to react quickly to blood borne 
pathogens. After antigen-exposure, they rapidly migrate to lymphoid follicles and in this 
way  are  able  to  efficiently  deliver  systemic  antigen  to  follicular  dendritic  cells  [562]. 
Although in mice MZ B cells mainly take part in T-independent responses, in humans MZ 
B  cells  constitute  a  heterogenous  population  including  cells  with  a  memory  phenotype 
displaying mutated VH genes [563]. The production of autoantibodies may not be the only 
contribution of MZ B cells to the development of autoimmune disease. For example, MZ B 
cells  are  efficient  APCs  and  can  promote  T  cell  activation,  proliferation  and  cytokine 
production [564]. They could therefore also take part in the presentation of auto-antigen to 
T cells leading to their activation, thereby further enhancing the autoimmune response. It is 
not  clear  why  high-affinity  self-reactive  B-1  and  MZ  B  cells  are  produced  and  how 
tolerance is broken but it has been speculated that polyreactive/self-reactive B cells are 
generally  recruited  into  the  MZ  and  maybe  also  B-1  B  cell  compartment  as  means  of 
keeping those B cells from any further diversification in order to prevent development of 
high-affinity self-reactivity [565]. A defect in the negative selection process that usually 
eliminates self-reactive clones could therefore lead to an increase in autoreactive cells 
which would be selected into the B-1 and MZ B cell compartment.  
 
4.1.3  B cell tolerance and its role in autoimmunity 
The  immune  system  has  to  generate  an  extremely  diverse  repertoire  of  antigen-
specific  B  and  T  cells  to  be  able  to  combat  all  the  pathogens  a  human  being  might 
encounter  during  a  lifetime.  The  drawback  to  this  diversity  is  the  potential  to  produce 
reactivities against host components. Thus both T cells and B cells are negatively selected 
during  their  development  by  mechanisms  which  ensure  that  the  vast  majority  of  
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autoreactive cells never reach the periphery (central tolerance). In addition, the immune 
system  has  developed  homeostatic  controls  to  ensure  that  immune  responses  are 
terminated after the clearance of pathogens as dysregulated responses lead to expanded 
pools of antigen-specific B lymphocytes which can persist in the periphery. Due to the 
relatively high frequency of such B cells recognising self-antigen with low-affinity this would 
increase the number of self-reactive B cells and therefore the chance for chronic activation 
of  these  clones.  This  is  potentially  a  very  dangerous  situation  and  therefore  normally 
regulated  by  a  cascade  of  checkpoints  ensuring  not  only  that  autoreactive  cells  are 
inactivated  and/or  deleted  but  also  that  there  is  homeostatic  regulation  of  cells  that 
recognise foreign antigen. 
 
4.1.3.1  Defects in B cell tolerance observed in autoimmune 
disease 
It has been postulated that in healthy humans, pathogenic autoreactive B cells are 
either  absent  or  kept  in  an  inactive  state  by  central  and/or  peripheral  tolerance 
checkpoints. Numerous studies in mice and humans have therefore tried to identify these 
checkpoints  and  potential  defects  affecting  these  checkpoints  in  individuals  with 
autoimmune diseases. As stated in section 1.3, the major central tolerance checkpoint 
during B cell development is at the level of immature B cells (Fig 1.8) as in healthy humans 
this checkpoint reduces the initial percentage of self-reactive clones from 75 to 40% [71]. 
Using CD10 as a marker to distinguish between B cells newly emigrated from the bone 
marrow  (CD19
+IgM
+CD10
+CD27
-)  and  mature  naïve  B  cells  (CD19
+IgM
+CD10
-    CD27
-), 
Yurasov et al [566] identified another checkpoint, which in healthy individuals removes 
some  further  50%  of  the  autoreactive  B  cells  that  have  managed  to  escape  central 
tolerance (Fig 1.8). Interestingly, this checkpoint seems to be non-functional in a subgroup 
of SLE patients and some patients with RA [566,567].  
A later checkpoint has recently been identified that normally appears to act at the 
mature naïve B cell stage: thus, in healthy humans such autoreactive B cells which make 
up about 20% of the naïve population are not selected into the IgM
+ memory compartment 
[568] (Fig 1.8). To date, there have not been any follow-up studies determining whether 
this  checkpoint  is  defective  in  patients  with  autoimmune  disease.  In  addition  to  being 
excluded from the IgM
+ memory cell pool, such autoreactive mature naïve B cells might 
also  be  prevented  from  entering  the  GC  reaction  as  it  was  shown  that  potentially 
autoreactive human B cells such as those specific for dsDNA and CD45 (9G4 B cells), 
which are present in normal healthy individuals, are excluded from the GC reaction [75] 
(Fig 1.8). Consequentially, these cells mainly display a naïve phenotype and do not take  
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part in the development of memory cells and IgG-production. However, the block of these 
self-reactive cells from IgG
+-memory cell development seems to be defective in some SLE 
patients as indicated by their higher prevalence (10-25 fold) of 9G4 IgG memory cells [75]. 
This defect in exclusion of 9G4 B cells does not seem to be a general mechanism involved 
in autoimmune diseases as patients with RA did not display an increased frequency of 
these cells in their IgG-memory compartment [75]. Moreover, this study only showed GC 
exclusion of one specific B cell clone and thus, it cannot be concluded that this mechanism 
applies to all autoreactive clones. It is therefore interesting that a recent study by Tiller and 
colleagues [569] has found that a higher percentage of IgG
+-memory B cells from healthy 
individuals express autoreactive BCRs compared to mature naïve B cells. The authors 
argue that the self-reactivity seen in those cells might be a by-product of affinity maturation 
and selection during the GC reaction leading to the enrichment of these clones [569]. It 
remains to be determined why these autoreactive memory cells do not induce disease in 
healthy individuals and it is therefore of interest to identify the mechanisms preventing 
these cells from being activated. 
Finally, there are some animal studies which indicate that there may be an additional 
final checkpoint ensuring that autoreactive B cells do not produce pathogenic antibodies. 
One such model system uses mice expressing an anti-Sm (ribonucleoprotein) transgenic 
BCR to investigate the activity of these self-reactive B cells in the context of autoimmune 
and  non-autoimmune  prone  backgrounds.  For  example,  in  normal  mice,  these 
autoreactive B cells were found to be unable to proceed past the pre-plasma cell stage to 
the plasma cell stage. By contrast, autoimmune prone mice exhibited a higher percentage 
of  anti-Sm-producing  B  cells  indicating  deregulation  of  a  checkpoint  governing 
development of plasma cells [570] (Fig 1.8). The molecular mechanisms preventing such 
cells from further development in non-autoimmune prone mice are not known, but could 
involve repression of these cells by other cells such as DCs or regulatory T cells or indeed 
B  cell  intrinsic  mechanisms  such  as  anergy  resulting  from  constant  antigen  exposure 
[570]. It has indeed been shown that TLR-4-activated myeloid DCs and macrophages can 
regulate B cell activation through the production of IL-6. Whereas IL-6 supports plasma 
cell differentiation in cells acutely exposed to antigen, it does not appear to be able to 
stimulate self-reactive cells which have been chronically exposed to antigen but rather acts 
to suppress antibody secretion by such self-reactive cells. These findings highlight that B 
cell tolerance is not solely a cell intrinsic process and hence emphasises the importance of 
other cells of the immune system in the regulation of self-reactive B cells. 
Recent evidence has suggested that negative selection at these multiple maturation 
checkpoints  is  not  the  only  mechanism  controlling  activation  of  self-reactive  B  cells,  
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however.  For  example,  competition  for  survival  factors  as  well  as  space  in  specific 
environmental niches might also influence the balance between healthy and autoreactive 
B cell survival. Thus, for example, in normal mice whilst high-affinity autoreactive B cells 
are arrested at the immature developmental stage and are also excluded from the B cell 
follicles in the spleen, lower-affinity autoreactive B cells of the same specificity are allowed 
to enter follicles. By contrast, in the absence of tolerant or low-affinity self-reactive B cells, 
high  affinity  self-reactive  B  cells  could  be  detected  in  the  follicles  indicating  that  the 
exclusion of high affinity autoreactive B cells might be due to competition [571].  
Probably the most important survival factor B cells compete for in the periphery is 
BAFF (B cell activating factor) which signals through the BAFF-receptor (BAFF-R). The 
need  for  BAFF-R  signalling  for  survival  first  occurs  at  the  transitional  stage  where  it 
coincides with upregulation of expression of the BAFF-R [572]. The importance of BAFF 
was  first  shown  using  BAFF-R-deficient  B  cells  which  proliferated  less  and  displayed 
impaired survival compared to wild-type B cells [33] and was further emphasised by the 
fact that BAFF-R-deficient B cells displayed a reduced lifespan which could be increased 
by  administration  of  BAFF  [573].  The  survival-enhancing  effect  of  BAFF  signaling  is 
achieved, at least in part, by the upregulation of anti-apoptotic Bcl-2 family members A1 
and Bcl-xL
.[573]. Thus, the reduced ability of high-affinity self-reactive cells to compete with 
low-affinity self reactive or non-self reactive cells might in part be due to an increased 
dependency on BAFF, as murine studies showed that elevated serum levels of BAFF were 
able to rescue autoreactive B cells which would normally be negatively selected at the 
transitional B cell stage [574]. It has been proposed that the higher dependency on BAFF 
of  autoreactive  B  cells  might  reflect  negative  signalling  via  the  BCR  by  self-antigen 
resulting  in  an  increased  threshold  for  positive  signalling  resulting  from  BAFF/BAFF-R 
interactions.  This  mechanism  might  have  some  relevance  for  human  autoimmune 
diseases  as  certain  SLE  and  RA  patients  have  been  found  to  express  significantly 
elevated serum levels of BAFF [575] which might have resulted in an increased survival 
rate of self-reactive B cell clones in these patients.  
 
4.1.4  Role of FcγRIIb in autoimmune disease 
FcγRIIb is a low affinity receptor for the Fc portion of IgG (section 1.5.5.3). Cross-
linking of BCR and FcγRIIb by immune complexes inhibits BCR-mediated activation and 
proliferation  of  B  cells  and  thus  provides  an  important  homeostatic  mechanism  for 
terminating ongoing B cell responses [576]. Many studies have examined the implications 
of genetic modulation of FcγRIIb expression on immune responses and the development 
of autoimmune and/or inflammatory diseases. For example, depending on their different  
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genetic  backgrounds,  FcγRIIb-deficient  mice  were  found  to  show  an  increased 
inflammatory  response  in  immune  complex  alveolitis  (Balb/C)  [577],  enhanced  IgE-
mediated anaphylactic responses (C57BL/6) [578] or increased susceptibility for induction 
of collagen-induced arthritis (CIA) (C57BL/6/129/SvJ hybrid) [579]. Other studies, using 
FcγRIIb
-/-  knockout  mice  on  the  C57BL/6  background  showed  that  such  mice  develop 
spontaneous  lupus-like  disease  with  premature  mortality  [580].  By  contrast,  studies 
overexpressing FcγRIIb specifically on B cells showed that such mice displayed reduced 
antibody production in T-dependent immune responses as well as milder disease in the 
CIA model and lower levels of disease incidence in the MRL/MpJ-Fas
lpr model of SLE 
[581]. The mechanisms involved are not clear but it is likely that the lack of this receptor on 
B cells is the cause of the increased susceptibility for autoimmunity seen in these mice. 
Consistent with this, retroviral transfection of FcγRIIb
-/- bone marrow cells with FcγRIIb and 
the transfer of these cells into an irradiated host can restore the normal phenotype with 
lower levels of autoantibodies, reduced immune complex deposition and inflammation in 
autoimmune prone strains [582].  
More  recent  studies  have  tried  to  further  elucidate  the  mechanisms  that  lead  to 
lupus-like disease in such FcγRIIb knockout mice. Two independent studies found that 
deficiency  in  this  receptor  increases  the  levels  of  circulating  RF  [583]  and  anti-DNA 
autoantibodies [584] and that the number of anti-DNA specific plasma cells, which mostly 
expressed IgG antibodies, was increased [584]. Thus, expression of FcγRIIb might also 
play a role in controlling the expansion and activation of high affinity self-reactive B cells. 
Consistent with this, FcγRIIb-deficient mice, expressing a transgene-encoded heavy chain 
rendering their B cells specific for DNA, displayed an altered B cell repertoire comprising 
expansion  and  activation  of  high  affinity  anti-DNA  B  cell  clones  compared  to  that  of 
FcγRIIb-expressing mice [585]. Moreover, it has also been proposed that FcγRIIb plays a 
role in the GC reaction by regulating the development of antibody-forming cells versus 
memory cells. Consistent with this, it was found that levels of FcγRIIb on GC B cells are 
increased  compared  with  those  on  non-GC  cells  in  wild-type  mice  and  that  this  up-
regulation is missing in autoimmune mice [586]. The disturbance of any, or a combination, 
of  these  functions  could  therefore  influence  the  development  and  maintenance  of 
autoimmune diseases.  
There  have  not  been  many  studies  investigating  the  role  of  FcγRIIb  in  human 
autoimmune disease to date. However, Enyedy et al [587] have examined the FcγRIIb-
associated inhibition of BCR signalling in B cells from SLE patients and found that they 
showed  an  increased  intracytoplasmic  calcium  flux  upon  BCR  stimulation  relative  to 
healthy  volunteers.  To  investigate  if  this  hyperreactivity  was  due  to  reduced  FcγRIIb  
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signalling or expression, the effect of cross-linking BCR and FcγRIIb on B cells from SLE 
patients was tested. The inhibitory effect of FcγRIIb signalling on calcium flux upon BCR 
stimulation was reduced in SLE B cells, whilst the expression levels of FcγRIIb on the 
surface of these cells were found to be the same as on normal B cells indicating a defect 
in  the  signalling  mechanisms.  However,  more  recent  studies,  using  newly  developed 
FcγRIIb-specific antibodies, have looked in more detail at the expression of FcγRIIb by 
SLE patients [588] and have identified some major differences in B cell subsets. Thus, 
comparison between healthy controls and SLE patients showed that the upregulation of 
FcγRIIb  expression  on  memory  B  cells  and  plasmablasts  from  peripheral  blood  was 
decreased  in  autoimmune  patients  leading  to  increased  calcium  signalling  upon  BCR-
ligation. Interestingly, significantly more Afro-American patients showed this defect than 
patients of Caucasian background indicating involvement of a genetic component [588]. A 
reduction of FcγRIIb expression on memory and plasma cells could therefore be one of the 
mechanisms  leading  to  hyperactive  B  cell  responses  and  increased  autoantibody 
production  in  patients  with  autoimmune  diseases  such  as  SLE.  Interestingly,  a 
polymorphism of FcγRIIb which changes the isoleucine at position 232 to a threonine was 
found to be associated with SLE in some racial groups such as Japanese patient cohorts 
[589]. This amino acid is in the transmembrane domain of FcγRIIb and the polymorphism 
reduces the signalling capability of FcγRIIb due to its exclusion from lipid rafts [590]. Taken 
together these studies therefore provide another link between reduced FcγRIIb signalling 
and an increased risk of developing SLE. 
 
4.1.5  The role of toll-like receptor (TLR) signalling in B cells 
It  has  become  increasingly  apparent  that  TLR  signalling  might  not  only  play 
important  roles  in  the  innate  immune  system  but  also  in  regulating  adaptive  immune 
responses, including those of B cells. For example, recent data highlight the possibility that 
TLRs might act as a third signal for B cells to optimise their activation, isotype switching 
and terminal differentiation. Thus, proliferation of naïve human B cells was found to be 
prolonged after BCR stimulation in the context of T cell help, only in the presence of TLR 
ligands [37]. The possibility of self-reactive B cells with certain specificities such as anti-
DNA or anti-RNA being activated by their antigen not only through the BCR but also via 
TLRs  has  led  to  the  hypothesis  that  TLR  signalling  might  contribute  to  the  unwanted 
activation  of  autoreactive  B  cell  clones.  This  is  a  realistic  scenario  especially  in 
autoimmune  diseases like  SLE,  which  is  characterised  by  the  production  of  antibodies 
against  potential  TLR  ligands,  such  as  DNA.  In  addition  to  endogenous  TLR  ligands 
provided by the host itself, pathogens like bacteria or viruses might also induce activation  
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of such self-reactive B cells by providing costimulation via TLRs. This idea is supported by 
a  chronic  infection  model  in  which  Soulas  and  colleagues [591]  used a transgenic  RF 
(rheumatoid factor – antibodies specific for host IgG) - producing mouse model to examine 
the effect of chronic Borrelia burgdorferi infection on autoantibody production. They found 
that immune complexes of RF and Borrelia burgdorferi simultaneously stimulated the BCR 
(by the auto-antigen IgG) and TLR (B. burgdorferi antigen most likely through TLR1/2 by 
Pam3Cys-modified lipoproteins) and hence synergistically increased antibody production. 
The hypothesis that TLRs play a role in the activation of autoreactive B cell clones 
was  further  strengthened  by  findings  in  MRL/MpJ-Fas
lpr  mice,  a  strain  prone  to 
spontaneously  developing  lupus-like  disease.  Unlike  their  TLR9-expressing  littermates, 
TLR9-deficient  MRL/MpJ-Fas
lpr  mice  do  not  produce  anti-DNA  or  anti-chromatin 
antibodies.  Interestingly  however,  Sm,  cardiolipin  and  phospholipid  autoantibody 
responses  were  not  influenced  by  TLR9  deficiency  and  the  mice  were  not  protected 
against  disease  development,  indicating  that  the  ability  of  TLRs  to  play  a  role  in  the 
induction of specific autoantibodies may depend on the nature of the antigen (TLR ligand 
or not) [592]. Similarly, another study found that FcγRIIb-deficient mice which normally 
develop lupus-like disease were protected if they did not express TLR9 and these mice 
also did not produce any anti-DNA antibodies [593]. This latter study also showed that 
MyD88/TLR9  is  necessary  to  develop  pathogenic  IgG2a  and  IgG2b  autoreactive 
antibodies by inducing T-bet expression in B cells. Indeed, lack of TLR9 prevented the 
class switch to IgG2a/b specifically in anti-DNA B cells but not in other B cell clones. Thus, 
TLR 9 signalling in combination with BCR-ligation can induce class-switching to IgG2a and 
IgG2b, but it is not necessary for class-switching per se [593].  
Interestingly, in normal healthy individuals TLR engagement does not lead to the 
activation of autoreactive B cells and initiation of autoimmune disease, suggesting that 
there are normally potent mechanisms preventing stimulation of self-reactive B cells during 
an infection. Indeed, a mouse model widely used to study B cell anergy, the HEL/anti-HEL 
BCR double transgenic system has proved useful in the elucidation of the mechanisms 
that act to keep autoreactive B cells anergic even in the presence of TLR stimuli. For 
example,  in  the  presence  of  the  auto-antigen  HEL,  CpG  (TLR9)  stimulation  of  HEL-
reactive  B  cells  was  not  able  to  induce  proliferation  or  plasma  cell  differentiation. 
Moreover, signalling by this self-antigen uncoupled the BCR from downstream calcineurin-
dependent pathways thereby reducing proliferation, but led to constitutively elevated ERK 
activation which inhibited plasma cell differentiation [594]. These signals were reversible 
and removal of the self-antigen allowed stimulatory signalling through TLR9 [594]. These 
data therefore fit well with a recent report by Gauld et al [595] showing that constitutive  
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signalling is required to keep B cells in an anergic state. Here they used the Ars/A1 model 
for  anergy,  taking  advantage  of  the  fact  that  whilst  B  cells  of  these  mice  express  an 
antibody  specific  for  a  self-antigen  thought  to  be  ssDNA,  they  also  bind  the  hapten 
arsonate  with  slightly  higher  affinity  than  the  self-antigen.  Addition  of  excess  hapten 
therefore displaces the bound self-antigen and terminates signalling due to the monovalent 
nature of the hapten which is not able to cross-link the BCR. Consistent with the findings in 
the HEL/anti-HEL model, anergic Ars/A1 B cells show reduced life-span, slightly increased 
basal  levels  of  calcium,  ERK  and  MAPK  phosphorylation  and  activation  marker 
expression. The increased life span of B cells resulting from the removal of auto-antigen 
from the BCR by hapten application correlated with a reduction of basal calcium levels and 
ERK phosphorylation back to normal levels and the capacity of these cells to upregulate 
CD86 and mobilise calcium upon stimulation with anti-IgM [595]. Collectively, these data 
indicate that constant antigen binding and signalling maintains B cells in an anergic state 
and thus, in normal individuals, B cell anergy induced by self-reactivity is not overcome by 
synergistic TLR signalling. In mice with autoimmune-prone background, or patients with 
autoimmune disease, this negative control mechanism might be defective allowing TLR 
signals to enhance activation and differentiation of self-reactive B cells and production of 
autoantibodies. 
 
4.2  Aims 
 
It is well established that co-ligation of the BCR and FcγRIIb results in inhibition of B 
cell growth and apoptosis with a consequent reduction in antibody production [209,596]. 
Recent studies using FcγRIIb-knockout mice have shown that this inhibitory receptor might 
play a role in suppressing the development of some autoimmune diseases like SLE, as 
deficiency  can  lead  to  the  development  of  lupus-like  disease  [580].  However,  the 
mechanisms  underlying  growth  arrest  and  apoptosis  downstream  of  BCR/FcγRIIb  co-
ligation have not yet been fully elucidated. 
 
The specific aims of this chapter are therefore to: 
·  Characterise the key signals involved in growth arrest and apoptosis of B 
cells resulting from the cross-linking of BCR/FcγRIIb. 
·  Determine if FcγRIIb-mediated negative feedback inhibition is defective in 
MRL/MpJ-Fas
lpr mice.  
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·  Characterise  if  similar  signalling  occurs  in  human  B  cells  from  healthy 
individuals and is defective in RA/SLE patients.  
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4.3  Results 
 
4.3.1 Ligation of the BCR on mature B cells mediates survival and 
proliferation, whereas co-ligation with FcγRIIb induces growth 
arrest and apoptosis 
The effects of BCR/FcγRIIb co-ligation were investigated in purified mature splenic B 
cells by using different forms of anti-Ig antibodies to mimic stimulation by free antigen 
and/or  immune  complexes.  Thus,  as  a  control,  cells  were  cultured  in  media  alone 
(designated None in the figures) and stimulation with F(ab’)2 fragments of anti-IgM was 
used to cross-link the BCR and induce mitogenic signals (designated BCR in the figures). 
By contrast, as stimulation with intact anti-IgM/IgG results in the generation of negative 
signals induced by co-ligation of the BCR and FcγRIIb [209], these antibodies were used 
in combination with F(ab’)2 fragments of anti-IgM to mimic the inhibition of antigen-driven 
mitogenic signals by immune complexes resulting in growth arrest and apoptosis [209] 
(designated  BCR+FcγRIIb  in  the figures) (Fig.4.1).  It  should  be noted  that  it is widely 
established  that  primary  mature  B  cells  cultured  with  media  alone  are  prone  to  die  in 
culture and hence results acquired with unstimulated cells reflect the spontaneous growth 
arrest and  death  of  cells  lacking  survival signals  in  this  time  period.  By  contrast,  cells 
provided with survival signals such as IL-4 survive but do not undergo proliferation [309]. 
Thus, as expected, the spontaneous levels of DNA synthesis of mature splenic B 
cells after 48 hours are very low if cells are left untreated (Fig.4.2A). By contrast, cross-
linking the BCR induces mitogenic signalling as shown by the addition of F(ab’)2 fragments 
of  anti-IgM  therefore  inducing  substantial  DNA  synthesis  (Fig.4.2A).  These  data  are 
corroborated by cell cycle stage analysis (PI staining of DNA content) which demonstrated 
that the vast majority of the untreated cells were arrested in the G1 phase of cell cycle and 
only a very low number of cells were in the mitogenic phases of the cell cycle (S and G2/M 
phase)  (Fig.4.2B-C).  By  contrast,  ligation  of  the  BCR  reduced  the  percentage  of  cells 
arrested at the G1 stage and additionally promoted progress of cells into the S and G2/M 
phases of the cell cycle indicating proliferation of these cells (Fig.4.2B-C). 
Cross-linking the FcγRIIb and BCR on the other hand is known to induce growth 
arrest and apoptosis in B cells [597]. Thus, as expected, co-ligation of FcγRIIb and BCR 
on purified splenic B cells reduced the levels of BCR-driven DNA synthesis compared to 
cells stimulated through their BCR alone (Fig.4.2A). This reduced proliferation is due to 
both  growth  arrest  and  apoptosis  as  there  is  a  strong  increase  in  the  percentage  of 
subdiploid  cells  in  comparison  to  BCR-stimulated  cells  (Fig.4.2C).  Additionally,  BCR-
mediated  progression  through  the  cell  cycle  was  also  inhibited  by  FcγRIIb  co-ligation  
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shown by a reduction of cells in S and G2/M phase at 48 hours and indeed, analysis of the 
live cell gate revealed that there are proportionally more of this population in G0/G1 phase 
(Fig.4.2C-ii). Dissipation of the MMP is an early hallmark of apoptosis and consistent with 
this, ligation of the BCR protects the integrity of the mitochondria as shown by the strong 
DiOC6  staining  intensity  (MMP-sensing  dye)  which  directly  correlates  with  higher  and 
therefore more stable MMP compared to untreated cells at 48 h (Fig. 4.2D). Nevertheless, 
a  proportion  of  these  cells  displayed  lower  MMP  correlating  with  the  cell  cycle  data 
showing that some BCR-stimulated cells were also undergoing growth arrest and/or or 
dying (Fig.4.2C). Similarly, untreated cells exhibited low MMP consistent with their status 
of G0/G1 arrest and consequent apoptosis. However, inhibition of BCR-driven signalling 
by  co-ligation  of  the  BCR  with  FcγRIIb  resulted  in  the  strongest  reduction  of  MMP 
indicating that such FcγRIIb-mediated signals, at least in part, initiate apoptosis through 
dissipation of the MMP (Fig.4.2D). 
 
4.3.2 Caspase-8 inhibition reduces FcγRIIb-induced apoptosis 
It  was  shown  by  this  laboratory  that  FcγRIIb-mediated  apoptosis  initiates  the 
dissipation of the MMP and leads to the release of cytochrome C [309]. This mitochondrial-
dependent  apoptotic  pathway  seems  to  be  induced,  at  least  in  part,  by  the  FcγRIIb-
mediated  reduction  of  PI3  kinase-activity  as  inhibition  of  PI3  kinase  induces  apoptosis 
even in the presence of BCR-signalling [309]. PI3 kinase signalling, through activation of 
Akt, keeps the pro-apoptotic molecule Bad in an inactive state [598] and thus, reduced 
levels of activated Akt would therefore result in increased activation of Bad which in turn 
could sequester Bcl-xL/Bcl-2 and stop them from protecting mitochondrial integrity [309]. 
The execution phase of such apoptosis did not appear to be dependent on caspases or 
any other executioner proteases such as cathepsin B or calpain as evidenced by the lack 
of effect on FcγRIIb-mediated apoptosis by the administration of pharmacological inhibitors 
against  any  of  these  proteases.  Rather,  the  combination  of  such  inhibitors  and  hence 
presumably inhibition of more than one of these executioner proteases, was sufficient to 
protect  cells  from  BCR/FcγRIIb-mediated  apoptosis  [309]  suggesting  that  concerted 
activation of these executioner proteases was required for apoptosis. Caspase 8 is an 
initiator caspase which is known to be able to initiate the intrinsic mitochondrial apoptotic 
pathway as well as the activation of executioner caspases such as caspase 3. As both 
dissipation of the MMP as well as activation of executioner proteases seems to play a role 
in FcγRIIb-induced apoptosis, caspase 8, which also controls both these pathways, might 
therefore  be  potentially  involved  in  the  regulation  of  this  as  yet  undefined  signalling  
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cascade. Therefore, a caspase 8-specific pharmacological inhibitor was used to analyse 
the effects of caspase 8 inhibition on FcγRIIb-mediated B cell responses (Fig. 4.3).  
As  shown  above,  cross-linking  the  BCR  in  the  presence  of  negative  signalling 
resulting from co-ligation of the BCR and FcγRIIb, strongly increased the percentage of 
apoptotic cells with subdiploid DNA content compared to that observed following mitogenic 
stimulation of the cells via the BCR (Fig.4.3A). This increase was efficiently blocked by the 
addition of a caspase 8 inhibitor which reduced the levels of apoptosis downstream of 
BCR/FcγRIIb  ligation  from  48%  to  22%  (Fig.4.3A).  Caspase  8  inhibition  also  slightly 
reduced  the  percentage  of  untreated  or  BCR-stimulated  cells  undergoing  apoptosis 
suggesting that caspase 8 played a general regulatory role in the apoptosis of mature B 
cells.  As  the  caspase  8  inhibitor  was  shown  to  efficiently  reduce  FcγRIIb-mediated 
apoptosis almost to the levels observed in BCR-stimulated cells, it was further analysed 
whether  this  protection  from  apoptosis  was  due  to  increased  stability  of  mitochondria. 
However, when caspase 8 activation was blocked, it was found that co-ligation of BCR and 
FcγRIIb still reduced the percentage of cells with high MMP to the same extent as seen in 
cells treated with DMSO as a control (Fig.4.3C/D). Furthermore, caspase 8 inhibition did 
not modulate the MMP in either untreated cells or BCR-stimulated cells (Fig.4.3B-E). It is 
therefore  concluded  that  during  spontaneous,  BCR-  or  FcγRIIb-mediated  apoptosis  of 
mature B cells, dissipation of the MMP is a process induced upstream or in parallel with 
caspase 8 activation.  
Consistent with these results, cleaved active caspase 8 was found at higher levels in 
cells  after  BCR/FcγRIIb  co-ligation  compared  to  these  observed  in  untreated  or  BCR-
stimulated  cells,  hence  further  confirming  the  association  of  caspase  8  with  FcγRIIb-
mediated apoptosis (Fig.4.4A). Moreover, although it is still somewhat controversial as to 
the exact role cFLIPL plays, as it has been shown to both inhibit and enhance apoptosis 
[599],  cFLIPL  has  been  proposed  to  be  a  major  regulator  of  death  receptor  signalling 
involving  caspase  8.  For  example,  it  has  been  suggested  that  cFLIPL  may  act  as  an 
inhibitor  of  caspase  8  activation  when  present  at  physiological  levels,  whereas 
overexpression  of  cFLIPL  might  drive  apoptosis  [599].  Perhaps  consistent  with  this, 
preliminary  results  showed  that  whilst  cFLIPL  could  be  detected  in  untreated,  BCR-
stimulated as well as BCR/FcγRIIb costimulated cells, it was most highly expressed in 
cells  in  which  the  BCR  and  FcγRIIb  were  crosslinked  (Fig.4.4B),  indicating  that  this 
molecule may play some role in negative signalling during FcγRIIb-mediated apoptosis. 
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4.3.3 FcγRIIb-mediated regulation of p53 expression and localisation 
and induction of Noxa 
These initial experiments established that caspase 8 is important in the regulation of 
FcγRIIb-mediated apoptosis. In order to shed some light on the downstream molecules 
involved in the apoptotic pathways utilised by FcγRIIb, it was decided to examine the role 
of known key regulators of apoptosis such as p53, a tumor suppressor which regulates 
growth arrest and apoptosis [600,601]. The main function of p53 is that of a transcription 
factor and as such it regulates genes important in the induction of growth arrest like the 
cell cycle inhibitor p21, or in apoptosis such as the pro-apoptotic BH3-only proteins Puma, 
Noxa [484] and Bax [485]. Interestingly, p53 has also recently been found to be able to 
initiate apoptosis by transcription-independent mechanisms. Thus, whilst for its role as a 
transcription factor  p53 has  to be  localised  in  the  nucleus  where  it is  able  to regulate 
transcription of its target genes, it was recently shown that p53 can translocate to the 
cytoplasm  and  mitochondria  where  it  interacts  with  Bcl-2  family  members.  Thus, 
translocation of p53 to the mitochondria allows it to interact with Bcl-xL and Bcl-2 liberating 
the  pro-apoptotic  Bax  and  Bak  and  inducing  the  intrinsic  apoptosis  pathway  [486]. 
Furthermore, p53 was also shown to be capable of activating Bax in the absence of any 
other Bcl-2 family members [602]. Thus, to fully assess p53 activity it might therefore be 
important  to  analyse  not  only  its  overall  expression  levels  but  also  its  subcellular 
localisation.  
To address the role of p53 in FcγRIIb-induced apoptosis its expression at the mRNA 
and protein levels downstream of BCR/FcγRIIb co-ligation was first analysed. Levels of 
p53  mRNA  were  found  to  be  highest  in  untreated  cells  and  suppressed  by  mitogenic 
stimulation through the BCR. Perhaps rather surprisingly, this reduction of p53 expression 
was partially reversed due to co-ligation of the FcγRIIb, remaining at considerably lower 
levels  than  in  unstimulated  cells  (Fig.4.5A).  To  determine  if  these  changes  at  the 
transcriptional  level  translated  into  protein  expression,  whole  cell  lysates  were  also 
analysed for p53 expression. At 48 h, p53 protein expression was indeed found to be 
suppressed by BCR signalling and this effect was not only reversed by FcγRIIb-co-ligation 
but  p53  expression  was  strongly  upregulated  relative  to  the  levels  observed  in  naïve, 
untreated cells (Fig.4.5B). Collectively, these results suggest that p53 may play a role not 
only in driving FcγRIIb-mediated negative signalling but also in maintaining naïve cells in 
an inactive form. Moreover, as the profiles of p53 mRNA and protein expression were 
distinct,  these  results  suggest  that  the  upregulation  of  p53  observed  in  response  to 
FcγRIIb signalling likely reflected predominantly protein stabilisation rather than de novo 
gene induction.   
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As stated above, the functional consequences of p53 activity are highly dependent 
on  its  localisation.  In  the  nucleus,  p53  functions  mainly  as  a  transcriptional  regulator 
whereas  in  the  cytoplasm  and  at  the  mitochondria  it  seems  to  be  directly  involved  in 
regulating  the  balance  between  the  activity  of  pro-  and  anti-apoptotic  molecules.  To 
determine the effects of BCR and/or FcγRIIb signalling on p53 localisation, subcellular 
fractions (cytoplasmic and nuclear) were prepared 48 hours after stimulation and the levels 
of  p53  protein  expression  determined.  In  both  the  cytoplasmic  as  well  as  the  nuclear 
fractions, p53 could only be detected in samples derived from cells undergoing FcγRIIb-
mediated negative signalling (Fig.4.5C/D). Having established that p53 is indeed regulated 
by BCR and FcγRIIb signalling, the potential connection between p53 and caspase 8 was 
analysed  by  investigating  the  effects  of  caspase  8  inhibition  on  p53  expression  and 
localisation. Inhibition of caspase 8 did not affect the protein levels of p53 detected in 
whole cell lysates in untreated cells or BCR-stimulated cells (Fig.4.5B) but did appear to 
slightly reduce p53 expression in cells stimulated via the BCR and FcγRIIb (Fig.4.5B). 
More striking effects of caspase 8 inhibition, however, could be detected in terms of the 
subcellular  localisation  of  p53.  Thus,  whilst  BCR/FcγRIIb-mediated  signalling 
predominantly  induced  cytoplasmic  p53  expression,  inhibition  of  caspase  8  induced  a 
striking re-localisation of p53 from the cytoplasm to the nucleus thereby strongly reducing 
the cytoplasmic levels of p53 (Fig.4.5C/D).  
There are various potential effects of increased p53 activity. For example, increased 
p53 levels could enhance the transcription and hence protein levels of its targets such as 
Noxa [603], a pro-apoptotic BH3-only protein. Following transcriptional upregulation Noxa 
can translocate to mitochondria where it binds to anti-apoptotic Bcl-2 family members such 
as Mcl-1 but does not directly bind Bax [289,604]. Noxa-dependent apoptosis is therefore 
most  likely  initiated  by  indirect  release  of  Bim  and  Bak  from  Mcl-1  allowing  them  to 
destabilise the mitochondria [605]. In melanoma cells Noxa has also been found to locate 
to  the  endoplasmic  reticulum  where  it  induces  intracellular  calcium  release,  but  the 
relevance  of  this  mitochondrial-independent  pathway  has  yet  to  be  analysed  in  other 
cellular  systems  [606].  Taken  together  these  studies  indicate  that  Noxa  can  play  an 
important  role  in  p53-dependent  apoptosis.  One  of  the  functional  outcomes  of  the 
increased levels of p53 detected upon ligation of BCR/FcγRIIb (Fig.4.5B) could therefore 
potentially be the upregulation of Noxa expression. It was therefore decided to analyse the 
regulation  of  Noxa  in  FcγRIIb-mediated  apoptosis.  Indeed,  Noxa,  which  could  not  be 
detected in freshly isolated cells (0 h) was upregulated by cross-linking of the BCR and 
FcγRIIb  at  24  and  particularly,  48  hours  (Fig.4.6A).  Untreated  cells  also  slightly 
upregulated  the  expression  of  Noxa  over  time,  but  not  to  the  same  extent  as  cells  
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stimulated  through  BCR/FcγRIIb  ligation  (Fig.4.6A).  Noxa  expression  was  below  the 
detection limit in BCR-stimulated cells, indicating that BCR-signalling perhaps maintained 
suppression  of  upregulation  of  Noxa  by  reducing  p53  expression  (Fig.4.5B  and  4.6A). 
Taken together these results suggest that FcγRIIb-mediated negative signalling induces 
p53 expression thereby increasing Noxa expression. Both Noxa, and also p53 itself, could 
translocate to the mitochondria and induce dissipation of the MMP by either interacting 
with Bcl-2 family proteins or through direct mechanisms [484,602].  
 
4.3.4 Caspase 8 does not inhibit FcγRIIb-mediated activation of 
effector caspases 
As described above, data from this laboratory suggested that that FcγRIIb-mediated 
apoptosis  might  depend  on  the  concerted  activation  of  multiple  executioner  proteases 
such as effector caspases, cathepsins and calpains [309]. Caspase 8 seems to play an 
important role in apoptosis induced by BCR/FcγRIIb co-ligation and it is known to activate 
caspase 3 [607]. Thus, it was investigated whether blocking of caspase 8 activity resulted 
in  inhibition  of  BCR/FcγRIIb-mediated  activation  of  caspase  3  subfamily  caspases  as 
evidenced by binding of the FITC-labelled pan-caspase inhibitor, VAD-FMK that can bind 
and inhibit ICE like proteases/group 1 proteases (including caspases 1, 4, 5) and, to a 
lesser  extent,  caspase  3  subfamily  proteases  (including  caspases  2,  3,  6,  7,  9)  [608]. 
Cells, which had been left untreated over the 24 h stimulation period, displayed high levels 
of caspase activation (Fig.4.6B-E) which were not influenced by mitogenic stimulation of 
cells through the BCR (Fig.4.6C-E). By contrast, co-ligation of BCR/FcγRIIb increased the 
level  of  FITC  fluorescence  detected  after  labelling  of  the  cells  with  FITC-VAD-FMK 
indicating an increase in caspase activation (Fig.4.6C-E). Having established a role for 
caspase  activation  in  the  FcγRIIb-signalling  pathway,  the  role  of  caspase  8  in  the 
regulation of such caspase activity was assessed. Again taking advantage of the specific 
caspase  8  inhibitor,  it  was  shown  that  caspase-8  inhibition  did  not  increase  or  inhibit 
caspase activation in either untreated, BCR/FcγRIIb or BCR-ligated cells (Fig. 4.6C-E). 
The activity of calpain as well as cathepsin B was tested as well, but no activity could be 
detected. Collectively, these results suggest either that caspase 8 activity is not needed for 
the concerted activation of executioner caspases or perhaps that the combined protease 
inhibitors, which have been previously described to inhibit FcγRIIb-mediated apoptosis, 
might have been targeting caspase 8 activity. 
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4.3.5 Caspase 8 inhibition does not affect BCR/FcγRIIb induced 
growth arrest 
The experiments described so far have established that caspase 8 plays a pivotal 
role in the regulation of BCR/FcγRIIb-induced apoptosis. Initial cell cycle data indicated 
that although caspase-8 inhibition reduced the level of subdiploid/apoptotic cells (Fig.4.3A-
iv), it did not decrease the percentage of cells arrested in the G1 phase of the cell cycle in 
BCR/FcγRIIb-stimulated cells (Fig.4.7A/B). Indeed, more detailed analysis of the cell cycle 
stages showed that whilst cross-linking of the BCR and FcγRIIb in the presence of the 
caspase 8 inhibitor increased the percentage of live cells in G1 growth arrest (Fig.4.7A and 
B), it did not prevent the FcγRIIb-mediated suppression of BCR-mediated S-phase and 
G2-M phase progression (Fig.4.7C/D). Further corroboration of these results came from 
DNA synthesis experiments in which addition of the caspase 8 inhibitor did not influence 
proliferation of cells at 48 and 72 h, regardless of the stimuli used (Fig.4.7E/F). Thus, 
caspase 8 inhibition protected cells from apoptosis but was not able to restore cell cycle 
progression and proliferation, leading to an accumulation of growth arrested cells. 
 
4.3.6  Effects of FcγRIIb-signalling on cell cycle regulation 
Having established that cross-linking of the BCR and FcγRIIb results in growth arrest 
in the G1 phase of the cell cycle that ultimately leads to apoptosis, the effects of FcγRIIb-
signalling on regulators of cell survival and cell cycle progression were analysed. c-Myc is 
an  important  regulator  of  the  cell  cycle  [609]  at  multiple  levels:  for  example,  c-Myc 
promotes  cell  cycle  progression  by  increasing  the  expression  of  cyclins  and  indirectly 
leading to degradation of p27 [610,611]. c-Myc itself is regulated at the transcriptional and 
protein level, therefore, firstly, to assess if c-Myc was regulated by BCR or BCR/FcγRIIb-
signalling  in  mature  B  cells,  c-Myc  expression  at  the  mRNA  and  protein  levels  were 
analysed. As expected, c-Myc mRNA levels were indeed found to be upregulated following 
mitogenic stimulation via the BCR, but this was transient returning to basal levels within 7 
h (Fig.4.8A). By contrast, and consistent with the growth arrest-inducing effects of FcγRIIb-
mediated signalling, simultaneous cross-linking of the BCR with FcγRIIb suppressed the 
BCR-mediated upregulation of c-Myc RNA levels, although the levels observed were still 
higher  than  those  of  untreated  cells  (Fig.4.8A).  Reflecting  the  differential  induction 
observed  at  the  mRNA  level,  c-Myc  protein  expression  at  24  h  was  higher  in  cells 
mitogenically stimulated via the BCR than in those stimulated via the BCR and FcγRIIb 
(Fig.4.8B). Moreover, c-Myc could not be detected at all in untreated cells at this time 
point, presumably reflecting the fact that these cells were spontaneously dying. Although 
c-Myc  mRNA  levels  did  not  differ  between  untreated,  BCR  or  BCR/FcγRIIb-stimulated  
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cells  at  24  h,  the  differential  protein  levels  observed  not  only  probably  represent  the 
delayed kinetics of c-Myc regulation at the protein compared to RNA level (Fig.4.8B), but 
may also reflect the involvement of other regulatory mechanisms such as c-Myc protein 
stabilisation through phosphorylation.  
The  key  step  in  the  progression  of  cells  through  G1  phase  and  into  S  phase  is 
governed by the hyperphosphorylation-status of Rb proteins [612]. Mitogenic stimuli can 
induce an increase in the activity of Cdk/cyclin complexes which phosphorylate Rb which 
in turn reduces the binding of Rb to E2F and releases E2F to induce the transcription of 
genes  controlling the  entry  into S  phase  [613]. In  order to  examine  the  effect  of  BCR 
stimulation, as well as inhibitory FcγRIIb-signalling, on this major regulatory mechanism, 
the  expression  of  hyperphosphorylated  Rb  (phospho-serine  807/811)  was  detected  by 
Western Blotting. Levels of pRbS807/811 were found to be below the detection limit in 
untreated cells but were strongly upregulated upon BCR stimulation (Fig.4.8B) correlating 
with  increased  proliferation  and  cell  cycle  progression  in  these  cells  (Fig.4.2A/B).  Co-
ligation of the BCR with FcγRIIb reduced the levels of pRbS807/811, correlating with the 
observed  reduced  c-Myc  expression  (Fig.4.8B).  Thus,  FcγRIIb-signals,  probably  by 
reducing the activation  of mitogenic pathways  such as PI3 kinase or ERK, reduce the 
upregulation of c-Myc. This in turn could decrease the activation of Cdk/cyclin complexes 
by c-Myc which would explain the reduced levels of phosphorylated Rb. 
The  analysis  of  cell  cycle  progression  and  cellular  proliferation  (DNA  synthesis) 
performed above suggested that caspase 8 signalling was not involved in the FcγRIIb-
mediated  regulation  of  growth  arrest  of  B  cells  mitogenically  stimulated  via  the  BCR 
(Fig.4.7A). It was therefore not surprising to find that inhibition of caspase 8 did not restore 
the expression of c-Myc or pRbS807/811 observed in cells costimulated through the BCR 
and FcγRIIb to the levels found in cells mitogenically stimulated via the BCR (Fig.4.8B). 
Moreover,  inhibition  of  caspase  8  did  not  have  any  effects  on  c-Myc  or  phospho-Rb 
expression in untreated or BCR-stimulated cells (Fig.4.8B).  
 
4.3.7 Involvement of regulatory elements of the ERK MAPK cascade 
in FcγRIIb-mediated inhibitory effects 
FcγRIIb-mediated  negative  feedback  inhibition  downregulates  multiple  signalling 
pathways including the ERK MAPK cascade. This cascade is important for survival and 
proliferation of mature B cells [331] with inhibition of ERK activation being shown to be 
linked to growth arrest and apoptosis [310], most likely by modulating cyclin D expression 
as well as c-Myc stability, as seen in immature WEHI-231 B cells (section 3.3.9). The 
downregulation of ERK MAPK signalling by FcγRIIb-ligation is therefore one of the major  
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mechanisms inducing growth arrest upon BCR/FcγRIIb co-ligation. This is consistent with 
the  finding  that  the  major  effector  recruited  to  FcγRIIb  is  SHIP,  which  reduces  Ras 
activation by several mechanisms and thereby inhibits the activation of ERK [214,614]. It 
was shown previously by this laboratory that ERK activation is rapidly abrogated upon co-
ligation of FcγRIIb within the first 5 minutes and, consistent with its important role in BCR-
induced proliferation and survival, such inhibition is sustained for up to 96 hours [309,453]. 
FcγRIIb-signalling not only inhibits initiation of the ERK cascade, it also decreases ongoing 
activation of ERK, as it has been shown to recruit PAC-1, an ERK-specific MAP kinase 
phosphatase,  thereby  leading  to  dephosphorylation  of  previously  activated  ERK  [209]. 
However, it has not been shown in these previous studies how PAC-1 was regulated by 
FcγRIIb-signalling, and hence it was investigated whether PAC-1 mRNA expression levels 
were influenced by BCR/FcγRIIb co-ligation. Thus, using Taqman RT-PCR to detect PAC-
1 mRNA levels, it was shown that co-ligation of the BCR and FcγRIIb increased PAC-1 
mRNA  expression  relative  to  that  observed  following  mitogenic  BCR  signalling  at  all 
timepoints analysed (7-24 hours) (Fig.4.9A-ii). This could in turn lead to increased PAC-1 
at the protein level and would further contribute to the FcγRIIb-mediated downregulation of 
ERK signalling. 
It has been proposed that activation of the ERK MAPK cascade in B cells might not 
only depend on Ras activation, but potentially involves another small G protein, Rap which 
couples to the B-Raf/MEK pathway [411]. Indeed, in the DT40 chicken B cell line, B-Raf 
was found to be the major Raf-isoform involved in the activation of MEK and hence ERK 
phosphorylation [170]. SPA-1 is a Rap specific GTPase activating protein and therefore 
able to increase the intrinsic GTPase-activity of Rap leading to the inactivation of Rap 
[396]. It was therefore hypothesised that SPA-1 mediated inhibition of Rap-1 (and hence 
ERK) could also play a part in the FcγRIIb-mediated downregulation of ERK in mature B 
cells.  Indeed,  SPA-1  mRNA  expression  was  found  to  be  strongly  reduced  by  BCR 
stimulation compared to levels observed in untreated cells at all timepoints analysed (3-24 
hours) (Fig.4.9B-i). Thus, assuming that Rap is linked to the activation of ERK in mature B 
cells, reduction of SPA-1 expression would increase the levels of active Rap and hence 
enhance ERK activation. According to this hypothesis, FcγRIIb-mediated signalling would 
most likely increase the expression of SPA-1 to further strengthen the inhibition of ERK 
activation.  Indeed,  it  was  observed  that  BCR/FcγRIIb  co-ligation  enhanced  SPA-1 
expression between 3 and 24 hours after stimulation (Fig.4.9B-ii). Taken together, these 
results  imply  that  FcγRIIb-signalling  induces  the  transcription  of  genes  which  encode 
negative regulators of the ERK cascade. This would allow the sustained repression of ERK 
signals ensuring the commitment of cells to growth arrest and apoptosis.   
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4.3.8 FcγRIIb-dependent regulation of Fas/FasL expression 
The results reported in section 4.3.2 suggested that caspase 8 is the major initiator 
caspase  involved  in  FcγRIIb-induced  apoptosis  of  mature  B  cells.  Caspase  8  is  best 
known, however, for its role in death receptor signalling. Thus, ligation of death receptors 
such as Fas leads to the assembly of the DISC complex which activates caspase 8 [615]. 
As B cells can express Fas and be killed by Fas/FasL-dependent apoptosis [284,616], it 
was therefore hypothesised that FcγRIIb-signalling might influence caspase 8 activation by 
enhancing Fas/FasL signalling by, for example, increasing Fas/FasL levels. Indeed, cell 
surface expression of Fas, detected by staining cells with a fluorochrome labelled anti-Fas 
antibody followed  by  FACS  analysis,  was found to  be  strongly  enhanced following  co-
ligation of the BCR/FcγRIIb both in terms of the percentage of cells expressing Fas as well 
as an increase in the fluorescence intensity. Fas expression was also increased by BCR 
stimulation at 24 h (Fig.4.10A) but on much fewer cells and the increase in fluorescence 
intensity was minimal when compared to the levels detected after BCR/FcγRIIb co-ligation 
(Fig.4.10A/B),  presumably  reflecting  the  low  percentage  of  BCR-stimulated  cells 
undergoing  apotosis  at  this  time  point  (Fig.4.2).  By  contrast,  no  expression  could  be 
detected in unstimulated cells, suggesting that these cells dying by neglect do not employ 
a  Fas/FasL  death  mechanism.  These  findings  correlated  with  protein  expression  data 
acquired  by  Western  Blotting.  Again,  expression  of  Fas  was  enhanced  upon  FcγRIIb-
signalling at 24 h but it was below the detection limit in samples from untreated as well as 
BCR-stimulated cells (Fig.4.10C). Upregulation of Fas by FcγRIIb-mediated signals and 
hence increased Fas-death receptor signalling could therefore participate in the initiation of 
apoptosis by activating caspase 8. 
Fas signalling is initiated by FasL binding. FasL can be expressed on other cells or 
on activated B cells themselves [617]. It is therefore possible that upregulation of FasL on 
B cells in our purified cultures could induce Fas/FasL-dependent apoptosis. Consistent 
with this, analysis of FasL protein expression showed that a decrease could be detected in 
BCR-stimulated cells when compared either to untreated cells or to cells in which FcγRIIb-
signalling  had  been  initiated  (Fig.4.10C).  Thus,  BCR  stimulation  not  only  seems  to 
increase Fas levels but also at the same time reduces FasL expression (Fig.4.10A and B). 
By contrast, in combination with the observed increase of Fas levels, the presence of high 
FasL expression in cells after BCR/FcγRIIb co-ligation would therefore allow the efficient 
induction  of  Fas/FasL-signalling  followed  by  initiation  of  apoptosis  in  a  caspase  8-
dependent fashion.  
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As  a  major  mechanism  of  modulating  Fas/FasL  signalling  involves  transcriptional 
regulation of their expression [618], Fas and FasL mRNA levels were analysed after BCR- 
or BCR/FcγRIIb co-ligation. Although Fas mRNA was generally found to be expressed at 
low levels at all timepoints analysed, the levels observed following co-ligation of BCR and 
FcγRIIb were higher than those seen in BCR-stimulated cells (Fig.4.11A). It was shown 
that protein levels of FasL had not changed much due to the different stimuli, at least at 24 
hours (Fig.4.10C). To confirm that there were not any major changes at the mRNA level 
either, FasL expression was also analysed by quantitative RT-PCR. Consistent with this, 
the overall levels of FasL were found to be even lower than those of Fas, at all timepoints 
analysed (Fig.4.12A). Untreated cells had no detectable levels of FasL mRNA at 7 and 20 
h, but slightly increased the expression at 24 h allowing detection of very low levels of 
FasL  mRNA  (Fig.4.12A).  BCR  stimulation  induced  detectable  levels  of  FasL  at  all 
timepoints analysed, whereas ligation of the BCR and FcγRIIb did so only at 20 and 24 h 
(Fig.4.12A). Thus, similar to the situation for Fas, regulation at the transcriptional level 
does not seem to be the major mechanism controlling the protein levels of FasL in these 
cells.  
To further dissect the role of caspase 8 in FcγRIIb-mediated cell death, the influence 
of caspase 8 inhibition on the BCR/FcγRIIb-mediated increase of Fas/FasL expression 
was  analysed.  Perhaps  unsurprisingly,  given  that  caspase  8  is  located  downstream  of 
Fas/FasL signalling in the typical death receptor pathway, the lack of caspase 8 activity did 
not reduce the FcγRIIb-induced upregulation of Fas protein, detected by FACS staining or 
Western Blotting (Fig.4.10B/C). Moreover, caspase 8 inhibition also did not change the 
protein expression of FasL in combination with any of the stimulations used (Fig.4.10C). 
Similarly,  caspase  8  inhibition  also  did  not  alter  the  expression  of  Fas  or  FasL  at  the 
mRNA level at 24 h (Fig.4.11/12B). In summary, Fas and FasL expression were regulated 
in a caspase 8-independent manner at both the mRNA and protein levels downstream of 
FcγRIIb-signalling. 
 
4.3.9 The FcγRIIb-mediated apoptosis response is affected in B cells 
from MRL/MpJ-Fas
lpr mice 
MRL/MpJ-Fas
lpr  mice  are  a  widely  used  animal  model  for  SLE  [619].  They  are 
homozygous for a spontaneous mutation (Fas
lpr) in the Fas gene reducing the expression 
of  Fas  and  hence  show  systemic  autoimmunity,  massive  lymphadenopathy  associated 
with  aberrant  proliferation  of T cells, arthritis,  and immune  complex glomerulonephritis. 
Starting at about three months of age, levels of circulating immune complexes rise greatly 
in the MRL/MpJ-Fas
lpr mice but not in the MRL/MpJ parental strain [620]. The MRL/MpJ- 
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Fas
lpr  model  therefore  provides  the  opportunity  to  analyse  the  role  of  Fas-mediated 
apoptosis downstream of FcγRIIb-signalling in B cells.  
B cells from MRL/MpJ-Fas
lpr mice of varying age (9, 12, 16, 20 weeks old) were 
found to show a reduced inhibition of proliferation upon BCR/FcγRIIb co-ligation compared 
to cells from MRL/Mp mice or mice on Balb/C background (Fig.4.13A). This reduction of 
growth arrest was accompanied by a reduced ability of B cells from MRL/MpJ-Fas
lpr mice 
to undergo apoptosis upon cross-linking of BCR/FcγRIIb (Fig.4.13B) and examination of 
the changes in the MMP upon BCR/FcγRIIb co-ligation showed that the reduced increase 
in apoptosis observed in B cells from MRL/MpJ-Fas
lpr was at least in part due to failed 
induction of MMP dissipation. Thus, an increased percentage of B cells from MRL/MpJ-
Fas
lpr mice displayed a high MMP after cross-linking of the BCR and FcγRIIb compared to 
B cells from MRL/MpJ mice (Fig.4.13C).  
Overall,  these  experiments  indicate  that  B  cells  defective  for  Fas-signalling  have 
impaired  FcγRIIb-dependent  inhibitory  responses.  This  implies  that  Fas/FasL-mediated 
signals play a role in FcγRIIb-induced apoptosis.  
 
4.3.10  Inhibition of Fas/FasL signalling reduces FcγRIIb-
mediated apoptosis 
Given that Fas/FasL expression is differentially regulated by mitogenic BCR- and 
FcγRIIb-mediated negative signalling and that impaired expression of Fas, as observed in 
MRL/MpJ-Fas
lpr  mice,  was  found  to  impact  on  the  ability  of  B  cells  to  be  inhibited  by 
FcγRIIb-dependent  signals,  these  data  strongly  suggested  that  FcγRIIb-mediated 
apoptosis is linked to Fas/FasL signalling. To more directly prove a connection between 
these two events, Fas/FasL signalling was inhibited with blocking anti-FasL antibodies, 
which  act  to  interfere  with  Fas/FasL  binding,  and  the  effects  on  FcγRIIb-mediated 
apoptosis analysed. Consistent with the above results, it was shown that inhibition of Fas-
signalling  decreased  the  percentage  of  subdiploid  cells  in  BCR/FcγRIIb  stimulated 
samples at 24 h (Fig.4.13D). Both concentrations of the blocking antibody tested were 
shown to be effective and the reduction of apoptosis was not a non-specific antibody-
effect, as treatment with isotype control antibodies did not affect the response (Fig.4.13D). 
These preliminary findings suggest that upregulation of Fas followed by enhanced Fas-
signalling and downstream activation of caspase 8 is indeed one of the major pathways 
inducing apoptosis downstream of BCR/FcγRIIb co-ligation. 
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4.3.11  Inhibitory FcγRIIb signalling affects proliferation of 
human peripheral B cells 
Although  the  important  role  of  FcγRIIb-mediated  induction  of  growth  arrest  and 
apoptosis in the homeostatic regulation of B cell activation has been widely established in 
the  murine  immune  system  [73,576],  the  investigation  of  FcγRIIb-associated  inhibitory 
mechanisms in human B cells has been less  extensive. However, there are promising 
findings that FcγRIIb-mediated inhibition of BCR signalling is defective in B cells from SLE 
patients [587] and that plasmablasts and memory B cells from SLE patients express lower 
levels of FcγRIIb [588]. Moreover, a polymorphism of FcγRIIb which reduces its signalling 
capacity  has  been  found  to  be  associated  with  SLE  in  some  racial  groups  [589]. 
Nevertheless, the effects of such reduced expression or signalling efficiency of FcγRIIb on 
B  cell  proliferation  has  not  been  examined  in  any  of  these  studies.  Thus,  functional 
analysis of the FcγRIIb-mediated inhibitory response in human B cells from RA and SLE 
patients would therefore give further insight into potential defects in tolerance checkpoints 
in autoimmunity. It was therefore decided to compare the responses of peripheral B cells 
from healthy individuals and patients with RA and SLE, as both of these diseases involve 
autoantibody production and activation of autoreactive B cells. Hence, dysregulated B cell 
activation might be one of the underlying causes of both of these diseases. 
Firstly, the proliferative capacity of human B cells (derived from peripheral blood) 
stimulated  via  the  BCR  or  following  co-ligation  of  FcγRIIb  was  assessed.  As  with  the 
murine system, cells were treated with F(ab)2 fragments of anti-human IgG+IgM antibodies 
to cross-link the BCR (designated BCR in the figures) or with intact anti-human IgG+IgM 
antibodies to co-ligate the BCR and FcγRIIb (designated BCR + FcγRIIb in the figures). 
Moreover,  the  inhibitory  effect  of  FcγRIIb-mediated  signalling  upon  mitogenic  BCR 
stimulation was tested by treating cells with F(ab)2 anti-human IgG+IgM in combination 
with  intact  anti-human  IgG+IgM  (designated  mitogenic  BCR+  FcγRIIb  in  the  figures). 
Finally, unstimulated purified B cells (designated None in the figures) were included in the 
experiments. Similarly to murine B cells, unstimulated human B cells do not survive well in 
culture and slowly die by neglect. 
CFSE staining and DNA synthesis were the methods chosen to detect proliferation in 
cultures.  The  comparison  of  [
3H]-labeled  thymidine  incorporation  assays  and  CFSE 
staining  indicated,  however,  that  CFSE  staining  was  not  a  suitable  method  to  detect 
proliferation  of  purified  human  B  cells  as  the  data  showed  that  the  intensity  of  CFSE 
staining of purified B cells declined rapidly, having decreased within 4 hours even in the 
absence of stimuli suggesting that the cells were leaky to CFSE (Fig.4.14B-D). To confirm 
that CFSE analysis was indeed not a suitable assay to detect proliferation in such B cell  
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cultures, multiple experiments varying the incubation times, purification methods, stimuli 
and concentrations of antibodies, as well as FCS concentrations used for culture were 
carried out (data not shown). In confirmation with the data shown in Figure 4.14 these 
experiments yielded similar results, with no changes detectable between untreated cells or 
cells treated with different stimuli. By contrast, analysis of DNA synthesis by [
3H] thymidine 
incorporation indicated that BCR-stimulated cells did indeed proliferate significantly more 
than untreated cells at 48 hours (Fig.4.14A), indicating that this was the best assay to 
screen for FcγRIIb-mediated growth arrest in CD19
+-purified human B cells from the blood. 
Thus,  following  activation  of  BCR  signalling,  DNA  synthesis  increased  whereas  it  was 
found to be reduced as a result of FcγRIIb/BCR co-ligation (Fig.4.14A). This confirmed that 
human B cells, similar to murine B cells, are sensitive to FcγRIIb-mediated growth arrest.  
Further preliminary experiments were carried out in order to examine how long the 
purified  human  B  cells  could  be  cultured  before  their  proliferative  response  started  to 
decline,  and  to  determine  the  optimal  timepoint  to  detect  the FcγRIIb-mediated growth 
arrest response. To this end, purified human B cells were stimulated as described before 
with BCR and BCR/FcγRIIb cross-linking antibodies, and the proliferation was measured 
after 48, 72 and 96 hours. Increased proliferation following BCR and BCR/FcγRIIb cross-
linking  could  be  detected  at  all  timepoints  (Fig.4.14A-ii).  The  inhibitory  effect  due  to 
simultaneous  BCR  and  FcγRIIb  activation  is  most  pronounced  at  48  hours,  but  still 
detectable after 72 hours (Fig.4.14A-ii). Due to a decline of BCR-mediated proliferation at 
96 hours there was no difference between the level of DNA synthesis between BCR and 
BCR/FcγRIIb stimulated cells at this timepoint. In consideration of these results, it was 
decided to routinely analyse B cell responses 48 hours after stimulation. 
 
4.3.12  Correlation between growth inhibition, mitochondrial 
membrane potential and cell cycle status of human B cells 
It has been shown in murine B cells that FcγRIIb-signalling not only induces growth 
arrest but also apoptosis [597]. Thus, to directly assess any correlation between growth 
inhibition  and  apoptosis  in  human  B  cells,  their  cell  cycle  status  after  BCR-ligation  or 
BCR/FcγRIIb co-ligation  was  examined.  Rather  surprisingly, FcγRIIb  co-ligation did  not 
substantially increase the percentage of cells with subdiploid DNA content or arrested in 
G0/G1 relative to the levels observed in BCR-stimulated cells at this time point (Fig.4.15-
ii).  These  effects  were  observed  in  a  healthy  control  (Fig.4.15A)  as  well  as  three  RA 
patients  (Fig.4.15B)  whose  B  cells  displayed  low,  but  detectable  levels  of  FcγRIIb-
mediated inhibition of BCR-induced DNA synthesis (Fig.4.15-i). Moreover, although the 
FcγRIIb-mediated reduction of cells observed in the mitotic phases of the cell cycle (G2/M  
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and S phase) fitted well with the growth arrest indicated by the DNA synthesis studies 
(Fig.4.15-i/iii), the percentage of B cells, particularly those of patients, cycling at 48 h was 
very low. This suggests that differential effects between the control and patient groups 
might be masked by culture exhaustion as indicated by the high levels of G0/G1 arrest and 
apoptosis in response to both mitogenic and negative feedback stimuli. Cell cycle analysis 
by  PI  staining  of  DNA  content  therefore  represents  a  potentially  useful  tool  for  the 
examination  of  proliferation/apoptosis  in  human  B  cells,  but  it  should  preferentially  be 
assessed at a range of time points and used in combination with additional methods such 
as DNA synthesis assays. 
Apoptosis initiated by FcγRIIb-signalling has been shown to induce the dissipation of 
the  MMP  in  murine  B  cells.  To  test  whether  mitochondrial  disintegration  was  also  a 
hallmark of FcγRIIb-mediated apoptosis in human B cells, their MMP was examined by 
DiOC6 staining of mitochondria. This showed a trend towards a reduction of cells with high 
MMP  and  a  corresponding  increase  of  cells  with  low  MMP  upon  FcγRIIb-signalling 
(Fig.4.15-iv). Collectively, it was shown that although BCR/FcγRIIb co-ligation on human B 
cells initiates similar functional responses as those observed with murine B cells, such as 
reduced proliferation, detected as a decrease of cells in the mitotic phases of the cell cycle 
as well as decreased DNA synthesis, these effects are much less pronounced. Moreover, 
it seems that disruption of the MMP and consequent apoptosis might play only a minor role 
in  FcγRIIb-mediated  negative  feedback  inhibition  of  human  peripheral  B  cells.  Rather 
surprisingly, it appeared that the patient samples were, if anything, more susceptible to 
growth  arrest  and  apoptosis  in  response  to  both  mitogenic  and  negative  feedback 
signalling, suggesting that such circulating cells may not be directly comparable to murine 
splenic B cells. 
 
4.3.13  Some patients with RA and SLE show a defect in FcγRIIb 
inhibitory signalling 
Having  established  that  FcγRIIb-mediated  signalling  inhibited  BCR-driven 
proliferation of purified human B cells from a healthy control subject (Fig.4.14A), it was 
investigated whether B cells from patients with autoimmune disease are refractory to such 
homeostatic regulation. Analysis of B cell responses from a panel of patients and normal 
subjects showed that there was no significant difference between the responses of control 
cells and those derived from patients with RA or SLE. However, closer analysis suggested 
that whilst the B cells from all the healthy controls showed normal inhibitory responses, 
albeit of varying strength, a small percentage of RA and SLE patients showed decreased 
FcγRIIb-mediated  inhibitory  capacity  (Fig.4.16).  Some  patients  whose  samples  were  
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analysed for inhibition of growth arrest through FcγRIIb-mediated signalling did not suffer 
from  RA  or  SLE,  but  from  other  autoimmune  disease  or  a  combination  of  diseases 
including Connective tissue disease, Sjogrens’s syndrome or Psoriatic arthritis (Fig.4.16). 
The data acquired from these patients was therefore grouped separately. Similar to the 
other patient cohorts, no significant differences were found between the responses of B 
cells from healthy controls and patients, again confirming that reduced FcγRIIb-mediated 
inhibitory responses are not a general feature of autoimmune disease. 
Although it was possible that the inhibitory defects observed in a small percentage of 
RA and SLE patients might reflect a long lasting defect, it was also possible that this defect 
might be due to their specific immune-status at the time of analysis. Thus, the B cells of 
two patients who showed defective inhibitory responses were tested again six months later 
to determine whether the refractoriness of their B cells to FcγRIIb-mediated signalling was 
indicative of a stable phenotype. However, whilst the B cells of one of the RA patients 
were again refractory to inhibition (Fig.4.17A), the B cells from the other patient with RA 
responded  more  normally  (Fig.4.17B).  These  differential  responses  indicate  that  the 
responsiveness of B cells to inhibitory signaling by FcγRIIb might indeed change over time 
due to as yet unidentified influences. Thus, to confirm any correlation between immune 
status or different treatments and effective FcγRIIb-mediated inhibition of B cells, a study 
with more patients and more detailed information on the status of the patient would be 
needed. 
 
4.3.14  Patients with autoimmune disease display changes in 
the expression of FcγRIIb isoforms 
Human FcγRIIb encodes three transcripts, FcγRIIb1, FcγRIIb2 and FcγRIIb3, which 
arise by alternative splicing mechanisms. FcγRIIb isoforms are widely expressed by cells 
of haematopoetic origin, with preferential expression of FcγRIIb1 on B cells and FcγRIIb2 
on myeloid cells. The mature forms of FcγRIIb1 and FcγRIIb3 are identical but they differ 
in  their  peptide  leader  sequences  [621].  FcγRIIb3  lacks  the  information  required  for 
surface  expression,  encoded  on  the  S2  exon,  and  is  thus  not  expressed.  FcγRIIb2  is 
capable  of  mediating  rapid  IgG  endocytosis  by  means  of  clathrin-coated  vesicles. 
However, due to an insertion of 19 amino acids in the cytoplasmic tail, FcγRIIb1 is not able 
to mediate receptor internalisation as the insertion disturbs the cytoskeletal attachment 
domain (Fig.4.18) [622].  
Thus, FcγRIIb1 and FcγRIIb2 expression dictates the threshold for BCR signalling 
whereas FcγRIIb2 may be the isoform predominantly utilised by B cells for antigen uptake 
and processing. By downregulating expression of FcγRIIb1, whilst keeping FcγRIIb2 levels  
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constant,  an  autoreactive  B  cell  might  remain  responsive  to  stimulation  by  immune 
complexes and costimulatory T cell help. CD40 ligand-expressing, activated T cells, in 
conjunction  with  T  cell  derived  IL-4,  will  induce  proliferation,  antibody  production  and 
isotype switching by B cells in addition to overcoming the inhibitory effects of FcγRIIb1.  
Examination of FcγRIIb1/2 mRNA expression levels in PBMCs from healthy controls 
as  well  as  patients  suffering  from  RA  or  SLE  showed  that  the  mRNA  levels  of  both 
FcγRIIb1  and  2  are  significantly  reduced  in  PBMCs  from  RA,  but  not  SLE,  patients 
compared to healthy controls (Fig.4.19). This suggests that, as indicated by the B cell 
functional studies, the B cells from at least some patients may be refractory to FcγRIIb-
mediated  negative  feedback  inhibition.  Moreover,  analysis  of  the  ratio  of 
FcγRIIb1/FcγRIIb2 levels in control and patient cohorts indicated that the FcγRIIb1/2 RNA 
expression ratio is significantly decreased in both the RA and SLE patient groups relative 
to control subjects. This might be important, as the two isoforms differ in their capacity to 
endocytose bound IgG and these data might indicate that the cells from patients are more 
efficient at auto-antigen-presentation and T cell activation than those of healthy individuals 
(Fig.4.19E/F) [623].  
This  analysis  of  FcγRIIb1/2  expression  levels  was  carried  out  on  PBMCs  which 
contain multiple cell types such as B and T cells, monocytes as well as natural killer cells. 
The  observed  differences  of  FcγRIIb1/2  expression  levels  and  ratio  between  healthy 
controls and patients might therefore theoretically be due to changes in any of these cell 
types.  Thus,  to  assess  the  overall  contribution  of  FcγRIIb1/2  expressed  by  B  cells, 
preliminary experiments were carried out to determine the transcript levels in different cell 
preparations. Purification of B cells enriched the levels of FcγRIIb1 or FcγRIIb2 transcripts 
detected 50- or 20-fold compared to levels found in non-B cells (PBMCs after B cells were 
negatively selected), respectively (Fig.4.20A). Indeed, and as expected, CD3
+-purified T 
cells were found to express negligible levels of either FcγRIIb1 or FcγRIIb2 (Fig.4.20B). 
Interestingly,  purified  B  cells  displayed  a  different  pattern  of  FcγRIIb1/2  expression 
compared  to  PBMCs  or  non-B  cells,  as  they  expressed  higher  levels  of  FcγRIIb1 
compared  to  FcγRIIb2  (Fig.4.20B).  The  recent  development  of  anti-human  FcγRIIb-
specific antibodies made it possible to also detect the protein expression of FcγRIIb by 
FACS. Thus, it was shown that around 17% of human PBMCs express FcγRIIb on their 
surface and that almost all B cells express it at relatively high levels (Fig.4.20C). CD11b-
positive cells which includes monocytic cells as well as granulocytes, natural killer cells 
and B-1 B cells are the other major cell class expressing FcγRIIb on the surface, albeit at 
generally  lower  levels  than  B cells (Fig.4.20C).  Most  of  the  CD11b/FcγRIIb-expressing 
cells  were  found  to  be  relatively  large  cells  judging  by  their  forward  and  side  scatter  
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characteristics  on  the  FACS  (data  not  shown),  and  therefore  most  likely  represent 
monocytes  or  granulocytes.  A  small  proportion  of  the  cells  though  is  smaller  and  less 
granular and hence might be natural killer or B-1 B cells. It would therefore be of interest to 
carry out further studies examining the contribution of the different cell types in peripheral 
blood  towards  the  significant  change  of  isoform  expression  observed  in  SLE  and  RA 
patients.  
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4.4  Discussion  
 
During B cell development harmful self-reactive clones are deleted at various stages 
of  development,  with  negative  selection  of  immature  B  cells  in  the  bone  marrow 
representing a major checkpoint. Nevertheless, a considerable proportion of autoreactive 
cells escapes this mechanism and is released into the periphery. Further checkpoints in 
the periphery therefore ensure the removal or inactivation of these cells at later stages. 
FcγRIIb is an inhibitory receptor which influences the threshold for B cell activation by 
transducing negative signals. This receptor is important in sustaining homeostasis of B 
cells ensuring that activated B cells are removed from the system in a timely manner once 
an infection is under control, hence avoiding an overreaction of the immune system. Due 
to  this  function,  FcγRIIb  seems  to  play  an  important  regulatory  function  in  preventing 
autoimmune  disease  by  reducing  activation  of  a  large  pool  of  potentially  weakly  self-
reactive B cells. 
 
4.4.1 FcγRIIb-mediated apoptosis is caspase 8 dependent 
FcγRIIb signalling plays an important role in the downregulation of B cell responses 
by negatively regulating BCR-dependent proliferation in mature B cells (Fig.4.2). Besides 
growth arrest, BCR/FcγRIIb co-ligation was also shown to induce apoptosis [624] which 
was  found  to  lead  to  the  disruption  of  the mitochondrial  membrane  potential  (Fig.4.2). 
Previous  findings  in  this  laboratory  indicated  that  the  apoptotic  pathway  induced  by 
FcγRIIb-mediated signals led to the release of cytochrome C from mitochondria as well as 
upregulation  of  pro-apoptotic  Bcl-2  family  members  [309].  However,  activation  of  the 
classical  executioner  protease  of  the  intrinsic  pathway,  caspase  3,  was  only  slightly 
increased  upon  cross-linking  of  BCR/FcγRIIb,  and  inhibition  of  this  protease  had  only 
marginal effects on the levels of apoptosis observed suggesting that caspase 3 activation 
was not sufficient for such cell death. Likewise, whilst inhibition of calpain or cathepsin B 
executioner  protease  activities  also  failed  to  block  FcγRIIb-mediated  apoptosis,  by 
contrast, combined inhibition of executioner caspase, calpain and cathepsin B activities 
prevented FcγRIIb-mediated apoptosis [309]. It was therefore unlikely that the caspase-
dependent intrinsical mitochondrial pathway was the only contributor to FcγRIIb-mediated 
apoptosis of B cells. As another major pathway of apoptosis is the caspase 8-mediated 
death receptor signalling pathway, it was decided to examine the role of caspase 8 in 
FcγRIIb-dependent apoptosis. The results presented in this chapter showed that in mature 
B  cells  caspase  8  is  indeed  crucial  for  the  induction  of  cell  death  downstream  of 
BCR/FcγRIIb co-ligation, as inhibition of this initiator caspase reduced the percentage of  
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cells undergoing apoptosis (Fig.4.3). Although dissipation of the MMP was a hallmark of 
apoptosis  observed  in  mature  B  cells  due  to  cross-linking  of  the  BCR  and  FcγRIIb, 
inhibition of caspase 8 did not rescue the cells from disruption of the MMP (Fig. 4.3). 
Activation of caspase 8 might therefore be downstream of the disruption of mitochondrial 
function or indeed represent a parallel contributing apoptotic pathway. 
The  precise  signalling  events  downstream  of  caspase  8  in  FcγRIIb-mediated 
apoptosis  have  not  been  elucidated  yet,  but  the  major  effects  of  caspase  8  inhibition 
suggested  that  caspase  8  might  orchestrate  the  activation  of  multiple  executioner 
proteases  such  as  caspase  3,  calpain  and  cathepsin  B.  Caspase  3  is  a  well  known 
substrate for caspase 8, and caspase 3 activation occurs downstream of caspase 8 in 
various models of apoptosis [607]. Previous findings showed that caspase 3 was slightly 
upregulated  by  BCR/FcγRIIb  co-ligation  [309],  but  the  level  of  caspase  activation,  as 
determined by the binding of a pan-caspase reagent, was found not to be significantly 
changed by caspase 8 inhibition (Fig.4.6). Although these data suggest that caspase 8 is 
not  essential  for  the  FcγRIIb-mediated  activation  of  these  caspases,  changes  in  the 
executioner caspases 3/6 might be masked by other caspases such as caspase 1/2. 
There is some evidence in the literature that cathepsin B and calpain could also be 
activated downstream of caspase 8. For example, caspase 8 dependent cleavage of Bid 
has been found to be involved in a TNFα-dependent apoptosis pathway which induces 
lysosomal permeabilisation and consequent release of cathepsin B in a rat hepatoma cell 
line [625]. Moreover, in a cellular model for Alzheimer’s disease involving Amyloid beta 
peptide-dependent cell death of the neuronal cell line PC12, calpastatin was cleaved by 
caspase 8, leading to calpain activation [626]. Similarly, calpains were found to be involved 
in Fas-dependent apoptosis of CD8
+ T cells [627] and as caspase 8 activation is known to 
be downstream of Fas signalling, it therefore suggests itself that calpain activation might 
be caspase 8-dependent in this system. The cascades involved in apoptosis are further 
complicated by the fact that calpains and cathepsin can also be part of positive feedback 
loops in that both enzymes have been shown to activate caspases such as capase 8 [628] 
whilst caspase 3 and 7 can in turn cleave and inactivate the calpain inhibitor calpastatin 
[629,630]. Caspase 8 could therefore represent the major switch potentially integrating all 
these signals. 
 
4.4.2 FcγRIIb-signalling leads to p53 upregulation and translocation 
Interestingly, p53 expression was found to be enhanced at both the transcriptional 
and  protein  levels  upon  BCR/FcγRIIb  co-ligation  (Fig.4.5).  p53  is  a  major  regulator  of 
growth arrest and apoptosis acting predominantly as a transcription factor, for example, to  
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increase gene expression of p21, Bax or Fas [485,631]. However, p53 can also induce 
apoptosis by translocating to the cytoplasm or the mitochondria where it interacts with Bcl-
2  family  members  [486].  It  is  therefore  interesting  that  p53  was  mainly  found  in  the 
cytoplasm  of  cells  following  co-ligation  of  the  BCR  and  FcγRIIb  and  that  caspase  8 
inhibition reduced the levels of p53 found in the cytoplasm by seemingly sequestering it in 
the nucleus (Fig.4.5C/D). Caspase 8 might therefore be involved in the regulation of p53 
localisation  by,  for  example,  degrading  proteins  involved  in  the  nuclear  retention 
mechanism of p53. Hence, this would allow p53 to localise to the cytoplasm where it could 
potentially  bind  to  and  activate  pro-apoptotic  Bcl-2  members  to  induce  mitochondrial 
destabilisation  and  drive  FcγRIIb-mediated,  p53-dependent  apoptosis  of  B  cells.  There 
have been many studies examining the regulation of caspase 8 by p53. For example, p53 
can upregulate Fas expression and thereby potentially activate caspase 8 [631]. Moreover, 
in tumor cells p53 was found to directly increase caspase 8 mRNA and protein levels, 
thereby  rendering  these  cells  sensitive  to  induction  of  apoptosis  [632].  Additionally,  a 
cleavage product of caspase 8 (DEDa) can induce p53-dependent transcription of caspase 
8 thereby creating a positive feedback loop [633]. On the other hand, caspase 8-mediated 
cleavage of Bid might be one of the mechanisms involved in p53-dependent apoptosis 
[634]. Moreover, caspase 8 not only seems to play a role in p53-mediated apoptosis that is 
dependent on the transcription factor-function of p53, but it has also been found to be 
involved in a transcription-independent form of p53-mediated apoptosis [635]. Collectively, 
these studies show that caspase 8 activity can be regulated by p53 and hence plays an 
important role in p53-mediated apoptotic pathways in some systems.  
As mentioned above, a major function of p53 is that of a transcription factor. Besides 
the above mentioned targets, p53 can also upregulate Noxa and Puma, two pro-apoptotic 
Bcl-2  family  members  [484].  BCR/FcγRIIb  co-ligation  increased  Noxa  protein  levels 
(Fig.4.6),  implying  that  p53  could  promote  FcγRIIb-mediated  apoptosis  by  the  more 
classical  transcription-dependent,  as  well  as  transcription-independent,  mechanisms.  In 
addition to regulating the apoptotic response downstream of BCR/FcγRIIb co-ligation, p53 
could  also  potentially  influence  FcγRIIb-mediated  growth  arrest.  For  example,  PAC-1 
which can de-activate ERK was found to be transcriptionally upregulated by BCR/FcγRIIb 
co-ligation (Fig.4.9A), and whilst the mechanisms responsible for this increase are as yet 
unknown, p53 has been shown to regulate PAC-1 expression [369]. ERK itself might be 
involved in the regulation of p53, as it has been shown by this group that p53 activity is 
increased due to the pharmacological inhibition of ERK [309]. p53 therefore represents an 
interesting candidate for the regulation of multiple pathways involved in FcγRIIb-mediated  
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growth  arrest  and  apoptosis  but  further  studies  are  needed  to  define  the  connection 
between caspase 8 and p53. 
 
4.4.3 Caspase 8 is not involved in FcγRIIb-dependent growth arrest 
response  
Previous studies in this laboratory have identified ERK as an important regulator of 
proliferation  and  apoptosis  in  B  cells  [310].  In  mature  B  cells  ERK  was  shown  to  be 
induced by mitogenic signals through the BCR and this activation was found to be reduced 
by simultaneous FcγRIIb-signalling [623]. Moreover, inhibition of ERK mimicked the growth 
arrest-inducing effects of FcγRIIb [309]. Many signalling events leading to decreased ERK 
activation downstream of BCR/FcγRIIb co-ligation have been identified. These include the 
direct competition of SHIP for Shc binding and hence reduced Ras activation, as well as 
events further downstream such as PAC-1 recruitment [209,213,614,636]. In this study we 
identified  further  potential  regulatory  events,  namely  the  transcriptional  upregulation  of 
PAC-1 and SPA-1 (Fig.4.9). PAC-1 can directly inactivate ERK by dephosphorylation [368] 
and SPA-1 could contribute to decreased ERK levels through the inhibition of the Rap/B-
Raf pathway. The FcγRIIb-dependent increase of both of these molecules could therefore 
influence growth arrest by downregulation of ERK activation. 
This  study  has  shown  that  caspase  8  is  a  major  regulator  of  FcγRIIb-mediated 
apoptosis. Even though multiple caspases, including caspase 8, have been implicated in 
the regulation of apoptosis-independent events such as cell cycle entry/progression and 
hence  proliferation  [637]  the  results  obtained  in  this  study  did  not  support  a  role  for 
caspase  8  in  FcγRIIb-mediated  growth  arrest.  Thus,  inhibition  of  caspase  8  did  not 
influence the levels of DNA synthesis of either untreated, BCR- or BCR/FcγRIIb-stimulated 
cells (Fig.4.7). Moreover, although caspase 8 inhibition efficiently prevented apoptosis, it 
could not re-instate cycling in BCR/FcγRIIb co-ligated cells leading to an accumulation of 
cells  arrested  in G1  phase  (Fig.4.7).  Another  sign  of growth  arrest  is  the  reduction  of 
positive regulators  of  the  cell  cycle  and,  in  confirmation with  the  previously  mentioned 
results, caspase 8 inhibition was not able to prevent the FcγRIIb-mediated downregulation 
of c-Myc or hyperphosphorylated Rb levels. FcγRIIb-signalling therefore seems to initiate 
separate  signalling  pathways  regulating  apoptosis  (caspase  8-dependent)  and  growth 
arrest (caspase 8-independent).  
 
4.4.4 FcγRIIb-mediated apoptosis depends on Fas/FasL signalling 
Caspase 8 is known to be activated downstream of death receptors such as Fas 
[282]. Thus, as it was shown in this study that caspase 8 is crucial for FcγRIIb-mediated  
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apoptosis,  Fas/FasL  signalling  provided  an  interesting  candidate  for  the  upstream 
regulation  of  caspase  8.  Indeed,  preliminary  results  indicated  that  Fas  and  to  a  lower 
extent FasL are upregulated due to BCR/FcγRIIb ligation at both the RNA and protein level 
(Fig.4.10-12). Subsequently, FcγRIIb-mediated apoptosis was found to be reduced due to 
inhibition of Fas signalling with anti-FasL blocking antibodies confirming the involvement of 
this death receptor cascade (Fig.4.13D). Thus, FcγRIIb-signalling might upregulate Fas 
which, due to the presence of FasL in these B cells, can induce death receptor signalling 
and hence caspase 8 activation. 
Further support for this hypothesis comes from the MRL/MpJ-Fas
lpr mouse model. 
These  mice  are  on  an  autoimmune  background  (MRL/MpJ  strain)  and  developed  a 
spontaneous mutation in the gene encoding Fas and hence do not express normal levels 
of Fas. Subsequently, Fas/FasL induced apoptosis is defective in these mice leading to 
the accumulation of immune cells and development of lupus-like disease [638]. MRL/MpJ-
Fas
lpr mice express high levels of self-reactive pathogenic antibodies such as anti-DNA 
antibodies  that  contribute  to  the  disease  by  forming  immune  complexes  which  can  be 
deposited in the kidney and hence have the potential to induce glomerunephritis [638]. The 
massive  production  of  self-reactive  antibodies  indicates a  breach  of  tolerance  in  these 
mice,  allowing  autoreactive  B  cells  to  be  activated.  Defects  in  FcγRIIb-mediated 
homeostasis of activated B cells could therefore potentially play a role in the accumulation 
of self-reactive cells in this model. Indeed, purified splenic B cells from MRL/MpJ-Fas
lpr 
mice displayed reduced levels of inhibition of DNA synthesis upon BCR/FcγRIIb co-ligation 
indicating a defect in the growth arrest response of these mice (Fig.4.13A). Moreover, their 
apoptotic response also seemed to be reduced as indicated by reduced percentages of 
subdiploid cells as well as increased numbers of cells with high MMP (Fig.4.13B/C). The 
reduced potential of these cells to undergo FcγRIIb-mediated apoptosis might be due to 
the inability of these cells to signal through Fas/FasL due to the disruptive mutation in the 
Fas gene. It can therefore be hypothesised that the lack of Fas expression in B cells from 
MRL/MpJ-Fas
lpr mice affects their ability to apoptose due to inhibitory signals downstream 
of BCR/FcγRIIb co-ligation, hence making them insensitive to negative regulation. This in 
turn could lead to an increase of activated B cells, including self-reactive clones. Fas/FasL 
signalling  might  therefore  be  an  important  part  of  the  signals  controlling  FcγRIIb-
dependent homeostatic regulation of mature B cells in these mice.  
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4.4.5 A small proportion of B cells from RA and SLE patients display 
a defect in FcγRIIb-mediated growth arrest 
Homeostatic  regulation  of  B  cells  is  crucial  in  the  human  immune  system  as 
dysregulated activation of weakly self-reactive cells has been implicated in the pathology 
of  autoimmune  diseases  such  as  SLE  and  RA.  The  important  role  of  FcγRIIb  in  the 
regulation of B cell responses and hence autoimmunity has been firmly established in the 
murine system [73]. Dissection of the role of FcγRIIb in the human system is obviously 
more  complicated.  There  have  been  few  studies  examining  the  connection  between 
dysregulation  of  FcγRIIb-dependent  responses  and  autoimmune  disease  in  humans. 
However, it was shown that FcγRIIb-expression is indeed reduced on plasma and memory 
B cells from SLE patients [588]. Nevertheless, these studies did not address the functional 
outcome of these lower FcγRIIb levels. Here it was investigated whether mature B cells 
from patients with autoimmune disease (RA and SLE) displayed defective growth arrest 
responses upon BCR/FcγRIIb co-ligation. Generally, the FcγRIIb-mediated growth arrest 
response  of  human  B  cells  did  not  seem  to  be  as  strong  as  that  of  murine  B  cells 
(Fig.4.14).  This  might  be  due  to  the  expression  of  FcγRIIa  in  the  human  system,  an 
activating Fcγ receptor which is not present in mice [576]. Human B cells might therefore 
express  both  FcγRIIa  and  FcγRIIb  which  would  compete  for  binding  to  IgG  and  thus, 
positive  signals  through  FcγRIIa  would  reduce  the  inhibitory  FcγRIIb-response.  Even 
though the growth arrest response in human B cells was not as pronounced as in the 
murine system, B cells from healthy individuals all displayed an intact inhibitory response 
upon BCR/FcγRIIb co-ligation (Fig.4.16). 
Interestingly,  a  small  proportion  of  patients  displayed  little  or  no  inhibition  of 
proliferation upon FcγRIIb ligation (Fig.4.16). The differences between the healthy control 
and  RA  or  SLE  cohorts  were  not  statistically  significant though, due to  the majority  of 
patients still displaying a normal response. Thus although FcγRIIb-mediated regulation of 
proliferation of mature peripheral B cells might not be a major disease-driving mechanism 
in most patients, it might contribute to the disease in some. It remains to be seen if more 
detailed  analysis  of  responses  of  plasma  cells  and  memory  cells,  the  developmental 
stages which were found to display reduced expression of FcγRIIb in SLE patients, would 
render clearer results as the percentage of these cells in B cells purified from blood is very 
low,  and  any  changes  in  their  response  to  inhibitory  signalling  might  therefore  be 
overlooked due to their small numbers. 
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4.4.6 Patients with autoimmune disease display changed FcγRIIb-
isoform expression pattern 
The  B  cell  numbers  achieved  by  purification  from  patient  blood  were  usually  not 
sufficient to carry out functional studies as well as analyse FcγRIIb protein levels by FACS 
or isolate RNA to examine FcγRIIb mRNA expression. This would have been interesting to 
allow  the  correlation  between  reduced  FcγRIIb-mediated  inhibitory  responses  and 
expression of the receptor. Moreover, changes in the expression of the different FcγRIIb 
isoforms, FcγRIIb1 and FcγRIIb2, could potentially influence the response of B cells due to 
the  lack  of  endocytic  capacity  of  FcγRIIb1  [622].  Thus,  higher  expression  of  FcγRIIb2 
could increase antigen uptake and hence presentation to T cells. Therefore, to gain some 
insight into the regulation of FcγRIIb in peripheral immune cells, transcriptional regulation 
of this receptor was analysed in PBMCs from patients and healthy controls, as analysis in 
purified B cells from a bigger panel of patients was not feasible. Interestingly, expression 
of  both  FcγRIIb1  and  FcγRIIb2  was  found  to  be  downregulated  in  PBMCs  from  RA 
patients (Fig.4.19). This was not the case for PBMCs from SLE patients, as no significant 
differences were found between the patients and the healthy controls concerning either 
FcγRIIb1 and FcγRIIb2 mRNA expression (Fig.4.19). A small proportion of RA patients 
displayed a reduced growth arrest response upon BCR/FcγRIIb co-ligation and, although 
there was no statistically significant difference, there was a noticeable trend for more RA 
patients  showing  this  defect  compared  to  either  healthy  controls  or SLE  patients. This 
seems to correlate with the FcγRIIb RNA expression data, which showed that PBMCs from 
RA  patients,  but  not  cells  from  SLE  patients,  express  reduced  levels  of  FcγRIIb1.  For 
future experiments it would therefore be interesting to obtain information about FcγRIIb 
RNA levels and the extent of growth arrest of purified B cells from the same patient to 
identify a potential correlation. 
The  most  striking  change  between  the  RA/SLE  patient  cohorts  and  the  healthy 
patients was the reduction of the FcγRIIb1/FcγRIIb2 ratio (Fig.4.19). The cause of this 
phenomenon was a relative increase of FcγRIIb2 levels in patients compared to healthy 
controls. As discussed before,  this  change of relative  levels  of  FcγRIIb1  and FcγRIIb2 
could tip the balance between antigen uptake and presentation and inhibitory signalling 
towards an increased ability of cells to present antigen. In an autoimmune-prone setting 
this could increase the presentation of self-antigen by autoreactive B cells, followed by 
activation of autoreactive T cells and thereby create an amplification loop. 
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4.4.7 Concluding remarks 
In  conclusion,  it  has  been  demonstrated  that  BCR/FcγRIIb  co-ligation  results  in 
growth  arrest  and  apoptosis.  The  signalling  pathways  underlying  apoptosis  have  been 
further elucidated and it has been shown that caspase 8 is the major initiator caspase 
involved. Moreover, FcγRIIb was found to stimulate expression of Fas and its ligand FasL 
and signalling through this death receptor presumably activates caspase 8. Inhibition of 
Fas/FasL  signalling  and  caspase  8  activation  were  both  sufficient  to  block  apoptosis, 
underscoring  the  crucial  role  these  signals  play.  Furthermore,  this  study  has  clearly 
demonstrated  that  p53  is  regulated  by  FcγRIIb-dependent  mechanisms  inducing  its 
upregulation and translocation. Thus, various scenarios can be envisaged, as p53 can 
achieve  the  initiation  of  the  apoptotic  programme  by  different  pathways.  p53  could 
increase  Fas  and  caspase  8  expression,  thereby  initiating  as  well  as  propagating  this 
signalling axis. Additionally, it might trigger apoptosis by enhancing the expression of pro-
apoptotic  molecules  such  as  Noxa  or  by  translocating  to  the  mitochondria  and  hence 
interaction  with  pro-  and  anti-apoptotic  molecules  at  this  interface.  The  growth  arrest 
response has not been examined in detail in this study, but some progress has been made 
towards fully elucidating the signals involved. Thus, another level of negative regulation of 
the ERK MAPK pathway has been identified to be transcriptional upregulation of PAC-1 
and SPA-1. Furthermore, FcγRIIb-mediated growth arrest was found to be linked to the 
reduction  of  positive  regulatory  elements  of  the  cell  cycle,  including  c-Myc  and 
hyperphosphorylated Rb (Fig.4.21).  
The  ultimate  goal  of  immunological  research  is  to  apply  findings  to  the  human 
immune system and support development of disease treatments. This study therefore set 
out to begin to translate some of the findings acquired in the murine system to humans. 
Encouragingly, it was demonstrated that human B cells, like their murine counterparts, 
undergo growth arrest and apoptose upon BCR/FcγRIIb co-ligation. Furthermore, it was 
shown that the B cells of a proportion of patients exhibit a defective inhibitory response, 
indicating  that  FcγRIIb-mediated  negative  signalling  is  affected  in  these  patients. 
Furthermore,  major  differences  between  RA  patients  and  healthy  controls  were  found 
concerning the expression of FcγRIIb isoforms. It is therefore concluded that this inhibitory 
receptor  could  be  one  of  the  many  contributing  factors  towards  development  or 
propagation of autoimmune diseases. 
 
4.5  Figures  
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Figure 4.1 Diagram of stimulations 
Antibodies  were  used  to  mimic  stimulation  of  B  cells  by  free  antigen  and/or  immune 
complexes. Stimulation with F(ab’)2 fragments of anti-IgM cross-links the BCR and induces 
mitogenic signals (designated BCR). By contrast, as stimulation with intact anti-IgM/IgG 
results  in  the  generation  of  negative  signals  induced  by  co-ligation  of  the  BCR  and 
FcγRIIb, these antibodies were used in combination with F(ab’)2 fragments of anti-IgM to 
mimic the inhibition of antigen-driven mitogenic signals by immune complexes resulting in 
growth arrest and apoptosis (designated BCR+FcγRIIb). 
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Figure 4.2 BCR/FcγRIIb co-ligation induces growth arrest and apoptosis 
Purified mature mouse B cells (10
6 cells/ml) were stimulated for 48 h in the presence of 50 
µg/ml F(ab’)2 anti-mouse IgM (BCR) or 50 µg/ml F(ab’)2 anti-mouse IgM in combination 
with 75 µg/ml anti-mouse IgG+IgM (BCR+FcγRIIb), as indicated. Cells stimulated in the 
presence of medium alone were included as a control (None). 
(A) DNA synthesis was assessed by pulsing the cells with 0.5 µCi/well [
3H] thymidine for 
the last 6 h of culture and measurement of incorporated label using a liquid scintillation 
counter.  Data  are  shown  as  counts  per  minute  (cpm)  +/-  standard  deviation  (SD)  of 
triplicate values. *** p<0.001 
(B)  DNA  content  was  determined  by  propidium  iodide  (PI)  staining  followed  by  FACS 
analysis.  A  representative  histogram  is  shown  and  data  are  presented  as  (C-i)  mean 
percentage of all cells in each cell cycle stage or as (C-ii) mean percentage of live cells 
(excluding  cells  with  subdiploid  DNA  content)  in  each  cell  cycle  stage  (+/-  range  of 
duplicate values). 
(D) For the assessment of the mitochondrial membrane potential the cells were stained 
with DiOC6 and analysed by FACS. A representative histogram is shown and data are 
presented as the mean percentage of cells with high or low membrane potential (+/- range 
of duplicate values). 
Data are representative of at least three independent experiments. 
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Figure 4.3 Caspase 8 inhibition reduces FcγRIIb-mediated apoptosis 
Purified mature splenic B cells (10
6 cells/ml) were stimulated for 48 h in the presence of 50 
µg/ml F(ab’)2 anti-mouse IgM (BCR) or 50 µg/ml F(ab’)2 anti-mouse IgM in combination 
with 75 µg/ml anti-mouse IgG+IgM (BCR+FcγRIIb), as indicated. Furthermore, cells were 
treated with a caspase 8 inhibitor or DMSO as a control. Cells stimulated in the presence 
of medium alone were included as a control (None). (A) DNA content was determined by 
propidium iodide (PI) staining followed by FACS analysis. Representative FACS histogram 
plots  are shown  for  media  (A-i),  F(ab’)2  anti-mouse  IgM  stimulated  cells  (A-ii) or  cells 
treated with F(ab’)2 anti-mouse IgM in combination with anti-mouse IgG+IgM (A-iii). Data 
represents the mean percentage of subdiploid cells (+/- range of duplicate values) (A-iv).  
For the assessment of the mitochondrial membrane potential the cells were stained with 
DiOC6 and analysed by FACS, representative histograms are shown in (B) and (C). Data 
are  expressed  as  the  mean  percentage  of  cells  with  (D)  high  or  (E)  low  membrane 
potential  (+/-  range  of  duplicate  values).  Data  are  representative  of  at  least  three 
independent experiments. 
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Figure 4.4 Expression of caspase 8 and cFLIP 
To  determine  caspase  8  (A)  and  cFLIP  (B)  expression  in  whole  cell  lysates,  purified 
mature splenic B cells (10
7 cells/well) were stimulated with 50 µg/ml F(ab’)2 anti-mouse 
IgM (BCR) or 50 µg/ml F(ab’)2 anti-mouse IgM in combination with 75 µg/ml anti-mouse 
IgG+IgM  (BCR+FcγRIIb)  for  24  or  48  h  and  whole  cell  lysates  were  prepared.  Cells 
stimulated with medium were included as a control (None). Expression of caspase 8 was 
assessed by SDS-PAGE gel electrophoresis followed by Western Blotting. 
Gel loading was as follows: Lane 1 None, Lane 2 BCR, Lane 3 BCR+FcγRIIb. 
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Figure 4.5 p53 expression is upregulated by BCR/FcγRIIb co-ligation 
(A) Purified mature splenic B cells (10
6 cells/ml) were stimulated for 3, 7, 20 or 24 h in the 
presence of 50 µg/ml F(ab’)2 anti-mouse IgM (BCR) or 50 µg/ml F(ab’)2 anti-mouse IgM in 
combination  with  75  µg/ml  anti-mouse  IgG+IgM  (BCR+FcγRIIb).  Whole  mRNA  was 
isolated and transcribed into cDNA. p53 expression levels were detected by TaqMan® 
quantitative RT-PCR using GAPDH as endogenous control. Data are shown as mean % 
expression relative to GAPDH, as indicated, +/- SD of triplicate values. 
(B-D) For the detection of p53 protein levels purified mature splenic B cells (10
7 cells) were 
stimulated for 48 h in the presence of 50 µg/ml F(ab’)2 anti-mouse IgM (BCR) or 50 µg/ml 
F(ab’)2 anti-mouse IgM in combination with B7.6 anti-IgM to ligate the BCR (50 mg/ml), 
2.4G2 IgG to ligate FcγRIIb (50 mg/ml) and 75 mg/ml Donkey anti- Rat IgG to crosslink the 
B7.6  and  24G.2  Abs  and  hence  coligate  the  BCR  and  FcγRIIb  (BCR+FcγRIIb). 
Furthermore,  cells  were  treated  with  caspase  8  inhibitor  or  DMSO  as  a  control.  Cells 
stimulated in the presence of medium alone were included as a control (None). After 48 h 
(B) whole cell  lysates or (C) nuclear and (D) cytoplasmic fractions were prepared and 
expression of p53 was assessed by SDS-PAGE gel electrophoresis followed by Western 
Blotting. Gel loading was as follows: Lane 1 +DMSO, Lane 2 + caspase 8 inhibitor. 
 
  
  232 
Figure  4.6  Noxa  expression  and  effector  caspase  activation  are  increased  by 
FcγRIIb-mediated signalling 
(A) To determine Noxa expression in whole cell lysates, purified mature splenic B cells 
(10
7 cells/well) were stimulated with 50 µg/ml F(ab’)2 anti-mouse IgM (BCR) or 50 µg/ml 
F(ab’)2 anti-mouse IgM in combination with 75 µg/ml anti-mouse IgM (BCR+FcγRIIb) for 24 
or 48 h and whole cell lysates were prepared. Cells stimulated with medium were included 
as a control (None). Expression of Noxa was assessed by SDS-PAGE gel electrophoresis 
followed by Western Blotting. Gel loading was as follows: Lane 1 None, Lane 2 BCR, Lane 
3 BCR+FcγRIIb. 
(B-E) For the assessment of caspase activation cells (10
6 cells/ml) were stimulated as 
described above. Furthermore, cells were treated with caspase 8 inhibitor or DMSO as a 
control. After 24 h the cells were labeled with FITC-VAD-FMK and analysed by FACS. 
Representative histograms are shown of the (B) unlabeled control cells as well as (C) 
treated and labelled cells. Data are shown as either (D) the percentage of cells positive for 
FITC-expression  or  (E)  as  MFI.  Data  are  representative  of  at  least  two  independent 
experiments. 
 
 
 
 
  
  233 
Figure 4.7 Caspase 8 inhibition does not affect FcγRIIb-dependent growth arrest 
Murine purified splenic B cells (10
6 cells/ml) were stimulated for 48 h in the presence of 50 
µg/ml F(ab’)2 anti-mouse IgM (BCR) or 50 µg/ml F(ab’)2 anti-mouse IgM in combination 
with 75 µg/ml anti-mouse IgG+IgM (BCR+FcγRIIb), as indicated. Furthermore, cells were 
treated with caspase 8 inhibitor or DMSO as a control. Cells stimulated in the presence of 
medium  alone  were  included  as  a  control  (None).  DNA  content  was  determined  by 
propidium iodide (PI) staining followed by FACS analysis. (A) Data are displayed as the 
percentage of cells in the different phases of cell cycle after stimulation with 50 µg/ml 
F(ab’)2 anti-mouse IgM in combination with 75 µg/ml anti-mouse IgG+IgM (BCR+FcγRIIb) 
in the presence or absence of caspase 8 inhibitor, as indicated. (B) % of cells in G1-G0 
phase, (C) % cells in S phase, (D) % of cells in G2-M phase of cell cycle. Data represents 
each cell cycle stage expressed as the mean percentage of the total number of live cells 
(excluding cells with subdiploid DNA content) analysed (+/- range of duplicate values). 
(E-F) To assess DNA synthesis by analysis of labelled thymidine incorporation additional 
cells were stimulated for (E) 48 or (F) 72 h as described above. Proliferation was assessed 
by  pulsing  the  cells  with  0.5  µCi/well  [
3H]  thymidine  for  6  h  and  measurement  of 
incorporated label using a liquid scintillation counter. Data are shown as counts per minute 
(cpm) +/- SD of triplicate values. Data are representative of at least three independent 
experiments. 
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Figure 4.8 Proteins involved in cell cycle control are not regulated by caspase 8 
(A) Mature purified splenic B cells (10
6 cells/ml) were stimulated for 3, 7, 20 or 24 h in the 
presence of 50 µg/ml F(ab’)2 anti-mouse IgM (BCR) or 50 µg/ml F(ab’)2 anti-mouse IgM in 
combination  with  75  µg/ml  anti-mouse  IgG+IgM  (BCR+FcγRIIb).  Whole  mRNA  was 
isolated and transcribed into cDNA. c-Myc expression levels were detected by TaqMan® 
quantitative RT-PCR using GAPDH as endogenous control. Data are shown as mean % 
expression relative to GAPDH +/- SD of triplicate values. 
(B)  Cells  were  stimulated  for  24  h  with  50  µg/ml  F(ab’)2  anti-mouse  IgM  (BCR)  or  a 
combination of 50 µg/ml F(ab’)2 anti-mouse IgM, 50 µg/ml rat anti-mouse IgM, 50 µg/ml rat 
anti-mouse FcγRIIb and 75 µg/ml donkey anti-rat IgG (H+L) antibodies (BCR+FcγRIIb) 
and whole cell lysates prepared. Expression of c-Myc, phospho-RbS807/811 or β-actin 
was  assessed  by  SDS-PAGE  gel  electrophoresis  followed  by  Western  Blotting  (15  µg 
protein/lane). Gel loading was as follows: Lane 1 +DMSO, Lane 2 + caspase 8 inhibitor. 
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Figure 4.9 BCR/FcγRIIb cross-linking regulates SPA-1 and PAC-1 mRNA expression 
Purified mature splenic B cells (10
6 cells/ml) were stimulated for 3, 7, 20 or 24 h in the 
presence of 50 µg/ml F(ab’)2 anti-mouse IgM (BCR) or 50 µg/ml F(ab’)2 anti-mouse IgM in 
combination  with  75  µg/ml  anti-mouse  IgG+IgM  (BCR+FcγRIIb).  Whole  mRNA  was 
isolated  and  transcribed into  cDNA.  (A) PAC-1  and  (B)  SPA-1  expression  levels  were 
detected  by  TaqMan®  quantitative  RT-PCR  using  GAPDH  as  an  endogenous  control. 
Data  are  shown  as  mean  %  expression  relative  to  GAPDH,  as  indicated,  +/-  SD  of 
triplicate values. 
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Figure 4.10 Co-ligation of BCR/FcγRIIb induces Fas expression 
Purified mature splenic B cells (10
6 cells/ml) were stimulated for 48 h in the presence of 50 
µg/ml F(ab’)2 anti-mouse IgM (BCR) or 50 µg/ml F(ab’)2 anti-mouse IgM in combination 
with 75 µg/ml anti-mouse IgG+IgM (BCR+FcγRIIb), as indicated. Furthermore, cells were 
treated with caspase 8 inhibitor or DMSO as a control. Cells stimulated in the presence of 
medium alone were included as a control (None). Extracellular expression of Fas (CD95) 
was detected by staining with a Fas-specific antibody. (A) Representative histograms are 
shown and (B) data are expressed as (i) mean percentage of B220
+ cells expressing Fas 
or  (ii)  MFI  (+/-  range  of  duplicate  values).  Data  are  representative  of  at  least  two 
independent experiments. 
(C) Cells were stimulated with 50 µg/ml F(ab’)2 anti-mouse IgM (BCR) or a combination of 
50 µg/ml F(ab’)2 anti-mouse IgM, 50 µg/ml rat anti-mouse IgM, 50 µg/ml rat anti-mouse 
FcγRIIb and 75 µg/ml donkey anti-rat IgG (H+L) antibodies (BCR+FcγRIIb) for 24 h and 
whole cell lysates were prepared. Expression of Fas, FasL or β-actin was assessed by 
SDS-PAGE gel electrophoresis followed by Western Blotting (15 µg/lane). Gel loading was 
as follows: Lane 1 +DMSO, Lane 2 + caspase 8 inhibitor.  
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Figure 4.11 Caspase 8 is not involved in the regulation of Fas mRNA levels 
(A) Purified mature splenic B cells (10
6 cells/ml) were stimulated for 3, 7, 20 or 24 h in the 
presence of 50 µg/ml F(ab’)2 anti-mouse IgM (BCR) or 50 µg/ml F(ab’)2 anti-mouse IgM in 
combination with 75 µg/ml anti-mouse IgG+IgM (BCR+FcγRIIb). 
(B) Cells were treated for 24 h as described above in the presence or absence of 10 µM 
caspase 8 Inhibitor or DMSO as control. Whole mRNA was isolated and transcribed into 
cDNA and Fas (CD95) expression levels were detected by TaqMan® quantitative RT-PCR 
using GAPDH as an endogenous control. Data are shown as mean % expression relative 
to GAPDH +/- SD of triplicate values. 
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Figure 4.12 FasL mRNA expression is not influenced by caspase 8 activation 
(A) Purified mature splenic B cells (10
6 cells/ml) were stimulated for 3, 7, 20 or 24 h in the 
presence of 50 µg/ml F(ab’)2 anti-mouse IgM (BCR) or 50 µg/ml F(ab’)2 anti-mouse IgM in 
combination with 75 µg/ml anti-mouse IgG+IgM (BCR+FcγRIIb). 
(B) Cells were treated for 24 h as described above in the presence or absence of 10 µM 
caspase 8 Inhibitor or DMSO as control. Whole mRNA was isolated and transcribed into 
cDNA and FasL (CD178) expression levels were detected by TaqMan® quantitative RT-
PCR  using  GAPDH  as  endogenous  control.  Data  are  shown  as  mean  %  expression 
relative to GAPDH +/- SD of triplicate values. 
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Figure  4.13  FcγRIIb-dependent  growth  arrest  and  apoptosis  are  reduced  in 
MRL/MpJ-Fas
lpr    mice  and  inhibition  of  Fas/FasL  signalling  prevents  FcγRIIb-
mediated apoptosis 
Purified mature splenic B cells were stimulated for 48 h in the presence of 50 µg/ml F(ab’)2 
anti-mouse IgM (BCR) or 50 µg/ml F(ab’)2 anti-mouse IgM in combination with 75 µg/ml 
anti-mouse  IgG+IgM  (BCR+FcγRIIb),  as  indicated.  Cells  stimulated  in  the  presence  of 
medium alone were included as a control (None). 
(A) DNA synthesis was assessed by pulsing the cells (5 x 10
5 cells/well) with 0.5 µCi/well 
[
3H] thymidine for 6 h of culture and measurement of incorporated label using a liquid 
scintillation counter (A-i; 17 wks old MRL/MpJ, A-ii; 12 wks old MRL/MpJ-Fas
lpr ). (A-iii) 
The data represents values from experiments using B cells from Balb/C mice, MRL/MpJ 
mice and pooled values for B cells from 9, 12, 16 and 20 week old MRL/MpJ-Fas
lpr  mice. 
*** p<0.001, ** p<0.01, * p<0.05 
(B)  DNA  content  was  determined  by  propidium  iodide  (PI)  staining  followed  by  FACS 
analysis. Data are shown as the percentage of subiploid cells (B-i; 17 wks old MRL/MpJ, 
B-ii;  12  wks  old  MRL/MpJ-Fas
lpr  ).  (B-iii)  Data  represents  subdiploid  cells  (normalised 
against values from BCR-stimulated cells) and is expressed as a ratio of the MRL/MpJ 
control cells. The values from experiments using B cells from 9, 12, 16 and 20 week old 
MRL/MpJ-Fas
lpr  mice were pooled. 
(C) The dissipation of the MMP was assessed by staining cells with DiOC6 and data are 
expressed as the percentage of cells with high MMP (C-i; 17 wks old MRL/MpJ, C-ii; 12 
wks  old  MRL/MpJ-Fas
lpr  ).  (C-iii)  Data  represents  cells  with  high  DiOC6  fluorescence 
(normalised against values from BCR-stimulated cells) and is expressed as a ratio of the 
MRL/MpJ control cells. The values from experiments using B cells from 9, 12, 16 and 20 
week old MRL/MpJ-Fas
lpr  mice were pooled. 
(D) Purified mature splenic B cells (10
6 cells/well) were stimulated as described above. 
Furthermore, cells were treated with 5 or 10 µg/ml armenian hamster IgG as a control or 5 
or 10 µg/ml anti-FasL blocking antibody. Cells stimulated in the presence of medium alone 
were  included  as  a control (None).  For  the  assessment  of  cell  cycle  status  cells  were 
stained with PI and analysed by FACS. Data are shown as the % subdiploid cells after 
treatment  with  BCR+FcγRIIb.  Data  are  representative  of  at  least  two  independent 
experiments. 
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Figure  4.14  Proliferation  analysis of  purified  peripheral  B  cells  by  [
3H]  thymidine 
incorporation and CFSE labelling  
Purified  peripheral  B  cells  (CD19
+-selected)  from  a  healthy  control  were  subjected  to 
proliferation analysis. The cells (10
5 cells/well) were stimulated for (A-i) 4, 24, 48 or (A-ii) 
48, 72 or 96 h in the presence of 50 µg/ml F(ab’)2 anti-human IgG+IgM (BCR), 75 µg/ml 
anti-human IgG+IgM (BCR+FcγRIIb) or the combination of both (mitogenic BCR+FcγRIIb), 
as indicated. Cells stimulated in the presence of medium alone were included as a control 
(None). DNA synthesis was assessed by pulsing the cells with 0.5 µCi/well [
3H] thymidine 
for the  last  8  h  of  culture  (for  4  h  for  the  4  h  timepoint) followed  by  measurement  of 
incorporated label using a liquid scintillation counter. (A) Data are shown as counts per 
minute (cpm) +/- SD of triplicate values. *** p<0.001, BCR against BCR+FcγRIIb, BCR 
against mitogenic BCR+FcγRIIb 
(B-D) To analyse proliferation by a different method, cells were stained with CFSE after 
CD19
+-purification and harvested after the indicated times followed by FACS analysis. The 
data are shown as the percentage of all cells analysed and the number of divisions they 
have undergone (B – 4 h, C – 24 h, D – 48 h).  
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Figure 4.15 Correlation between proliferation, cell cycle stages and apoptosis  
Purified peripheral B cells (CD19
+-selected) from a (A) healthy control and (B) three RA 
patients were subjected to proliferation analysis. The cells (10
5 cells/well) were stimulated 
for  48  h  in  the  presence  of  50  µg/ml  F(ab’)2  anti-human  IgG+IgM  (BCR)  or  50  µg/ml 
F(ab’)2 anti-human IgG+IgM in combination with 75 µg/ml anti-human IgG+IgM (mitogenic 
BCR+FcγRIIb),  as  indicated.  Cells  stimulated  in  the  presence  of  medium  alone  were 
included as a control (None). (i) DNA synthesis was assessed by pulsing the cells with 0.5 
µCi/well for the last 8 h of culture and measurement of incorporated label using a liquid 
scintillation counter. Data are shown as counts per minute (cpm) +/- SD of triplicate values 
(data from the three patients was pooled). (ii) DNA content was determined by propidium 
iodide  (PI)  staining  followed  by  FACS  analysis.  Data  represents  each  cell  cycle  stage 
expressed as a percentage of the total number of cells analysed or (iii) the percentage of 
cells in the mitotic phases of the cell cycle. (iv) For the assessment of the mitochondrial 
membrane potential the cells were stained with DiOC6 and analysed by FACS. Data are 
shown as percentage of cells with high or low membrane potential. (B) The data from the 
three patients was pooled.  
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Figure 4.16 Inhibition of proliferation after BCR/FcγRIIb cross-linking is reduced in 
some patients suffering from autoimmune disease 
Purified peripheral B cells (CD19
+ selected) from 12 healthy controls and 16 RA patients, 
10  SLE  patients  as  well  as  9  patients  with  other  autoimmune  diseases  (Sjogren’s 
syndrome, Connective tissue disease, Dermatomyositis, Psoriatic arthritis) were tested for 
their  inhibitory  capacity  upon  BCR/FcγRIIb  cross-linking.  The  data  are  shown  as  %-
inhibition of DNA synthesis upon stimulation with F(ab’)2+Intact anti-IgG+IgM (the BCR 
response represents 100%). 
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Figure 4.17 Proliferation analysis of purified peripheral B cells from recalled patients 
with RA 
Purified peripheral B cells (CD19
+-selected) from two different patients with RA who had 
been tested before, were subjected to proliferation analysis. The cells (10
5 cells/well) were 
stimulated for 48 h in the presence of 50 µg/ml F(ab’)2 anti-human IgG+IgM (BCR) or 50 
µg/ml  F(ab’)2  anti-human  IgG+IgM  in  combination  with  75  µg/ml  anti-human  IgG+IgM 
(mitogenic BCR+FcγRIIb), as indicated. Cells stimulated in the presence of medium alone 
were included as a control (None). DNA synthesis was assessed by pulsing the cells with 
0.5 µCi/well [
3H] thymidine for the last 8 h of culture and measurement of incorporated 
label using a liquid scintillation counter. Data are shown as counts per minute (cpm) +/- SD 
of triplicate values. (A) Patient 72 (i) first experiment, (ii) recall experiment. (B) Patient 66 
(i) first experiment, (ii) recall experiment. 
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Figure 4.18 Differences in the function of the two FcγRIIb isoforms FcγRIIb1 and 
FcγRIIb2  
(A) Separate exons encode the transmembrane and cytoplasmic domains of FcγRIIb; thus 
several  isoforms  can  be  created  by  alternative  splicing  of  mRNA  transcripts.  Human 
FcγRIIb  encodes  three  transcripts,  FcγRIIb1,  FcγRIIb2  and  FcγRIIb3,  which  arise  by 
alternative splicing mechanisms. The mature forms of FcγRIIb1 and FcγRIIb3 are identical 
but differences in their peptide leader sequences prevent the expression of FcγRIIb3. 
(B) Upon IgG binding, FcγRIIb2 is capable of mediating rapid endocytosis by means of 
clathrin-coated  vesicles  allowing  antigen  processing  and  presentation  on  MHC  II. 
However, an insertion of 19 amino acids in the cytoplasmic tail of FcγRIIb1 disrupts the 
cytoskeletal attachment domain responsible for modulating receptor internalisation. Thus, 
FcγRIIb1 mainly carries out the inhibitory functions described in this chapter.  
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Figure 4.19 FcγRIIb1/FcγRIIb2 expression of PBMCs from patients with RA or SLE 
and healthy controls 
Total RNA was extracted from PBMCs from patients with RA (left panel) or SLE (right 
panel) or healthy controls and reverse transcribed. Expression levels of FcγRIIb1 (A-B) 
and  FcγRIIb2  (C-D)  were  assessed  by  TaqMan®  quantitative  RT-PCR  and  the 
FcγRIIb1/FcγRIIb2  ratio  calculated  (E-F).  Individual  mRNA  levels  are  expressed  as  a 
percentage relative  to  HPRT  mRNA  levels. Some  of  the  data  were  acquired  by Kirsty 
Brown and used with her permission. *** p<0.001, ** p<0.01, * p<0.05 
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Figure 4.20 Expression of FcγRIIb in cells of the immune system 
Total RNA was extracted from either purified peripheral B cells, B cell-depleted PBMCs 
(Non-B cells) (A), whole PBMCs, purified T cells or T cell-depleted PBMCs (Non-T cells) 
(B).  Whole  mRNA  was  then  transcribed  into  cDNA  and  FcγRIIb1/FcγRIIb2  RNA 
expression  levels  were  detected  by  TaqMan®  quantitative  RT-PCR  using  β-actin  as 
endogenous control. Data are shown as % expression relative to β-actin. 
(C) PBMCs from a healthy control were stained with anti-FcγRIIb, anti-CD19, anti-CD11b 
antibodies or relevant isotype controls. Data are shown as representative histograms of 
FcγRIIb-positive cells as well as plots showing CD19/FcγRIIb or CD11b/FcγRIIb double-
positive cells.  
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Figure 4.21 FcγRIIb signalling reduces cell cycle progression/proliferation 
Co-ligation of the BCR and FcγRIIb reduces the strength of BCR-mediated signalling by 
reducing the activation of various signalling cascades including the ERK MAPK pathway. 
This  is  achieved  by,  for  example,  reducing  the  activation  of  Ras/Raf  through  the 
recruitment  of  p62  Dok.  Furthermore,  another  level  of  negative  regulation  of  the  ERK 
MAPK pathway has been identified to be transcriptional upregulation of PAC-1 and SPA-1. 
PAC-1  dephosphorylates  and  thereby  inactivates  ERK,  whereas  SPA-1  decreases  the 
levels of active Rap. Furthermore, FcγRIIb-mediated growth arrest was found to be linked 
to  reduction  of  positive  regulatory  elements  of  the  cell  cycle,  including  c-Myc  and 
hyperphosphorylated  Rb  which  could  be  partially  due  to  the  reduced  levels  of  ERK 
activation observed upon BCR/FcγRIIb co-ligation. 
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5  General Discussion 
 
The immune system has evolved to protect the host from invading pathogens. Thus, 
the  mammalian  immune  system  consists  of  highly  specialised  tissues  and  cells  that 
orchestrate  the  defense  against  different  pathogens  such  as  viruses,  bacteria  and 
parasites.  B  cells  and  the  antibodies  they  produce  are  a  major  part  of  the  protective 
mechanisms of the immune system. The large number of BCR specificities necessary to 
recognise and mount responses against the numerous pathogen antigens that the host is 
likely to encounter in a lifetime is best achieved by random recombination events. The side 
effect of this efficient mechanism, however, is the potential creation of self-reactive antigen 
receptors. Hence the evolution of negative selection events which ensure that autoreactive 
B  cells  are  removed  from  the  repertoire  has  generally  provided  the  solution  to  this 
problem. In addition, homeostatic mechanisms have developed in which B cell responses 
in the periphery are tightly regulated and efficiently switched off upon successful removal 
of  the  pathogens  by  inhibitory  feedback  mechanisms  such  as  those  depending  on 
interactions between immune complexes and FcγRIIb. Thus, co-ligation of this receptor 
with the BCR by the engagement of antigen-antibody immune-complexes allows the cell to 
sense  the  balance  between  free  and  antibody-bound  antigen.  As,  in  the  event  of  a 
succesful immune response against pathogens, the majority of antigen will be present in 
immune  complexes  rather  than  free  monomeric  antigen,  simultaneous  signalling  via 
FcγRIIb and the BCR desensitises the activatory signalling cascades allowing the B cell 
response to be switched off. 
Perturbations in the checkpoints controlling negative selection or in the homeostatic 
balance  between  activation  and  termination  of  responses  due  to  changes  in  the 
expression  of  FcγRIIb,  can  therefore  potentially  increase  the  chances  of  survival  and 
activation of self-reactive B cell clones or indeed an expanded pool of pathogen-specific B 
cells that are weakly cross-reactive with self-antigens. Such an increase in autoreactive 
cells  might  therefore  lead  to  the  initiation  of  autoantibody  production  and  hence 
autoimmune diseases such as RA and SLE. Thus the eventual outcome of the core aims 
of this thesis, to identify and dissect the key signalling pathways underlying BCR-mediated 
negative selection of immature B cells as well as those underpinning inhibitory FcγRIIb 
signalling,  could  therefore  shed  light  on  the  mechanisms  permitting  the  progression  of 
autoimmune  disorders  and  provide  information  to  further  the  development  of  targeted 
therapies. 
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5.1  Immature B cell signalling 
 
In confirmation of previous evidence [310], the activation of the MAPK ERK1/2 was 
found to be crucial for the survival of WEHI-231 cells. The WEHI-231 B cell lymphoma, 
which exhibits the phenotype (sIgM
+, sIgD
-/low, FcγR
low, Fas
low, MHC class II
low) of immature 
B cells, has been widely used as a model for the dissection of the signalling mechanisms 
controlling BCR-mediated negative selection of immature B cells and their rescue by T 
cell-derived and survival factors. Previous studies from this laboratory [310] suggested that 
whilst a strong transient BCR-stimulated spike of ERK activation (1-4 h) correlated with 
induction  of  apoptosis  in  WEHI-231  B  cells,  maintenance  of  sustained,  yet  cycling 
activation of the MAPK, ERK1/2 was crucial for the survival and proliferation of WEHI-231 
cells.  Indeed,  the  abrogation  of  such  sustained  ERK  activation  is  one  of  the  major 
signalling events leading to BCR-mediated growth arrest and apoptosis of WEHI-231 B 
cells [310]. The mechanisms involved were not fully delineated but these earlier studies 
suggested  that  in  addition  to  partially  suppressing  activation  of  MEK1/2,  the  upstream 
regulator of ERK1/2, BCR signalling also resulted in termination of ongoing ERK signalling 
by  recruitment  of  the  ERK  MAPK  phosphatase,  PAC-1.  Rather  surprisingly,  however, 
given  the  desensitisation  of  MEK  activity,  it  was  found  that  Ras  activation  was  not 
suppressed by such BCR-signalling. 
This study has now confirmed and extended these previous findings to show that the 
reduction of such MEK and ERK activation coincides with the downmodulation of the Rap-
1/B-Raf signalling pathway. Thus, ligation of the BCR diminished the levels of active Rap-1 
in the cells (Fig.3.12). These findings are intriguing as Rap-1/B-Raf signalling has been 
shown in various models, including B cells, to activate the ERK cascade [411]. In B cells, 
Rap-1B is the dominant form of Rap-1 [423], and Rap-1B-deficiency impacts on B cell 
development  reducing  the  number  of  immature  B  cells  in  the  bone  marrow  [423], 
consistent with the proposal that such Rap-1-mediated ERK activation promotes immature 
B  cell  survival.  However,  both  isoforms  of  Rap,  Rap-1  and  Rap-2,  which  share  60% 
homology and are mainly regulated by the same activators/inhibitors, have been shown to 
be activated upon BCR-ligation in WEHI-231 B cells [418,419]. Nevertheless, such Rap-1 
activation is maximal within the first 1-4 hours [373,418] and hence perhaps correlates with 
the  coupling  of  the  BCR  to  the  strong,  transient  spike  of  apoptotic  ERK  signalling 
[310,373]. Interestingly, although Rap-1 and Rap-2 seem to carry out similar functions, 
they  differ  in  their  interaction  with  RapGAPs.  Thus,  Rap-2  has  lower  sensitivity  to 
deactivation by RapGAPs and therefore remains active for longer providing a more long-
lasting Rap signal [395]. It would therefore be interesting to analyse the relative amounts  
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and  subcellular  localisation  of  active  Rap-1  and  Rap-2  after  BCR-ligation  or  in 
spontaneously proliferating WEHI-231 cells to determine if both forms of Rap are needed 
for the activation of ERK, and if indeed inhibition of both forms is necessary to achieve 
abrogation of the ERK signal.  
WEHI-231 cells also express two isoforms of Raf, B-Raf and Raf-1, both of which 
can interact with Rap. However, binding of Rap to Raf-1 and B-Raf is thought to induce 
very different signals. Thus, whilst Rap/B-Raf has been found to mainly activate the ERK 
cascade  [411],  Rap/Raf-1  interaction  has  been  shown  to  inhibit  ERK  activation 
sequestering Raf-1 away from Ras [408]. Indeed, it has been reported previously, that in 
chicken  B  cells,  B-Raf  rather  than  Raf-1  is  the  major  upstream  regulator  of  the  ERK 
cascade  [170].  Interestingly,  the  forced  expression  of  B-Raf  in  peripheral  T  cells 
transformed Rap-1 into an activator of the ERK cascade whereas in normal peripheral T 
cells, which express little or no B-Raf, Rap-1 generally signals to inhibit ERK activation by 
sequestering Raf-1 [412]. The relative amounts of B-Raf and Raf-1 or characterisation of 
which isoform is generally found complexed with Rap-1 has not been addressed in this 
study. It would therefore be of interest to determine how cells, such as WEHI-231 cells, 
which express both isoforms regulate the binding and activation of one or the other Raf 
isoform. 
Rap signalling can be regulated by various mechanisms including modulation of the 
levels  of  specific  GEFs  (responsible  for  their  activation)  or  RapGAPS  (proteins  that 
increase  the  intrinsic  GTPase  activity  of  Rap  leading  to  its  deactivation)  that  act  to 
homeostatically regulate Rap activity [393]. As the precise mechanisms regulating Rap 
activity after BCR-ligation in WEHI-231 cells have not been identified, this study therefore 
contributed to the dissection of these signalling pathways by establishing a potential role 
for SPA-1. Thus, BCR-ligation was found to upregulate SPA-1 whereas CD40-mediated 
positive  signals  actively  suppressed  SPA-1  expression  (Fig.3.13)  suggesting  that  the 
reduction  of  Rap  signalling  observed  due  to  BCR-ligation  could  therefore  be  partly 
achieved by an increase in SPA-1 levels (Fig.5.1). The biological importance of SPA-1 
mediated suppression of Rap-1 in immature B cells has been recently confirmed as SPA-1 
deficient B cells showed signs of skewed receptor editing creating higher numbers of auto-
antigen specific B cells [429]. Thus, the Rap-1/SPA-1 signalling module seems to play a 
crucial role in regulating tolerance checkpoints in developing B cells.  
Although Rap-1 has been found to be important in the regulation of ERK activation, 
more  recently  its  role  in  the  regulation  of  adhesion  and  migration  has  been  a  major 
research focus [639]. Thus, in B cells Rap was found to be essential for the spreading 
response  and  immune  synapse  formation  upon  antigen  encounter  [426].  Thus,  the  
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possibility  that  the  reduction  of  Rap  activity  in  WEHI-231  cells  also  influences  cell-cell 
interactions or migration and adhesion, processes which could also affect BCR-signalling, 
can not be excluded. Moreover, these functions might explain why Rap is activated via the 
BCR at early time points (< 4 h). Further studies to dissect these separate effects of Rap 
might provide insight into the relative roles of Rap signalling in immature and mature B 
cells. Indeed, studies to address the differential roles of Rap were initiated by attempting to 
analyse  the  effects  of  over-expressing  dominant  negative  or  constitutively  active  Rap 
mutants on the regulation of the ERK cascade and consequent functional outcomes of 
WEHI-231 B cells. However, technical difficulties hampered the transfection and selection 
of stable clones and hence further studies examining the effects of forced Rap expression 
are  therefore  still  needed  to  confirm  the  role  of  Rap  in  ERK  signalling.  Alternatively, 
primary immature B cells from SPA-1-deficient mice would provide another tool to dissect 
the effects of Rap overexpression. As mentioned above, these mice display defects in their 
B cell development as well as negative selection processes [429]. The analysis of BCR-
mediated responses in SPA-1-deficient immature B cells would therefore potentially yield 
information on the role of SPA-1 and Rap-1 in the negative selection process. 
The  experiments  analysing  SPA-1  expression  following  BCR  ligation  revealed 
additional layers of regulation involving PI3 kinase- and ERK-mediated negative feedback 
loops (Fig.5.1). For example, PI3 kinase signalling was found to hamper the transcription 
of  SPA-1  as  well  as  PAC-1  mRNA,  whereas  the  ERK  cascade  only  regulated  the 
expression of PAC-1, but had no influence on SPA-1 levels (Fig.3.14/15). The inhibition of 
these  negative  regulators  therefore  strengthens  the  survival  programme  of  positively 
stimulated cells by stabilising or even increasing the activity of ERK. These findings are 
not unexpected as other regulatory elements of the ERK cascade, such as DUSPs, have 
previously  been  shown  to  be  regulated  by  negative  feedback  inhibition  [361].  The 
elements controlling SPA-1 and PAC-1 RNA expression, especially downstream of PI3 
kinase and ERK signalling have not been identified in this study and it would therefore be 
of interest to determine these factors. 
The functional outcome of ERK activation does not solely depend on the strength of 
the signal but also on its timing. As stated above, previous studies in this laboratory have 
not only confirmed the importance of sustained ERK signalling for proliferation of WEHI-
231 cells but also demonstrated that strong but transient ERK activation, following BCR 
ligation,  induces  apoptosis  [310].  These  distinct  effects  of  temporally  regulated  signals 
could  be  further  influenced  by  the  location  of  the  activated  ERK  signal.  For  example, 
depending on the type of cell, GT1-7 cells or HEK293 cells, treatment with gonadotropin-
releasing hormone was found to induce a transient or sustained ERK signal, respectively,  
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which influenced the functional outcome of such ERK activation. Thus, whilst the transient 
signal did not allow the translocation of active ERK to the nucleus, sustained signalling did 
[640],  suggesting  that  the  duration  of  the  ERK  signal  might  determine  downstream 
signalling  by  dictating  differential  localisation  of  activated  ERK.  Indeed,  in  this  present 
study it was shown that the transient ERK signal induced by the ligation of the BCR was 
reflected by reduced expression of activated ERK in the nucleus when compared to that 
resulting from the sustained signal in cells rescued from BCR-mediated growth arrest by 
CD40 (Fig.3.16). Thus the strength, duration and localisation (cytoplasmic versus nuclear) 
of ERK activation might influence the balance between pro-survival and apoptotic ERK 
signalling. 
Relating to this, the results in Chapter 3 implicate c-Myc as the major downstream 
effector of sustained cycling ERK signalling in survival and proliferation of WEHI-231 B 
cells  and  presumably  reflect  the  ability  of  c-Myc  to  enhance  cell  cycle  progression  by 
various  mechanisms  such  as  increasing  the  transcription  of  cyclin  D  genes  or  the 
suppression  of  p27  expression  [274,278].  With  respect  to  the  mechanisms  involved, 
pharmacological inhibition of the ERK pathway supported the notion that ERK is involved 
in  the  stabilisation  of  c-Myc  protein  levels  as  abrogating  ERK  signalling  reduced  the 
expression of c-Myc protein but hardly affected its’ transcriptional levels (Fig.3.23-25). The 
stabilisation of c-Myc expression therefore provides a link between ERK signalling and 
proliferation and survival of WEHI-231 cells (Fig.5.2). Further support for the importance of 
activated ERK as well as c-Myc for cell cycle progression and proliferation came from the 
experiments utilising LSC analysis to directly correlate the expression and activation of 
molecules of interest with cell cycle stage on a single cell basis. Thus in confirmation of 
their known roles in cell cycle progression, this analysis revealed that both ERK and c-Myc 
expression  levels  were  found  to  be  highest  in  mitotic  cells  and  severely  diminished  in 
growth arrested and apoptotic cells (Fig.3.10 and 3.27). Thus, sustained activation of ERK 
induces stable levels of c-Myc and hence enables cells to overcome the G1 restriction 
point and enter mitosis. 
Both  ERK  and  c-Myc  have  been  implicated  in  the  induction  of  cyclin  expression 
[274,372] and hence the enhanced activation of cyclin D/Cdk complexes and consequent 
hyperphosphorylation of Rb resulting in the release of the E2F transcription factor required 
for induction of S-phase genes [245]. Consistent with this, the reduced levels of c-Myc 
(achieved  by  the  abrogation  of  ERK  activation  secondary  to  either  BCR-ligation  or 
pharmacological inhibition) correlated with increased levels of the cyclin/Cdk inhibitor, p27 
(Fig.3.30)  and  severely  compromised  levels  of  hyperphosphorylated  Rb  (Fig.3.30  and 
3.32/33).  
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CD40-dependent proliferation requires the induction of cyclin D/Cdk complexes to 
progress  through  the  G1/S  transition  [336]  and  the  importance  of  this  is  indicated  by 
studies in which forced expression of E2F can protect Bcl-xL-overexpressing WEHI-231 
cells  from  BCR-driven  growth  arrest  [641].  CD40-mediated  rescue  from  growth  arrest 
appears to be achieved by sustaining ERK activation [310,373] and hence c-Myc levels, 
thereby inducing hyperphosphorylation of Rb proteins and release of E2F via the induction 
of  cyclin/Cdk  complexes  (Fig.5.2).  Indeed,  CD40  signalling  reverses  BCR-mediated 
upregulation of the cell cycle inhibitor p27 and likely overcomes the suppression of E2F by 
inducing Rb hyperphosphorylation (Fig.3.30 and 3.32/33).  
The ubiquitination of proteins is important in many cellular processes and signalling 
pathways.  It  plays  a  major  role  in  the  regulation  of  cellular  protein  levels  by  targeting 
proteins for degradation by the proteasome. Interestingly, many of the proteins involved in 
cell  cycle  regulation,  including  c-Myc  and  p27,  can  be  targeted  for  ubiquitination  and 
proteasomal degradation. It was therefore hypothesised that ubiquitination would be an 
important process in BCR-mediated signalling leading to growth arrest. Indeed, c-Myc as 
well as p27 were found to be regulated by proteasomal degradation and inhibition of the 
proteasome  partially  protected  these  molecules  from  degradation  especially  in 
spontaneously proliferating WEHI-231 cells (Fig.3.35). These findings are preliminary and 
more in depth studies of the role of ubiquitination might provide a more detailed insight into 
the role of this modification in the signalling leading to growth arrest or survival.  
Consistent with this, E3 ligases, the enzymes carrying out the transfer of ubiquitin to 
target proteins, have been implicated in T cell anergy by, for example, determining the 
signalling threshold and need for costimulation for T cell priming [229]. Some of these E3 
ubiquitin ligases, such as the Cbl family of proteins, have also been found to regulate B 
cell responses [229], where in the majority of cases these enzymes appear to function as 
negative regulators of B cell signalling [431]. Indeed, in this present study, the expression 
of the E3 ubiqutin ligase Cbl-b was found to be regulated by BCR-signalling as ligation of 
the BCR increased the levels of Cbl-b (Fig.3.37), indicating a role for this E3 ligase in 
negative signalling induced by the BCR. Interestingly, Cbl-b has been implicated in the 
regulation of Rap activation by influencing C3G, Crk and Rap complex formation and in T 
cells,  Cbl-b  mediated  ubiquitination  of  Crk  reduced  the  activation  of  Rap  [438]. 
Grb2/C3G/Crk/Cbl complexes have also been found to be recruited to the BCR in B cells 
and  hence  Cbl-b  might  inihibit  Rap  activation  in  these  cells  as  well  (Fig.5.2)  [495]. 
Constructs encoding wild-type or a dominant negative form of Cbl-b are available in this 
laboratory and thus transfection of WEHI-231 cells with these constructs might provide  
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further  insight  into  the  role  these  molecules  play  in  BCR-mediated  growth  arrest  and 
apoptosis in immature WEHI-231 B cells. 
 
5.2  FcγRIIb signalling in mature B cells 
 
FcγRIIb-mediated suppression of immune responses is known to be important for 
the maintenance of B cell homeostasis as indicated by the findings that FcγRIIb-deficient 
animals  exhibit  increased  inflammatory  responses  and  enhanced  susceptibility  to 
autoimmune disorders [577,579,580]. FcγRIIb-signalling acts, at least in part, by reducing 
the antigen-driven activation of B cells resulting in growth arrest and apoptosis [309]. Such 
apoptosis reflects the dissipation of the mitochondrial membrane potential and ultimately 
the  release  of  cytochrome  C  and  apoptosis  [309].  Similar  to  other  types  of  apoptosis 
induced in B cells, such as that observed in germinal centre B cells [642], execution of 
FcγRIIb-mediated apoptosis did not appear to depend on effector caspases (3,6 or 9) or 
even a single type of protease but rather seemed to involve simultaneous activation of 
multiple executioner proteases including caspases, cathepsins and calpains [309].  
The study presented in Chapter 4 extended these findings by shedding light on the 
role of caspase 8, and the signals controlling it, in this process. Thus, caspase 8 was 
found to be crucial for the induction of FcγRIIb-dependent apoptosis as pharmacological 
inhibition of caspase 8 reduced the levels of apoptosis dramatically (Fig.4.3). As caspase 8 
is the major initiator caspase utilised during death receptor signalling, it was hypothesised 
that FcγRIIb might induce the expression and consequent autocrine signalling of death 
receptors and their ligands, such as Fas/FasL. Indeed, Fas and FasL were found to be 
upregulated due to BCR/FcγRIIb ligation at both the mRNA and protein level. Importantly, 
FcγRIIb-mediated  apoptosis  was  reduced  due  to  inhibition  of  Fas  signalling  (Fig.4.13). 
Consistent with this, B cells from MRL/MpJ-Fas
lpr  mice, a strain harbouring a deleterious 
mutation of the Fas gene, displayed defective growth arrest and apoptotic responses upon 
inhibitory  BCR/FcγRIIb  co-ligation.  Collectively,  therefore,  these  results  suggest  that 
Fas/FasL  death  receptor  signalling  might  be  involved  in  controlling  FcγRIIb-dependent 
homeostatic regulation of mature B cells.  
The downstream effector mechanisms are not yet clear but p53, which is a major 
regulator of growth arrest and apoptosis, is an important candidate signal. For example, in 
its  function  as  a  transcription  factor,  it  can  result  in  growth  arrest  and  apoptosis  by 
increasing gene expression of p21, Bax or Fas [485,631]. Moreover, it has recently been 
shown  to  transduce  apoptotic  signalling  in  a  transcription-independent  manner  by 
translocating to the cytoplasm or the mitochondria where it interacts with anti-apoptotic  
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Bcl-2 family members and hence induces the release of pro-apoptotic Bcl-2 proteins such 
as Bax [486]. Consistent with a key role for p53, signalling resulting from BCR/FcγRIIb co-
ligation  regulates  the  expression  levels  as  well  as  the  localisation  of p53  (Fig.4.5).  Of 
particular  interest,  it  was  found  that  inhibition  of  caspase  8  prevented  p53  from 
translocating from the nuclear to the cytoplasmic/mitochondrial compartments suggesting 
that caspase 8 plays a role in allowing p53 to localise to the cytoplasm where it could 
potentially  bind  to  and  activate  pro-apoptotic  Bcl-2  members  and  hence  induce 
mitochondrial  destabilisation.  Additionally,  p53  has  been  implied  in  the  transcriptional 
regulation of caspase 8 [632,643] which could create a positive feedback loop between 
p53 and caspase 8. Moreover, the expression of one of the pro-apoptotic downstream 
targets of p53, the BH3-only Bcl-2 family member Noxa, was also found to be increased by 
FcγRIIb-mediated signals further confirming the involvement of p53 and suggesting that a 
signalling axis including Fas/FasL, caspase 8, p53 and Noxa, may be induced by FcγRIIb-
signalling. 
Although the results of this study have provided a model based on such Fas/FasL 
signalling for fully dissecting the mechanisms underlying apoptosis induced by co-ligation 
of BCR and FcγRIIb (Fig.5.3), there are still many unanswered questions. For example, it 
will  be  of  interest  not  only  to  determine  the  mechanisms  regulating  the  expression  of 
Fas/FasL downstream of BCR/FcγRIIb co-ligation, but also to elucidate how the regulation 
of p53 and its’ subcellular localisation impact on B cell responses. 
 
5.3  FcγRIIb-mediated inhibition in human B cells 
 
B  cells  participate  in  the  immune  response  through  various  functions  such  as 
antibody production, antigen-presentation and cytokine production and hence influence the 
responses  of  other  cells  including  T  cells.  Thus,  de-regulated  and  excessive  B  cell 
activation may increase the likelihood of developing autoimmunity. Mechanisms controlling 
B cell homeostasis such as inhibitory FcγRIIb-signalling therefore might play a crucial role 
in  determining  the  threshold  for  B  cell  activation  and  autoantibody  production  in 
autoimmune diseases such as RA and SLE. Indeed, the pathology of these diseases have 
been shown to be linked to antibody production and B cell depletion has proven beneficial 
in many cases [551]. Moreover, a polymorphism of FcγRIIb which reduces its signalling 
capacity [590] has been found to be associated with SLE in some racial groups such as 
Japanese  patients  [589].  Thus,  FcγRIIb  provides  a  candidate  which  could  potentially 
regulate B cell activation in the human system in the context of autoimmune disease.   
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Interestingly, therefore, in this study it was shown that cells from a small proportion 
of RA and SLE patients displayed little or no inhibition of BCR-driven proliferation upon 
FcγRIIb ligation in vitro (Fig.4.16), although, overall, the differences between the healthy 
control  and  RA  or  SLE  cohorts  were  not  statistically  significant.  However,  only  small 
cohorts of patients were studied, thus investigations of FcγRIIb expression in B cells from 
larger  cohorts  of  patients,  potentially  from  varying  ethnic  backgrounds,  may  provide 
statistically significant data to support a role for FcγRIIb function in the dysregulation of B 
cell responses in RA or SLE patients in certain populations. Indeed, it has previously been 
shown that de-regulation of FcγRIIb expression on memory and plasma B cells is more 
apparent in SLE patients with African-American background [588]. Thus, if the defects of 
the inhibitory response observed in this study correlate with overall expression levels of 
FcγRIIb they could also be more obvious and statistically significant in populations of other 
ethnic  backgrounds.  Nevertheless,  the  results  presented  in  Chapter  4  indicate  that 
FcγRIIb-mediated regulation of proliferation of mature peripheral B cells is not a dominant 
disease-driving  mechanism.  However,  there  is  a  possibility  that  changes  in  FcγRIIb-
signalling might contribute to the disease in some patients. Consistent with the theory that 
FcγRIIb expression is important for maintenance of self-tolerance, FcγRIIb1 and FcγRIIb2 
were found to be downregulated in PBMCs from RA patients. However, the most striking 
change between the RA/SLE patient cohorts and the healthy patients was the reduction of 
the  FcγRIIb1/FcγRIIb2  ratio  (Fig.4.19)  due  to  a  relative  increase  of  FcγRIIb2  levels  in 
patients compared to healthy controls. This change could influence the balance between 
antigen uptake and presentation and inhibitory signalling towards increased ability of cells 
to present antigen. In an autoimmune prone setting this could increase the presentation of 
self-antigen by autoreactive B cells which in turn could activate autoreactive T cells thus 
perpetuating auto-inflammatory responses. 
The results described in Chapter 4 therefore support a role for FcγRIIb in human 
autoimmune disease. However, there are many areas which are still unexplored such as 
the  mechanisms  regulating  the  differential  expression  of  FcγRIIb1  and  FcγRIIb2. 
Furthermore, it would be of interest to identify the contribution of the various cell types 
making  up  the  PBMC  compartment  (B  cells,  monocytes,  dendritic  cells)  towards  the 
changes  seen  in  FcγRIIb1/FcγRIIb2  expression.  More  detailed  studies  analysing  a 
potential correlation between expression levels of FcγRIIb and changes in the inhibitory 
function of B cells would also contribute to further dissecting the function of this receptor in 
human  B cells.  Finally,  examination of  B  cells  in  the  location  of  the  auto-inflammatory 
response such as the joint in RA patients would be of even more interest, as circulating B 
cells might not necessarily represent the status of tissue-resident B cells actively involved  
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in  inflammation. Thus, the  evidence  of  a role for  FcγRIIb  in  the  negative  regulation  of 
inappropriately  activated  B  cells  might  provide  necessary  information  for  potential 
therapeutic intervention during autoimmune inflammatory diseases. 
 
5.4  Figures 
 
  
  258 
Figure 5.1 Regulation of the ERK cascade in WEHI-231 B cells 
Cross-linking  of  the  BCR  on  WEHI-231  cells  reduces  ERK  signalling  by  multiple 
mechanisms.  Thus,  BCR-ligation  suppresses  the  activation  of  the  Rap/B-Raf  pathway 
which is most likely achieved by the upregulation of SPA-1 levels but might also involve 
the increased expression and recruitment of the E3 ubiquitin ligase Cbl-b. The formation of 
the adaptor complex consisting of C3G, Grb2 and Crk can be inhibited by Cbl-b-dependent 
ubiquitination of Crk. C3G is a GEF for Rap and reduced recruitment and formation of this 
complex  therefore  reduces  the  activation  of  Rap.  SPA-1  and  the  ERK-specific 
phosphatase PAC-1 were both found to be regulated by negative feedback loops involving 
ERK and PI3 kinase signalling. Hence, abrogation of ERK/PI3 kinase signalling induced 
the increase of SPA-1 and PAC-1 mRNA transcription by as yet unknown transcription 
factors. BCR-mediated downregulation of ERK ultimately leads to the reduction of c-Myc 
levels and growth arrest. 
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Figure 5.2 Cell cycle regulation by the ERK/c-Myc cascade 
Activated ERK phosphorylates c-Myc on serine 62 which stabilises nuclear c-Myc. c-Myc 
and  ERK  itself  facilitate  the  G1/S  transition  by  inducing  cyclin  D  gene  expression. 
Moreover, c-Myc reduces the levels of p27 by inhibiting its transcription and increasing the 
expression  of  the  SCF  E3  ubiquitin  ligase  complex.  This  complex  ubiquitinates 
phosphorylated  p27  leading  to  its  degradation  by  the  proteasome.  Finally,  active 
cyclin/Cdk complexes phosphorylate Rb proteins and hence induce the release of the E2F 
transcription factor to transactivate the expression of S phase genes. The lack of ERK 
activation  due  to  BCR-ligation  reduces  c-Myc  stabilisation  and  hence  protein  levels 
thereby  contributing  to  increased  levels  of  p27  and  reduced  activation  of  cyclin/Cdk 
complexes. Rb therefore remains in its hypophosphorylated state, inhibiting the release of 
E2F and hence G1/S phase transition.  
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Figure 5.3 Model for FcγRIIb-mediated apoptosis 
BCR/FcγRIIb  co-ligation  results  in  dissipation  of  the  MMP  and  apoptosis.  FcγRIIb-
signalling increases the expression of Fas and its ligand FasL and signalling through this 
death receptor can activate caspase 8 which was shown to be the major initiator caspase 
involved  in  FcγRIIb-mediated  apoptosis.  Furthermore,  p53  is  upregulated  by  FcγRIIb-
dependent mechanisms and in turn could increase Fas and caspase 8 expression at the 
transcriptional  level,  thereby  initiating  as  well  as  propagating  this  signalling  axis. 
Additionally,  p53  could  trigger  apoptosis  by  enhancing  expression  of  pro-apoptotic 
molecules  such  as  Noxa  or  by  translocating  to  the  mitochondria  itself  and  hence 
interacting with pro- and anti-apoptotic molecules at this interface.  
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9Specificity of antibody Host Clone Manufacturer
anti-mouse IgM Rat B7.6 made in house
anti-mouse CD40 Rat FGK45 made in house
anti-mouse FcγRII Rat 24G2 made in house
anti-mouse FasL Armenian Hamster MFL3 BioLegend
Armenian Hamster IgG Armenian Hamster HTK888 BioLegend
anti-mouse IgG+IgM (H+L) Rabbit 315-005-044 Jackson ImmunoResearch
F(ab')2  anti-mouse IgM Goat 115-006-020 Jackson ImmunoResearch
anti-human IgG+IgM (H+L) Rabbit 309-005-107 Jackson ImmunoResearch
F(ab')2  anti-human IgG+IgM Goat 109-006-127 Jackson ImmunoResearch
anti-rat IgG (H+L) Donkey 712-005-150 Jackson ImmunoResearch
(A) FACS
(B) Antibodies used for stimulation
Specificity of antibody Reactivity Isotype Clone Conjugated  Manufacturer
CD3 Human Mouse IgG1 UCHT1 APC BD Pharmingen
CD11b Human Mouse IgG1 ICRF44 (44) APC BD Pharmingen
CD14 Human Mouse IgG2a M5E2 FITC BD Pharmingen
CD19 Human Mouse IgG1 HIB19 APC/FITC BD Pharmingen
CD20 Human Mouse IgG2b 2H7 PE BD Pharmingen
CD32B Human Human chimeric mouse ch2B6N297Q AF488 MacroGenics
CD56 Human Mouse IgG1 B159 PE BD Pharmingen
Isotype controls Clone Conjugated  Manufacturer
Mouse IgG1 MOPC-21 AF488/APC/FITC/PE BD Pharmingen
Mouse IgG2b 27-35 PE BD Pharmingen
Mouse IgG2a G155-178 FITC BD Pharmingen
Specificity of antibody Reactivity Isotype Clone Conjugated  Manufacturer
B220 Mouse Rat IgG2a RA3-6B2 FITC BD Pharmingen
CD95 (Fas) Mouse Hamster IgG Jo2 Biotin BD Pharmingen
Isotype controls Conjugated  Manufacturer
Rat IgG2a FITC BD Pharmingen
Hamster IgG Biotin BD Pharmingen
Secondary reagents Reactivity Isotype Clone Conjugated Manufacturer
Streptavidin APC 554067 APC BD Pharmingen
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1(C) Western Blotting
(D) Immunofluorescent staining
Specificity of antibody Host Clone/ID Dilution Manufacturer
β-Actin Mouse sc-47778 1:5000 Santa Cruz
Caspase-8 Mouse Clone 1G12 1:1000 Alexis Biochemicals
Cbl-b Rabbit sc-1705 1:1000 Santa Cruz
c-Cbl Mouse Clone 17 1:1000 BD Transduction Laboratories
FLIP, C-terminus Rabbit 06-864 1:1000 Upstate
c-Myc Rabbit 9402 1:1000 Cell Signaling Technology
c-Myc pThr58 Rabbit ab28842 1:1000 Abcam
c-Myc Ser62 Rabbit ab51156 1:1000 Abcam
c-Myc pThr58/Ser62 Rabbit 9401 1:1000 Cell Signaling Technology
CTCF Rabbit sc-28198 1:1000 Santa Cruz
Fas (CD95) Mouse Clone 13 1:2500 BD Transduction Laboratories
FasL (CD178) Mouse Clone 33 1:1000 BD Transduction Laboratories
Grail Rat Clone H11-744 1:150 BD Pharmingen
HDAC-1 Rabbit sc-7872 1:1000 Santa Cruz
HA tag Rat Clone 3F10 1:1000 Roche
Itch Mouse 32/Itch 1:500 BD Transduction Laboratories
Noxa Rabbit ab13687 1:500 Abcam
p27 Rabbit sc-776 1:1000 Santa Cruz
p53 Rabbit sc-6243 1:1000 Santa Cruz
p42/44 (ERK) Rabbit 9102 1:1000 Cell Signaling Technology
p42/44 (ERK) pThr202/Tyr204 Rabbit 9101 1:1000 Cell Signaling Technology
Rap1 Rabbit sc-65 1:1000 Santa Cruz
B-Raf Rabbit sc-9002 1:1000 Santa Cruz
Raf-1 Rabbit sc-133 1:1000 Santa Cruz
Rb pSer780 Rabbit 9307 1:1000 Cell Signaling Technology
Rb pSer807/811 Rabbit 9308 1:1000 Cell Signaling Technology
SPA-1 Mouse 3/SPA-1 1:250 BD Transduction Laboratories
Ubiquitin Mouse Clone P4D1 1:1000 Cell Signaling Technology
VDAC-1 Rabbit 4866 1:1000 Cell Signaling Technology
Secondary antibodies Host Clone/ID Dilution Manufacturer
anti-rabbit-HRP Goat 7074 1:2000 Cell Signaling Technology
anti-mouse-HRP Horse 7076 1:2000 Cell Signaling Technology
anti-rat-HRP Goat 7077 1:2000 Cell Signaling Technology
Primary antibodies Host Clone/ID Dilution Manufacturer
p42/44 (ERK) pThr202/Tyr204 Rabbit 9101 1:50 Cell Signaling Technology
c-Myc Rabbit 9402 1:50 Cell Signaling Technology
c-Myc Ser62 Rabbit ab51156 1:500 Abcam
Rap-1 Rabbit sc-65 1:100 Santa Cruz
RalGSD-RBD recombinant E.coli Z02039 1:5000 GenScript/Bioquote Ltd.
Rb pSer780 Rabbit 9307 1:500 Cell Signaling Technology
Rb pSer807/811 Rabbit 9308 1:50 Cell Signaling Technology
Isotype control Dilution Manufacturer
Rabbit IgG  appropriate Sigma
Secondary antibodies Host Clone/ID Dilution Manufacturer
anti-GST Rabbit 2622 1:100 Cell Signaling Technology
anti-rabbit-HRP Goat 7074 1:100 Cell Signaling Technology
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9Primers human Sequence
FcγRIIb1 fw 5’ ggccttgatctactgcaggaa 3’
FcγRIIb1 fw 5’ gggcgggtctctcccatttc 3’
FcγRIIb2 fw 5’ tgctgctgtagtggccttga 3’
FcγRIIb2 rv 5’ ccccaactttgtcagcctcat 3’
Probes human
FcγRIIb1 FAM - 5’ cggatttcagctctcccaggataccct 3’ - TAMRA
FcγRIIb2  FAM - 5’ aggaaaaagcggatttcagccaatcccacta 3’ - TAMRA  
HPRT Kit (AB Applied Biosystems)
β-Actin Kit (AB Applied Biosystems)
Primers murine
Cbl-b fw 5’ tgtgcacttcgtgccttacc 3’
Cbl-b rv 5’ tgggctccgttccttttatct 3’
c-Cbl fw 5’ tgatccttggaatgggagaga 3’
c-Cbl rv 5’ ttccatttgtgagggcaatg 3’
cMyc fw  5’ agctgaagcgcagctttttt 3’
cMyc rv  5’ gtaggcggtggcttttttga 3’
CTCF fw 5’ ttgtagacaggagcggcacat 3’
CTCF rv 5’ gctgtttctggcggaaggt 3’
p53 fw 5’ aagacgtgccctgtgcagtt 3’
p53 rv 5’ acctccgtcatgtgctgtga 3’
PAC-1 fw 5’ gctggatctctcgctcag 3’
PAC-1 rv 5’ ccccgacgttgcttaacaaa 3’
SPA-1 fw 5’ tcctgaggaagcgtcatatcg 3’
SPA-1 rv 5’ ctggaagtgagagcggattgt 3’
Probes murine
Cbl-b FAM - 5’ ccaaggctgccccttctgtcgc 3’ - TAMRA
c-Cbl FAM - 5’ ttgaccaatcggcactcgcttcc 3’ - TAMRA
cMyc FAM - 5’ ccctgcgtgaccagatccctgaat 3’ - TAMRA
CTCF FAM - 5’ atcatgcacaagcgcactcacacg 3’ - TAMRA
GAPDH Kit (AB Applied Biosystems)
p53 FAM - 5’ tggtcagcgccacacctcca 3’ - TAMRA
PAC-1 FAM - 5’ caccatctgcctggcatacctgattca 3’ - TAMRA
SPA-1 FAM - 5’ caacgatattgtgaccatcgtgttccagg 3’ - TAMRA
Fas Taqman gene expression assay (Applied Biosystems - Mm01204974_m1)
FasL Taqman gene expression assay (Applied Biosystems - Mm00438864_m1)
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25x106 cells
resuspended in 
cytoplasmic buffer
108 cells
resuspended in 
cytosolic buffer
Supernatant  Pellet ‐
discard
15 min on ice,
40 strokes in 
homogeniser,
400 x g 20 min
Supernatant 
Pellet ‐
wash in cytosolic buffer
Supernatant ‐
cytoplasmic
fraction
Pellet ‐
membrane/organelle 
buffer
10 min at 4oC
1000 x g, 10 min
Supernatant ‐
membrane/organelle
fraction
Pellet ‐
nuclear buffer
30 min at 4oC
6000 x g, 10 min
Supernatant ‐
nuclear fraction
Pellet ‐
cytoskeletal buffer
cytoskeletal fraction
10 min at 4oC
6800 x g, 10 min
800 x g 10 min
Pellet ‐
discard
8000 x g 20 min
8000 x g 10 min
Pellet ‐
Resuspend in complete 
mitochondria lysis buffer
mitochondrial fraction
on ice 15 min
vortex 10 sec
107 cells
resuspended in 
hypotonic buffer
Supernatant –
cytosolic
fraction 
Pellet ‐
Complete lysis buffer
15 min on ice,
25 µl detergent,
Vortex
14 000 x g 30s
Supernatant –
nuclear fraction
Vortex
On ice 30 min
14 000 x g 10 min
Pellet ‐
discard
(A)
(B)
(C)
Supernatant ‐
cytosolic fraction
F
i
g
u
r
e
 
2
.
1
0Vector Inserted via          
restriction sites
Supplier
pcDNA
TM3.1 (+) Invitrogen
pcDNA
TM3.1/Zeo (-) Invitrogen
pIRES2-AcGFP1 Clontech
pLVX-IRES-ZsGreen1 Clontech
pcDNA
TM3.1 (+) - Rap1A WT Missouri S&T cDNA Resource Center 
pcDNA
TM3.1 (+) - Rap1A G12V Missouri S&T cDNA Resource Center 
pcDNA
TM3.1 (+) - Rap1A S17N Missouri S&T cDNA Resource Center 
pcDNA
TM3.1/Zeo (-) - Rap1A WT Nhe I/Xho I
pcDNA
TM3.1/Zeo (-) - Rap1A G12V Nhe I/Xho I
pcDNA
TM3.1/Zeo (-) - Rap1A S17N Nhe I/Xho I
pIRES2-AcGFP1 - Rap1A WT Nhe I/Xho I
pIRES2-AcGFP1 - Rap1A G12V Nhe I/Xho I
pIRES2-AcGFP1 - Rap1A S17N Nhe I/Xho I
pLVX-IRES-ZsGreen1 - Rap1A WT Eco RI/Xba I
pLVX-IRES-ZsGreen1 - Rap1A G12V Eco RI/Xba I
pLVX-IRES-ZsGreen1 - Rap1A S17N Eco RI/Xba I
Final construct Parental plasmid for vector Parental plasmid for insert Restriction enzymes 
pcDNA
TM3.1/Zeo (-) - Rap1A WT pcDNA
TM3.1/Zeo (-) pcDNA
TM3.1 (+) - Rap1A WT Nhe I/Xho I
pcDNA
TM3.1/Zeo (-) - Rap1A G12V pcDNA
TM3.1/Zeo (-) pcDNA
TM3.1 (+) - Rap1A G12V Nhe I/Xho I
pcDNA
TM3.1/Zeo (-) - Rap1A S17N pcDNA
TM3.1/Zeo (-) pcDNA
TM3.1 (+) - Rap1A S17N Nhe I/Xho I
pIRES2-AcGFP1 - Rap1A WT pIRES2-AcGFP1  pcDNA
TM3.1 (+) - Rap1A WT Nhe I/Xho I
pIRES2-AcGFP1 - Rap1A G12V pIRES2-AcGFP1  pcDNA
TM3.1 (+) - Rap1A G12V Nhe I/Xho I
pIRES2-AcGFP1 - Rap1A S17N pIRES2-AcGFP1  pcDNA
TM3.1 (+) - Rap1A S17N Nhe I/Xho I
pLVX-IRES-ZsGreen1 - Rap1A WT pLVX-IRES-ZsGreen1  pcDNA
TM3.1 (+) - Rap1A WT - PCR fragment Eco RI/Xba I
pLVX-IRES-ZsGreen1 - Rap1A G12V pLVX-IRES-ZsGreen1  pcDNA
TM3.1 (+) - Rap1A G12V - PCR fragment Eco RI/Xba I
pLVX-IRES-ZsGreen1 - Rap1A S17N pLVX-IRES-ZsGreen1  pcDNA
TM3.1 (+) - Rap1A S17N - PCR fragment Eco RI/Xba I
(A)  Vectors
(B) Primers
(C) Cloning strategy
Primers Sequence
pcDNA3.1-Rap FW (Eco RI) 5' gagagaattcgctggctagcgtttaaactta 3'
pCDNA3.1-Rap RV (Xba I) 5' gagatctagataaacgggccctctagactc 3'
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(A)  pcDNA3.1 (+)
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(A)  pIRES2-AcGFP1
F
i
g
u
r
e
 
2
.
1
2N
F
‐
K
B
c
‐
M
y
c
,
 
B
c
l
‐
x
L
C
D
4
0
T
R
A
F
s
N
F
‐
K
B
N
u
c
l
e
u
s
E
R
K
c
P
L
A
2
c
P
L
A
2
M
i
t
o
c
h
o
n
d
r
i
a
B
c
l
‐
x
L
B
c
l
‐
x
L
A
A
A
A
A
A
∆
ψ
m
A
T
P
C
a
t
h
B
A
P
O
P
T
O
S
I
S
B
C
R
F
i
g
u
r
e
 
3
.
1T
5
8
S
6
2
P
P
r
o
t
e
a
s
o
m
e
U
b
i
q
u
i
t
i
n
a
t
i
o
n
D
e
g
r
a
d
a
t
i
o
n
c
‐
M
y
c
S
6
2
P
S
t
a
b
i
l
i
s
a
t
i
o
n
c
‐
M
y
c
E
R
K
A
c
c
u
m
u
l
a
t
i
o
n
S
6
2
P
S
6
2
P
S
6
2
P
P
r
o
l
i
f
e
r
a
t
i
o
n
G
r
o
w
t
h
 
a
r
r
e
s
t
G
S
K
3
S
C
F
E
3
 
l
i
g
a
s
e
P
I
3
‐
K
F
i
g
u
r
e
 
3
.
2p38
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B‐Raf
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Rap
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cAMP
Integrins
Ca2+
DAG
PTK
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1p c D N A 3 . 1 ( + ) W E H I  231 500 µg/ml G418 linearised Amaxa Nucleofector System (Amaxa/Lonza)
2 pcDNA3.1(+) WEHI 231 250 then 500 µg/ml  G418 linearised Amaxa Nucleofector System (Amaxa/Lonza)
3p c D N A 3 . 1 ( + )  Zeo WEHI 231‐Bcl‐xl 200 µg/ml  Zeocin linearised Amaxa Nucleofector System (Amaxa/Lonza)
4p I R E S 2 ‐AcGFP1 WEHI 231‐Bcl‐xl 500 µg/ml G418 not linearised Amaxa Nucleofector System (Amaxa/Lonza)
5 pIRES2‐AcGFP1 WEHI 231 300 µg/ml G418 not linearised Amaxa Nucleofector System (Amaxa/Lonza)
6p I R E S 2 ‐AcGFP1 WEHI 231 300 then 500 µg/ml G418 not linearised Amaxa Nucleofector System (Amaxa/Lonza)
7 pIRES2‐AcGFP1 WEHI 231 300‐1000 µg/ml G418 not linearised Amaxa Nucleofector System (Amaxa/Lonza)
8 pIRES2‐AcGFP1 WEHI 231 500 then 600 µg/ml G418  linearised Amaxa Nucleofector System (Amaxa/Lonza)
9p c D N A 3 . 1 ( + )  Zeo WEHI 231‐Bcl‐xl 200 µg/ml  Zeocin linearised Amaxa Nucleofector System (Amaxa/Lonza)
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pcDNA3.1(+) WEHI 231 150‐1000 µg/ml G418 Gene Pulser Xcell Electroporation System (BioRad) 
pcDNA3.1(‐)Zeo WEHI 231‐Bcl‐xl 50‐500 µg/ml Zeocin Amaxa Nucleofector System (Amaxa/Lonza)
pIRES2‐AcGFP1 MP‐100 Microporator (Labtech)
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